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Abstract 
 
The study of counterfeiting and falsification of medicinal products, from a legal 
perspective, is a relatively new area in the EU. Specific regulations that focus on 
falsification of medicines came as recently as 2011. Therefore, this discipline is 
also new for research. 
 
There are two primary objectives of the thesis. The first is to analyse how EU law 
addresses counterfeiting and falsification of medicinal products, (Directive 
2011/62/EU, Directive 2004/48/EC, and Regulation 608/2013) – de lege lata. The 
second is to analyse whether the law containing tools to combat counterfeiting and 
falsification of medicinal products meets the social objectives of public health 
(Articles 9 and 168) and consumer protection (Articles 12 and 169), as envisaged 
by the Treaty on the Function of the European Union.  
 
The thesis establishes that the problem of counterfeiting and falsification of 
medicinal products lies at the intersection of three spheres of law - IP law, 
Medicine law, and Criminal law. This insight provides the foundation for the 
understanding of the weaknesses in the legal regime that contains tools for 
combatting counterfeiting and falsification of medicines in the EU. 
 
In order to set the context and illustrate the main problem of counterfeiting and 
falsification of medicinal products, three cases are analysed - Operation Robin 
(Sweden), Operation Singapore (the UK), and Operation Volcano (Italy). Through 
the case studies, the common challenges confronting the law are identified, such 
as the infiltration of the legal supply chain, manipulation of medicinal products, 
insufficient control over online sale of counterfeit medicines, and the use of small 
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consignments to transport such products. These issues underline the gaps that exist 
in the legal framework in the EU and serve as the basis for the analysis of the legal 
framework. 
 
The legal analysis reveals that counterfeiting and falsification of medicines is 
addressed in a compartmentalised and mutually exclusive manner by the different 
streams of law. As a result, the legal framework does not operate at the most 
effective level possible. 
 
In order to draw inspiration to strengthen the current legal framework in the EU, 
initiatives taken at the international level with particular emphasis on the 
Medicrime Convention, the ACTA, and multilateral and bilateral agreements are 
also analysed. 
 
Thereafter, on the basis of the issues identified in the case studies and the analysis 
of the law, it is examined whether the law containing tools to combat 
counterfeiting and falsification of medicinal products meets the social objectives 
of public health and consumer protection, as envisaged by the TFEU.  
 
In conclusion, it is reasserted that the problem of counterfeiting and falsification of 
medicinal products lies at the intersection of IP law, Medicine law, and Criminal 
law. Even though the legal instruments are successful to some extent, there is still 
scope for improvement, especially in the area of criminal enforcement of 
counterfeiting and falsification of medicinal products, securing authorisation 
certificates for the market players and building overall synergies within and 
amongst authorities representing the three streams of law, within and across the 
Member States.  
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Abstract in Danish/Resumé på dansk   
 
Forfalskning af medicin fra et juridisk perspektiv er et relativt nyt område inden 
for EU. En særregulering af forfalskninger af medicin så dagens lys så sent som i 
2011, og som følge deraf er dette emne nyt inden for den juridiske forskning. 
 
Denne afhandling har to primære formål. Det første formål er at analysere, 
hvordan EU håndterer forfalskning af medicin. I den forbindelse tages der 
udgangspunkt i direktiv 2011/62/EU, Direktiv 2004/48/EC og forordning 
608/2013 – de lege lata. Det andet formål er at analysere, hvorvidt det 
omhandlede lovgrundlag opfylder de sociale mål om dels folkesundhed (artikel 9 
og 168) og dels forbrugerbeskyttelse (artikel 12 og 169) som forudsat i traktaten 
om den Europæiske Unions funktionsmåde. 
 
I afhandlingen konkluderes det, at det juridiske problem vedrørende regulering af 
forfalskning af medicin ligger i skæringspunktet mellem 3 lovgivningssfærer, 
immaterialret, lægemiddelret og strafferet. Denne indsigt skaber grundlaget for at 
forstå svaghederne i lovgivningen med midlerne til bekæmpelse af forfalskning af 
medicin i EU.  
 
For at illustrere problemstillingen indeholder afhandlingen en analyse af tre sager - 
Operation Robin (Sverige), Operation Singapore (Det Forenede Kongerige), og 
Operation Volcano (Italien). Gennemgangen af sagerne identificerer de 
problemstillinger, som lovgivningen står over for, såsom infiltration af den legale 
forsyningskæde, manipulation af produkterne, utilstrækkelig kontrol med online 
salg af forfalsket medicin og brugen af små forsendelser. 
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Den juridiske analyse af immaterialretten, lægemiddelretten og strafferetten 
afdækker, at forfalskning af medicin håndteres isoleret i de forskellige 
lovgivninger, og at der ikke er tænkt i synergier. Det konkluderes på den 
baggrund, at den juridiske regulering som følge heraf ikke er optimal. Dernæst 
analyseres en række internationale initiativer – særligt Medicrime konventionen 
og ACTA samt en række andre multilaterale og bilaterale initiativer - med henblik 
på at undersøge, om de kan give inspiration til en styrkelse af den gældende EU 
regulering på området. 
 
På grundlag af sagsgennemgangene og den juridiske analyse vurderes det, 
hvorvidt lovgivningen indeholder de nødvendige midler til bekæmpelse af 
forfalskning af medicin og dermed hvorvidt de sociale mål om folkesundhed og 
forbrugerbeskyttelse som forudsat i traktaten om den Europæiske Unions 
funktionsmåde kan anses som opfyldt. 
 
Som konklusion konsolideres udgangspunktet om, at problemet med forfalskning 
af medicin ligger i skæringspunktet mellem immaterialret, lægemiddelret og 
strafferet. Skønt lovgivningen i nogen grad kan anses som effektiv, konkluderes 
det, at der stadig er potentiale for forbedringer, særligt i relation til strafferetlig 
håndhævelse, forhøjelse af sikkerheden omkring certifikater for markedsaktørerne 
samt i tilvejebringelse af synergier mellem myndigheder inden for de tre 
lovområder, både inden for hver enkel medlemsstat og på tværs af 
medlemsstaterne.
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Glossary 
 
Adulteration: The process of altering a product by intentionally manipulating 
the product by  
adding something that ordinarily is not supposed to be in the 
product.  
 
API: Active Pharmaceutical Ingredient is that part of the drug that 
contains the healing or disease preventive or curing agent of the 
pharmaceutical product. 
 
Counterfeit 
drug: 
A drug having an unauthorised representation of a registered 
trademark on a product identical or similar to one for which the 
trademark is registered. 
 
Drug Recall: A drug recall means removal of a prescription or over-the-
counter drug from the market by the national competent 
authority, usually a medicines agency. 
 
Drug: A medication or a substance used in the preparation of 
medication. 
 
Excipient: A pharmacologically inactive substance like a colouring agent, 
filler or a preservative that is used with other active substances 
in a medicinal product. 
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Fake drug: A synonym used for the falsified or counterfeit drug. 
 
Falsified  
drug: 
A drug that falsely represents a product’s origin or sources or 
history. 
 
GDP: Good Distribution Practice are the guidelines regarding quality 
control, warranty system, requirements for purchase, receiving, 
storing, and exporting medicinal products that must be upheld 
for distribution of medicinal products for human use. 
 
Generic 
medicines: 
Generic medicines are copies of brand-name drugs, which have 
the same pharmacological effect as the brand-name drugs. The 
generic drugs, therefore, have equivalent risks, safety, and 
strength, side effects, route of administration and dosage as the 
brand-name drugs. 
 
GMP: Good Manufacturing Practice is a system to ascertain that 
pharmaceutical products adhere to a quality standard. It is 
formulated with an aim of reducing the risk concerning 
pharmaceutical products that cannot be done away with by 
means of testing the finished product. 
 
Illegal 
medicine: 
 
Illegal medicine is a medicine not authorised by law. 
 
Lifesaving 
drugs: 
Life-saving medicines are the antibiotics that help in saving 
lives, such as drugs that treat cancer, etc. 
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Lifestyle  
drugs: 
A lifestyle drug is a term used to describe medications that treat 
conditions like wrinkles, erectile dysfunction, or acne, which are 
not life-threatening and non-painful. 
 
Medicines: A substance or preparation used for treating a disease. 
 
NUI: Non-Urgent Information. 
 
Over-the-
counter: 
An OTC is a pharmaceutical drug that does not require a 
prescription in order to be dispensed. 
 
Parallel  
import: 
A parallel import, often referred to as grey product is a non-
counterfeit product imported without the authorisation of the 
intellectual property owner. 
 
Pharmaceutical: A drug with medicinal property. 
 
Prescription 
drug: 
A prescription medicine is a pharmaceutical drug that requires a 
medical prescription by law, to be dispensed. 
. 
Substandard: A drug that does not meet the national specification outlines by 
a national competent authority. These drugs are manufactured 
by legitimate manufacturers but are substandard because of 
quality failures. 
 
Market An official document issued by the competent medicines 
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authorisation: regulatory authority for the purpose of marketing after 
conducting evaluations for safety, efficacy, and quality. It sets 
out the name of the product, the dosage form, the quantitative 
formula, the shelf life and storage conditions required along with 
packaging characteristics. 
 
Manufacturing 
authorisation:   
It is part of the series of controls which the legislation states in 
the form of requirements pertaining to market authorisation, 
distribution authorisation or market authorisation depending 
upon the precise activity being discharged. 
 
 
   
  
  
  
  
  
  
 
 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
 
 
 
List of contents  
 
 
Acknowledgements ................................................................................................... 3 
Abstract ..................................................................................................................... 5 
Abstract in Danish/Resumé på dansk ........................................................................ 7 
Abbreviations ............................................................................................................ 9 
Glossary ................................................................................................................... 12 
List of contents ........................................................................................................ 17 
List of tables and figures ......................................................................................... 22 
Part I: Introduction .................................................................................................. 25 
Chapter 1: Introduction ..................................................................................... 27 
1.2. Intersection of laws .................................................................................... 34 
1.3. Objectives of the thesis .............................................................................. 38 
1.4. Perspective ................................................................................................. 40 
1.5. Delimitation ............................................................................................... 42 
1.6. Terminology ............................................................................................... 44 
1.7. Structure of the thesis................................................................................. 50 
Chapter 2: Legal Theory, Sources and Method ................................................ 54 
2.1. Introduction ................................................................................................ 54 
17 
 
 
 
 
2.2 Legal Theory - Legal Positivism and EU law ............................................. 55 
2.3. Sources of Law ........................................................................................... 59 
2.4. Method ........................................................................................................ 94 
2.5. Concluding remarks ................................................................................. 101 
Part II: Legal Case studies ..................................................................................... 103 
Chapter 3: Legal Case Studies ........................................................................ 106 
3.1 Introduction ............................................................................................... 106 
3.2. Operation Volcano ................................................................................... 109 
3.3 Operation Singapore .................................................................................. 117 
3.4. Operation Robin ....................................................................................... 124 
3.5. Problems highlighted the case studies ...................................................... 129 
3.6. Concluding remarks ................................................................................. 135 
PART III: Legal Analysis ...................................................................................... 139 
Chapter 4: Analysis of the Falsified Medicines Directive (Directive 
2011/62/EU) .................................................................................................... 142 
4.1. Introduction .............................................................................................. 142 
4.2. The Medicinal product – safety features .................................................. 146 
4.3. The supply chain ...................................................................................... 153 
4.4. Online sale of medicinal products ............................................................ 172 
4.5. Concluding remarks ................................................................................. 178 
Chapter 5: Analysis of Enforcement Directive (Directive 2004/48/EC) ........ 182 
5.1. Introduction .............................................................................................. 182 
18 
 
 
 
 
5.2. Private rights vis-à-vis public rights ........................................................ 188 
5.3. Lack of cross-border applicability of the Enforcement Directive ........... 190 
5.4. The role of Intermediaries ........................................................................ 198 
5.5. Lack of criminal measures ....................................................................... 202 
5.6. Concluding remarks ................................................................................. 204 
Chapter 6: Analysis of the Customs Regulation (Regulation 608/2013) ....... 207 
6.1. Introduction .............................................................................................. 207 
6.2. Small Consignments ................................................................................ 212 
6.3. Goods in transit ........................................................................................ 215 
6.4. Travellers’ Luggage ................................................................................. 218 
6.5. Parallel Imports ........................................................................................ 222 
6.6. Concluding remarks ................................................................................. 225 
Chapter 7: Global Initiatives ........................................................................... 228 
7.1. Introduction .............................................................................................. 228 
7.2. Medicrime Convention ............................................................................ 232 
7.3. ACTA ....................................................................................................... 245 
7.4. Multilateral and bilateral agreements ...................................................... 255 
7.5. Concluding remarks ................................................................................. 265 
Part IV: Evaluation & Conclusion ........................................................................ 269 
Chapter 8: Are the social objectives of public health and consumer protection 
met? ................................................................................................................. 271 
8.1. Introduction .............................................................................................. 271 
19 
 
 
 
 
8.2. Recapitulation of laws that combats counterfeiting and falsification of 
medicines in the EU ................................................................................ 271 
8.3. Social objectives of public health in the TFEU ....................................... 274 
8.4. Social objectives of consumer protection in the TFEU ........................... 279 
8.5. Does the law that provides tools to combat counterfeiting and falsification 
of medicinal products, meet the social objectives of public health and 
consumer protection? .............................................................................. 282 
8.6. Concluding remarks ................................................................................. 292 
Chapter 9: Conclusion ..................................................................................... 294 
Appendix I: Bibliography ...................................................................................... 302 
Books ............................................................................................................... 302 
Articles ............................................................................................................ 309 
Appendix II: List of EU sources ............................................................................ 325 
Primary sources ............................................................................................... 325 
Secondary sources ........................................................................................... 326 
Other official reports and preparatory works .................................................. 331 
Guidelines ........................................................................................................ 331 
Proposals & Communications ......................................................................... 331 
European Commission Documents ................................................................. 334 
Press Release ................................................................................................... 336 
Notice .............................................................................................................. 337 
20 
 
 
 
 
Council Resolutions ........................................................................................ 337 
Appendix III: List of cases .................................................................................... 339 
CJEU Cases ..................................................................................................... 339 
National cases ................................................................................................. 341 
Sweden ............................................................................................................ 341 
UK 341 
Italy 341 
US 342 
Germany .......................................................................................................... 342 
Appendix IV: Additional sources .......................................................................... 343 
International .................................................................................................... 343 
EU ................................................................................................................... 346 
National ........................................................................................................... 348 
German National Competent Authority (NCA)- Paul-Ehrlich-Institut (PEI). 348 
Italian NCA Agenzia Italiana del Farmace (AIFA). ....................................... 349 
The UK NCA – Medicines and Healthcare Products Regulatory Agency 
(MHRA) .................................................................................................. 350 
The Danish NCA – The Danish Medicines Agency ....................................... 350 
US 350 
 
 
21 
 
 
 
 
List of tables and figures 
 
Table 1 ..................................................................................................................... 96 
Table 2 ................................................................................................................... 146 
Table 3 ................................................................................................................... 186 
 
Figure 1 .................................................................................................................... 35 
Figure 2 .................................................................................................................... 53 
Figure 3 .................................................................................................................... 79 
Figure 4 .................................................................................................................. 111 
Figure 5 .................................................................................................................. 148 
Figure 6 .................................................................................................................. 156 
Figure 7 .................................................................................................................. 156 
Figure 8 .................................................................................................................. 168 
 
 
 
 
 
 
 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
 
 
 
Part I: Introduction 
  
 
 
 
 
 
 
 
 
Part  IV  (Evaluation & Conclusions)   
Chapter 8 Are the social objectives of  
public health and consumer protection met? 
Chapter 9 Conclusion 
Part III  (Legal Analysis) 
Chapter 4 Analysis of Falsified 
Medicines Directive 
Chapter 5 Analysis of 
Enforcement Directive 
Chapter 6 Analysis of Customs 
Regulation Chapter 7 Global Initiatives 
Part II (Legal Case Studies) 
Chapter 3 Case Studies Operation Volcano Operation Singapore  Operation Robin 
Part I (Introduction) 
Chapter 1 Introduction Chapter 2 Legal Theories, Sources and Method 
25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part I consists of two chapters and lays down the foundation of the thesis. In the 
first chapter, the topic is introduced by providing the background, establishing the 
relevance and stating the objectives of the thesis. Next, the perspective of the 
thesis is indicated followed by delimitations of the areas that are relevant but are 
not addressed in the thesis. The first chapter ends with the structure of presentation 
of the thesis, which serves as a roadmap to the thesis, and provides the practical 
direction. Subsequently, in the second chapter of Part I, the theory of law that is 
considered and employed in the thesis is discussed, followed by the sources of law 
that are utilised in the legal analysis. Thereafter, the methods that are used in the 
various parts of the thesis are discussed. Thus, Part I provides the basis on which 
the rest of the thesis stands. 
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Chapter 1: Introduction 
 
 
 
 
1.1. Relevance 
Counterfeiting1 is not a new phenomenon; in fact, it has been known to exist for at 
least the past 2000 years. Pliny The Elder described counterfeit coins as popular 
collectors’ items for Romans.2 Counterfeiting existed then and it exists now, but 
the forms of counterfeiting have transformed and multiplied. All kinds of 
counterfeiting have a negative effect on economy, growth, jobs and innovation – 
be it counterfeiting of currency, wine, fine arts or of luxury goods. The latest 
survey conducted by the Organisation for Economic Co-operation and 
Development (OECD) & European Union Intellectual Property Office (EUIPO) 
reported that the global trade in fake goods was worth almost half a trillion dollars 
per year.3 Other more serious types of counterfeit products, including falsified 
1 Counterfeiting is commonly understood to mean – “to forge; to copy or imitate, without authority or right, and 
with a view to deceive or defraud, by passing the copy or tiling forged for that which is original or genuine.” See 
more in Black, H.C., Nolan, J.R., & Nolan-Haley, J.M. (1990). Black’s Law Dictionary.  (Sixth Edition). St. Paul, 
Minn. West Publishing Co. 349. 
2 Barry, K. (2007). Counterfeits and counterfeiters: The ancient world. In Chaudhry, P. E., & Zimmerman, A. 
(2009). The economics of counterfeit trade: governments, consumers, pirates and intellectual property rights. 
Springer Science & Business Media.7. 
3 OECD/EUIPO (2016), Trade in Counterfeit and Pirated Goods: Mapping the Economic Impact, OECD 
Publishing, Paris. It was estimated that the value of imported fake goods worldwide was estimated to be USD 461 
million in 2013, compared to the total imports in world trade at USD 17.9 trillion. It was also reported that up to 5% 
of goods imported into the European Union are fakes. 
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medicines, fake automobile spare-parts, and counterfeit toys have led to a large 
number of avoidable deaths across the globe.4  
Medicine counterfeiting also has a long history.5 Dioscorides, a Greek physician, 
pharmacologist and botanist wrote about the detection of counterfeit drugs in his 
‘Materia Medica’, in 40-90 A.D. The other Greco-Roman medical and natural 
history writers who have written about falsification of medicine include 
Theophrastus and Galen.6 In the nineteenth century, because of the rapid pace of 
technological and economic development, there was a parallel rise in production 
and distribution of counterfeit goods.7 In 1985, the World Health Organisation 
(WHO) recognised counterfeit medicines as a global problem.8 The exponential 
increase in worldwide trade of counterfeit goods has been noticed by the WHO,9 
the International Police Organisation (INTERPOL),10 and the academic circles.11  
In this thesis, the focus is on counterfeiting and falsification in the pharmaceutical 
sector of the EU as this can lead to life threatening incidents. The pharmaceutical 
sector is especially vulnerable and lucrative for the criminals. Firstly, with 
relatively little investment, it is possible to make huge profits. Also, the cost 
associated with the manufacturing of fake pills is negligible as compared to the 
profits that are made by the sale of each counterfeit pill. The International Institute 
4 The result of use of counterfeit medicines has resulted in death of patients around the world. Such deaths were 
reported, for instance, in the USA, Canada and New Zealand. Wertheimer, A. I., & Wang, P. G. (2012). Counterfeit 
Medicines: Policy, economics, and countermeasures (Vol. 1). ILM Publications. 75-76. 
5 See further in Stieb, E.W. (1966). Drug Adulteration: Detection and Control in the 19th century Britain, Madison, 
WI. The University of Wisconsin Press. 
6 See further in Stieb, E.W. (1966). Drug Adulteration: Detection and Control in the 19th century Britain, Madison, 
WI. The University of Wisconsin Press. 
7 Bate, R. (2008). Making a killing: the deadly implications of the counterfeit drug trade. AEI Press, Washington, 
D.C. 
8 World Health Organization (WHO). (2012). Substandard/spurious/falsely labelled/falsified/counterfeit medical 
products: report of the working group of member states. WHO. Geneva. 
9 ibid. 
10 INTERPOL. (2014). Operation Pangea VII report. INTERPOL, Lyon. 
11 Blackstone, E. A., Fuhr Jr, J. P., & Pociask, S. (2014). The health and economic effects of counterfeit 
drugs. American health & drug benefits, 7(4). 
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of Research against Counterfeit Medicine (IRACM) has reported that an 
investment of USD 1,000 generates USD 20,000 in the trafficking of heroin or a 
return of USD 43,000 for counterfeit cigarettes. However, with the investment of 
USD 1,000 in counterfeit pharmaceuticals, a return of USD 500,000 can be 
expected. In fact, the INTERPOL evaluates the annual turnover from 
pharmaceutical crime at USD 75 million.12 Secondly, counterfeiting in the 
pharmaceutical sector is attractive for the criminals, not only because of the 
relatively easy profits associated with counterfeiting but also due to the low 
probability of getting caught. Also, even if the counterfeiters are found, the 
penalty for counterfeiting of medicines is minimal as compared to other offences. 
In the EU, the average sentence for a pharmaceutical crime is less than three years 
in prison.13  
Another significant reason to thoroughly deal with counterfeiting of medicines is 
the fact that, contrary to popular belief, it is not only lifestyle drugs, such as 
weight loss tablets, erectile dysfunction medication, or steroids for muscle 
enhancement, but also life-saving medicines that are targeted by counterfeiters. 
The lifesaving medicines, such as cancer treatment medications, diabetes 
medicines, as well as equipment, remain in demand for a longer period of time and 
are highly essential medicines, and, therefore, they always tend to be consumed.14   
The rising numbers of counterfeit products in the pharmaceutical industry put the 
public health and safety at risk, as is evident from the rising number of counterfeit 
12 Office of Harmonisation in the Internal Market & Europol. (2015). Situation Report on Counterfeiting in the 
European Union – A joint project between Europol and the Office for Harmonization in the Internal Market. 11. 
13 In Slovakia, the penalty is three years and in Poland the prison sentence for pharma crime is currently only two 
years, as reported in the Office of Harmonisation in the Internal Market & EUROPOL.  See EUROPOL & OHIM. 
(2015). Situation Report on Counterfeiting in the European Union – A joint project between Europol and the Office 
for Harmonization in the Internal Market. 39. 
14 ibid., 13. 
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medicines all across the globe15 also reported by the INTERPOL in 2014,16 and 
the WHO in 2012.17 In 1985, the WHO recognised the public health issues 
connected with counterfeit medicines and by 2010, they had revealed that the 
global counterfeit market had a turnover of USD 75 billion.18 Recent estimates peg 
the global market share in counterfeit pharmaceuticals at USD 200 million, 
emphasising a 90% increase in the revenues since 2005.19 Moreover, in the EU, a 
recent study conducted on 5000 European citizens in five countries cast light on 
the fact that 5% of the consumers suspected that they had been at the receiving end 
of counterfeit prescription drugs, whereas 1% of the consumers were sure that they 
had actually received a counterfeit prescription medicine. This estimate implies 
that nearly 12.8 million consumers were at risk of consuming counterfeit 
medicines in these countries.20 
The issue of counterfeit medicine has been addressed in various fora. For instance, 
since the 1980s, a global congress on combatting counterfeiting and piracy was 
organised at the WHO21 by a public private partnership with representatives from 
the INTERPOL; World Customs Organisation (WCO); the World Intellectual 
Property Rights Organisation (WIPO); the International Chamber of Commerce/ 
Business Action to Stop Counterfeiting and Piracy (ICC /BASCAP Initiative); and 
the International Trademark Association (INTA).22 As will also become apparent 
15 Blackstone, E. A., Fuhr Jr, J. P., & Pociask, S. (2014). The health and economic effects of counterfeit 
drugs. American health & drug benefits, 7(4).  
16 INTERPOL (2014) Operation Pangea VII report, INTERPOL, Lyon. 
17 World Health Organization (WHO) (2012) Substandard/spurious/falsely labelled/falsified/ counterfeit medical 
products: report of the working group of Member States. WHO. Geneva. 
18 ibid. 
19 IRACM (2013) Counterfeit medicines and criminal organizations, IRACM, Paris. 
20 Jackson, G., Patel, S., & Khan, S. (2012). Assessing the problem of counterfeit medications in the United 
Kingdom. International journal of clinical practice, 66(3), 241-250. 
21 WHO. (2006). WHO launches task force to fight counterfeit drugs. In Bulletin of the World Health Organization, 
Volume 84, (9), September 2006. 685-764. 
22 The Global Congress on Combating Counterfeiting and Piracy, where business leaders, law enforcement officers, 
inter-governmental authorities and non-governmental organisations were represented to discuss vital questions 
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from the subsequent chapters, efforts have been made at international, regional, 
and national levels to counter this problem. However, the efforts have not proven 
to be adequate. 
In the EU, the regulation of pharmaceutical sector became stricter as an aftermath 
of the Thalidomide tragedy23 when the potential harm from inadequately regulated 
medicinal products was revealed. Thalidomide was a drug that was marketed 
under the trade-name Contergan in West Germany in 1957 and thereafter, was 
also marketed in Austria. This drug was prescribed to pregnant women to alleviate 
morning sickness and resulted in around 7,000 infants being born with a 
malformation of the limbs (phocomelia).24 Approximately 10,000 cases of infants 
born with phocomelia were reported around the world, and only 50% of these 
infants survived. Moreover, the surviving children lived with severe limb25 and 
other organ defects.26 This case led to stricter and more comprehensive regulation 
of medicines including over-the-counter (OTC) drugs. Consequently, in the 1960s 
and 1970s, safety and efficacy began to form the bedrock of authorisation criteria 
for medicines in Europe.27 There was the introduction of stricter liability standards 
at the national level,28 and also at the supranational level. At the EU level, Public 
Health Protection Guidelines were introduced in 1965 followed by 65/65/EEC 
rules regarding authorisation for drugs.29 In 1995, an independent EU agency, 
pertaining to counterfeiting, including the question about the evolving nature of counterfeiting and the impact on 
future of public health and safety. 23 Dally, A. (1998). Thalidomide: was the tragedy preventable? The Lancet, 351(9110). 1197-1199. 
24 McBride, W. G. (1961). Thalidomide and congenital abnormalities. The Lancet, 278(7216), 1358. 
25 Annas, G. J., & Elias, S. (1999). Thalidomide and the Titanic: reconstructing the technology tragedies of the 
twentieth century. American journal of public health, 89(1), 98-101. 
26 Koren, G., Pastuszak, A., & Ito, S. (1998). Drugs in pregnancy. New England Journal of Medicine, 338(16), 
1128-1137. 
27 Permanand, G. (2006). EU pharmaceutical regulation: the politics of policy-making. Manchester University 
Press. 
28 In the UK, The Medicines Act was introduced in 1968 and in West Germany, a new drug law was introduced in 
1961. 
29 Council Directive, 65/65/EEC, of 26 January 1965 on the approximation of provisions laid down by law, 
regulation or administrative action relating to proprietary medicinal products. OJ L 178, 17.07.2000. 1-16. 
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European Medicines Agency (EMEA) was established to oversee approvals of 
medicines and other related tasks.30 According to the European Commission, the 
EMEA’s establishment was a significant part of the overall strategy for the 
creation of a Single Market for pharmaceuticals. It was anticipated that the EMA 
would facilitate free movement within the Single Market.31 
However, despite being the most highly regulated sector at EU level, there is still 
no Single Market for pharmaceutical products in the EU, more than twenty years 
after the establishment of the EMA.32 This is due to the unique character of the 
pharmaceutical market and the nature of EU competences. Firstly, the 
pharmaceutical sector is atypical as compared to other sectors. This is because the 
patients are dependent on the doctors, as regards to prescription.33 The patients 
cannot usually purchase a prescription medicine as only OTC medications are 
available to consumers without a prescription. Secondly, the State is the largest 
purchaser of medicines and besides Defence sector, no other sector is financed to 
such a great extent by public expenditure as the pharmaceuticals. The interest of 
the State also lies in the fact that public health and safety is a State responsibility. 
Therefore, the high level of regulation in the pharmaceutical sector is not unusual 
due to the public health and safety being at stake. Also, the State has a key 
involvement in healthcare budgets, as well as social security measures. Therefore, 
three different angles are in constant attrition - public health issues of drug quality, 
safety and efficacy; healthcare perspective pertaining to financing and 
reimbursement; and industrial policy such as ensuring successful, competitive and 
productive pharmaceutical sector.  
30 Inauguration of the European Agency for the evaluation of Medicinal Products. (January  1995). Press release, 
DN: IP/95/64, 26, Brussels: Commission of the European Communities. CEC (IP 1995). 
31 ibid. 
32 Permanand, G. (2006). EU pharmaceutical regulation: the politics of policy-making. Manchester University 
Press. 
33 ibid. 
32 
 
                                           
 
 
 
EU derives its healthcare mandate from Article 168 of the (Treaty on the 
Functioning of the European Union) TFEU,34 which authorizes the EMA for 
deciding on the authorisation of new drugs. However, Article 168, TFEU also 
requires the EU to respect the responsibility of the Member States for the 
organisation and delivery of health services and medical care. The policy trade-off 
between community’s legal and policy frameworks is obvious.35 The friction 
between the principle of subsidiarity on the one hand, and free movement of 
goods, persons, services and capital of the Single Market, on the other, is evident. 
The principle of subsidiarity stipulates that the competence lies at the lowest level 
at which it can be effectively carried out.36 This allows the Member States to 
determine the healthcare policy and the pharmaceutical policy. However, the free 
movement of goods, services, people and capital treats the pharmaceutical 
products as industrial goods and in this way, the pharmaceutical products fall 
under the competence of the EU governing the Single Market. Consequently, the 
responsibility of the pharmaceutical policy is divided between the EU and the 
individual Member States. Due to the principle of subsidiarity and EU’s limited 
competence in this area, the harmonisation in the pharmaceutical sector has not 
been at the same rapid pace as in other sectors.37 
 
 
34 Consolidated version of the Treaty on the European Union and the Treaty on the Functioning of the European 
(TFEU), Union O. J. 2012, C - 326/13. 
35 Permanand, G. (2006). EU pharmaceutical regulation: the politics of policy-making. Manchester University 
Press. 
36 See Articles 4(2)(k) and 6(2) of the TFEU. 
37 Permanand, G. (2006). EU pharmaceutical regulation: the politics of policy-making. Manchester University 
Press. 
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1.2. Intersection of laws 
It is significant to indicate why the efforts made to fight against counterfeiting and 
falsifications of medicinal products seem to be inadequate and insufficient. The 
reasons that will be elaborated in the subsequent chapters, boil down to the fact 
that counterfeiting lies at the intersection of three different streams of law. Firstly, 
a large part of issues relating to counterfeiting of medicines concerns the 
Intellectual Property (IP) law area. For instance, a counterfeit or falsified medicine 
packaged in a manner aimed at imitating an authentic medicinal product would be 
counterfeit, as well as falsified, as provided for in the provisions of the 
Trademarks Directive (Directive 2015/2436/EU)38 and the Falsified Medicines 
Directive (Directive 2011/62/EU).39 Both the legal instruments concern the 
packaging of a product in addition to other provisions. Whereas the Falsified 
Medicines Directive concerns the packaging of a falsified medicinal product, the 
Trade Marks Directive relates to packaging of any product, which would also 
include medicinal products. Therefore, in the context of the counterfeiting and 
falsification of medicine, it is always more than an IP rights violation as the 
medicines sold in a false packaging are inevitably tampered with.40 In August 
2017, the Danish Medicines Agency reported a counterfeit product that was 
discovered in the legal supply chain, Xeplion150 mg, which is primarily used to 
treat schizophrenia.41 This report illustrates how the provisions of Medicine law 
38 See Article 10 and 11 of the Directive (EU) 2015/2436 of the European Parliament and of the Council of 16 
December 2015 to approximate the laws of the Member States relating to trade marks. OJ L 336, 23.12.2015, 1–2. 
39 See Article 1(1) (c), Directive, 2011/62/EU, of 8 June 2011 amending Directive 2001/83/EC on the Community 
code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain 
of falsified medicinal products. OJ L 174, 1.7.2011, 74–87. Henceforth, referred to as, ‘Directive 2011/62/EU’. 
40 An example is that of Herceptin, a cancer treatment drug being manufactured by Roche, which was intercepted in 
Germany in false packaging. It was later found out that the drug was manufactured in Italy, and was stolen from an 
Italian hospital and was tampered with and re-introduced in the legal supply chain. (See Chapter 3, Section 3.2., 
Operation Volcano). 
41 Danish Medicines Agency. (August 1, 2017). Withdrawal of one more batch of counterfeit packs of the 
schizophrenia medicine Xeplion 150 mg. Retrieved from  
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will usually find application besides IP law. 
 
Thus, the second stream of law that deals with the problem of counterfeiting is 
Medicine law. In the EU, it is specifically the Falsified Medicines Directive that 
deals with the issues of falsified medicine. The Falsified Medicines Directive 
primarily addresses the Medicine law aspect and does not address the IP law 
related to counterfeiting. This is also clearly stated in the preamble to the Falsified 
Medicines Directive.42 The line of demarcation between the Medicine law 
perception of a counterfeit medicinal product and the IP law perception of a 
counterfeit product is marked from the very name of the directive, which uses the 
term ‘falsified’ rather than ‘counterfeit’. The choice of ‘term’ is like opening a 
Pandora’s Box and will be shortly addressed in Section 1.6. 
 
Figure 1 
The third stream of law, besides IP and Medicine law that is related to 
counterfeiting and falsification is the Criminal law. The role of national and/or 
https://laegemiddelstyrelsen.dk/en/news/2017/withdrawal-of-one-more-batch-of-counterfeit-packs-of-the-
schizophrenia-medicine-xeplion-150-mg/ last accessed 8 August 2017. 
42 Recital 5, Directive 2011/62/EU. 
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transnational organised crime has been established in the counterfeiting of 
medicines43  and the harmonisation of criminal measures for counterfeiting has 
been discussed at various fora in the EU as well as at international level. A 
directive on criminal measures aimed at ensuring the enforcement of intellectual 
property right (popularly known as (IPRED II)44 was proposed in 2005, but was 
later withdrawn. Also, Anti–Counterfeiting Trade Agreement (ACTA)45, which 
contained provisions of criminal measures against acts of counterfeiting, failed. In 
2011, the Medicrime Convention was proposed by the Council of Europe and has 
been signed by many and ratified by at least four Member States by June 2017.46 
The Medicrime Convention’s primary contribution is the criminalisation of the act 
of counterfeiting of medicines.47 Therefore, it contains measures that should be 
adopted to criminalise the act of counterfeiting of medicines and other related 
crimes.48 
 
The intersection of the three different streams of law has proved to be problematic 
as the issue of counterfeit and falsified medicine is dealt with under different types 
of law, depending on where the problem is detected at first. If the medicines 
authorities detect the issue, the Medicines law is applied and if the customs 
authorities discover the problem, the IP law is activated. If the proprietor of a trade 
marks becomes acquainted with the violation first, then the proprietor would 
report the case to the police authorities and Criminal law may be applied.  
43 See Chapter 3, Section 3.5.2., for more details. Also see in Chapter 3, Section 3.2. Operation Volcano, the 
legitimate medicines were stolen from a truck supplying medicines to an Italian hospital by organized criminals, 
which were later tampered with and re-introduced in the legal supply chain. See also Chapter 3, Section 3.4. is 
Operation Robin, where the organized structure of the criminal network was discovered. Similar examples have 
been witnessed in the United States as well.  
44 Proposed Directive on criminal measures aimed at ensuring the enforcement of intellectual property rights 
(2005/0127/COD) was aimed at supplementing the Directive 2004/48/EC.  
45 Anti-counterfeiting Trade Agreement, 2011. 
46 The Medicrime Convention has been ratified by Albania, Armenia, Belgium, France, Hungary, Spain, Moldova, 
Ukraine from amongst the Members of the Council of Europe. (Status as of 14.7.2017). 
47 See discussion in Section 7.2. 
48 ibid.  
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Theoretically, it should not be difficult to earmark the areas that should be dealt 
with, under a particular type of law. However, in practice, it has been challenging 
because it is yet to be recognised that counterfeiting and falsification of medicines 
are two sides of the same coin. Any act of falsification of medicines essentially 
involves an act of counterfeiting, and hence, is a violation of IP laws, as well.  
Therefore, it is neither prudent nor expedient to divide the responsibilities of the 
authorities representing the different streams of law into mutually exclusive 
watertight compartments.  
As a result of the fact that counterfeiting and falsification of medicinal products 
lies at the intersection of laws, and this context is not taken into consideration 
while dealing with the cases of counterfeiting and falsification of medicinal 
products, on the one hand, there is a risk that the right holders or the aggrieved 
patient’s complaints fail to be addressed. On the other hand, the people engaging 
in counterfeiting and falsification of medicinal products are able to take advantage 
of the state of the legal framework in the EU.  
This also creates practical institutional problems for the health regulators, customs 
authorities and enforcement officers as it leads to the cases vacillating between the 
different authorities, due to lack of clarity pertaining to what constitutes purely 
‘falsification’ of a medicinal product and what entails ‘counterfeiting’ of a 
medicinal product. Therefore, the authority that would lead the investigation of a 
case is not always clear. For instance, in Operation Volcano,49 the Italian 
Medicines Agency led the Operation whereas, in Sweden, in the case of Operation 
Robin,50 it was the Swedish Customs and Law Enforcement Authority that steered 
the operation. This problem of lack of clarity regarding the institution responsible 
for dealing with the crime and other institutions’ coordination does create 
49 See Chapter 3, Section 3.2. 
50 See Chapter 3, Section 3.4. 
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obstructions for an effective enforcement of the law concerning the counterfeit and 
falsified medicines. 
 
1.3. Objectives of the thesis 
In this thesis, a holistic picture of the problem concerning regulation of counterfeit 
and falsified medicinal products51 in the EU is presented. In the thesis, the legal 
framework dealing with counterfeit and falsified medicines is outlined in the 
beginning. This is followed by an illustration of the practical manner in which 
counterfeiting and falsification occurs in the pharmaceutical sector in the EU 
through three case studies. The relevant legal instruments are thereafter, analysed 
tin the light of the case studies. Thereafter, the extent to which legal instruments 
are successful in meeting the social objectives of public health and consumer 
protection of the TFEU is assessed.  
The thesis asserts that counterfeiting and falsification of medicines lie at the 
intersection of Medicine law, Intellectual Property law and Criminal law. In the 
EU, the falsification of medicinal products is governed by the Falsified Medicines 
Directive (Directive 2011/62/EU) and counterfeit medicinal products are dealt 
with under IP law (Directive 2004/48/EC and Regulation 608/2013). However, the 
Criminal law aspect is not harmonised in the EU as yet.  
In the light of the above, the primary objectives of the thesis are: 
51 A medicinal product is understood, as defined in Article 1 (2) of Directive 2001/83/EC, to mean any substance or 
combination of substances that have the properties for treatment or prevention of disease in human beings. The 
definition of a medicinal product also includes any substance or a combination thereof that may be employed in 
administering the substances with the goal of restoring, correcting, or modifying physiological functions.  
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1. To analyse how counterfeiting and falsification of medicinal products is 
addressed by the law (Directive 2011/62/EU, Directive 2004/48/EC, and 
Regulation 608/2013) in the EU (de lege lata). 
2. To analyse whether the law containing tools to combat counterfeiting and 
falsification of medicinal products meets the social objectives of public health 
(Articles 9 and 168, TFEU) and consumer protection (Articles 12 and 169,TFEU) 
as envisaged by the Treaty on the Functioning of the European Union. 
In the thesis, the measures against falsification and counterfeiting of medicines are 
identified in three different legal instruments in the EU - the Directive 2011/62/EU 
(Falsified Medicines Directive, henceforth, referred to as, ‘the FMD’),52 Directive 
2004/48/EC (henceforth, referred to as, ‘the Enforcement Directive’)53 and 
Regulation (EU) No. 608/2013 (henceforth, referred to as, ‘the Customs 
Regulation’).54 The FMD addresses the regulation of health and medicinal law 
with respect to prevention of entry of falsified medicines in the EU. It makes a 
distinction between ‘counterfeit medicines’ and ‘falsified medicine’ and the focus 
is entirely on the ‘falsified medicines’. The FMD contains specific measures that 
aim at securing the legal supply chain in the pharmaceutical sector in the EU.  
The Enforcement Directive and the Customs Regulation primarily address the 
aspects related to IP law. It also contains some important general anti-
counterfeiting measures that find application in the pharmaceutical sector, 
especially when the violation is IP related, such as false packaging. In addition to 
the FMD and the Enforcement Directive, the Customs regulation also contains 
important anti-counterfeiting measures. The Customs Regulation is especially 
52 Directive 2011/62/EU. 
53 Directive 2004/48/EC of the European Parliament and of the Council of 29 April 2004 on the enforcement of 
intellectual property rights OJ L 157, 30.4.2004. 
54 Regulation, 608/2013/EU, of 12 June 2013 concerning customs enforcement of intellectual property rights and 
repealing Council Regulation (EC) No 1383/2003. OJ L 181, 29.6.2013, 15–34.  
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activated when the counterfeit medicines or counterfeit APIs are imported from 
other countries.  
The research objectives indicate that the focus of the thesis is exclusively in the 
context of the European Union. Contrary to the popular belief that counterfeit 
medicine is mostly associated with Asia and Africa, it is illustrated in this thesis 
that counterfeit and falsified medicine also prevail in the EU. In fact, counterfeit 
and falsified medicines are widespread in the EU, and EU citizens are just as 
vulnerable as citizens in other parts of the world. Therefore, counterfeiting and 
falsification in the pharmaceutical industry in the EU needs to be addressed. While 
it may be true that the Asian and the African continents are more vulnerable55 to 
counterfeit and falsified medicines, the developed world – the US, the EU, and 
Australia are also susceptible. Many of the similar problems exist in the EU, 
though on a different scale. There are instances of the problem of sale of 
counterfeit medicine on the internet through parallel imports, illegal supply chain 
and infiltration of the legal supply chain also in the EU.  
 
1.4. Perspective 
The activity of falsification and counterfeiting of medicinal products has a far 
reaching impact. It affects the patients (access to safe, effective and good quality 
drugs), the pharmaceutical industry (manufacturing, research and development, 
innovation, etc.) and the State (public health and safety). The patients are directly 
55 From the perspective of developing countries, substandard medicine is better than no medicine. Due to poverty, 
there is demand for medicine in the black market. From the perspective of a poor person, it would make sense to get 
some medicine, which would be partly effective rather than have no access to medicine at all. Therefore, when 
there is more demand for medicines in the black market – it is extremely difficult to decipher whether the medicine 
that is being sold in the black market is substandard medicine; or illegal medicine by virtue of the illegal channel of 
sale, which has all the correct ingredients and is not typical counterfeit medicine; or adulterated medicine or ‘just 
falsely labelled’ medicine. 
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affected as they may become the victims of the falsification and counterfeiting of 
medicinal products. The patient community can stand to suffer direct loss, ranging 
from not being cured of the disease to building drug resistance to losing their life. 
The pharmaceutical industry also endures an economic loss because of 
falsification and counterfeiting of medicinal products especially the 
pharmaceutical companies that invest in innovation, Research & Development, 
run clinical trials, manufacture drugs and apply for authorisations and approvals.56 
The State also confronts challenges because of the falsification and counterfeiting 
of medicinal products, especially because the States have the responsibility of 
safeguarding public health and safety on the one hand, and need to assure safe, 
most cost effective medicines are delivered to the public, on the other hand. 
Therefore, each of these interest groups is affected by the falsification and 
counterfeiting of medicinal products and have a vested interest. Essentially, the 
patients would like safe and cost effective medicines to be available, while the 
pharmaceutical industry lobbies for a competitive business environment, with 
enough safeguards against counterfeit products that are a threat to their reputation 
and goodwill. The State needs to prioritise protection of public health and safety,57 
as well as ensure maintenance of affordable prices of the medicines for the 
common public. 
The perspective of each of the stakeholder group – patients, the pharmaceutical 
industry and the State– is significant. However, this is a legal thesis and the focus 
is on the legal instruments that are employed to combat the falsification and 
counterfeiting of medicinal products at the EU level. Therefore, the perspective of 
the concern of the State as regards maintenance of public health and safety is 
predominant in the thesis. The legal instruments, specifically, the FMD (Directive 
56 Permanand, G. (2006). EU pharmaceutical regulation the politics of policy-making. Manchester University Press. 
57 See Article 168, TFEU. 
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2011/62/EU), the Enforcement Directive (Directive 2004/48/EC) and the Customs 
Regulation (Regulation 608/2013) are analysed, which contain measures that 
provide tools to combat falsified and counterfeit medicines in the EU. 
 
1.5. Delimitation 
Counterfeiting and falsification in the pharmaceutical sector is a worldwide 
problem. However, this thesis concentrates on counterfeiting and falsification in 
the pharmaceutical sector in the EU. It needs to be recognised that falsification and 
counterfeiting of medicinal products has been accorded serious attention by law 
makers only in the past two decades in the EU. Therefore, the case law and 
scholarly works available on this subject are limited.  
An important element about counterfeiting, in general that also applies to 
counterfeiting in the pharmaceutical sector is the fact that counterfeiting is an 
illegal activity by nature. Therefore, it is difficult to accurately account for, for an 
activity, which is primarily conducted in the dark. Any statistics and figures that 
represent counterfeiting or falsification of medicinal products are, therefore, not 
exact. At best, these statistics can provide a rough estimate, and in all likelihood, 
the reality is larger and greater than what is visible in the statistics. Therefore, 
even though all the figures and statistics are gathered from reputable sources like 
the OECD; WHO; INTERPOL; and Europol, these must be used only as 
indicators.  
It is also important to specify that while exploring IP law, the focus is not on 
substantive law. Therefore the detailed provisions of, for instance, trade mark law, 
will not be addressed. An overview of the enforcement of IP law in the EU, 
particularly with respect to enforcement of trademarks, which is directly relevant 
to counterfeiting of medicines, will be explored.  
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As will become apparent, the act of counterfeiting and falsification of medicinal 
products is generally accompanied by associated crimes like money laundering, 
smuggling, theft, forgery of documents, fraud and IP violations.58 Even though the 
exploration of these associated crimes is relevant and important, in this thesis, the 
focus remains exclusively on the crime of counterfeiting and falsification of 
medicinal products. The accompanying crimes are mentioned but not explored 
further. 
It is also acknowledged that the thesis would have benefitted with a comparative 
analysis with another country, such as the US. However, a comparative analysis 
was not done as an in-depth analysis would also require an in-depth discussion on 
the legal framework existing in the US and the analysis of cases from that 
jurisdiction. Even though a few references have been made at relevant points, a 
thorough analysis has not been undertaken.  
Another important aspect that may have contributed would have been a discussion 
on the role of the private sector and other stakeholders in the fight against 
counterfeiting. However, other stakeholders’ role has been left out on purpose as 
the focus is primarily on the legal framework. It is recognised that in order to 
effectively control the problem of counterfeiting in the pharmaceutical sector, all 
stakeholders need to make a collective effort. There are instances where collective 
action against counterfeiting of medicine has been fruitful, such as Operation 
Pangea,59 wherein an annual initiative is taken by INTERPOL in collaboration 
with customs authorities, health regulators, and national police and private sector 
organisations of the countries involved. It is conducted for one week’s duration 
every year, when all the countries that participate in the operation conduct raids on 
58  See Section 3.3 and 3.4, Operation Singapore and Operation Robin for more details. 
59 INTERPOL. (2017). INTERPOL Operation Pangea Factsheet on Illicit goods and global health. COM/FS/2017-
03/GHS-01. 
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online sellers of counterfeit medicines.60  The stakeholders include not only the 
manufacturers of pharmaceutical products, but also innovators, patients, and 
consumers, in addition to many others. However, the primary focus in the thesis is 
on the legal framework dealing with falsification and counterfeiting in the 
pharmaceutical sector in the EU, and the private stakeholder initiatives are not 
addressed. 
In any discussion on counterfeiting in any sector, besides the legal framework, the 
policy and political discussions are equally vital. As this is a legal thesis, the 
political discussions have been left out of the scope of the thesis, even though, 
wherever it was deemed vital for the thesis, references have been made to policy 
issues, but are not discussed further.  
 
1.6. Terminology 
While considering counterfeiting in the pharmaceutical sector, a number of terms 
are employed in the academic literature. The most frequently used terms are 
‘counterfeit’61  ‘falsified’,62 ‘falsely labelled’,63 ‘substandard’,64 ‘spurious’65, 
60 Nine such operations have been conducted under the leadership of INTERPOL, so far. In addition to Operation 
Pangea, the INTERPOL also led the Operation Storm (Southeast Asia) and Operation Mamba (Eastern Africa) 
which aim to sell not only on illicit websites but also physical outlets, in order to disrupt transnational criminal 
networks involved in pharmaceutical crime. These operations underline the success of multidisciplinary 
enforcement action. See more at Operation Pangea, INTERPOL Factsheet on Illicit goods and global health.  See 
COM/FS/2017-03/GHS-01. 
61 TRIPS: Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Marrakesh 
Agreement Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197 (1994) 
[hereinafter TRIPS Agreement]. Footnote 14 to Article 51; See Council of Europe. (2011). Council of Europe 
convention on counterfeiting of medical products and similar crimes involving threats to public health. Strasbourg. 
Council of Europe. (Also known as the Medicrime Convention). Council of Europe Treaty Series. No.211. 
Henceforth, referred to as ‘the Medicrime Convention, 2011’; See also Definition of a counterfeit drug, US Food, 
Drug and Cosmetic Act, 21 U.S.C. 321 Section 201 (g) (2). 
62 Article 1 (1) (c), Directive 2011/62/EU. 
63 WHO. (2012). Substandard/spurious/falsely labelled/falsified/counterfeit medical products: report of the working 
group of member states. WHO, Geneva. 
64 ibid. 
65 ibid. 
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‘fake’66, ‘adulterated’67, ‘illicit’ and ‘illegal’. It is important to clarify the meaning 
and scope of the different terms in order to address the problem of counterfeiting 
and falsification in the pharmaceutical sector in the EU. Therefore, the different 
terms utilised are discussed in this section. 
The term ‘counterfeit’ in general, has been used for the goods that use an identical 
or confusingly similar trademark, without authorisation, either on the goods or on 
the packaging of goods, in a manner that rights of an authorised right holder are 
violated.68 This definition extends to all types of goods, including pharmaceutical 
products. This general understanding of the term distilled into the EU legal 
instruments from the TRIPS Agreement.69 It is evident in the application of the 
Enforcement Directive, Directive 2004/48/EC,70 as well as the Customs 
Regulation, Regulation 608/2013.71 However, specifically, ‘counterfeit medicine’ 
is not defined in the EU legal instruments, except for in the Preamble to the 
Falsified Medicines Directive and Directive 2011/62/EU, which states that 
counterfeit medicines are construed to be the medicines that are in violation of IP 
laws.72 The Medicrime Convention, which has been signed and ratified by a few 
Member States of the EU, has defined counterfeit medicine as a “…medicinal 
product with a false representation regarding identity and/or source”.73 This 
66 Isles, M. (2017). What’s in a word? Falsified/counterfeit/fake medicines–the definitions debate; Also see used by 
EMA, in public communications, for instance, European Commission. (2015). ‘Buying Medicines Online, Think 
you know what you are getting?’ Brussels. European Commission. 
67 Wertheimer, A. I., & Wang, P. G. (2012). Counterfeit medicines volume I: Policy, economics and 
countermeasures. ILM Publications. 114. 
68 TRIPS Agreement. Footnote 14 to Article 51. 
69 ibid. 
70 Directive 2004/48/EC of the European Parliament and of the Council of 29 April 2004 on the enforcement of 
intellectual property rights. 
71 Regulation, 608/2013/EU, of 12 June 2013 concerning customs enforcement of intellectual property rights and 
repealing Council Regulation (EC) No 1383/2003. OJ L 181, 29.6.2013, 15–34. 
72 Recitals 5 and 29, Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending 
Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the 
prevention of the entry into the legal supply chain of falsified medicinal products. Henceforth referred to as 
‘Directive 2011/62/EU’. 
73 Article 4 (j), The Medicrime Convention, 2011. 
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definition put forth by the Medicrime Convention is extremely close to the 
definition of a falsified medicinal product according to the Falsified Medicines 
Directive.74 
From the aforementioned, it can be deduced that usually the term counterfeiting is 
used in the context of IP Law, as reflected in the Enforcement Directive75 and the 
Customs Regulation76 in the EU. However, at times, counterfeit can also be 
employed in the context of medicines with a false representation regarding identity 
and/or source, as indicated in the Medicrime Convention.77 The understanding of 
counterfeit and falsified medicines gets complicated as the WHO continued to 
employ the term SSFFC (spurious, falsely labelled, falsified, and counterfeit)78 
until May 2017. In addition to ‘counterfeit’ and ‘falsified’, ‘spurious’ and ‘falsely 
labelled’ were introduced in the academic literature by this definition put forward 
by the WHO. However, in the latest policy document, distinctions have been made 
between substandard, unregistered/unlicensed, and falsified medicinal products. 
The move to do away with SSFFC definition and use only substandard and 
falsified as the terms of reference have been approved by the World Health 
Assembly in May 2017.79 While spurious, falsely labelled and falsified medicines 
can be encompassed under the umbrella of falsified medicines and be addressed by 
Medicines Law, ‘counterfeit medicines’ will usually fall under the umbrella of IP 
law, have been left out of the scope by the WHO, since the WHO only looks at the 
public health implications of medicinal products. 
74 Article 1 (1) (c), Directive 2011/62/EU. 
75 Directive 2004/48/EC. 
76 Regulation 608/2013. 
77Article 4 (j), The Medicrime Convention, 2011. 
78 WHO. (2012). Substandard/spurious/falsely labelled/falsified/counterfeit medical products: report of the working 
group of Member States. WHO, Geneva. 
79 WHO. (2012). Appendix 3, WHO Member State Mechanism on substandard/ spurious/ falsely labelled/ 
counterfeit (SSFFC) medical products working definitions. WHO. Geneva. 
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Besides the WHO (until May 2017), the Medicrime Convention, there are other 
international organisations that use the term ‘counterfeit medicine’ for what is 
known as ‘falsified medicine’ in the EU, such as the IRACM.80 Even the 
pharmaceutical companies prefer the general term ‘counterfeit medicine’.81 In 
addition, many other countries also still use the term ‘counterfeit medicine’, which 
the EU now calls ‘falsified medicines’. For instance, the US Food and Drug 
Administration (FDA) uses the term ‘counterfeit medicine’ and not ‘falsified’ 
medicine. In fact, counterfeit medicine is defined as a fake medicine, which may 
be contaminated or contain the wrong dosage, and could be illegal.82 The term 
‘fake’ medicine is also used in the awareness raising campaigns conducted in the 
EU. The European Commission produced awareness raising material83 regarding 
the new EU logo that is required to be affixed by all legitimate websites offering 
medicines for sale over the internet in the EU. Herein, the terms that are used 
include ‘fake medicine’, ‘false medicine’, and illegal medicine’.84 The term ‘fake’ 
medicine is used by the US FDA to refer to ‘counterfeit’ medicines and in the EU, 
the term fake medicine is used to denote ‘false medicine’ that does not contain the 
active ingredient that is required in the medicinal product; or may contain harmful 
or fatal substances.85 Thus, the confusion regarding the most appropriate term 
continues amongst the regulatory authorities, where a counterfeit medicine can be 
understood as fake medicine or falsified medicine.  
80 IRACM. (2013). Counterfeit medicines and criminal organisations, IRACM, PARIS. 
81  See Sanofi. (May 2017). The fight against counterfeit medicines. Press Book. Sanofi; See also Roche. (April 
2011, reviewed April 2017). Position paper – Roche position on counterfeiting.  1-7. 
82 U.S. Food & Drug Administration. (2016). Counterfeit Medicine, US Food & Drug Administration. Silver 
Spring. Human Drug Information.  
83 European Commission. (2015). ‘Buying Medicines Online, Think you know what you are getting?’ Brussels. 
European Commission. 
84 ibid.  
85 ibid. 
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In addition to the above, term ‘substandard’ medicine is also used in academic 
literature,86 and also by the WHO.87  A substandard medicine, also known as ‘out 
of specification’ (OOS) products, is perceived to be the medicine, which is an 
original product manufactured by an authorised manufacturer but may not live up 
to the requirements of the National Medicines Regulatory Authority. A 
substandard drug is no less dangerous than a falsified medicine.88 Another term 
that is frequently used in academic literature and is sometimes confused with 
counterfeit/falsified medicines is ‘adulterated’ medicines. An adulterated medicine 
is the one wherein the composition of the medicine is altered by the deliberate 
addition of a component that is not ordinarily a part of that substance, which 
usually leads to the debasement of that substance.89 
There are two umbrella terms that are also commonly used in the context of 
counterfeit and falsified medicines, which are ‘illicit medicines’ and ‘illegal 
medicines’. Usually, these medicines may or may not be medicines that are 
authentic but appear in the illegal supply chain. In other words, illegal and illicit90 
medicines refer more to the channel of trade rather than the quality of the 
medicinal product in question. However, these medicines can also be counterfeit 
and falsified. For instance, in the EU illegal medicine has been referred to as either 
counterfeit or fake medicine.91 
86 Attaran, A., Barry, D., Basheer, S., Bate, R., Benton, D., Chauvin, J.,  & Newton, P. N. (2012). How to achieve 
international action on falsified and substandard medicines. BMJ, 345, e7381. 
87 WHO. (2012). Appendix 3, WHO Member State Mechanism on substandard/ spurious/ falsely labelled/ 
counterfeit (SSFFC) medical products working definitions. WHO. Geneva. 
88 Johnston, A., & Holt, D. W. (2014). Substandard drugs: a potential crisis for public health. British Journal of 
Clinical Pharmacology, 78(2), 218–243.  
89 Miller-Keane. (2009). Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Revised 
Edition. London. Elsevier Health Science. Inc. 
90 UNDOC. (2016).Terminology and Information on Drugs, 3rd ed., Vienna. UNODC. 
91 European Commission. (2015). ‘Buying Medicines Online, Think you know what you are getting?’ Brussels. 
European Commission. 
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It is vital to indicate that authentic and original medicines can be found in the 
illegal supply chain. The reason for their appearance in the illegal supply chain is 
usually linked to lack of required authorisations and approvals because of the non-
fulfilment of requirements of the National Competent Authorities (NCA) 
provisions. Therefore, it will be incorrect to state that all illegal and illicit 
medicines are counterfeit medicines. Likewise, it needs to be reiterated that 
substandard drugs are not counterfeit drugs. They are authentic drugs, 
manufactured by authorised market authorisation holders. They are considered 
substandard because they do not meet the requirements of the NCAs.  
It is apparent from the foregoing discussion that clarification of the terminology 
that is used in the context of counterfeit and falsified medicines is significant. At 
the EU level, there is an apparent agreement that the IP law perspective of 
counterfeiting revolves around the enforcement of the private rights of the right 
holders of a trademark. In other words, the term counterfeiting indicates only IP 
violations and infringements,92 and the public health and safety aspect is not dealt 
with. For instance, as regards to the definition of ‘counterfeit goods’ in the 
Customs Regulation (Regulation 608/2013),93 the focus is on infringement of 
trademarks. 
On the other hand, whenever the term ‘falsified medicine’ is employed, the health 
and medicine law perspective comes into play, whereby the public law perspective 
of safeguarding public health and safety being the primary goal takes the centre 
stage. The Falsified Medicines Directive defines a falsified medicine and focuses 
on the identity, sources and history of the medicinal product. The Falsified 
92 As used in, for instance, Article 2(5), Regulation 608/2013; See also Recital 5 of Directive 2011/62/EU. 
93 Article 2 (5) Regulation 608/2013. 
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Medicines Directive clearly leaves out the IP law related aspects,94 because it 
differentiates between counterfeit medicine and falsified medicine.95  
When law and policy documents and academic literature use the terminology 
interchangeably, not only does it lead to confusion, but it also has bearing on how 
the authorities interpret a particular offence. The interpretation of the offence 
would subsequently determine the applicable law. Whether it would be IP law or 
Medicine law would depend upon the type of violation involved. For instance, if 
fake packaging material is intercepted – it is an IP infringement as it is a violation 
of the right holder’s right with respect to trademarks rights.96 However, the crucial 
link between IP violation and Medicines law violation is that a trademark 
violation, which is of the nature of the false packaging, is also a violation of the 
Falsified Medicines Directive, Article 1(1) (c).97 In this way, an IP violation 
related to pharmaceuticals is closely linked to Medicines law violation.   
For the purposes of this thesis, the terms falsified medicine will be used in the 
context of Falsified Medicines Directive and the term counterfeit medicine will be 
used in the context of the Enforcement Directive and Customs Regulation, as 
determined by the respective legal instruments.  
 
1.7. Structure of the thesis 
In the light of the legal case studies, the legal instruments providing tools to 
combat counterfeiting and falsification of medicines in the EU are analysed. This 
is followed by a chapter on global initiatives for the purpose of assessing the 
94 See Article 1(1) (c) Directive 2011/62/EU. 
95 Recital 5, preamble of Directive 2011/62/EU. 
96 See Articles 10 and 11, Directive (EU) 2015/2436. 
97 See Article 1(1) (c), Directive 2011/62/EU. 
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measures being undertaken at the international level. Thereafter, it is analysed 
whether the law governing counterfeiting and falsification of medicinal products 
meets the social objectives of public health and consumer protection as envisaged 
by the TFEU. 
To summarise (also see Figure 2), the thesis will be presented in the following 
manner: 
 
Part I (Introduction) 
Part I presents the relevance of the thesis, states the parameters and establishes that 
the thesis stands at the intersection of the IP law, Medicine law and Criminal law. 
The objectives of the thesis are presented and analysed to highlight the focus of 
the thesis. It also explains the philosophy of law that is used in the thesis – legal 
positivism. In consonance with the philosophy of law, the methods – legal 
dogmatic method and case studies method, used in the thesis are discussed. 
Thereafter, the relevant primary sources of law – the TEU, the TFEU and, the 
CFREU, and the secondary sources of law - Falsified Medicines Directive 
(Directive 2011/62/EU), Enforcement Directive (Directive 2004/48/EC) and 
Customs Regulation (Regulation 608/2013), are discussed with regard to their 
relevance, scope and application in context of the thesis.  
 
Part II (Legal case studies) 
Part II of the thesis illustrates the problem of counterfeiting and falsification of 
medicinal products. By setting the context and providing an insight into the real 
life examples through case law, the gaps in the legal framework dealing with 
counterfeiting in the EU emerge to the surface. Three operations are discussed in 
this regard – Operation Robin, Operation Singapore, and Operation Volcano. 
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These three operations highlight the problems associated with overlapping and 
intersection of IP law and Medicine law along with the lack of criminal sanctions 
and penalties. The common issues of concern are identified in Part II, such as the 
inability to keep the legal supply clear of infiltration by the illegal supply chain 
and insufficient control over the online sale of counterfeit medicine. 
 
Part III (Legal analysis) 
Part III of the thesis is divided into four chapters. In chapters 4, 5 and 6, the 
analysis of the legal instruments is conducted in the light of the issues identified in 
Chapter 3. In Chapter 4, an analysis of the Falsified Medicines Directive is 
conducted with focus on the legal supply chain, the online sale of medicines and 
the safety of the medicinal product. In Chapter 5, the Enforcement Directive is 
analysed with special focus on the provisions for enforcement of IP as well as 
those issues that have not been addressed. The Customs Regulation is analysed in 
Chapter 6, wherein the analysis of Customs Regulation is carried out with special 
reference to measures that may be taken by the authorities at the borders to prevent 
entry of counterfeit and falsified medicines. A chapter on global initiatives forms 
the last chapter of Part III that analyses how the problem of counterfeiting and 
falsification of medicinal products has been and is being tackled at the 
international level, with a focus on the Medicrime Convention, ACTA, and 
multilateral and bilateral agreements such as TPP, TTIP, RCEP.  
 
Part IV (Evaluation & Conclusion) 
Part IV of the thesis is divided into two chapters. In Chapter 8, it is analysed 
whether the law (Directive 2011/62/EU, Directive 2004/48/EC, and Regulation 
608/2013) providing tools to combat counterfeiting and falsification of medicinal 
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products in the EU meets the social objectives of public health (Article 9 and 168, 
TFEU) and consumer protection (Article 12 and 169, TFEU), as envisaged by the 
TFEU. This is followed by Chapter 9 that presents the summary and conclusion of 
the thesis.  
 
 
Figure 2 
 
  
Part  IV  (Evaluation & Conclusion)   
Chapter 8 Are the social objectives of  
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Chapter 9 Conclusion 
Part III  (Legal Analysis) 
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Chapter 3 Case Studies Operation Volcano Operation Singapore  Operation Robin 
Part I (Introduction) 
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Chapter 2: Legal Theory, Sources and Method 
 
 
 
 
 
 
 
2.1. Introduction 
This chapter explains the philosophy of law, which is employed, the legal method 
that is used and the sources of law consulted in order to deal with the primary 
issues raised in the thesis. The main objectives of the thesis are to analyse how 
counterfeiting and falsification of medicinal products are addressed by the law 
(Directive 2011/62/EU, Directive 2004/48/EC, and Regulation 608/2013) in the 
EU - de lege lata- and to analyse whether the law that provides tools to combat 
counterfeiting and falsification of medicinal products in the EU meets the social 
objectives of public health (Article 9 and 168) and consumer protection (Article 
12 and 169) of the Treaty on the Functioning of the European Union (TFEU). 
Essentially, the purpose of explaining the theoretical and methodological approach 
used in the thesis is to explain the scientific method used to arrive at the criteria 
for determining the valid law, and the interpretation of sources of law employed in 
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this thesis.98An analysis of the black letter law is conducted and how the law ‘is’ 
(de lege lata), is analysed as regards to measures dealing with counterfeiting and 
falsification of medicinal products in the EU. Thereafter, it is analysed if the law 
meets the social objectives of public health and consumer protection in the EU. 
 
2.2 Legal Theory - Legal Positivism and EU law 
A legal theory provides the philosophical basis and sets the relevant parameters 
for a body of academic work. In the EU, there are two main prevailing of legal 
theories that are employed – the theory of legal positivism and the theory of legal 
realism.99 The theory of legal realism believes the valid law to be the rule of courts 
or the State apparatus in general who establish the legal norm. Legal positivist 
such as Hans Kelsen, H.L.A. Hart and Tuoari, believe in the importance of 
measuring each legal instrument against a higher norm. This is contrary to the 
legal realists, like Ross,100 who directly look at the legal instrument and not 
beyond. The legal positivists believe in man-made laws and a higher norm that 
grants legitimacy to the lower norms.  
In the EU, the theory of legal positivism and the theory legal realism are the most 
commonly applied theories. In the context of this thesis, EU law is the focus of 
analysis, wherein three legal instruments belonging to the body of secondary 
legislation will be measured against ‘higher norms’ of public health and consumer 
protection, identified in the TFEU, which is the part of primary legislation. 
98 Nielsen, R. New European Legal Realism – New Problems, New Solutions? in Neergaard, U., & Nielsen, R. 
(Eds.). (2013). European Legal Method - towards a new European Legal Realism? Copenhagen. Jurist-og 
Økonomforbundets Forlag. 78-79. 
99 Nielsen, R. New European Legal Realism – New Problems, New Solutions? In Neergaard, U., & Nielsen, R. 
(Eds.). (2013). European Legal Method - towards a new European Legal Realism? Jurist-og Økonomforbundets 
Forlag.75. 
100 Ross, A. (1959). On law and justice. Berkeley. University of California Press. 
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Therefore, the theory of legal realism is inapplicable because it does not believe in 
the existence of a norm higher than the legal instrument in question.  
In this thesis, the guiding philosophy is that of legal positivism as the higher norm 
is perceived to be residing in the EU Treaties. The higher norm being that of 
public health and consumer protection as envisaged in the TFEU. In that light, the 
legal instruments are analysed at first and subsequently, they are assessed against 
the higher norm identified in the TFEU. In this thesis, EU law is the unit of 
analysis and in the EU, the valid law is recognised law as articulated in the 
primary and secondary legislations.  In the EU, the secondary legislation does not 
exist independently of the primary legislation. It is provided by law that the 
secondary legislation has to take cognisance of the primary legislation. In other 
words, the EU treaties house the higher norms. The theory of legal realism does 
not accord importance to a ‘highest norm’ over and above the legal instrument in 
consideration, as in legal positivism. It is important to clarify that in this thesis, 
legal cases are used in Chapter 3 as illustrations and for setting the context of the 
problem of counterfeiting and falsification of medicines, and not as ‘higher 
norms’. Therefore, the most suitable theory for this thesis is the theory of legal 
positivism. 
This is because legal positivism primarily focuses on ‘how the law is’. The legal 
positivists believed that ‘law is law’ and it should be upheld. The law is not 
interdependent on contemporary morals, ethics or religion.101 Therefore, a positive 
law can be unfair or unreasonable.102 The thesis is concerned with the analysis of 
the legal instruments (Directive 2011/62/EU, Directive 2004/48/EC, and 
101 As perceived in the theory Natural Law, Jens Evald og Sten Schaumburg-Müller, Retsfilosofi, retsvidenskab og 
retskildere, Kbhvn. 9. In Tvarnø, C.D. & Nielsen, R. (2014). Retskilder & Retsteorier. 4. Reviderede udgave. Jurist 
–og Økonomforbundets Forlag. 389. 
102 Tvarnø, C. D., Nielsen, R.. (2014) Retskilder & Retsteorier. 4. Reviderede Udgave, Kbhvn Jurist- og 
Økonomforbundets Forlag. 390. 
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Regulation 608/2013) that contain provisions, which are used to combat 
counterfeiting and falsification of medicines in the EU. The legal analysis of ‘how 
the law is’, being guided by the philosophy of legal positivism is the core of the 
legal analysis of the thesis, discussed in Chapters 4, 5, 6 and 7.   
This school of thought has a long history that can be traced back to the nineteenth 
century to thinkers like Jeremy Bentham (1784-1832) and John Austin (1790-
1869).103 Hans Kelsen and H.L.A. Hart104 were the most well-known figures in the 
20th century and are the pillars of classical legal positivism. Kelsen was a monoist 
and believed that a legal order can be defined as a plurality of general and 
individual norms, which would constitute a unity if all those norms conformed to a 
single basis of validity.105 Regarding the validity of norms, Kelsen claimed that a 
high norm served as a basis of validity for a lower norm. Kelsen believed that all 
law can be traced back to a basic norm, i.e. a constitution in a nation state. 
Moreover, all legal norms needed to be in tune with the basic norm and if it were 
so, it would be a valid law. This belief fits well with the way EU law is 
interpreted, as is the case in this thesis, where three EU legal instruments are 
analysed. In this thesis, Kelsens’ brand of legal positivism is utilised, where the 
valid law is recognised as the law made by a recognised law making the body and 
can be traced back to one basic norm. 
Kelsens’ norm approach has been further developed in the 21st century by Tuori, 
who has developed legal positivism into critical legal positivism,106 wherein law is 
seen as having two sides. On the one hand, the law is considered as a legal order, 
103 Nielsen, R. New European Legal Realism – New Problems, New Solutions? in Neergaard, U., & Nielsen, R. 
(Eds.). (2013). European Legal Method - towards a new European Legal Realism? Jurist-og Økonomforbundets 
Forlag. 81. 
104 Hart, H. L. (1994). The Concept of Law (with a postscript). Oxford, 21994, 238-276. 
105 Kelsen, H., Paulson, B. L., & Paulson, S. L. (1992). Introduction to the problems of legal theory. Oxford: 
Clarendon Press. 37. 
106 Kaarlo, T. (2002). Critical legal positivism. London, Routledge.; Tuori, K. (2016). Ratio and voluntas: the 
tension between reason and will in law. London. Routledge. 
57 
 
                                           
 
 
 
a symbolic normative being, comprising a set of norms and on the other hand, it is 
seen as a legal practice, consisting of a set of social practices.  These two 
phenomena of law continuously interplay.107 In critical legal positivism, it is 
believed that law is composed of three levels108 – the surface level of law, the 
legal culture and the deep structure of law.109 Moreover, the surface level is 
claimed to be in a perpetual state of flux,110 as a consequence of new regulations 
and new court decisions, as well as new articles and books by legal scholars. 
Therefore, on the surface, the changes are apparent and occur most frequently, but 
the legal culture takes more time to change while the deep structures of the law 
take the longest to transform and are the most stable part of the edifice of law.111 
Kaarlo Tuori maintained that the EU’s legal order was primarily concerned with 
laws and individual decision at the surface level. He accepted that fundamental 
rights, democracy and the rule of law could ultimately constitute a Union-wide 
deep structure but claimed that a legal structure and deep culture had not yet 
developed. This view was later challenged and explained in the joined cases C – 
402/05 and C – 415/05 Yassin Abdullah Kadi and others v Council.112 It was 
stated that Tuori’s layered model is not incompatible with pluralist perceptions of 
European law, where on the one hand the EU Treaties and law influence domestic 
law and vice versa. There is a shared common deep-rooted understanding of 
fundamental rights, rule of law and other such values that serve as a reference 
point for the entire community. 
107 ibid. 
108 See more in Tvarnø & Nielsen. (Forthcoming 2017). Retskilder & Retsteorier. Kbhvn Jurist- og 
Økonomforbundets Forlag. 22. 
109 See Kaarlo, T. (2002). Critical legal positivism. London, Routledge. 
110 Neergaard, U., Nielsen, R., & Roseberry, L. (2011). European Legal Method-Paradoxes and Revitalisation. 
Djøf/Jurist-og Økonomforbundet. 101. 
111 Kaarlo, T. (2002). Critical legal positivism. London, Routledge. 191-192 and 316-317. 
112 More in Case C – 465/07 Elgafaji v Staatssecretaris van Justitie; and Gráinne de Búrca. The Evolution of EU 
Human Rights Law.In Paul Craig and Gráinne de Búrca (Eds.). The Evolution of EU Law. (2011). 488-489. 
58 
 
                                           
 
 
 
In the thesis, the issue of counterfeiting and falsification of medicines has led to 
changes in laws occurring rapidly over the past seven years, especially in the field 
of Medicine law, wherein a new directive, several implementing regulations and 
guidelines giving effect to the directive have emerged.113 Consequently, the 
guiding theory of critical legal positivism, providing the parameters to explore 
(using the legal dogmatic method, discussed in Section 2.4.1.) the legal framework 
containing tools to combat counterfeiting and falsification of medicines in the EU, 
would be the most compatible choice for the thesis. 
 
2.3. Sources of Law 
2.3.1. Introduction 
The purpose of this section is to introduce the sources of law that have been 
utilised in this thesis. As established in Section 2.1, the valid law is identified 
according to the legal positivist approach to law. Hence, valid sources of law are 
the laws that have been adopted by a recognised law-making body, whether 
national, regional or international. As primarily EU sources of law are used in this 
thesis, the focus of this section will be on the EU sources. It must be stated at the 
outset that in the thesis, legal instruments from different streams of law are 
discussed. For instance, the legal instruments belong to the realm of Medicine law 
(Directive 2011/62/EU) and IP law (Directive 2004/48/EC and Regulation 
608/2013). One of the challenges of attempting an analysis addressing different 
fields of law is that the goals of each stream are essentially different. While the 
113 See Commission Delegated regulation (EU) 2016/161 of 2 October 2015; Commission Implementing Regulation 
(EU) No. 699/2014 of 24 June 2014. See more in Table 1 in Chapter 4, which lists out in detail. 
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sphere of Medicine law falls within the scope of the public law, the legal 
instruments protecting IP law enforce private rights. This basic difference between 
the legal instruments added to the complexity of the analysis. 
The genesis of EU lies against the backdrop of World War II and is based on 
international treaties entered by its Member States. Initially, the European Coal 
and Steel Community (ECSC)114 was formed in 1951. Thereafter, the Treaty of 
Rome (1957) led to the formation of the European Economic Community 
(EEC).115 The next big step towards the formation of the EU in its current form 
was the Treaty on the European Union at Maastricht116 in 1992, followed by the 
Reform Treaty of Lisbon that re-named the EC Treaty to the Treaty on the 
Functioning of the European Union117 (TFEU) in 2007, which subsequently came 
into force in 2009.  
 
The sources of law in the EU can be divided into two broad categories – the 
primary sources and the secondary sources. The primary sources of law include 
the Treaty on the European Union (TEU), the Treaty on the Functioning of the 
European Union (TFEU), the Charter of Fundamental Rights of the European 
Union (CFREU) and General Principles of Union Law. On the other hand, the 
secondary sources of EU law include international agreements and secondary 
legislations, which consist of regulations, directives and decisions. Besides these 
114 The European Coal and Steel Community (ECSC) consisted of six countries - Belgium, France, Germany, Italy, 
Luxembourg and the Netherlands. The main goal of the ECSC was to control coal and steel production. Treaty 
Establishing the European Coal and Steel Community. ( April 18, 1951). 261 U.N.T.S. 140 [hereinafter ECSC 
Treaty]. 
115 Treaty Establishing the European Economic Community. ( March 25, 1957). 298 U.N.T.S. 11. 
116 Streit, Manfred E., and Werner Mussler. (1995).The Economic Constitution of the European Community: From 
‘Rome’ to ‘Maastricht’. European Law Journal 1.1. 5-30. 
117 Consolidated versions of the Treaty on European Union and the Treaty on the Functioning of the European 
Union - Consolidated version of the Treaty on the Functioning of the European Union - Protocols - Annexes - 
Declarations annexed to the Final Act of the Intergovernmental Conference which adopted the Treaty of Lisbon, 
signed on 13 December 2007 - Tables of equivalences; OJ C 326, 26.10.2012, 1 – 390. 
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two main categories, the case law from the (Court of Justice of the European 
Union) CJEU is also another significant source of EU law.  
The preparatory works such as EU commission reports, proposals, 
communications, white papers, green papers, reports authorised by the EU bodies, 
and the reports of national agencies of the Member States are also a vital resource 
and provide supplementary information. In this thesis, the primary and secondary 
sources are supplemented by official preparatory reports and works.118    
 
2.3.2. Doctrine of the sources of law 
The doctrine of the sources of law is primarily used to arrive at the hierarchy of 
sources of law. The doctrine of sources of law applies to national law, EU law and 
also international law. In the context of globalisation, international law, in the 
form of treaties and agreements, has an impact and is incorporated at the regional 
level,119 for example, in EU law. It is translated or recognised in national laws, and 
therefore, clarity regarding sources of law is pertinent. Although the national, 
international and EU law have their own sources of law, they cannot be 
independent of each other. There is interaction and influence of one law on the 
other. Since in this thesis, the sources of law that are used, are primarily EU law 
sources, only the EU doctrine of sources of law is being discussed. 
In the EU, there is a distinct doctrine of sources of law. At the apex, lies the Treaty 
of the European Union120 (TEU) and the Treaty on the Functioning of the 
European Union (TFEU),121 which serve as the primary sources of law. In this 
118 See Appendix II for a detailed list of primary, secondary and preparatory works used in the thesis. 
119 The TRIPS Agreement has been recognised and implemented through the Enforcement Directive 2004/48/EC 
and further in the national legislations of the Member States. 
120 European Union. (1992) Treaty on European Union (Consolidated Version), Treaty of Maastricht, 7 February 
1992, OJ C 325, 24.12.2002, 5-32. Henceforth, referred to as ‘TEU’. 
121 Consolidated version of the Treaty on the Functioning of the European Union. O. J. 2012, C - 326/13. 
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thesis, specific emphasis is on the public health (Articles 9 and 168) and consumer 
protection (Articles 12 and 169) provisions of the TFEU. The Directives and 
Regulations form the second tier and are considered the secondary sources of law. 
In the thesis, two directives (Directive 2011/62/EU and Directive 2004/48/EC) and 
one regulation (Regulation 608/2013) are the units of legal analysis. In practice, it 
implies that the secondary sources must always abide by, and give precedence to 
the primary sources of law. Moreover, the directives and regulations must not be 
in conflict with the treaties.  
In the hierarchy of doctrine of sources of law for the EU, the Court of Justice of 
the European Union (CJEU) has asserted that the international treaties entered into 
by the EU and the customary law is to be considered above secondary EU law.122 
Therefore, it can be construed that the secondary law must be compatible with the 
international treaties and agreements entered by the EU.123  
 
2.3.3. Primary sources of law 
Broadly, the TEU and the TFEU form the legal bases of the European Union124 
and the foundation of the EU.125 These two treaties are complementary in nature 
Henceforth, referred to as ‘TFEU’. 
122 See Case: C -366/10, Air Transport Association of America and others v. Secretary of State for Energy and 
Climate Change (2011) E.C.R. I- 13755, paras 28-29 and 51-54. In this case the question was raised as to whether 
EU Directive including aviation activities (in context of the scheme for greenhouse gas emission allowance) trading 
within the Community, was consistent with International treaty law and customs. In this case, the CJEU listed out 
the requirements that needed to be fulfilled for an international treaty to take precedence over secondary EU law. It 
was further stated that the EU was bound by a treaty, which was sufficiently precise. 
123 See joined cases C 320/11, C330/11, C- 382/11 and C – 383/11, Digitalnet and Others (2011) E.C.R. I-00167, 
para.39. The cases were regarding payment of customs duties concerning the import of set-top boxes having a 
communication function from Korea to Bulgaria. The EU had entered into an international agreement regarding 
trade in information technology (ITA) and the CJEU held that EU Regulations regarding the classification of goods 
for the goal of settling the rate of customs applicable to those goods were to be understood in consonance with the 
international agreement. 
124 Article 1, TEU. See also Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a 
Commentary: Treaty on European Union: Treaty on the Functioning of the European Union. Hart.12. 
125 Article 1 (2), TFEU. See also Tsoukalis, L., & Emmanouilidis, J. A. (2011). The Delphic oracle on Europe: is 
there a future for the European Union? Oxford University Press. 
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and there is no explicit form of hierarchy and along with the CFREU, the three 
documents form the primary law of the EU.  
2.3.3.1 The Treaty of the European Union 
The TEU established the legal personality of the EU126 and created a legal order 
sui generis.127 It also states the common values of the Member States, such as 
respect for human dignity, freedom, democracy, equality, and the rule of law.128 
These values underline the self-conception of the Union, as well as underpin the 
obligations of Union and the Member States as regards to the common values.129 
Under Article 3, the aims of the Union are established wherein the primary goal of 
promotion of peace, common values and well-being of the people is paramount. 
The establishment of the area of freedom, security and justice emanates from this 
provision, whereby the right to free movement of persons within the Union is 
granted to every EU citizen. 
 
While considering the EU doctrine of the sources of law, it is vital to discuss the 
synergy between the EU law and the national laws of the Member States. There 
are two fundamental doctrines that steer the relationship between the EU law and 
national laws – the doctrine of supremacy and the doctrine of direct effect.130 
These two principles are essential and are the measures that facilitate the 
maintenance of uniformity in the EU. Also, the doctrine of supremacy primarily 
relates to the acknowledgement of the fact that the primary and secondary EU law 
takes precedence over national laws of the Member States.131 The doctrine of 
126 Article 47, TEU. 
127 Piris, J. C. (2011). The future of Europe: towards a two-speed EU? Cambridge University Press. 
128 Article 2, TEU. 
129 Biondi, Eecckhout, Ripley (Eds.). (2012). EU Law after Lisbon. Oxford. Oxford University Press. 
130 Articles 4 and 288, TFEU. 
131 See Cases: C-26/62, Van Gen den Loos v Nederlandse Administratie der Belastingen [1970]E.C.R. 1- The CJEU 
referred to the supremacy of the EU law over National laws of the Member States for the first time in this case. The 
CJEU held that “(…) … the Community constitutes a new legal order of international law for the benefit of which 
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direct effect implies that the provisions of the EU Treaty can have a direct effect 
on the Member States and the individuals can employ them.132 The primary 
purpose of establishing the supremacy of the EU law over the national law is to 
ensure uniformity in the EU. The doctrine of supremacy and the doctrine of direct 
effect have been accepted by the national courts, except in very rare incidents, 
when national courts challenged the doctrine of supremacy.133  
 
The TEU establishes the competences of the Union and the Member States under 
Article 4, where it is stated that the competences that are not conferred upon the 
Union by the Treaties, lie within the purview of Member States. In this manner, 
the basic State functions are protected and the respect for the unique national 
identity of the Member State is also maintained. The duty of sincere cooperation134 
is established by this provision, whereby the Union institutions are obliged to 
respect the fundamental interests of the Member States135 and the Member States 
are obliged the assist the Union.136 From this provision, flows the application of 
Union law in the domestic sphere, and is applicable in its entirety, otherwise 
known as the principle of ‘direct effect’. It has also been established that the 
Union law precedes national law.  
the states have limited their sovereign rights, albeit within limited fields, and the subjects of which comprise not 
only Member States, but also their nationals.. (…)” and C-6/64, Flaminio Costa v E.N.E.L. [1964] E.C.R. 585, 
when the doctrine of supremacy was firmly settled. 
132 See C 26/62, Van Gen den Loos, It was the landmark case wherein the principle of direct effect originated. It 
was held by the CJEU,”It follows from the foregoing considerations that, according to the spirit, the general 
scheme and the wording of the Treaty, Article 12 must be interpreted as producing direct effects and creating 
individual rights which national courts must protect.” 
133 In German case law in the Solange decision from 1974 and 1986(BVerfGE 37, 271 case no.2 BvL 52/71, case 
no: 2 BvR 197/83), the Maastricht decision in 1993 (BVerfGE 89, 155 case no: 2 BVR 2142 and 2 BvR 2159/92), 
and the Honeywell (BVerfGE 126.286, case no: 2 BVR 2661/06) decision in 2010. These decisions show that the 
German Constitutional Court has reserved the right to question the supremacy of the EU law over the German 
Constitution. 
134 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart. p.12. 
135 ibid. 
136 ECJ cases C -45/93 C v Spain (1994) ECR I- 935; C 40/92 C v UK (1994) ECR I - 989. 
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Article 5 of the TEU provides for limits of the competences of the Union. 
The limitations include the principle of conferral of competences137 and the 
principle of subsidiarity and proportionality. These principles are binding by 
Union law and are cumulative in nature whereby, application of all the principles 
is necessary. Therefore, these principles are applicable to all legal instruments in 
the EU since these are binding principles. For instance, the Falsified Medicines 
Directive (Directive 2011/62/EU) contains provisions on specific reference to 
Article 5, TEU. 
 
The principle of limited conferral implies that the Union may act in a limited 
manner and only in a manner so as to achieve the objective of the relevant 
provision. The aim of this provision is to avoid intrusion on the competences of 
the Member States while at the same time achieving the objectives. In other 
words, the EU is not endowed with powers to extend its competences and 
secondly, the EU is not bestowed with general law-making capacity.138 Every EU 
action needs to have one or more legal bases in the Treaties and is subject to 
judicial review.139The principle of conferral determines vertical (determination of 
the question whether the Union has the competence) as well as horizontal (if the 
Union has the competence, which institution may carry out the competences) 
bifurcation of competences.140 
 
The principle of subsidiarity is considered an ‘architectural principle in Europe’141 
137 Craig, P. P. (2009). Competence and member state autonomy: causality, consequence and legitimacy. 
138 Barnard, C., & De Baere, G. (2014). Towards a European social union: achievements and possibilities under the 
current EU constitutional framework. 6. 
139 Case C-658/11 Parliament v Council EU:C:2014:2025, para 43. 
140 See Case C-301/06 Ireland v Parliament and Council EU:C:2009:68, para 56. 
141 See resolution of the conference on ’Europe of the Regions of 19 October 1989. 
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and defined as a fundamental principle of the Union Law,142 whereby it is stated 
that a larger unit must not undertake a task that a smaller unit can successfully 
execute. In other words, there is a binding guideline on how competences are to be 
used. In specific subject areas like education (Article 165, para 4, TFEU), culture 
(Article 165, para 5, TFEU) and public health (Article 168, TFEU), which is the 
primary concern of the thesis, specific rules exist, which set limitation on the 
Union activities and the Union is relegated to play a supporting role and there is 
explicit exclusion of harmonisation of domestic laws in such cases.143 The 
principle of proportionality is one of the most significant general principles of 
Union law144 that states that the measures must be appropriate and necessary for 
the legitimate aim to be achieved. It relates to the type of measures that are used (a 
recommendation is preferable to a directive and a directive is preferable to a 
regulation) and the density of the content (replacing a measure by a statement of 
principles, a regulation by mere cooperation of the Member States).  
 
2.3.3.2. The Treaty on the Functioning of the European Union 
 
The Treaty on the Functioning of the European Union (TFEU), formed by the 
Reform Treaty of Lisbon 2007, substantiates and elaborates on the provisions of 
the TEU.145 It is an international treaty concluded by the Member States and 
therefore is recognised under Public International law and the Vienna Conventions 
on the Law of Treaties. One of the objectives of the thesis is to assess how far the 
legal instruments employed in the thesis are successful in meeting the objectives 
142 Article 5, para 3. TEU. 
143 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart. 37. 
144 Sauter, W. (2012-13). Proportionality in EU law: A Balancing Act? Cambridge Yearbook of European Legal 
Studies. 439. 
145 Article 1, TFEU. 
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of the public health as envisaged in Articles 9 and 168 of the TFEU and the aim of 
protection of consumers under Article 12 and 169. In order to conduct this 
assessment, the goals of public health and consumer protection, as conceived in 
the TFEU, need to be ascertained.146  
 
Counterfeit and falsified medicines have the potential to inflict direct harm on the 
consumers. Therefore, the Union has horizontal rules as well as specific rules on 
the protection of consumers and public health and safety in the TFEU. In addition 
to conducting this assessment, it is also important to assess the goals of the Single 
Market of free movement of goods, services, people and capital. The attainment147 
of these objectives is a recognised aim of all legal instruments in the EU, including 
the legal instruments being employed in the thesis.  
 
The concept of an internal market was conceived by the Commission (White 
Paper 1985),148 with the primary goal of doing away with trade barriers in product 
markets and formulation of policies that would encourage competition and bring 
about economic integration. The proposed Single Market Program (SMP) listed 
three main objectives – the removal of physical, technical and fiscal barriers.149 
The SMP developed over a period of time and exhibited consistent development. 
It began with the Maastricht Treaty, 1992; Action Plan 1997; formation of the 
Economic and Monetary Union, 1999; strategy for Europe’s Internal Market, 
1999; expansion of EU 2002; Internal Market Strategy 2003-2006; and expansion 
of the EU Membership, 2007 and developed into the concept that is now 
146 Hervey, T. K., & McHale, J. V. (2004). Health law and the European Union. Cambridge. Cambridge University 
Press. 
147 Craig, P. P. (2012). The stability, coordination and governance treaty: principle, politics and pragmatism; See 
also Mossialos, E. (2010). Health systems governance in Europe: the role of European Union law and policy. 
Cambridge University Press. 
148 Completing the Internal Market, COM (1985) 310 final. 
149 Completing the Internal Market, COM (1985) 310 final. 
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recognised and defined under Article 26 of the TFEU. The ultimate goal of the 
internal market is to achieve an overall integration and absence of barriers to intra-
EU trade.150 Even though the differences between the Member States are 
recognised in terms of legal systems, economic policies, the level of economic 
development, and cultural and historical diversity, Article 26 para. 1 stipulates the 
development of the internal market to achieve the overall goal of further 
integration.151 
 
The internal market as defined in Article 26 of the TFEU refers to the area without 
‘internal frontiers’ and where there is free movement of goods, services, capital 
and people.152 The four freedoms are extended to all EU citizens and are 
elucidated in the secondary legislation. For example, the free movement of goods 
is ensured in both the harmonised sectors as well as the non-harmonised sectors. 
The harmonised sectors are subject to common rules all over the EU, thereby 
providing predictable, common legal framework for facilitating free movement of 
goods, by virtue of shared competences between the Union and the Member 
States, under Article 4, TFEU and Article 3 (3) TEU. In non-harmonised sectors, 
such as healthcare, there is an absence of common rules in the EU as they fall 
under the purview of the Member States, under provisions of Article 4, TFEU and 
the EU plays a supporting and supplementary role, as envisaged in Article 6, 
TFEU.   
 
The competences regarding governing public health153 and consumer protection154 
150 ECJ Case 15/81 Gaston Schul (1982) ECR 1409;  See also Radaelli, C. M. (2007). Whither better regulation for 
the Lisbon agenda? Journal of European public policy, 14(2), 190-207.  
151 Gabel, M. J. (2009). Interests and integration: Market liberalization, public opinion, and European Union. 
University of Michigan Press. 
152 Article 26, para 2, TFEU. 
153 Article 168, Title XIV, Public Health (contribution of the Union to public health, ensuring a high level of 
protection) 
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are shared between the Union and the Member States as provided for in the Article 
4 para 2 lit k. TFEU (shared competences) and Article 6 para 2, TFEU 
(competence to support, coordinate or supplement). In other words, the Union 
does not have the authority to pursue its own health policies. While the Union has 
a supplementary role to the Member States,155 the EU can encourage and support 
cooperation between the Member States in the area of public health.  
 
One of the objectives of the thesis is to analyse whether the legal instruments 
containing provisions to combat counterfeiting and falsification of medicines in 
the EU meet the social objectives of public health (Articles 9 and 168, TFEU) and 
consumer protection (Article 12 and 169). 156 Therefore, it is imperative to explain 
the goals of Article 168, which is done in greater detail in Chapter 8.157 
 
Article 9 
Through Article 9 of the TFEU, human health has been included in the general 
horizontal health policy in addition to other basic qualities.158 Besides having an 
area of general health under its purview, there are also specific provisions dealing 
with protection of health and safety of workers.159 
 
 
 
154 Article 169, Consumer Protection, TFEU. 
155 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart. 679. 
156 See detailed analysis in Chapter 8. 
157 Chapter 8.  
158 See Article 9, TFEU which introduces a horizontal clause on social protection, whereby the Union is required to 
promote high level of employment, guarantee adequate social protection, fight against social exclusion, high level 
of education, training and protection of human health.  
159 Articles 153 para 1, 115, 36, 53 para 2, 62 TFEU. 
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Article 168 
Article 168, TFEU clarifies, specifies, and enlarges the competence of the Union 
in the public health sphere. The specific significance of public health is underlined 
by Article 168(1), wherein it is required that all Union policies and activities 
ensure a high level of protection of public health, while determining and 
implementing Union policies. This is required at the horizontal level and implies 
that public health concerns are to be ensured in all policies and activities and not 
just in health regulations.160  
 
Although Article 168 provides for the targets that must be achieved in the EU with 
respect to public health, there are some restrictions in achieving the goals. As 
explained above, public health is a shared competence between the Member States 
and the Union. While the Member States are the primary architects of their 
respective national healthcare systems and policies, the Union has a supporting 
role and steps in only when there is an aspect involving and affecting all Member 
States and it is deemed expedient to undertake steps at the Union level. Therefore, 
in the area of public health, the Union cannot formulate a Union health policy. 
Consequently, the effectiveness of Article 168 is difficult to assess in isolation. Its 
primary contribution is that secondary legislation needs to uphold the provisions 
of Article 168 and strive to attain the objectives. 
 
Article 169 
In addition to provisions of explicitly stating the importance of public health in the 
160 Cabezas, M. D. (2012). Current trend in pharmaceutical law in EU. Pharmaceuticals Policy and Law, 14(2-4), 
195-207. 
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TFEU, there are provisions related to protection of consumers161 that are also 
relevant for the thesis. The protection of the consumers against counterfeit and 
falsified medicines also falls under the goals of consumer protection. The TFEU 
also explicitly provides for consumer protection in Article 12, where it is 
introduced as a horizontal clause. In addition to Article 12, TFEU, the issue of 
consumer protection is also exclusively governed in Title XV, Article 169, TFEU. 
It provides for the promotion of interests of the consumers and that the Union shall 
contribute to the protection of the health, safety and economic interests of the 
consumers as well as promoting the right to information, education and to 
organize themselves in order to safeguard their interests.162 
 
Article 118 
The thesis analyses the provisions governing counterfeiting of medicines and in 
this regard employs the Enforcement Directive (Directive 2004/48/EC) and 
Customs Regulation (Regulation 608/2013). These two legal instruments deal with 
Intellectual Property Rights (IPRs). Also, Article 118 of the TFEU is important to 
consider because it provides for the protection of the IPRs in the context of the 
internal market.163 It states the European IPRs should be established for uniform 
protection of IPR in the EU. The protection of IP is recognised as a fundamental 
right in the CFREU, Article 17 (2). It is further acknowledged that success of the 
internal market is affected by the protection of IP164 because of its bearing on 
161 Micklitz, H. W., Reich, N., & Weatherill, S. (2004). EU Treaty revision and consumer protection. Journal of 
Consumer Policy, 27(4), 367-399. 
162 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart. 682. 
163 Hilty, R. M. (2004). Intellectual Property and the European Community's Internal Market Legislation-Copyright 
in the Internal Market-Harmonisation vs. Community Copyright Law. IIC-international review of intellectual 
property and competition law, 35(7), 760-775. 
164 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart. 569. 
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innovation and investment. Moreover, uniform Union-wide level of protection of 
IP was deemed important. Therefore, Article 118 is especially relevant while 
considering the protection of IP of the owners of pharmaceutical trademarks and 
patents that are violated because of counterfeiting and falsification of medicine. 
 
Article 288 (Legal acts) 
There are many legal instruments that may be used in the EU, such as Directives, 
Regulations, Decisions, Recommendations, Opinions, and Guidelines. 165 Article 
288, TFEU defines the different legal instruments that are utilized in the EU.166 An 
EU directive is a type of legislation that is aimed at the Member States. It is a 
legally binding instrument167 that sets out the objectives that need to be achieved 
by the Member States (normally in the preamble of the directive, in the form of 
recitals). In addition to the general goals of the directive, there are specific 
provisions that need to be integrated into the domestic legislation, which are 
usually written in the Articles of the directive. The Member States are required to 
transpose the provisions of the directive into their national legislation within a 
provided time frame, which is normally two years.168 The directives are commonly 
used to realise the goals of the free movement, free trade and competition. They 
165 Bast, J. (2012). New Categories of Acts after the Lisbon Reform: Dynamics of Parliamentarisation in EU 
Law. Common Market L. Rev., 49, 885; Best, E. (2007). Legislative procedures after Lisbon: fewer, simpler, 
clearer? Maastricht Journal of European and Comparative Law, 15(1), 85-96. 
166 A ‘Decision’ can be issued in the context of one or more parties, for example, an EU Member State or an 
individual company. A decision can be issued by a body such as the Commission and is directly applicable. An 
important feature of a decision is that it is binding only in the context of the parties that are involved and not in 
general on all Member States. Amongst the non-binding instruments, ‘Opinions’ and ‘Recommendations’ are the 
most frequently used. While an ‘Opinion’ allows the institutions to make statements in a non-binding manner and 
without imposing any legal obligations, it is usually issued by one of the main EU institutions, such as the 
Commission, the Council or the Parliament. Another important but non-binding legal instrument that is used is 
‘Recommendations’.  This type of instrument does not impose any legal obligations on the EU Member States. It is 
helpful because it allows sharing of practices that may have successfully worked in some Member States and the 
other Member States could benefit without encountering any legal consequences. 
167 Article 288, para 3 TFEU. 
168 Once the EU Directive is adopted and passed into EU law, it can have force of law, even when it has not been 
enacted into national legislation. 
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may also be utilized to establish common social policies and lay down minimum 
EU standards. In this thesis, the Falsified Medicines Directive (2011/62/EU) and 
the Enforcement Directive (2004/48/EC) are closely examined. 
 
Another legal instrument used in the EU to realise common goals is using a 
regulation.169 A regulation is understood to mean a legal act that becomes 
enforceable as soon as it comes into existence. In other words, a regulation is 
binding and does not need to be transposed into national law but simultaneously 
becomes enforceable in all Member States upon being approved as a law at the EU 
level. In this thesis, the subject of Customs Regulation (608/2013) will be 
analysed. 
 
2.3.3.3. Charter of Fundamental Rights of the European Union 
In the thesis, the legal instruments governing counterfeiting and falsification of 
medicines are analysed because of the serious consequences they can have on 
human life, causing serious illness, development of drug resistance or even 
death.170 In the light of these circumstances, it becomes imperative to underline 
the importance that is bestowed upon the right to life, and right to health in the 
CFREU.171 The CFREU was initially proclaimed in 2000 and became legally 
binding on the EU institutions and on national governments like the EU Treaties in 
2009 when the Treaty of Lisbon came into force.172 The CFREU combines the 
fundamental rights and freedoms, which are extended to each individual in the EU 
169 Article 288, para 2, TFEU. 
170 Mackey, T. K., & Liang, B. A. (2011). The global counterfeit drug trade: patient safety and public health 
risks. Journal of pharmaceutical sciences, 100(11), 4571- 4579. 
171 Kokott, J., & Sobotta, C. (2010). The Charter of Fundamental Rights of the European Union after Lisbon; 
Morano‐ Foadi, S., & Andreadakis, S. (2011). Reflections on the architecture of the EU after the Treaty of Lisbon: 
the European judicial approach to fundamental rights. European Law Journal, 17(5), 595-610. 
172 European Union. (2012). Charter of Fundamental Rights of the European Union. OJ C 326, 26.10.2012, 391-
407.  
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into a single document. These freedoms are entitled to Dignity, Freedoms, 
Equality, Solidarity, Citizen’s Rights and Justice. These rights emerged from the 
case law of the CJEU — the rights and freedoms as guaranteed in the European 
Convention on human rights and other rights and principles as enshrined in 
international instruments. The Charter is primarily addressed to the EU institutions 
and bodies and extends due respect to the principle of subsidiarity and to national 
authorities, while the national authorities implement EU law. The Charter applies 
only to the areas that are mentioned in the EU Treaties and does not have 
competence beyond the EU Treaties.  
 
Under Article 2 (1), the Right to life is guaranteed to all. Furthermore, under 
Article 35 of the CRFEU, everyone is entitled to right health care. Also, a 
horizontal provision is provided for to ensure a high level of human health 
protection in definition and implementation of all Union policies and activities.173 
It is vital to state that the CFREU also recognises the protection of IP as an 
important goal under Article 17(2), which is important because the thesis is 
addressing both IP law and Medicine law perspective. 
 
2.3.4. Secondary sources of law 
In this thesis, the focus is on the secondary sources of law, which must be 
interpreted in consonance with the primary sources of law174 and international 
agreements. As discussed in Chapter 1,175 the problem of counterfeiting and 
falsification in the pharmaceutical sector in the EU lies at the intersection of IP 
law, Medicines law and Criminal law, there is no one legal instrument that 
173 Lenaerts, K. (2012). Exploring the limits of the EU charter of fundamental rights. European Constitutional Law 
Review, 8(03), 375-403. 
174 See ECJ Case C-168/01 Bosal Holding (2003) ECR I 9409. 
175 Chapter 1, Section 1.2. 
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exclusively addresses the issue of counterfeit medicine. As health policy only has 
the broadest outlines in the Treaties, it has been necessary to pass a number of 
laws covering both health and Single Market aspects of the issue. The provisions 
are found in various legal instruments. The secondary legal instruments that are 
employed while dealing with the broad problem of counterfeiting in the EU are the 
Falsified Medicines Directive,176 the Enforcement Directive177, and the Customs 
Regulation.178 It also needs to be mentioned at the outset that each discussed legal 
instrument has its own purpose of origin, and the aim of one legal instrument may 
not necessarily be in consonance with the aim of another instrument. For instance, 
the primary objective of the Falsified Medicines Directive is to safeguard public 
health and safety by ensuring the authenticity of medicines. On the other hand, the 
Enforcement Directive aims at streamlining the protection of rights and interests 
of the IPR holders. Elimination of counterfeit and falsified medicine happens to be 
a common goal because interests intersect concerning the containment of the 
problem of counterfeit medicines. However, this may not always be the case. 
Therefore, it is vital to establish that the reasons as to why these legal instruments 
came into being, and what these instruments try to resolve, support or implement, 
which may not always be a common goal. 
 
2.3.4.1. The Falsified Medicines Directive (Directive 2011/62/EU) 
The FMD came into being as an amendment to the Medicines Directive (Directive 
2001/83/EC)179 in the light of an enormous increase in the number of falsified 
176 Directive 2011/62/EU.  
177 Directive 2004/48/EC.  
178 Regulation (EU) No. 608/2013. 
179 Directive 2001/83/EC, on the Community code relating to medicinal products for human use, as regards the 
prevention of the entry into the legal supply chain of falsified medicinal products. OJ L 311, 28.11.2001, p. 67. 
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pharmaceutical products entering the EU.180 The Medicines Directive was 
developed in 2001 to even out the disparities in the provisions relating to 
medicinal products between the Member States as it was having a direct impact on 
the functioning of the Single Market. It harmonised the Community code relating 
to medicinal products for human use in the EU. In tune with the primary sources 
of law concerning the maintenance of the sanctity of the Single Market and Public 
health concerns in Articles 168, 114, and 169 of the TFEU, Articles 4, 5, and 9 of 
the TEU and Article 2, 17, and 35 of the CFREU, the Falsified Medicines 
Directive, Directive 2011/62/EU181 forms the core legislation as regard to 
falsification of medicines in the EU. Due to the common concern for public health 
in the EU, and in accordance with the principle of subsidiarity and 
proportionality,182 it was deemed appropriate that the crucial nature of the matter 
of public health must be partially dealt with at the Union level, even though 
healthcare policies are generally left to the Member States.183 
 
Objectives and Scope 
The main objective of the FMD, as stated in Recital 33 of the FMD184 is to ensure 
that the Internal Market functions smoothly with respect to medicinal products and 
overall to combat falsification of medicines in the EU. The safety of the type of 
medicinal products that enter and are sold185 in the EU,186  take into consideration 
the risk profiles that threaten to disturb the flow of medicine in the internal market. 
In this regard, the FMD introduces safety features to be employed on the 
180 Recital 2, Directive 2011/62/EU; In 2011, 30 million counterfeit medicines were intercepted at EU borders, 
EFPIA, Stamping out Falsified Medicines, www.efpia.eu/topics/industry-economy/falsified-medicines, accessed 
April 2016. 
181 Directive 2011/62/EU.  
182 See Article 5, TEU. 
183 Taaffe, T. (2012). European Union has the falsified medicines directive. BMJ, 345, e8356. 
184 ibid. 
185 Recital 11, Directive 2011/62/EU. 
186 Recital 10, Directive 2011/62/EU. 
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medicinal products.187 The FMD aims to prevent falsified medicines from entering 
the legal supply chain and ensure that EU citizens are able to buy high-quality 
medicines through pharmacies across the EU and online through verifiable sources 
in the European Union.188  The FMD aims to overcome potential market 
distortions that might hamper competition in the internal market189 through its 
provisions concerning harmonised principles and guidelines for inspections of 
manufacturers and wholesale distributors of medicinal products.190  
 
Essentially, the FMD only deals with falsified medicines entering the legal supply 
chain and illegal supply chain, where the counterfeit and falsified medicines find a 
huge market is not governed by it.  However, this illegal supply chain is regulated 
by other provisions of the Medicines Directive (Directive 2001/83/EC).191 
Moreover, the FMD does not govern the impact on IPRs192 in any manner, which 
is categorically stated in the Preamble to the FMD. The FMD clearly underlines its 
focus on the ‘public health and safety’ perspective while dealing with falsified 
medicines. This line of demarcation is strong as the FMD does not use the term 
‘counterfeit’ but utilizes the term ‘falsified’ medicines’.193 The term falsified is 
defined so as to include any medicinal product with a false representation of 
identity, source, or history of the product.194 The FMD emphasizes that the term 
counterfeit medicine is used to indicate when a medicinal product does not uphold 
187 Bogaert, P. B. C., & Burton, C. (2015). The mysteries of the Falsified Medicines Directive-where is the logic on 
safety features. London: Script Regulatory Affairs, 1-3. 
188 Lavorgna, A. (2015). The online trade in counterfeit pharmaceuticals: new criminal opportunities, trends and 
challenges. European Journal of Criminology, 12(2), 226-241. 
189 Recital 18, Directive 2011/62/EU. 
190 See Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good 
manufacturing practice in respect of medicinal products for human use and investigational medicinal products for 
human use. 
191 Tremblay, M. (2013). Medicines counterfeiting is a complex problem: a review of key challenges across the 
supply chain. Current drug safety, 8(1), 43-55. 
192 Recital 29, Directive 2011/62/EU. 
193 See discussion on the term in Chapter 1 
194 Article 1 (3), Directive 2011/62/EU. 
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the IP laws. These situations could relate to an infringement of a trademark. As 
asserted in Chapter one,195 falsification of medicine inevitably leads to violation of 
an IP right, resulting in violations of medicine law and IP law. However, the issues 
relating to IP violations do not fall within the scope of the FMD. 
Relevance 
The FMD needs to be considered in this thesis as it is the FMD that sets out the 
rules and regulations pertaining to falsified medicinal products.196 As will become 
apparent, counterfeit medicines can be introduced at any point in the legal supply 
chain. For the purposes of understanding, the entire process can be divided into 
four stages. A falsified medicinal product can enter the supply chain at stage 1 
(when the active ingredient is imported, which can be a counterfeit and/or falsified 
ingredient), stage 2 (manufacturing stage, where counterfeit and/or falsified 
medicine can be injected into original packaging), stage 3 (distribution stage, 
where distributors can knowingly or unknowingly introduce counterfeit and/or 
falsified  medicines) or stage 4 (sale through pharmacies or online pharmacies or 
websites,197 when counterfeit and/or falsified medicines can be offered for sale). 
The FMD addresses each of these stages, where counterfeiting and falsification 
can occur.  
 
195 See Chapter 1, Section 1.2. 
196 Jones, G. (2014). The Falsified Medicines Directive: time to get it right. The Pharmaceutical Journal, 293, 
7832. 
197 Hall, A., & Antonopoulos, G. A. (2016). Introduction. In Fake Meds Online (1-17). Palgrave Macmillan UK. 
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Figure 3 
 
The FMD recognises its primary purpose, which is to harmonise and strengthen 
safety and control measures in Europe,198 in four specific areas — safety features 
of medicines, the supply chain199 including application of Good Distribution 
Practices (GDP) for active substances and excipients, and sale over the Internet. 
These areas encompass the entire life cycle of a medicine, from the time of 
conception (pre-manufacturing stage) to the last stage of sale by a retailer to a 
potential consumer. Therefore, the FMD is extremely relevant for the thesis as it 
especially came into being to address the issue of falsification of medicines in the 
EU. 
198 Naughton, B. D., Vadher, B., Smith, J., Smith, G., Chapman, S. R., Dopson, S., & Brindley, D. A. (2015). EU 
Falsified Medicines Directive mandatory requirements for secondary care: a concise review. Journal of Generic 
Medicines, 12(3-4), 95-101. 
199 Smith, G., Smith, J. A., & Brindley, D. A. (2014). The Falsified Medicines Directive: How to secure your supply 
chain. 
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2.3.4.2. The Enforcement Directive (Directive 2004/48/EC) 
 
Objectives and Scope 
Directive 2004/48/EC of the European Parliament and of the Council of 29 April 
2004 on the enforcement of intellectual property rights (also known as "IPR 
Enforcement Directive" or "IPRED") is a European Union directive in the field of 
IP law, made under the internal market provisions of the Treaty of Rome.200 A 
more efficient IP enforcement is a primary goal of the Enforcement Directive201 as 
it also ensures freedom of movement202 and eradication of distortions of 
competition. The goal of enforcement of IP is also in tune with provisions of Right 
to Property as mentioned in the Charter of Fundamental Rights of the European 
Union.203 In this regard, the protection of IP cannot be underestimated, especially 
with reference to the promotion of innovation and improvement of 
competitiveness.204 The type of covered IP rights include trademark rights, 
copyrights, sui generis right of a database maker, rights of the creator of the 
topographies of a semiconductor product, patent rights, including rights derived 
from supplementary protection certificates, geographical indicators, design rights, 
utility model rights, plant variety rights, trade names, in so far as these are 
protected as exclusive property rights in the Union law or in the concerned 
national law.205 
200 The Treaty of Rome, officially the Treaty establishing the European Economic Community (TEEC), is an 
international agreement that led to the founding of the European Economic Community (EEC) on 1 January 1958. 
It was signed on 25 March 1957 by Belgium, France, Italy, Luxembourg, the Netherlands and West Germany. 
201 See Recital 1, Directive 2004/48/EC. 
202 See Article 26, TFEU. 
203 See Article 17(2), CFREU and Recital 32, Directive 2004/48/EC. 
204 Ellard, D. (2004). The EU's IPR Enforcement directive: Origin, key provisions and future of the EU's IPR 
Enforcement Directive. Computer law review international, (3), 65-71. 
205 Statement by the Commission concerning Article 2 of Directive 2004/48/EC of the European Parliament and of 
the Council on the enforcement of intellectual property rights (2009/295/EC). 
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The scope of application of the Enforcement Directive,206 thus, extends to IP law 
and does not have a public health orientation. The scope of protection includes the 
IP rights mentioned in the previous paragraph. As it is a protection of private 
rights, the goals are in consonance with the nature of private rights, which can be 
asserted by the right holder or a representative of the right holder.  
 
The Enforcement Directive seeks to achieve an internal market, where IP is not 
only protected but is part of facilitating an environment207 that is conducive for 
investment and innovation, coupled with developing employment and improving 
competitiveness.208 The goals of encouraging innovation and investment in the 
internal market can be realised if the IPRs are effectively protected in the 
Community. Therefore, through the Enforcement Directive, it is anticipated that 
the disparities concerning substantive law on IP in the Member States can be 
minimized.209 
 
The objective of the Enforcement Directive210 is to approximate legislative 
systems with the aim to achieve an equivalent and homogeneous level of 
protection of IP in the internal market, as also indicated in Recital 10 of the 
Directive.211 This is in tune with the goals of the TFEU, particularly the goal of 
approximation of laws in Article 114.212 The overall goal is to provide justice by 
way of measures, procedures and remedies that are effective, proportionate and 
206 Cook, T. (2015). Enforcement Directive and Harmonization of Remedies for Intellectual Property Infringement 
in the EU. 
207 Massa, C. H., & Strowel, A. (2004). The scope of the proposed IP Enforcement Directive: torn between the 
desire to harmonise remedies and the need to combat piracy. 
208 Recitals 1-3, Directive 2004/48/EC. 
209 Recital 8, Directive 2004/48/EC. 
210 Kur, A. (2004). The Enforcement Directive-Rough Start, Happy Landing? IIC-international review of 
intellectual property and competition law, 35(7), 821-830. 
211 Recital 10, Directive 2004/48/EC. 
212 See Article 114, TFEU in consonance with Article 26 of TFEU. 
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dissuasive. The Directive, by way of the provisions, seeks to avoid creation of 
barriers to legitimate trade. 
 
Relevance 
The Enforcement Directive is relevant to the thesis as while addressing the 
problem of counterfeiting and falsification of medicines, IP law related issues 
pertain to counterfeit medicine, such as false packaging, which is usually related 
to trademark rights infringement. When IP rights are infringed due to 
counterfeiting, Enforcement Directive provisions assist in enforcing the rights 
through the provisions of civil measures, which are transposed into the national 
legislations.213 The Enforcement Directive is concerned with enforcement of all IP 
rights, including trademark rights. The Directive is not sector specific, therefore, 
the Enforcement Directive houses the anti-counterfeiting measures that need to be 
employed in order to deal with the problem of counterfeiting214 when it also 
concerns the pharmaceutical sector.215 Since the Enforcement Directive does not 
have the specific goal of protection of public health, it does not focus on the 
repercussions of falsified medicines on health and safety and only stresses on the 
enforcement of the private rights of the IP right holder. 
 
The Enforcement Directive addresses in specific terms, evidence-gathering powers 
of judicial authorities216 to force offenders or other parties commercially involved 
in an infringement matter for providing information on the origin of infringing 
213 Cook, T. (2015). Enforcement Directive and Harmonisation of Remedies for Intellectual Property Infringement 
in the EU. 
214 Kierkegaard, S. M. (2005). Taking a sledgehammer to crack the nut: The EU Enforcement Directive. Computer 
Law & Security Review, 21(6), 488-495. 
215 Shrivastava, S. R., Shrivastava, P. S., & Ramasamy, J. (2014). Public health measures to fight counterfeit 
medicine market. International journal of preventive medicine, 5(3). 
216 Article 9, Directive 2004/48/EC. 
82 
 
                                           
 
 
 
goods. It further contains provisions for dealing with the distribution networks, 
provisional and precautionary measures,217 for instance, measures like 
interlocutory injunctions,218 or seizure of suspected goods and corrective 
measures219 including permanent injunctions,220 recall and removal of infringing 
goods from trade channels. In addition, the Directive deals with powers to force 
offenders for paying damages.221 Also, it concerns itself with only civil measures. 
However, it does acknowledge that in addition to civil measures and 
administrative procedures, criminal measures can also be introduced in appropriate 
situations.222   
 
2.3.4.3. The Customs Regulation (Regulation 608/2013) 
 
Objectives and Scope 
The EU Regulation 608/2013,223 henceforth called the ‘Customs Regulation’, 
concerning customs enforcement of IPRs, bolsters and consolidates customs 
procedures pertaining to the enforcement of IP rights in Europe. The Regulation is 
a result of the Council Regulation No. 1383/2003 review, which was requested by 
the Council’s resolution of 25th September 2008 on a comprehensive European 
217 Article 9, Directive 2004/48/EC. 
218  See more in Black, H.C., Nolan, J.R., & Nolan-Haley, J.M. (1990). Black’s Law Dictionary.  (Sixth Edition). St. 
Paul, Minn. West Publishing Co. “An interlocutory injunction is an injunction that may be issued at any point in 
time during the pendency of the litigation for the short-term purpose of preventing irreparable injury to the 
petitioner prior to the time that the court will be in a position to with grant or deny permanent relief on the merits”. 
See more in Black, H.C., Nolan, J.R., & Nolan-Haley, J.M. (1990). Black’s Law Dictionary.  (Sixth Edition). St. 
Paul, Minn. West Publishing Co. 784. 
219 Article 10, Directive2004/48/EC. 
220 A court order prohibiting someone from doing some specific act or commanding someone to undo some wrong 
or injury. This type of injunction is intended to be in force until the end of the specific law suit. See more in Black, 
H.C., Nolan, J.R., & Nolan-Haley, J.M. (1990). Black’s Law Dictionary.  (Sixth Edition). St. Paul, Minn. West 
Publishing Co.784. 
221 Article 13, Directive 2004/48/EC. 
222 Recital 28, Directive 2004/48/EC. 
223 Regulation (EU) No. 608/2013.  
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anti-counterfeiting and anti-piracy plan224. The review of the previous regulation 
sheds light on the legal framework, which had to be strengthened in order to 
impart legal certainty and better enforcement of IPRs by customs 
authorities.225The Regulation came into existence to set out the conditions and 
procedures to be followed by the customs authorities when they come across 
suspect goods of infringing character.226  
 
The Regulation governs the customs enforcement of IPRs227 at the border in the 
EU. The customs authorities play a significant role at the borders228 in intercepting 
goods that are suspected to be infringing in nature. The customs authorities 
execute the crucial task of facilitating enforcement of IPR, deriving their authority 
from the EU primary legislation,229 further strengthened by the EU action plan.230 
The primary goals of the action plan are an improvement in customs control, 
improving cooperation between the different sectors like industry and the 
international partners, and bringing about greater awareness amongst the end users 
regarding the negative impact of the purchase of counterfeit goods. As is evident 
from the statistics, in 2014, the customs authorities intercepted 35.5 million 
articles with an overall total value of over € 617 million.231 The main purpose of 
the Customs Regulation, in its amended form, is to give the customs authorities 
teeth to bite, in order to take action against counterfeiters.  
224 Recital 1, Regulation (EU) No 608/2013.  
225 Recital 3, Regulation (EU) No 608/2013.  
226 De Meyer, C., & Gommers, C. (2013). The transit dilemma revisited: the new Customs Regulation and the 
legislative package on trade marks. Journal of Intellectual Property Law & Practice, 8(10), 771-775. 
227 Chaudhry, P. E. (2006). Changing levels of intellectual property rights protection for global firms: A synopsis of 
recent US and EU trade enforcement strategies. Business Horizons, 49(6), 463-472. 
228 Regulation 608/2013. 
229 See Articles 26, 114, 118, and 169 of the TFEU. 
230 Communication from the Commission to the European Parliament, the Council and the European economic and 
Social Committee 'Towards a renewed consensus on the enforcement of Intellectual Property Rights: An EU Action 
Plan', COM (2014) 392 final. 
231 European Commission. (27 October 2015). New report highlights crucial role of EU customs authorities in 
fighting against counterfeit goods. Brussels. European Commission. IP/15/ 5919. 
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It is also one of the goals of the Regulation to assist in keeping goods that can 
have a harmful impact on the health and safety of the EU citizens outside the EU 
borders.232 Hence, the Regulation also gives priority to protect public health, 
specifically, with reference to goods in transit233 when there is a risk their entering 
the internal market.  
 
The Customs Regulations234 has IP violations within its scope and has the 
perspective of IP law enforcement. The Regulation contains procedural rules to be 
applied by the Customs authorities in case a product violating the IP law is 
detected. However, the Regulation does not contain any criteria for determining 
the existence of an infringement of an IPR.235 Although, it is stated in the 
preamble that the protection of public health and safety is an important goal but it 
does not govern the pharmaceutical sector exclusively and is applicable to all 
sectors. 
 
Relevance 
The counterfeiting medicinal products enter the EU borders through various 
means – over land, by air and sometimes in the luggage of passengers as also 
indicated in the legal case studies discussed in chapter 3,236 which indicate that an 
international element is usually involved in counterfeiting in the pharmaceutical 
sector. The Customs Regulation is extremely relevant and important for the thesis 
as customs authorities have the potential to stop the counterfeit and falsified 
medicine at the point of arrival into the EU borders.  
232 Recital 2, Regulation 608/2013. 
233 Recital 11, Regulation 608/2013. 
234 Bently, L., & Sherman, B. (2014). Intellectual property law. Oxford University Press, USA. 
235 Recital 10, Regulation 608/2013. 
236 See Chapter 3. 
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The Regulation defines the key terms, such as ‘counterfeit goods’, ‘pirated goods’ 
and ‘goods suspected of infringing an IPR’.237 The definition of ‘counterfeit 
goods’ revolves around the violation of the trade mark and geographical indication 
of the product.  Further, ‘goods suspected of infringing an IPR’ entail goods, 
devices, products or components, moulds and matrix that may be manufactured for 
the purpose of aiding in infringement of IPRs.238 These definitions are relevant for 
the purposes of this thesis as they spell out the products that may be intercepted at 
the borders and are connected with falsification and counterfeiting of medicines. 
False labels, packaging materials, active substances, etc. would also be covered 
under these categories.239 
 
The process and possible actions that the customs authorities may take have been 
simplified and specified clearly. This measure has the objective of strengthening 
the customs seizure process. It also implies that most of the counterfeit and 
falsified goods arriving in Europe from other parts of the world can be destroyed 
by the customs authorities under certain conditions.240 The Regulation also grants 
wider powers to customs authorities for destroying small consignments of 
counterfeit or pirated goods, without the consent of the rights holders in certain 
specific situations.241 The Regulation aims at protecting the IPRs of the rights 
holders by preventing, combatting and addressing the various dimensions of 
counterfeit trade.  
237 Article 2, Regulation 608/2013. 
238 Article 2 (7), Regulation 608/2013 
239 Article 2, Regulation 608/2013. 
240 Martinet, B. (2014). European regulation strengthens IP protection. Risk Management, 61(7), 10-12. 
241 If the rights holder has given the permission in the application and the owner of the goods does not oppose in the 
stipulated timeframe, the customs authorities may destroy counterfeit/pirated goods without further processing or 
obtaining explicit consent from the owner of the goods or the rights holder. See Article 26, Regulation 608/2013 
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2.3.4. Interpretation of Sources of law 
All tools of interpretation can only serve as general guidelines for interpreting the 
law since the mindset of the interpreter is bound to have some influence on the 
interpretation.242 The context of interpretation, such as whether EU, International 
or national law is being employed can also have a bearing on the final 
interpretation. Despite the probability of these variations in interpretation of 
sources of law, there has been and still is a need to have some semblance of 
uniformity. Therefore, philosophers and scholars have attempted to develop 
certain tools for interpretation to serve this very purpose.  
 
2.3.4.1. Rules of Interpretation of sources of law - Vienna Convention  
In this thesis, the Rules of Interpretation stated in Vienna Convention on the Law 
of Treaties (VCLT) are applied243 as the EU treaties are international treaties that 
bind the Member States to a common purpose. The Rules of Interpretation are 
enshrined in Articles 31, 32 and 33 of the VCLT244 and serve as the tools of 
interpretation for these treaties. While Article 31 states the ‘general rules of 
interpretation’, Article 32 provides ‘supplementary means of interpretation’ and 
Article 33 provides rules regarding ‘interpretation of treaties authenticated in two 
or more languages’. Moreover, Article 31 emphasizes the importance of 
interpreting a treaty in good faith and in consonance with the objectives and 
purpose of the treaty. The preamble and annexures normally embody the purpose 
and objectives of a treaty and should be considered in addition to the main 
provisions of the treaty in question.245 Furthermore, any agreement, instrument or 
242 See Kelsen, Hans. (1992) Introduction to the Problems of Legal Theory (A translation of the First edition of 
Reine Rechtslehre 1934). Oxford. 77-89; Also see Ross, A. (1959). On law and justice. Berkeley. University of 
California Press.108-109. 
243 Vienna Convention on the Law of Treaties, 1969. Henceforth, referred to as ,‘VCLT’. 
244 ibid. 
245 Article 31 (2), VCLT, 1969. 
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subsequent agreement should be taken into consideration while interpreting the 
document.246 Article 31 embodies the classic tools of interpretation, which are 
grammatical interpretation, systematic interpretation and teleological methods of 
interpretation.247 Grammatical interpretation focuses on the import of the words of 
the text in question;248 on the other hand, systematic interpretation lays emphasis 
on the context of law while teleological interpretation stresses on the purpose of 
the law. In this thesis, these methods of interpretation are applied in the format 
described below. 
 
2.3.4.2. Travaux préparatoires  
The travaux préparatoires are considered in Article 32 of the VCLT, wherein it is 
stated that preparatory works should be resorted to, in case application of Article 
31 results in ambiguity of meaning while interpreting the law. It is relevant for the 
thesis as counterfeiting and falsification is an issue, which has been tackled by the 
law for a relatively short period of time. Therefore, it is important to refer to 
preparatory works for fully comprehending the intentions and the background 
behind the specific provisions in the legislation addressing the issues of 
counterfeiting and falsification of medicines. In the thesis, the White papers, green 
papers, public consultation reports, EU customs enforcement reports, WTO 
reports, OECD reports, and EUIPO reports have been employed as supporting 
materials. In the legal case studies, for one of the three operations reliance is 
placed in the White paper produced by the Medicines Agency in Italy.  Even 
though supplementary means of interpretation are pushed back to secondary status 
246 Article 31(2) and Article 31(3), VCLT, 1969. 
247 See von Savigny, F. C. (1847). System des heutigen römischen Rechts (Vol. 6). Veit. 206. 
248 Mankowski, P. (2012). Brussels I Regulation. Munich. 34-38. 
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in the interpretation, the preparatory works play a decisive role.249 It mirrors the 
historical method of interpretation, which is a classic tool of interpretation.250 It 
gives importance to the aims of the framers of the law as well as the history 
associated with the development of the law, which is usually found in the 
preparatory works. If there is a conflict between different language versions of a 
Treaty, Article 33 of the VCLT is applied. It states that when a treaty is in two or 
more languages, the text is considered equally authoritative in each language. If 
differences arise in interpretation, the resolution should be sought by taking into 
consideration the purpose and object of the treaty.251 In the EU, the secondary 
legislation, which is the focal point of analysis in the various instruments like 
directives and regulations are made in different languages of the Member States. 
As the Directives and Regulation that are considered have been developed over the 
past twenty years and some of the legal instruments are still developing, it is vital 
to consult the preparatory works like the White Papers and public consultation 
reports to fully gauge the intention and impact of the legal instruments in question. 
 
Usually, the interpretation of EU law commences with a black letter law analysis, 
where the way in which the legal text is worded (Article 31(1) of VCLT (ordinary 
meaning/grammatical interpretation)), is given prominence while interpreting the 
law. However, it is possible that at times, especially if the law is framed in many 
different languages, it becomes difficult to interpret the law. This is relevant in the 
context of the EU, where the law is framed in varied languages.252 A note of 
caution that is exercised while interpreting EU law is the fact that the EU law 
exists in different languages of the Member States and each language version 
249 Special Focus Issue, Rules of Interpretation (Article 32 of the Vienna Convention on the Law of Treaties), 
Makane Moîse Mbengue, ICSID Reviews, Vol. 31, No. 2 (2016), 388-412. 
250 See von Savigny, F. C. (1847). System des heutigen römischen Rechts (Vol. 6). Veit. 206. 
251 Article 33 (4) VCLT, 1969. 
252 For example, the EU Directives and Regulations are framed in all languages of the Member States. 
89 
 
                                           
 
 
 
carries equal weight. If a situation arises where confusion occurs as a result of the 
wording of the legal text, other methods of interpretation may become necessary. 
 
In such circumstances, the teleological method of interpretation is usually 
employed.253 The teleological interpretation (Article 31 (1), VCLT) seeks to 
interpret the law, keeping the goals or original purpose of the text in context. The 
purpose of the legal texts may be revealed in the preparatory acts, and in the case 
of the EU law in the recitals of the legal instrument. The recitals of the EU legal 
instruments, located in the preamble reveal the intentions of the framers of the 
instruments, as well as set out the goals that are expected to be accomplished 
through the legal act. Although the recitals do not have any binding effect, they 
play a significant role, especially in the interpretation of the legal instruments. For 
the purposes of this thesis, the teleological method is especially relevant for 
discussing the second objective of the thesis – the analysis of whether the legal 
instruments containing provisions to combat counterfeiting and falsification of 
medicines in the EU have been successful in meeting the social objectives of 
public health and consumer protection in the EU. 
 
It is important to note that the four legal methods of interpretation collectively 
called the classic tools of interpretation are fluid and are not mutually exclusive. 
Therefore, in practice, all four methods may be simultaneously employed in the 
interpretation of EU law in no hierarchical manner. However, in case of any doubt, 
the Court of the European Union (CJEU) has ruled that the reasonable purpose of 
the provision in question should be determined.254  
253 Mankowski, P. (2012). Brussels I Regulation. Munich. 34-38. 
254 Mankowski, P. (2012). Brussels I Regulation. Munich.35. 
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2.3.5. Challenges of the legal sources 
The thesis uses both primary and secondary sources of EU Law. Amongst the 
primary sources of law, the TEU, the TFEU and the CFREU are employed. The 
provisions in the triad, especially those measures concerning the goals of the 
Single Market,255 the public health,256 and consumer protection257 aims of the 
Union and the Fundamental Rights to life,258 health259 and intellectual property260 
set the broad parameters for the thesis. 
 
The two Directives (FMD, Enforcement Directive) and one Regulation (Customs 
Regulation) form the secondary sources of law. As evident, each legal instrument 
– Falsified Medicines Directive and Enforcement Directive and the Customs 
Regulation – has its individual goals. The goal of the FMD is to ensure public 
health and safety, whereas the Enforcement Directive and the Customs Regulation 
deal with enforcement of IP rights.  
 
This leads to two major considerations; the first vital aspect relates to the fact that 
the FMD deals with Public law and is concerned with public health and safety, 
while the Enforcement Directive and Customs Regulation deal with enforcement 
of private rights, such as trademarks rights. Therefore, fundamentally there are 
some differences in the sources of law. While ‘private law’ regulates horizontal 
relationships261 between private parties (citizens, companies) or between the State 
playing the role in private – law capacity, and citizens, the public law regulates 
255 Articles 26 and114 TFEU. 
256 Article 168 TFEU. 
257 Article 169 TFEU. 
258 Article 2, CFREU. 
259 Article 35 CFREU. 
260 Article 17(2) CFREU. 
261 Gauttier, P. (2004). Horizontal coherence and the external competences of the European Union. European law 
journal, 10(1), 23-41. 
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vertical relationships, where the State exercises powers in relation to citizens or 
companies.262 Also, whenever public law comes into play, the State adopts the 
responsibility to protect the greater good of the public and takes initiative to 
prevent public harm. On the other hand, the enforcement of private rights always 
involves initiative that needs to be taken by the individual.263  
 
Therefore, there is a clear distinction between the manner in which FMD operates, 
which is State led and the manner in which the Enforcement Directive and 
Customs Regulations work, which is enforcement of private rights.264 
 
The second important general consideration is that the anti-counterfeiting 
measures are deduced from these three legal instruments, none of which aim at 
explicitly weeding out counterfeiting of medicines from the EU. The Falsified 
Medicines Directive states that it does not aim at combatting counterfeiting but 
only falsified medicines from the legal supply chain.  The Enforcement Directive 
and the Customs Regulation deal with enforcement of IP rights. Although the 
aforementioned legal instruments recognise that counterfeiting and piracy is a 
problem and the legal instruments have the goal of fighting counterfeiting and 
piracy in general but only in terms of IP, as a whole. 
 
The sources of law employed in the thesis are diverse and disparate. With specific 
reference to the secondary legislation, the three different streams of law – IP law, 
Medicine Law and Criminal law, and specific focus has been on two of the three 
262 Study Group on Social Justice in European Contract Law, ‘Social Justice in European Contract Law: a 
Manifesto*, European Law Journal 10.6(2004).653-674. 
263 It is recognised that the ED states that the actions can be initiated by Groups and organisations. 
264 Schulze, R., & Schulte-Nölke, H. (Eds.). (2011). European Private Law-Current Status and Perspectives (No. 
1). Walter de Gruyter; Sell, S. K. (2003). Private power, public law: the globalization of intellectual property 
rights (Vol. 88). Cambridge University Press.  
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streams. The challenge has been that the individual goals of the types of law are 
different. While on the one hand, the FMD falls under the category of public law, 
the Enforcement Directive and the Customs Regulation enforce private rights of 
the citizens.  
 
Secondly, there is negligible amount of case law, trustworthy empirical data and 
authentic statistics on the topic of counterfeiting and falsification of medicines 
because it is intrinsically a fast moving, behind the closed door type of illegal 
activity that hardly leaves any paper trail. Therefore, in Chapter 3, in one of the 
case studies, reliance is placed on a report – White paper on operation Volcano 
that has been written by the Italian Medicines Agency together with medicines’ 
agencies of other Member States.265For the other two case studies, reliance was 
placed on the case law. These legal case studies were supplemented by discussions 
with the representatives of the medicines agencies of Italy and the UK and head of 
investigations of operation Robin, Customs and Law Enforcement Agency in 
Sweden.266 The case law was supplemented by confidential case notes and 
preparatory documents made available. 
 
Against the backdrop of these sources of law and in the light of the case studies, 
the thesis will analyse as to how counterfeiting and falsification of medicinal 
products are governed by the legal instruments – Falsified Medicines Directive, 
Enforcement Directive and the Customs Regulation in the EU. 
265 White Paper on Operation Volcano, The Herceptin Case: story, lesson learned, proposals, AIFA, AEMPS, 
AGES, ICZ, MHRA. (2015). 
266 Discussions were carried out with Dr. Domenico Di, (AIFA, Italy), Ms. Lina Andersson (Head of investigations, 
Swedish customs and law enforcement, Sweden) and Mr. Alastair Jeffery (MHRA, UK). 
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2.4. Method 
 
2.4.1. Legal dogmatic method 
The traditional legal method, also known as the legal dogmatic method or 
doctrinal analysis is essential to the thesis for identifying the relevant sources of 
law that govern counterfeiting and falsification of medicinal products and is 
employed in Part III and IV of the thesis. This is followed by analysis of the legal 
sources, wherein considering issues that are identified in the preceding chapter, 
these sources are weighed against each other in accordance with the doctrine of 
sources of law, as traditionally carried out in the legal dogmatic method for 
analysing whether the legal instruments that govern counterfeiting and 
falsification of medicines meet the social objectives of public health and consumer 
protection as envisaged in the TFEU, which are identified as the higher norm. 
 
The legal dogmatic method is in consonance with the theory of legal positivism, 
which is the guiding philosophy of the thesis as legal dogmatic method typically 
relates to the elucidation of law as adopted by a recognised the law making body. 
In Part III of the thesis, the Falsified Medicines Directive (Directive 2011/62/EU), 
the Enforcement Directive (Directive 2004/48/EC) and the Customs Regulation 
(Regulation 608/2013) are analysed in the context of combatting counterfeiting 
and falsification of medicines in the EU using the legal dogmatic method. Initially, 
the provisions that are relevant for addressing counterfeiting and falsification of 
medicines are identified in the three legal instruments. Thereafter, the relevant 
provisions of the legal instruments are analysed with the focus on finding the gaps. 
Finally, the last chapter in Part III analyses some of the global initiatives that have 
been taken in the context of combatting counterfeiting and falsification of 
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medicine, such as the Medicrime Convention, ACTA and a few multilateral and 
bilateral agreements. The legal dogmatic method is also used in Part IV of the 
thesis, when the second objective of the thesis is analysed. In Part IV of the thesis, 
it is analysed if the law governing counterfeiting and falsification of medicines in 
the EU meets the social objectives of public health (Articles 9 and 168) and 
consumer protection (Articles 12 and 169) as envisaged in the TFEU. The 
provisions of the TFEU are identified as the ‘higher norm’ against which the 
secondary instruments are measured.  
 
In the thesis, three different streams of law (IP law, Medicine law and Criminal 
law) intersect while dealing with the problem of counterfeit and falsified 
medicines. Also, there is a plurality of legal sources (Conventions, Directives, 
Regulations, Guidelines, etc.) and players (medicines agencies, police, customs 
authorities, IP right holders). The problem of divided competence between 
different laws and agencies that implement the law while resolving the problem of 
counterfeit and falsified medicines is difficult to address.  
 
Furthermore, the effect of multi-level and multi-disciplinary regulation of dealing 
with the issue of counterfeiting and falsification of medicinal products lead to 
several basic norms (in IP law and Medicine law) that can be dealt with separately 
or tackled in an integrated manner. The thesis propagates the integrated approach 
where the issues are collectively tackled rather than individually. By integrated 
approach, it is implied that the problem of counterfeiting and falsification of 
medicinal products is looked at as two sides of the same coin, where 
counterfeiting is one side and falsification is the other. It needs to be asserted that 
the tools to combat this problem are spread in different legal instruments. 
However, while analysing, if the social objectives of public health and consumer 
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protection are met, the legal instruments are analysed collectively in a concurrent 
manner. 
2.4.2. Case study method 
The Case studies method is employed in Part II of the thesis, wherein three 
different legal ‘Operations’ are discussed.  
 
Operation 
Name 
Court case /Report Country 
Operation 
Volcano 
White Paper on Operation Volcano, Herceptin 
case - Story, lesson learned, proposals, 2014, 
(AIFA, AEMPS, AGES, ICZ, MHRA) 
Italy 
Operation 
Singapore 
Court case: R. v Gillespie (Peter Hugh), [2012] 2 
Cr. App. R. (S.) 24 (2011) 
 U.K. 
Operation 
Robin 
Court case: Case No. B 6262 -12, Stockholms 
Tingsrätt Judgment of 2013-06-25.  
Sweden 
 
Table 1 
 
Case studies, as a tool for research, have been used in social sciences for a long 
time and occupy a rather vexed position.267 Some methodologists question the 
validity of case study research268 as they question how a few examples can be 
illustrative of a broad reality. On the other hand, a large number of case studies 
continue to appear and have attained a position of classic works.269 As recent 
scholarly works indicate, case study research continues to thrive and is not limited 
to political science, IT or Business Management. Moreover, political economists 
267 John, G. (2005). What is a case study and what is it good for?American Political Science Review, Vol. 98. No.2. 
268 ibid., 341. 
269 Allen, William, S. (1965). The Nazi Seizure of Power: The Experience of a Single German Town, 1930-1935. 
New York: Watts. See also Johnson, Chalmers. (1983). MITI and the Japanese Miracle: The Growth of Industrial 
Policy, 1925-1975. Standford University Press; and Pressman. J. L., & Aron, W. (1973). Implementation. Berkeley: 
University of California Press. 
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and others270 are also adopting case study research. The reason for the continued 
use of case studies in different streams of research is because of the added value 
they generate in the discipline. When the term ‘legal case study method’ is used, it 
is sometimes confused with legal case study method of teaching, in legal studies. 
In this thesis, the term used is ‘case study method’ in order to distinguish it from 
the method of teaching law. In legal research, case study method is encouraged as 
it has borne significant results.271 
 
A case study has been defined in numerous ways. To some, it means that the 
method is qualitatively small,272 to others it means that the research features 
tracing a process;273 and to a few others, it can mean that the research investigates 
the properties of a single case.274 However, for the purposes of this thesis, the case 
studies in Chapter 3 are understood “…as complex examples which give an insight 
into the context of a problem as well as illustrating the main point”.275 
 
The legal case studies used in this thesis serve the purpose of illustrating the most 
common ways in which counterfeit and falsified medicines enter the legal supply 
chain and end up in the hands of the consumers. The case studies employed in the 
thesis are three different ‘operations’ carried out in three different EU Member 
270 Acemoglu, Daron, Simon, J., & James, A. R. (2003). An African Success Story: Botswana. In search of 
Prosperity: Analytic  Narratives on Economic Growth, ed. Dani Rodrik. Princeton, NJ: Princeton University Press, 
80-122; Bates, Robert, H., Avner. G., Margaret. L., Jean-Laurent, R., & Barry, W. (1998). Analytic Narratives. 
Princeton University Press; Rodrik, Dani (ed.). (2003). In Search of Prosperity: Analytic Narratives on Economic 
Growth. Princeton, NJ: Princeton University Press. 
271 See more in Webley, L. (2016). Stumbling Blocks in Empirical Legal Research: Case Study Research. Law and 
Method. 
272 Yin, Robert, K. (1994). Case Study Research: Design and Methods, Newbury Park, CA: Sage. 
273 George, Alexander, L., & Andrew, B. (2004). Case studies and Theory Development, Cambridge, MA: MIT 
Press. 
274 Campbell, D. T., & Stanley, J. C. (1966). Experimental and quasi-experimental designs for research. Handbook 
of research on teaching (NL Gage, Ed.), 171-246. See also Eckstein, Harry. (1975) 1992. Case Studies and Theory 
in Political Science. In Regarding Politics: Essays on Political Theory, Stability, and Change. Berkeley, University 
of California Press. 275 Fry, H., Ketteridge, S., & Marshall S. (1999). A Handbook for Teaching and Learning in Higher Education, 
Kogan Page, Glasgow. 408. 
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States and are based on real court cases, involving surrounding circumstances as 
well, in order to provide a full picture. Two of the three case studies are based on 
case law and one of them is based on White Paper produced by the medicines 
agency. Also, one of the operations revolves around counterfeiting and 
falsification orchestrated by a specific group of people. The number of medicines 
involved can vary and, the number of legal cases, if spread in different countries, 
can also differ.  
 
The information for undertaking the case analysis is based on the case law from 
within the EU and is supplemented by confidential case notes obtained from the 
national competent authorities of the respective countries. These case studies were 
chosen amongst many other cases as these cases are the largest, in terms of scale 
and are also few of the well-documented cases in the EU.  
 
The case study method is used in order to provide an insight into the context of the 
typical ways in which counterfeiting and falsification of medicines take place and 
for identifying the core issues that need to be addressed through the legal 
framework in the EU. The case study method was particularly chosen to study 
counterfeiting and falsification of medicines also because being an illegal activity, 
it typically occurs behind closed doors, and does not leave traces behind. 
Therefore, it is difficult to obtain authentic data and statistics on this issue. 
However, the lack of case law in the EU does not necessarily indicate that 
counterfeiting and falsification of medicines do not occur. In fact, it is indicative 
of the fact that it is extremely difficult to obtain evidence and hence, the cases 
generally fall through due to the lack of evidence. This activity is usually carried 
out by people having sophisticated knowledge of the pharmaceutical sector and 
financial structures, as will become apparent from the case studies. Therefore, the 
profile of the criminals in counterfeiting and falsification of medicines is unique. 
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Therefore, case study method facilitates exploring the full picture which will assist 
in the legal analysis. 
Operation Volcano (based on the White Paper produced by the Italian 
Medicines Agency) 
The first operation, ‘Operation Volcano’276 was headed by the Italian authorities, 
which illustrated the manner in which Herceptin, a cancer treatment drug was 
stolen from the legal supply chain, involving local organised criminals. After 
being stolen, the same drug was injected with falsified substances and re-
introduced in the legal supply chain. It was intercepted in Germany but by then, 
the drug had already travelled from Italy to the UK and then to Germany. This 
case study comprises of several cases and is based on a White Paper produced by 
the Italian Medicines Agency,277 with contributions and comments by the MHRA 
and a few other recognised bodies. It is recognised that a Report produced by an 
Agency can be biased, but its value cannot be underestimated. It exposed the 
mechanisms that are followed by criminals and the successful measures adopted 
by the authorities that may be replicated.278 
 
Operation Singapore (R. v Gillespie (Peter Hugh), [2012] 2 Cr. App. R. (S.) 24 
(2011)) 
The second case study, ‘Operation Singapore’279 was led by the MHRA, the 
British Medicines authority and is based on Crown Court Case.280 This operation 
276 See more in Chapter 3, Section 3.2 on Operation Volcano – The Herceptin Case, AIFA (Italian Medicines 
Agency), 2015. 
277 ibid. 
278 See more in Chapter 3, Section 3.2 on Operation Volcano – The Herceptin Case, AIFA (Italian Medicines 
Agency), 2015. 
279 See more in Chapter 3, Section 3.3 on Operation Singapore is the name given to the case Regina v Peter 
Gillespie, Richard Kemp, James Quinn, Ian Gillespie and Ian Harding, The Crown Court sitting at Croydon, 2010. 
Confidential case notes. 
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involved the import of medicines from Asia, which landed in Belgium and were 
transported over land and arrived in Britain. In Britain, these medicinal products 
were assembled and then re-introduced in the legal supply chain. It involved a 
multitude of players, and some of them were aware of the illegal activity. 
However, there were other players who were hired for specific market activity, 
such as printing packaging material and were unaware of the counterfeiting 
process. 
 
Operation Robin (Case No. B 6262 -12, Stockholms Tingsrätt Judgment of 
2013-06-25) 
The third case study considered in the thesis to illustrate the problem of 
counterfeiting in the EU is ‘Operation Robin’,281 which was spearheaded by the 
Swedish customs’ authority. This district court case282 exposed a complex, 
specialised and well-organised network of people executing the crime of 
counterfeiting. The investigation involved cooperation between more than thirty 
countries. It also confirmed that small consignments using postal services have 
become the preferred mode of transporting counterfeit medicine in the EU and 
also brought other factors to light. 
 
The legal case studies will intrinsically contribute to explain the particulars of the 
cases, as well as highlight similarities in the cases across different countries in a 
comparative manner. The three different operations used are illustrative legal case 
studies283 that will provide evidence of how three different countries within the 
280 ibid. 
281  EUROPOL & OHIM. (June 2013). Reports and Conclusions, Knowledge Building in IP Enforcement, 
Combating Pharmacrime A knowledge –building Conference on Counterfeit Medicines. Alicante. Spain.16. 
282 Case No. B 6262 -12, Stockholms Tingsrätt Judgment of 2013-06-25. 
283 Illustrative case studies are primarily descriptive studies. They typically utilize one or two instances of an event 
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EU grappled with the problem of counterfeit and falsified medicine and will 
underline the gaps in the legal framework.  
 
2.5. Concluding remarks 
This chapter shed light on the theory that is employed, legal sources of law that 
are consulted, and the methods that are followed in the thesis. The primary 
objectives of the thesis are to analyse how counterfeiting and falsification of 
medicinal products is addressed by law (Directive 2011/62/EU, Directive 
2004/48/EC and Regulation 608/2013) in the EU, and to analyse whether the law 
that contains tools to combat counterfeiting and falsification of medicinal products 
meets the social objectives of public health (Articles 9 and 168) and consumer 
protection (Articles 12 and 169) of the Treaty on Functioning of the European 
Union.  
 
In order to do so, the theory of legal positivism (discussed in Section 2.2) serves as 
the guiding philosophy in the thesis. In addition, the sources of law relied upon 
were discussed in this chapter, wherein the primary sources of law – the TEU, the 
TFEU and the CFREU, which set the overall parameters, and the secondary 
legislation – the Directive 2011/62/EU, the Directive 2004/48/EC and the 
Regulation 608/2013 that contains tools to combat counterfeiting and falsification 
of medicines, were introduced. These legal instruments along with global 
initiatives taken in context of counterfeiting and falsification of medicines are 
analysed in Part III, using legal dogmatic method (discussed in Section 2.4.1). The 
case study method (discussed in Section 2.4.2) is used in the following Part II, in 
to demonstrate a situation. Illustrative case studies serve primarily to make the unfamiliar familiar and to give 
readers a common language about the topic in question. 
  
101 
 
                                                                                                                                       
 
 
 
which the chapter on legal case studies sets the context and illustrates the issue of 
counterfeiting and falsification of medicinal products in the EU. 
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Part II is composed of one chapter on the legal case studies. Using the case study 
method, three different cases are analysed. The primary purpose of this chapter is 
to set the context of counterfeiting and falsification of medicines in the EU 
through the use of authentic cases for illustrating how counterfeiting and 
falsification of medicines transpires. These legal case studies will be instrumental 
in identifying the common issues and gaps that need to be addressed by the legal 
framework. The first case study, Operation Volcano is based on the White paper 
written by the Medicines Agency in Italy and is based on several cases connected 
to one crime in Italy, involving theft of a cancer treatment drug and how that 
entered the legal supply chain after being manipulated. The second case study is 
based on a court case in the UK, also known as Operation Singapore and was led 
by the Medicines and Healthcare Products Regulatory Agency (MHRA). It 
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involved counterfeit and falsified medicines entering the EU from China via 
Belgium into the UK. After repackaging of these medicinal products in the UK, 
these were planted in the legal supply chain. The third case study is based on a 
District court case from Sweden, which involved sale of counterfeit medicinal 
products over the internet. After the medicinal products were manipulated, they 
were offered for sale through three websites.  
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Chapter 3: Legal Case Studies 
3.1 Introduction 
The purpose of this chapter is to illustrate how counterfeit and falsified drugs can 
find their way into the hands of potential patients, based on legal case studies 
spanning the past decade within three EU Member States – Italy, Sweden, and the 
UK. As explained in Chapter 2, in this thesis, the term case study is used, as 
understood by Fry et al., 284 as ‘an example that provides insight, sets the context 
of a problem and illustrates the main point.285 In other words, the legal case 
studies discussed in this chapter have the primary goal of setting the context of the 
problem of counterfeiting and falsification of medicines, explaining how it 
typically transpires from the beginning to the end and underlines the main issues 
that have not been covered by the legal instruments. Thereby, highlighting the 
gaps that exist in the legal framework that combats counterfeiting and falsification 
of medicines in the EU. The larger goal is to utilise the gaps that are discovered in 
this chapter as guiding parameters for analysing the legal instruments. 
 
The counterfeiting and falsification of medicines take place in diverse ways – as 
‘transnational organised crime,286 involving a well-organised company with 
decentralised structures and documentation for each action,287 as close knit family 
284 Fry, H., Ketteridge, S., & Marshall S. (1999). A Handbook for Teaching and Learning in Higher Education, 
Kogan Page, Glasgow. 
285 See further explanation in Chapter 2, section 2.2. 
286 Attaran, A., Bate, R., & Kendall, M. (2011). Why and how to make an international crime of medicine 
counterfeiting. Journal of International Criminal Justice, 9(2), 325-354; Bate, R. (2012). Phake: the deadly world 
of falsified and substandard medicines. AEI Press; Lavorgna, A. (2015). The online trade in counterfeit 
pharmaceuticals: new criminal opportunities, trends and challenges. European Journal of Criminology, 12(2), 226 -
241. 
287 See Section 3.4. Operation Robin. 
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business,288 as fake doctor run business,289 as gym business,290 and also as an 
online business.291 Therefore, there is evidence to support the view that the 
counterfeiting and falsification of medicine is also carried out by small 
enterprises292 and not only by big organised structures at transnational levels.293 
 
This chapter highlights some of the common ways in which falsified counterfeit 
medicines enter the legal supply chain, the actors that are involved and the 
pathways that are adopted. In order to combat falsification and counterfeiting in 
the pharmaceutical sector, it is pertinent to understand the entire story from the 
beginning to the end. This is the first step towards finding a solution. After 
uncovering ‘what’ the problem is, the current state of laws governing the area of 
counterfeiting and falsification of medicines will be assessed in Part III. 
 
In this chapter, the focus will be on three case studies that were selected from 
amongst many instances of counterfeiting of medicines in the EU.294 Between 
2007 and 2015, three different operations - Operation Volcano (Italy); Operation 
Singapore (the UK); and Operation Robin (Sweden), took place in Europe. 
288 Case 2 (UK) & Case 4 (the Netherlands) in Hall, A., Koenraadt, R., & Antonopoulos, G. A. (2017). Illicit 
pharmaceutical networks in Europe: organising the illicit medicine market in the United Kingdom and the 
Netherlands. Trends in Organised Crime, 1-20. 
289 Case 3 (Netherlands) Source: Dutch prosecution service, Hall, A., Koenraadt, R., & Antonopoulos, G. A. 
(2017). Illicit pharmaceutical networks in Europe: organising the illicit medicine market in the United Kingdom and 
the Netherlands. Trends in Organised Crime, 1-20.  
290 ibid., Case 5 (UK) Source: MHRA case files. 
291 See Section 3.4. Operation Robin. 
292 Paoli, L. (2016). Towards a Theory of Organised Crime: Some Preliminary Reflections. In Illegal 
Entrepreneurship, Organised Crime and Social Control. Springer International Publishing. 3-17. 
293 Attaran, A., Bate, R., & Kendall, M. (2011). Why and how to make an international crime of medicine 
counterfeiting. Journal of International Criminal Justice, 9(2), 325-354; Bate, R. (2012). Phake: the deadly world 
of falsified and substandard medicines. AEI Press; Lavorgna, A. (2015). The online trade in counterfeit 
pharmaceuticals: new criminal opportunities, trends and challenges. European Journal of Criminology, 12(2), 226-
241. 
294 A few other examples of counterfeiting and falsification of medicines are available from the (AIFA) 
communication issued, are Alimta (Germany, Chez Republic, The Netherlands); Avastin (The United Kingdom, 
Switzerland, Germany, The Netherlands), Avonex (Germany, Sweden, Hungary). Source: AIFA case files. 
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Particularly, these cases were chosen as they were large in scale and 
comprehensively documented cases. Moreover, these were recent studies led by 
reliable Member States institutions like Medicines Agencies in Italy (Operation 
Volcano), MHRA in the UK (Operation Singapore) and the Customs Law 
Enforcement Authority in Sweden (Operation Robin).  The common goal of all the 
three operations was to weed out counterfeit and falsified medicines from the legal 
supply chain.  
 
All these operations are discussed in the subsequent sections using the case study 
method discussed in Chapter 2.295 The study of each of these case studies is called 
‘operation’ because the analysis of each of the cases involves more than the one 
case in the Member State. For instance, though Operation Robin involves only one 
district court case from Sweden,296 it is more than the District Court case as it also 
encompasses the sentencing of an accomplice in Thailand. Similarly, in the 
Operation Singapore, reliance is placed on the Crowns Court case and Court of 
Appeal’s decision in the UK.297 As opposed to Operation Singapore and Operation 
Robin, where facts are drawn from the proceedings of the court, while studying 
Operation Volcano (Italy), reliance is placed on the White Paper written by the 
AIFA298 (Italian Medicines Agency) as the court cases were not accessible.   
Moreover, the study of each case encompassed also studying the relevant cases 
that transpired in other countries, supplementary reports and confidential case 
files. The confidential case files, also employ the term ‘operation’ in the various 
Member States. The legal analysis conducted by the case law was supplemented 
295 Case study method is discussed in Chapter 2, Section 2.4.2. 
296 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
297 Regina v Gillespie and others (2010), Crowns Court at Croydon, UK; See also Regina v Peter Hugh Gillespie 
No. 2011/02816/B4 Court of Appeal Criminal Division 29 November 2011 [2011] EWCA Crim 3152. 
298 Di Giorgio, D. (Director of Publication). (2015). White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco.  
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by discussions with the representatives of the medicines agencies of Italy and the 
UK and head of investigations of Operation Robin, Customs and Law 
Enforcement Agency in Sweden.299 In the following sections these three 
operations, which are treated as case studies from three different Member States, 
are discussed.  
 
3.2. Operation Volcano 
3.2.1 Introduction  
The first operation that will be assessed is Operation Volcano,300 also known as 
the ‘Herceptin case’301 led by the Agenzia Italiana del Farmaco (the Italian 
Medicines Agency, henceforth ‘AIFA’). Herceptin302 or the generic name303 
Trastuzumab is a cancer treatment drug available only on prescription by a 
registered medical practitioner. The Operation was concluded in 2014 and 
revolves around the theft of legitimate medicines, stolen from a delivery truck on 
its way to deliver the medicine to an Italian hospital. These medicines were then 
tampered with and re-introduced in the legitimate supply chain.  
 
299 Discussions were carried out with Dr. Domenico Di Giorgio, Counterfeit Prevention Unit Director, AIFA  
(Italy), Ms. Lina Andersson, Deputy Chief of Customs investigation. Swedish Customs and Law Enforcement  
(Sweden) and Mr. Alastair Jeffery, Head of Enforcement, MHRA, U.K. 
300 Theft and laundering of medicines: early results of the AIFA project. The Herceptin case. (16 April 2014). Press 
release no.355. 
301 Herceptin case due to the name of the medicine – Herceptin that was stolen. 
302 Herceptin. (2013). EPAR- sammendrag for offentligheden. European Medicines Agency. EMA/444961/2013. 
London. U.K. 
303 A generic medicine is a medicine is defined as follows by The World Health Organisation: A generic drug is a 
pharmaceutical product, usually intended to be interchangeable with an innovator product that is manufactured 
without a license from the innovator company and marketed after the expiry date of the patent or other exclusive 
rights. Generic drugs are marketed under a non-proprietary or approved name rather than a proprietary or brand 
name. Generic drugs are frequently as effective as, but much cheaper than, brand-name drugs. The Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) agreement does not prevent governments from requiring accurate 
labelling or allowing generic substitution. The use of the name is reserved exclusively for its owner. 
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Between the year 2011 and 2015,304 there were reports of theft of medicines from 
hospitals and in the field, such as from delivery trucks, lorries and pharmacies in 
Italy.305 Such reports made rounds in the media306 and also inspired a University 
research project.307 As a result of the escalation in the theft of medicines, the 
AIFA established Counterfeit Prevention Unit with the collaboration of the 
industry in order to resolve the problem of medicine theft. In 2013, the “Theft 
project” was established and involved AIFA, Farmaindustria (manufacturers 
association), ASSORAM (warehousing services association), Carabinieri NAS 
(specialised police force), and was supported by the Ministry of Health in Italy. 
The Unit established a network with other similar agencies across Europe for the 
purpose of sharing information, drawing up blacklists of suspicious companies, 
lists of drugs that were rumoured to be compromised and lists of stolen batch 
numbers of drugs. This was done in order to understand the mechanisms of this 
criminal activity.  
 
3.2.2. Factual background 
In 2014, a few batches of Herceptin medicine (for the treatment of breast cancer 
and stomach cancer)308 were stolen from a truck delivering medicines to a hospital 
in Italy. In addition to Herceptin, the other medicines that were stolen were Alimta 
304 AIFA case files. Falsified, illegal and stolen medicines. (2014)  
305 Di Giorgio, D. (Director of Publication). (2015). White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco.7. 
306 Faucon, B., Plumridge, H. & Falconi, M. (1 May 2014). Italian Officials Probe Criminal Ties to Cancer Drug 
Theft: Investigators Find an Organised Criminal Ring Is Distributing Stolen Drugs in Western Europe. In The Wall 
Street Journal.   
307 Riccardi, M., Dugato, M., Polizzotti, M., & Pecile, V. (2014). The theft of medicines from Italian 
hospitals. Milan-Trento, Transcrime–Joint Research Centre on Transnational Crime. 
308 European Medicines Agency update on stolen vials of Herceptin, EU national Authorities and EMA cooperating 
in response to criminal activities. (17 April 2014). Batch numbers of the stolen Herceptin drug as revealed by the 
European Medicines Agency (EMA) H4311B07, H4329B01, H4284B04, H4319B02, H4324B03, H4196B01, 
H4271B01, H4301B09, H4303B01, H4143B01, H4293B01, H4180B01, N1010B02, Press Release, 
EMA/239072/2014. 
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(used for the treatment of lung cancer) and Remicade (used for the treatment of 
Crohn’s disease, ulcerative colitis, etc.).309 Local criminals were specifically hired 
for the purpose of executing the theft of medicinal products.310 This theft of 
medicines in this precise manner was symptomatic of the general trend in Italy at 
that time.311 However, the masterminds behind the complex transaction were not 
directly involved in the execution of the theft of medicines and merely 
orchestrated the first step.312 The following figure encapsulates how the 
falsification took place (Figure 4). 
 
Figure 4 
 
After the local criminals stole the medicines from the delivery trucks, which were 
meant to deliver to the hospitals, these batches of Herceptin were transferred to an 
Italian licensed wholesaler using fake invoices.313 These second level operators 
tampered with the medicines, which were manipulated in warehouses located in 
different parts of Italy. Three of such warehouses314 were discovered in Naples, 
309 ibid. 
310 Di Giorgio, D. (Director of Publication). (2015). White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco.,12. 
311 Thefts of Medicines, Trend of the phenomenon over the years. (2017).AIFA.  
312 Riccardi, M., Dugato, M., Polizzotti, M., & Pecile, V. (2014). The theft of medicines from Italian 
hospitals. Milan-Trento, Transcrime–Joint Research Centre on Transnational Crime. 
313 Di Giorgio, D. (Director of Publication). (2015).White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco. 
314 ibid., 6. 
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where manipulations and tampering with the medicines were done on a regular 
basis. Thereafter, the licensed wholesalers created falsified receipts for shipment 
and subsequently shipped the products to bogus non-licensed wholesalers set up in 
the numerous EU Member States like Hungary, Latvia, Cyprus, and the Czech 
Republic.315 It was later confirmed by the Italian authorities that these unlicensed 
wholesalers were part of a criminal organisation based in Italy and operated in the 
countries mentioned above.316 
 
These fake non-licensed wholesalers were the third level operators. It is believed 
that these “bogus operators” existed only on paper and the stolen medicines, which 
were tampered with never left the Italian shores in reality. The primary job of 
these third link operators was to contact authorised wholesalers in Italy and send 
them fake invoices. This was a way to “whitewash” the shipments.317 The 
unauthorised operators’ modus operandi was aimed at legitimising the supply 
chain.318 Later the investigations revealed the names and addresses of these 
“bogus wholesalers”, which were available in NUI319 issued by the Italian 
authorities. For instance, Carnela Limited, Cyprus; Mars Distributions KFT, 
Hungary, Euroriga Med Import Export, Riga, Latvia; Zeapharma S.R.L., Romania, 
Exim AZ-sros, Slovak Republic; Piramid D.O.O., Hildons Greece, Nixertron 
Iberica S.r.L., Italy.  
 
These unauthorised operators, based in Cyprus, Hungary, Romania, Greece, 
Latvia, Slovak Republic and Italy, issued fake invoices under the pretence of 
selling the stolen medicines to legally authorised Italian operators – the fourth 
315 AIFA case files (August 8, 2014). (Rapid Alert issued by Agencia Italiano del Farmaco,(AIFA). 
316 Di Giorgio, D. (Director of Publication). (2015). White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco. 
317 ibid., 11-12. 
318 ibid. 
319 ibid., 11. 
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level operators. Investigations revealed the names of these “bogus operators” that 
directly bought medicines from the “bogus wholesalers”. The names of these 
fourth level “bogus operators” were revealed in a NUI320 issued by the Italian 
authorities - Pharma Global SrL, Napoli; Farmaceutica Internazinale SrL, 
Avellino; Farmacia Cozzolino di Mario & CIRO, S. N.C. Napoli; Pharma-Trade 
SPA, Pompei; Pharmasea Ltd, Malta.321 
 
These fourth level operators, based in Italy, who received the whitewashed and 
legitimised medicines from the “bogus operators”322 based in the other EU 
Member States, sold to other authorised dealers in other Member States such as 
the UK, Germany, and Finland.323 In this specific case, the investigations revealed 
the names of these Italian operators that directly bought medicines from the 
“bogus wholesalers”. For instance, Pharma Global SrL, Napoli; Farmaceutica 
Internazinale SrL, Avellino; Farmacia Cozzolino di Mario & CIRO, S. N.C. 
Napoli; Pharma-Trade SPA, Pompei; and Pharmasea Ltd, Malta.324  
 
When one such batch arrived in Germany, it was detected in March 2014. The 
German parallel distributor informed the Italian authorities325 that a medicine 
bearing a batch number that was circulated in the blacklist had arrived in 
Germany. This blacklist had been developed by the Italian Authorities in the wake 
of escalating theft of medicines from hospitals and pharmacies326 and as a part of 
AIFA’s efforts to detect and eliminate trade in counterfeit medicine. This blacklist 
320 Di Giorgio, D. (Director of Publication). (2015). White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco. 
321 Di Giorgio, D. (Director of Publication). (2015). White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco.12. 
322 AIFA case files. (8 August 2014). List of bogus operators published by the AIFA. 
323 AIFA case files. (April 2014). Roche communication, April 2014.  
324 Di Giorgio, D. (Director of Publication). (2015). White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco.12. 
325 Counterfeit Prevention Unit created by AIFA. 
326 As discussed in Section 3.2.1. 
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of stolen medicinal products from Italian hospitals and pharmacies along with 
related batch numbers was shared with relevant authorities of the Member States. 
There was also a watch list that was created for the Member States and an alert 
procedure was set up by the Italian authorities, which was circulated to interested 
Drug Regulatory Authorities (DRAs) and stakeholders in Europe, asking to report 
any suspected incidents involving the listed products to AIFA.327 Consequently, 
this particular falsified medicine – ‘Herceptin’ was detected because of this system 
set in place by the AIFA. 
 
The German parallel distributor informed AIFA that this particular batch of 
Herceptin, which was received from an authorised wholesale parallel importer 
based in the U.K. and consisted of Herceptin 150 mg. There were clear signs that 
the medicines had been tampered with.328 Firstly, the batch numbers of the 
primary and secondary packaging were inconsistent. Secondly, even though the 
original product was in the form of a powder, the product in question was partially 
liquid. Thirdly, the container of the medicine that was ceased revealed that there 
was some form of residue on the container. The batch numbers329 of the medicines 
were communicated and seized samples were sent to the manufacturer, Roche, for 
further analysis. 
 
The next step was for the U.K. authorities, where the Medicines and Healthcare 
Regulatory Agency (MHRA)330 investigated the aspects of the matter pertaining to 
the U.K. wholesaler and the Italian authorities, NAS (specialised police force in 
327 Database was also made available to industries and operators so that they could report and signals from the field: 
any suspicion about a medicine could be processed. 
328 Di Giorgio, D. (Director of Publication). (2015).White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco.9. 
329 H4319B02; H4129B01; H4284B04. 
330 The MHRA is an executive agency, sponsored by the Department of Health and regulates medicines, medical 
devices and blood components for transfusion in the UK. 
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Italy), to trace the stolen medicine using its database.  The UK and Italian 
authorities worked in close cooperation to resolve the matter. NAS inspected the 
wholesalers in Italy who supplied to the UK wholesaler by scrutinising the 
invoices from the UK wholesaler.331Seizures were also made in Germany, Finland, 
and the UK.332  The investigations conducted by the Italian authorities revealed 
that the batch numbers333 of medicine in question could be traced to a theft from a 
truck in Italy. AIFA further corroborated the evidence that the identification of the 
products was “illegally exported” and “falsified”.  
 
The Italian authorities requested the authorities in the Member States in a NUI334 
to communicate to the wholesalers, relevant institutions and parallel distributors in 
their territory to temporarily quarantine medicinal products that were bought from 
the unauthorised operators listed in the NUIs, until the results of the investigations 
were reached in accordance with the standard practice of the Medicines 
Directive.335 
3.2.3 Revelations 
The collective evidence revealed that there were significant distribution channels 
and that this was not a one-time case,336 in fact, it was a premeditated scheme. The 
331 It further came to light that that there were also two other medical products that were detected – ALIMTA and 
Remicade. See Paul- Ehrlich Institut (PEI), an institution of the Federal Ministry of Health, Federal Republic of 
Germany (April 2014). Aktuelle Informationen zu gestohlenen Herceptin-Fläschchen, Nach neuen Erkenntnissen 
sind auch Chargen des Arzneimittelse Remicade betroffen. Germany.  
332 Di Giorgio, D. (Director of Publication). (2015).White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco.10. 
333 AIFA case files. (14 August 2014). Farmaci coinvolti in traffici illegali – Aggiornamento 14 aogosto 2014.   
334 See Paul- Ehrlich Institut, an institution of the Federal Ministry of Health, Federal Republic of Germany (4 April 
2014). Aktuelle Informationen zu gestohlenen Herceptin-Fläschchen, Nach neuen Erkenntnissen sind auch Chargen 
des Arzneimittelse Remicade betroffen. Germany. Follow-up information on suspected counterfeit of Herceptin 150 
mg.  
335 Article 117(a) Directive 2001/83/EC.  
336 Di Giorgio, D. (Director of Publication). (2015).White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco.11; See also 
Riccardi, M., Dugato, M., Polizzotti, M., & Pecile, V. (2014). The theft of medicines from Italian hospitals. Milan-
Trento, Transcrime–Joint Research Centre on Transnational Crime. 
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non-Italian wholesalers, apparently never questioned anything more than the 
Italian authorisation of the wholesaler. They apparently believed that they bought 
from a genuine wholesaler for selling medicines to the other Member States. They 
also claimed that as stated in the Good Distribution Practices (GDP) guidelines337 
under Article 84 and 85b (3), the Medicines Directive that governs this area 
requires that wholesalers need to verify only the direct wholesalers they are 
buying from. 
 
It is also evident from this particular case that life-saving drug for treatment of 
cancer was the target of counterfeiting and falsification. In the previous decade, 
the focus of counterfeiting and falsification was believed to be lifestyle drugs, 
such as weight loss tablets that were the target of counterfeiting.338 The highly 
developed and complex method of executing this criminal activity indicates that 
the motivation for steering this illegal activity was excessive profit and extremely 
low level of penalty for the commission of this crime.339 The decentralised system 
of execution (see Figure 4) where specialists were engaged at different steps - 
local criminals for carrying out the first step of stealing medicines; specialists for 
tampering with the medicines; unauthorised operators for issuing fake invoices - 
illustrates that the criminal masterminds had anticipated the way around the 
system. The path adopted by them made tracking the evidence long-winded, time-
consuming and resource craving. There are strong indications that this is not the 
first case of its kind in Italy.340 Many of the cases went unnoticed because the 
337 Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 
343/01). Chapter 5, point 5.2. 
338 Møldrup, C. (2004). The use of the terms ‘lifestyle medicines’ or ‘lifestyle drugs’. Pharmacy World and 
Science, 26(4), 193-196. 
339 Vander Beken, T. (Ed.). (2007). The European pharmaceutical sector and crime vulnerabilities. Maklu. 
340 Riccardi, M., Dugato, M., Polizzotti, M., & Pecile, V. (2014). The theft of medicines from Italian 
hospitals. Milan-Trento, Transcrime–Joint Research Centre on Transnational Crime; See also Riccardi, M. (2014). 
When criminals invest in businesses: Are we looking in the right direction? An exploratory analysis of companies 
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cases were not traceable because of the tactics adopted by the criminals. However, 
some of the cases341 did come to light later and many cases in the rest of Europe 
were revealed342 as an aftermath of this case. 
 
3.3 Operation Singapore 
3.3.1 Introduction 
Operation Singapore was one of the most serious breaches of the legitimate supply 
chain, in terms of the lifesaving drugs that were involved, as well as the sheer 
economic value of the medicines in the EU.343 It involved counterfeiting of three 
prescription only medicines - Plavix344 (clopidogrel), Zyprexa345 (olanzapine), and 
Casodex346 (bicalutamide), used for the treatment of psychosis, heart disease and 
prostate cancer, respectively in the UK. The investigation was headed by the 
MHRA in the U.K. and involved over twelve countries in the process, including 
the U.S.A., Belgium, China, and Singapore. Operation Singapore involved the 
counterfeit medicine entering the market disguised as legitimate medicines in the 
controlled by mafias. In Organised crime, corruption and crime prevention . Springer International Publishing. 
197-206. 
 
341 AIFA case files. (August 2014). “The initial focus of the Italian investigation was on a small number of 
medicinal products;  Herceptin, Remicade, Alimta, Avastin &  Mabthera.  The network was informed that there was 
no legitimate supply in the wholesaler supply chain for three of these medicinal products from Italian origin 
(Herceptin, Avastin and Mabthera), hence the initial alert issued by Germany and subsequent press statements by 
EMA.” 
342 AIFA case files. (2014). A few examples from the AIFA communication issued are Alimta (Germany, Chez 
Republic, The Netherlands); Avastin (The United Kingdom, Switzerland, Germany, The Netherlands), Avonex 
(Germany, Sweden, Hungary). 
343 Regina v. Gillespie and others. (2010). Crowns Court at Croydon. Confidential case notes. It was discovered that 
72,000 packs, 2.1 million doses which stand at a retail value of GBP 4.7 million were involved.. 
344 Plavix is the trade mark owned by Sanofi Aventis and is also a prescription only medicine and acts as an anti-
platelet against and is used in the treatment of heart disease. It was sold at GBP 35.31 per 28 tablet package. 
345 Zyprexa is the trade mark of a pharmaceutical owned by Eli Lilly and Company, used for bi-polar disorder and 
schizophrenia and is a prescription only medicine. It was sold at GBP 79.45 per 28 tablet package. 
346 Casodex is the trade mark of a pharmaceutical owned by Astra Zeneca. It is also a prescription only medicine 
used in the treatment of advanced prostate cancer. It was sold at GBP 128 per 28 tablet package. 
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legitimate supply chain in the UK in 2006/2007.347 The case hinges upon the 
illegal importation and distribution of counterfeit medicines, by planting them into 
the legitimate supply chain with an intention to replace the branded genuine 
medicines at the pharmacists so that the falsified and counterfeit medicines reach 
the patient. After arrival in the U.K., from China, the tampering of their packaging 
began and thereafter, they were planted in the legitimate supply chain in the U.K.  
 
Operation Singapore was a big investigation in magnitude348 to concrete facts and 
figures regarding trade in counterfeit medicines but also threw light on the social 
costs349 in the sense of damage to public health and safety. It was discovered that 
72,000 packs, 2.1 million doses, which stand at a retail value of GBP 4.7 million 
were involved.350 The MHRA had to issue four Class 1 Recalls,351 which needed 
immediate action as the product posed a life threatening risk to the patients. Even 
though the MHRA seized 40,000 packs before reaching pharmacies and 7000 
packs were recovered after the recalls were issued, 25,000 packs (700,000 doses) 
reached the pharmacies and patients. The counterfeit products that were recovered 
contained between 50 %-80% of Active Pharmaceutical Ingredients (API)352 along 
with unknown impurities. The counterfeits that were recovered resembled the 
original products to a great extent and could not be differentiated from the genuine 
347 Jackson, G., Patel, S., & Khan, S. (2012). Assessing the problem of counterfeit medications in the United 
Kingdom. International journal of clinical practice, 66(3), 241-250. 
348 93 witnesses from six countries provided evidence at the trial and 205 witnesses made written statements with a 
four month Crown Court trial. Regina v. Gillespie and others. (2010). Crowns Court at Croydon. Confidential case 
notes. 
349 Majid, Y. A. R. (2008). The other global drugs crisis: Assessing the scope, impacts and drivers of the trade in 
dangerous counterfeit pharmaceuticals. International journal of social inquiry, 1, 151-166. 
350 Regina v. Gillespie and others. (2010). Crowns Court at Croydon. Confidential case notes. 7. 
351 The MHRA’s Defective Medicines Report Centre (DMRC), issues alerts to healthcare professionals , General 
Practitioners, Hospitals, Surgeries, and wholesalers in order to inform about a medicine that may be a cause of 
concern with regard to its quality, effectiveness or safety. The alerts are graded with reference to the seriousness of 
the threat to public health, from Class 1 to Class 4, where Class 1 is the most serious form of recall. 
Sources:Defective Medicines Report Centre.(2012). Medicines &Medical Devices Regulation: What you need to 
know. London MHRA. 14; See Glossary for explanation of the term Recall. 
352 See Glossary for explanation of the term API.  
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products on the basis of visual identification.  
 
3.3.2 Factual background 
This case353 involved three key figures- a British national (henceforth referred to 
as ‘B’), a French National (henceforth referred to as ‘F’) and a Chinese national 
(henceforth referred to as ‘C’). Amongst the three main players, it was concluded 
that B was the mastermind of the conspiracy and was the one who orchestrated the 
purchase, forging of documents, testing, financing, collection, relabelling and 
delivery of the counterfeit medicines.354 He also created a web of companies in 
different parts of the world to make the movement of medicines and money 
possible.355 He was an ex-pharmaceutical parallel importer and a licensed 
wholesaler. His previous convictions included Medicines Act Offences in mid-
1990s.356 In 2005, he was arrested in the context with a £2 million fraud on the 
Royal Bank of Scotland. B understood the pharmaceutical market well, worked 
together with a group of people having a variety of skill sets and also tested 
falsified medicines and exported riskiest products to the United Arab Emirates 
(UAE).357 
 
B worked together with the French national ‘F’, (who was later arrested in Spain 
and extradited to France). F was involved in smuggling falsified high-value cancer 
products from China through Turkey, Switzerland, Germany, Malta and UK. His 
353 See also R. v Gillespie (Peter Hugh), Court of Appeal (Criminal Division) 29 November [2011] EWCA Crime 
3152; [2012] 2 Cr. App. R. (S.) 24. 
354 R v Gillespie and others, United Nations Office of Drugs and Crime, UNODC No.: GBRx001. 
355 See more in Almuzaini, T., Sammons, H., & Choonara, I. (2013). Substandard and falsified medicines in the 
UK: a retrospective review of drug alerts (2001–2011). BMJ open, 3(7), e002924. 
356 R v Gillespie and others, United Nations Office of Drugs and Crime, UNODC No.: GBRx001. 
357 ibid. 
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methods of operation involved shutting down companies358 and bank accounts, as 
soon as they were on the radar or were compromised. However, he would readily 
open new ones in the same city within a radius of 200 meters of the previous 
company/bank. Besides, F possibly had previous convictions for providing 
falsified HIV medicines to regions of French speaking West African countries.359  
 
F was hand in glove with C,360 a man of Chinese origin. C was a well-travelled 
person, especially in Ukraine and had wide business interests, including mining. 
He traded industrial quantities of APIs and attended International Fine Chemical 
and API conventions. C also hired a number of specialists and was involved in 
online business and business forums. He had commenced his business with Viagra 
and Cialis and moved on to certain specific medical products. It was discovered 
that C used online chat rooms for communication.361 
 
The process started with the purchase of the counterfeit medicines for £1.4 million 
(the retail value of the medicines was £4.7 million) through a company based in 
Luxembourg. B was the owner and ran this company. F was the middleman 
between B (end market) and C (counterfeiter). He would procure genuine 
medicines and send them to C. C would reverse engineer the medicines and would 
ask for the batch number, expiry date and language on the packaging. The 
chatrooms, web based emails and line anonymisers (TOR nodes) were used to 
communicate, control the movement of medicines and oversee the movement of 
358 See Davison, M. (2011). Pharmaceutical anti-counterfeiting: combating the real danger from fake drugs. John 
Wiley & Sons. 
359 R v Gillespie and others, United Nations Office of Drugs and Crime, UNODC No.: GBRx001. 
360 Kevin XU, owner of Orient Pacific International, based in China was caught in an undercover operation by the 
Immigration and Customs Enforcement (ICE), USA in 2007. The undercover agent was offered an unprecedented 
amount of medicines in a meeting in March 2007 in Bangkok, Thailand. Source: R v Gillespie and others, United 
Nations Office of Drugs and Crime, UNODC No.: GBRx001. 
361 ibid. 
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air freights.  C362 manufactured the counterfeit medicinal products and sent them 
from China via Hong Kong, Singapore, Belgium to the UK. They were brought by 
air to Belgium and via ferry/road to the UK. 363 There were nine instances of 
importation through this channel in a period of six months. There was a difference 
between the actual route that was adopted while transporting the counterfeit 
medicines and the route that was documented in the paper trail that was left. 364 
 
After arriving in the UK, the medicines reached the warehouse through postal and 
courier traffic,365 where the medicines were repackaged and relabelled. The 
repackaging and relabelling process were coordinated by B.366 The goal seemed to 
be to disguise these counterfeit medicines as parallel traded medicinal products 
that were of ‘French origin’, including the vignette details,367 the medicine, the 
cost, the rate of reimbursement and a bar code. The medicines were relabelled and 
bore the appearance of medicine originating in France by re-packaging with 
French leaflets and putting the counterfeit vignettes labels used in France.368 
Thereafter, these re-packaged medicines were sold to licensed wholesalers, who in 
good faith sold it to hospitals, clinics and care homes. In this manner, counterfeit 
362 C was detected in an undercover operation being carried out by the US authorities concerning falsified 
medicines. C met the US undercover agents in Bangkok to talk about supplying falsified medicines, where he 
proposed that he could provide falsified Zyprexa, Plavix and Casodex. US authorities informed the UK authorities 
about the ongoing investigations, based on which, the UK government recalled the medicines. C travelled to USA 
to supply the promised falsified medicines and was taken into custody upon arrival. His laptop, which was sent to 
the UK, for forensic analysis and the laptop revealed evidence of the sale of counterfeit medicine supplied to the 
UK. C was prosecuted in the US and was given 6 and half years of imprisonment by US District Court for the 
Southern District of Texas, Houston Division. He was convicted on the charges of conspiracy to traffic counterfeit 
goods (Zyprexa, Tamiflu, Casodex, Plavix, and Aricept and individual charges of dealing in misbranding drugs and 
charges of trafficking in counterfeit drugs. Source: Regina v. Gillespie and others. (2010). Crowns Court at 
Croydon. Operation Singapore. Confidential case notes, paragraph 240, 81 
363 Regina v. Gillespie and others. (2010). Crowns Court at Croydon. Operation Singapore. Confidential case notes, 
paragraph11(e),6. paragraphs 238 -239, 79-81.  
364 ibid., paragraph11 (f), 6. 
365 ibid.,The last batch of counterfeit medicine was recovered at a warehouse in Slough. 
366 ibid. 
367 ibid.,The colour of the vignette is determined by reimbursement rate. They are significant and their presence 
vouches for that the medicinal products are from the French market. 
368 ibid., paragraph 68, 21. 
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medicines infiltrated the legal supply chain. The counterfeiting scam was 
discovered when a licensed re-packager noticed an error on a batch number and 
reported to the MHRA. The Trademark right holder, Eli Lilly had already set up 
an independent investigation into the Chinese manufacturer with the assistance of 
the US authorities at that time.  
 
Therefore, a coordinated effort of more than twelve countries helped in unearthing 
the plot. The accused were charged with conspiracy, conspiracy to defraud; 
conspiracy to money laundering;369 fraudulent trading; trademarks offence,370 
marketing authorisation offence, and disqualified director offence.371 As a result of 
four years of investigation into one of the most lethal breach of the regulated 
supply chain in the U.K., where over 2 million doses of counterfeit medicine were 
involved, only one person was convicted and sentenced to eight years of 
imprisonment in the UK.372 The Chinese national was sentenced to six and a half 
years jail in the US.373 However, the other accused along with B were cleared of 
any fraud.374 
 
3.3.3. Revelations 
Operation Singapore, led by the MHRA revealed that the legal supply chain in the 
UK was infiltrated by counterfeit drugs, disguised as parallel imported medicines 
from France. The medicinal products were falsified products imported from 
369 Typically, it is connected to trade in counterfeit medicines. See more in Buckley, G. J., & Gostin, L. O. (Eds.). 
(2013). Countering the problem of falsified and substandard drugs. National Academies Press. 
370 See more general explanation in Attaran, A., Bate, R., & Kendall, M. (2011). Why and how to make an 
international crime of medicine counterfeiting. Journal of International Criminal Justice, mqr005. 
371 MHRA case files, Operation Singapore, 2010, Paragraphs 293-302, 106-111. 
372 See for general trend in the UK for comparison: Medicines and Healthcare products Regulatory Agency. (2011); 
MHRA annual statistics 2010/2011. In Safeguarding public health. London. MHRA. 
373 R v Gillespie and others, United Nations Office of Drugs and Crime, UNODC No.: GBRx01; See more in U.S. 
v. Xu, Not Reported in F.Supp.2d (2008). 
374 R. v Gillespie (Peter Hugh), Court of Appeal (Criminal Division) 29 November [2011] EWCA Crim 3152; 
[2012] 2 Cr. App. R. (S.) 24; Official Transcript. 
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China. They were re-packaged and the act of counterfeiting occurred. This was 
facilitated by insertion of leaflets in French in the medicine boxes as well as by 
affixing the French vignettes on the packaging. Therefore, when the medicines 
were sold to unsuspecting wholesalers, the wholesalers could not tell the 
difference because of the uncanny similarity to the original product. After the 
counterfeit medicines manufactured in China arrived in the UK, the counterfeit 
medicines were repackaged and relabelled. This was a well-organised and 
premeditated operation as is evident in this set up of one mastermind contracting 
out the job to manufacture a product to a ‘counterfeiter’ in China. This 
counterfeiter in China supplied not only to Europe but also negotiated a deal to 
supply this life-saving cancer treatment medicine to the US as well. In the process, 
he was arrested by the US Customs.375 
 
In addition to violating the Medicines law, the IPRs of the right holders were also 
violated - Sanofi Aventis (owner of the trademark ‘Plavix’), Elli Lilly (owner of 
the trademark ‘Zyprexa’, who was already conducting a private inquiry into the 
counterfeiter based in China) and Astra Zeneca (owner of the trademark ‘Casodex’ 
and ‘AZ’ and ‘AstraZeneca’). The counterfeit medicines were being portrayed as 
the authentic product, which is the unlawful adoption of the registered marks on 
the packaging that was done without the lawful consent of the owners of the 
registered mark.376       
   
375 See more in U.S. v. Xu, Not Reported in F.Supp.2d (2008). 
376 Regina v. Gillespie and others. (2010). Crowns Court at Croydon. Operation Singapore. Confidential case notes, 
paragraph 300. 109-110. 
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3.4. Operation Robin  
3.4.1 Introduction 
Operation Robin,377 a covert operation that lasted for a year and a half was 
conducted by the Swedish Customs Law Enforcement Department. The 
investigations covered the period from January 2009 until May 2012. A minor 
offence of the seizure of cigarettes in June 2009 revealed the link to payments 
being made for steroids that led to the unravelling of a huge operation in falsified 
and counterfeit medicines. The analysis of the evidence, surveillance and 
documentation of bank accounts showed evidence of movement of approximately 
450 million euros through Egypt, Hong Kong, Dubai, and Europe.378 Besides the 
offences of counterfeiting, falsification of medicines, money laundering in UAE, 
Marshall Islands, and the Cayman Islands, a complex smuggling operation of 
illegal medicinal products was revealed, employing small packets and parcels 
encompassing vast geographical expanse from Asia to Egypt to the U.K. to 
Denmark and then finally to Sweden.379  
 
3.4.2. Factual background 
The story began to unfold when a legal aid on a specific mission to Canada gained 
access to emails from 2007 to mid-2011 revealing that the production of steroids 
and falsified medicines were a well-organised crime being executed where 
Sweden and the rest of Scandinavia was the target audience.380 The organisation 
carrying out the Operation was very well organised, having a semblance of a 
377 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
378 ibid. 
379 EUROPOL & OHIM. (June 2013). Reports and Conclusions, Knowledge Building in IP Enforcement, 
Combating Pharmacrime A knowledge –building Conference on Counterfeit Medicines. Alicante. Spain. 16. 
380 Case No. B 6262 -12. Judgement of Stockholms Tingsrätt of 25 June 2013. Confidential case notes. 
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legitimate company.381 They had four groups each being led by a head of 
operations for economy, distribution, sale and marketing. In addition, there was a 
coordinator, who was meant to oversee that all the different departments worked 
well together. The production design was specialised with each person having a 
specialised field of work, taking orders, packaging, production of illegal products, 
sending threats etc. The organisation was so specialised that there were policy 
documents for everything, weekly reports, stock reports and accounts were also 
maintained. 
 
The modus operandi revealed that the raw materials or products were sent from 
Asia, especially China and Hong Kong, which sent APIs.382  The parcels 
dispatched from Asia and Egypt383 were received in London, England in 
mailboxes.384 Thereafter, the parcels were sent to mailboxes in Berlin, Germany, 
while a few of the parcels ended up in Business Service Frederiksberg, Denmark. 
Using the UPS services, the parcels were then transported to Sweden. These 
parcels were driven from one fake address to another.385 In this process, a person 
was involved who picked up the parcel in person from Brevia, a mailbox company 
in Stockholm, Sweden. It was deduced that the person who collected the package 
stored it for a few days before dispatching it off to another address in Sweden.386 
 
In January 2009, 102 kilos of pyrazinamide was seized in Stockholm and one man 
was apprehended with regard to the seizure. The same person received parcels 
containing equipment for making steroids, while still in custody. Simultaneously, 
381 Case No. B 6262 -12. Judgement of Stockholms Tingsrätt of 25 June 2013. Confidential case notes. 
382 See explanation in Glossary for APIs. 
383 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013, 76. 
384 ibid. 
385 ibid. 
386 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
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another person received a tablet making machine. The authorities were able to 
trace every payment to the same bank account, which pointed the authorities in the 
right direction to resolve the case. An analysis of the bank account revealed 
transactions of big amounts. In June 2009, two containers filled with 18 million 
cigarettes were seized in a harbour in Stockholm. The payment of customs fee was 
traced to two bank accounts, and one of these bank accounts also made the 
payments for the steroids. The cross-examination of the owner of the container 
brought to light the fact that he had bought the steroids from an internet website. 
 
In June 2011, a parcel containing 50,000 alprazolam and 20,000 tablets of 
Stanozolol was seized. 387 The parcel was addressed to a fake address that was 
altered several times before it arrived at its final destination in Sweden. The 
payment for the transportation of the parcel was facilitated by faceless credit 
cards. The movement of the parcel was enabled by using postal and courier 
services such as DHL, UPS, and Swedish postal services. The authorities began 
tracing the smuggling routes and documented the parcels to see what was in it. 
The key confiscation was made on September 8, 2011, when the parcel labelled 
Global Iron Tech was intercepted and 200,000 labels of this brand were 
discovered. Global Iron Tech offered products for sale on the website called 
www.steroidakuten.org. 
 
This seizure revealed to the authorities that the products were being 
manufactured/put together/assembled in Sweden at a warehouse at Borlänge.388 
The parcel was sent back to the normal postal channel after the contents of the 
parcel were documented for. On September 16, 2011, the parcel was collected at 
387 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
388 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013, 77. 
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Brevia389 by an unknown person. After another 12 days, the parcel was picked up 
at a post office in Borlänge, in the middle of Sweden. On the same day, the parcel 
arrived at its final destination, the factory producing liquid steroids. The means of 
transportation and communication was through mailbox companies such as ASA, 
DHL and UPS because these were faceless companies, where faceless credit cards 
and identities could be used in order to remain anonymous. Moreover, it would be 
difficult for the authorities to follow the consignments and discover the final 
destinations.390 In February 2012, a seizure at a dispatcher’s house in Sweden led 
to the discovery of 700,000 units of steroids, 800 narcotic tablets, 35,000 tablets of 
falsified medicines, an encrypted computer and addressed envelopes and parcels 
containing medicines and steroids ready to be dispatched to customers. 
 
The dots were connected when authorities executed an undercover operation to 
make the final bust. Three test purchases were made by the authorities from the 
different websites – Steriodakuten.org, Vikingstore.org and Anabolic.cc.391 
Instructions were strictly followed regarding payment and payment methods that 
gave further access to new bank accounts to be analysed. As instructed, a mailbox 
at Brevia was rented and illegal substances were delivered into the mailbox. The 
final coordinated bust392 that simultaneously took place at several places in 
Sweden revealed that the illegal organisation had made 450 million euros by 
selling steroids and fake medicine between January 2009 and May 2012. The 
leaders and the head of the organisation had earned 350 million euro by selling 
steroids and fake medicines. The twelve workers had made approximately 50 
389 Brevia is a rent a box company, which ensures a high level of confidentiality. 
390 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013, paragraph 4, 54. 
391 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013, 47 - 50.  
392 The final bust took place on May 8, 2012. And assets worth 700,000 Euros were confiscated. Source: Case No. 
B 6262 -12. Judgement of Stockholms Tingsrätt of 25 June 2013. Confidential case notes. 
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million euros.393 
 
The total seizures during Operation Robin amounted to 11 million units of active 
substances,394 550,000 narcotic tablets and 3 kilos of narcotic powder, 610,000 
tablets of falsified medicines, equipment for producing liquid steroids, labels, 
machines for making tablets and assets worth 70 million euros. In all, 23 people 
were sentenced395 to prison, with two people receiving 16 and 14 years of 
imprisonment. The four leaders were awarded life imprisonment in Thailand396 
and another one received seven years prison sentence. During the Operation, 
besides steroids and narcotics, two steroid producing factories were also 
uncovered. The perpetrators were charged with drug trafficking and gross drug 
smuggling offence, gross doping crime, smuggling and violating of law on 
pharmaceuticals trade. 
 
3.4.3. Revelations  
Operation Robin led by the Swedish Customs and Law Enforcement Authority 
revealed that falsified medicines and counterfeit products were offered for sale 
over the internet by making use of three websites.397 The counterfeit APIs were 
imported from Asia that arrived in Sweden in small packets using postal and 
courier services. After arriving in the EU, these packets were sent from one 
mailbox in one Member State to another mailbox in another Member State several 
times, before they ended up in the factory in Borlänge.398 In the factory, these 
393 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
394 11 million units of active substances imported from China, Hong Kong and Egypt, Case No. B 6262 -12, 
Judgement of Stockholms Tingsrätt of 25 June 2013, 50. 
395 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013, 1. 
396 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013, 90. 
397 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013: www. steriodakuten.org, 
www.vikingstore.org, and www.anabolic.cc. 
398 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
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products were put together and offered for sale through the websites. They were 
dispatched using the postal services. Operation Robin also revealed that the 
management was very well-organised and the structure of the organisation 
resembled the structure of a legitimate company with described and recorded work 
programs and flows.  
 
As in other cases of falsification and counterfeiting of medicinal products, 
Operation Robin also sheds light on the elements of premeditation — well-
structured and organised nature; use of small consignments for transportation; use 
of online method of sale and manipulation of products; and involvement of more 
than one country in the process of counterfeiting and falsification of the medicinal 
products. 
 
3.5. Problems highlighted the case studies 
An evaluation of Operation Volcano, Operation Singapore and Operation Robin 
reveals some similarities and certain differences in the manner in which 
counterfeit and falsified medicines are manufactured, marketed, sold and 
infiltrated in the legal supply chain. This section aims at detecting these patterns in 
order to discover the gaps in the legal framework dealing with counterfeit and 
falsified medicines in the EU. Even though only three case studies are addressed 
in this chapter, there are reports of more such similar incidents in the EU.399 
 
399  Hall, A., Koenraadt, R., & Antonopoulos, G. A. (2017). Illicit pharmaceutical networks in Europe: organising 
the illicit medicine market in the United Kingdom and the Netherlands. Trends in Organised Crime, 1-20; 
Valverde, J. L. (2017). Illegal medicines as threats to public health. Pharmaceuticals Policy and Law, 19(1-2), 1-
16; See more in AIFA case files. AIFA.(Update 14 August 2014). Drugs involved in illegal trafficking.  Inspections 
& Human Medicines Pharmacovigilance Division Batches of Herceptin, Alimta and Remicade concerned by on-
going investigation into stolen vials of medicine in Italy, (2014; A few examples from the AIFA communication 
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3.5.1. Infiltration of the legal supply chain 
The legal supply chain was infiltrated in all three Operations by using the guise of 
parallel import, fake authorisation and use of fake invoices, which were not 
detected. In Operation Volcano, the German parallel distributor discovered the 
counterfeit and falsified medicine by detecting the visible signs of tampering of 
the medicinal products.400 Operation Singapore revealed counterfeit and falsified 
medicine disguised as French parallel imported products, with elaborate French 
vignettes affixed on the packages.401  In addition to using the guise of parallel 
importing, fake invoices were also used. The legal supply chain was infiltrated by 
selling to authorised dealers through unauthorised dealers in order to ‘whitewash’ 
the medicinal products. In contrast to Operation Volcano and Operation 
Singapore, a trend which is widespread in the EU as well as in other parts of the 
world was evident in Operation Robin, where the legal supply chain was 
infiltrated by offering the steroids, narcotics and medicinal products for sale over 
the internet through three websites.402  
 
From these cases, it is apparent that some wholesalers were not following the 
regulations.403 As is evident from Operation Volcano, non-compliance with the 
regulatory framework resulted in a lot of wastage of time, money and other 
resources.  As stated in the investigations, the operators who bought the products 
from “non-authorised wholesalers” underwent sanctions from the competent local 
authorities because it was a violation of Article 80 of the Medicines Directive 
issued are Alimta (Germany, Czech Republic, The Netherlands); Avastin (The United Kingdom, Switzerland, 
Germany, The Netherlands), Avonex (Germany, Sweden, Hungary). EMA/329302/2014. (2014). 
400 See Chapter 3, Section 3.2. 
401 See Chapter 3, Section 3.3. 
402 Hall, A., & Antonopoulos, G. A. (2016). Introduction. In Fake Meds Online.  Palgrave Macmillan UK. 1-17. 
403 License of three operators were suspended as a result of the investigations by the competent local authority in 
Regione Campania and two of the operators withdrew and were no longer active. Source: Di Giorgio, D. (Director 
of Publication). (2015).White Paper on Operation Volcano, The Herceptin Case: story, lesson learned, proposals, 
AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco.  
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amended by the FMD,404 which requires the holder of distribution authorisation to 
meet certain minimum requirements. Furthermore, the cost of human life and the 
erosion of trust in the medical system and practice and machinery of law that is 
meant to safeguard the systems can take years to rebuild.   
 
 3.5.2. Well-organised and premeditated crime 
In all three operations based in the different EU Member States, the crime of 
counterfeiting and falsification of medicines was well-organised and designed. In 
all the three operations, whether they involved multiple countries or multiple 
continents, there were networks of specialised criminals in place. For instance, in 
Operation Singapore, there were three key figures that were at the helm of 
affairs.405 In Operation Robin, there was a clear organised structure with 
compartmentalisation of production, distribution, accounts etc.406 There was a 
coordinating mastermind, who employed and hired locals to execute the plan of 
theft. Thereafter, a separate set of people were asked to handle the paperwork and 
another set of people were hired to tamper with the medication. Similarly, in 
Operation Singapore, the Chinese partner was responsible for manufacturing the 
counterfeit medicine and transporting it to the U.K. through Belgium. In this way, 
Operation Singapore further lifted the veil over the local warehouses being set up 
for the purpose of tampering with the medicine or medicinal products.  
 
Moreover, in Operation Volcano, the local warehouses were located in Naples407 
and in Operation Singapore, the local warehouses were located in Slough.408 The 
404 Article 80, Directive 2001/83/EC.  
405 See Chapter 3, Section 3.3.2. 
406 See Chapter 3, Section 3.4.2. 
407 Di Giorgio, D. (Director of Publication). (2015).White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco. 
408 Regina v. Gillespie and others. (2010). Crowns Court at Croydon. Confidential case notes.  
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main purpose of the local warehouses was to give the products an appearance of 
the true likeness of the product that was being copied. In Operation Singapore, it 
was revealed that the packaging was touched up to appear as if it was being 
manufactured in France. In Operation Robin, the Swedish authorities were also 
able to trace two steroid producing factories409 that performed the same function.  
 
3.5.3. Small consignments 
In the case of Operation Singapore and Operation Robin, the local postal network 
was used to send and receive falsified medicines. In Operation Singapore, the 
active substances were imported from China and arrived at Brussels from 
Singapore in small packets.410 In Operation Robin, the small packages containing 
the counterfeit products were also imported from Asia via the UK, Germany, and 
Denmark into Sweden using mailbox services like Brevia, UPS and DHL.411These 
similarities in the method of operation in the three individual cases shed light on 
the fact that the packages sent through the postal system and packages arriving via 
airmail do not always get detected.  
 
3.5.4. Presence of cross-border element  
The three Operations discussed above highlight that typically, there are more than 
three countries involved. Operation Volcano shed light on the fact that even 
though the main activity of theft of medicine and re-introduction of the counterfeit 
medicine into the legal supply chain took place in Italy, the fake invoices were 
issued by players based in Malta, Romania, and Latvia. Operation Singapore 
409 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
410 Regina v. Gillespie and others. (2010). Crowns Court at Croydon. Operation Singapore. Confidential case notes, 
paragraph 146 (e), 53.  
411 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
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established that the counterfeit medicine was being manufactured in China, 
shipped to Hong Kong and ended up in Belgium. After the counterfeit medicine 
was collected in Belgium, finally reached the U.K. The cross-border element was 
already visible in Operation Singapore. Similarly, Operation Robin revealed that 
the parcels and packages that carried the counterfeit products moved from Asia, 
Egypt, the U.K., and Denmark and then ended up in Sweden. Therefore, the 
question of which country should take the lead in multi-jurisdictional cases must 
also be addressed as regards to such cases within the EU, at the very least. 
 
3.5.4. Type of medicines being falsified 
The investigations in Operation Volcano, pertaining to Herceptin case have 
indicated that the same business model and network was operating for falsification 
of other medicines like “Pegasys”, “Avastin”412, “Alimta” and “Remicade”.413 In 
2013, Oeprazole (for gastroesophageal reflux disease) was detected in 
Germany.414 In the same year, 1.2 million doses of fake aspirin were seized in 
France, consisting of glucose and no active ingredients.415 The common 
denominator is that all these medicines are lifesaving medicines. There seems to 
be a clear expansion in the kind of pharmaceutical products that are being 
falsified. In the preceding decade, the focus of falsified medicines was more on 
412 See Paul- Ehrlich Institut (PEI), an institution of the Federal Ministry of Health, Federal Republic of Germany.  
(19 November 2014). Warning issued by PEI on Falsified Avastin of Romanian origin.  
413 SEE EUROPEAN MEDICINES AGENCY. (JUNE 3 2014). NEWS. UPDATE ON INVESTIGATION BY 
ITALIAN AUTHORITIES INTO THE SUPPLY OF STOLEN MEDICINES.U.K.; SEE MORE PEI (JUNE 4 2014). 
ARZNEIMITTELDIEBSTÄHLE IN ITALIEN - WEITERE INFORMATIONEN. GERMANY. 
414 Jack, A. (2013). Teva discovers Sophisticated Fakes of Popular drug. Financial Times. 
415 AIFA. (2010). The Handbook. IMPACT - International Medical Products Anti-Counterfeiting Taskforce – Facts, 
Activities, Documents developed by  the Assembly and the Working Groups of IMPACT 2006-2010). AIFA. Italy. 
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lifestyle drugs.416 However, it is apparent that recently the life-saving drugs have 
become the target of falsification. For instance, in Operation Singapore, 417 carried 
out by MHRA, it was discovered that fake life-saving medicines were being 
manufactured in China and finding their way into the U.K. through Belgium in 
2006-07.   The medicines that were falsified were Plavix (clopidogrel), a 
prescription only medication, which acts as an anti-platelet and is used in the 
treatment of preventing heart attacks; Zyprexa (olanzapine) a prescription only 
medicine used to treat schizophrenia and bipolar disorder; and Casodex 
(bicalutamide) used in the treatment of advanced prostate cancer.  
 
3.5.5. Institutional issue 
Operation Volcano, as well as Operation Singapore, and Operation Robin reveal 
that there is a need for appropriate coordination and clarity regarding the 
appropriate structure and chain of command to follow when such incidents take 
place. This problem affects many Member States, especially in the light of the fact 
that counterfeiting and falsification of medicines usually involve more than one 
EU Member State. While a few Member States are housing the “bogus operators”, 
others are bearing the “flood of falsified medicines” in their territories. The 
institutional coordination at the Member State level and between the Member 
States does not seem to be optimal. However, each country dealt with the problem 
in their own way as highlighted by the case studies. In Sweden, it was the Swedish 
416 Bulletin of the World Health Organisation. (April 2010). Growing threat from counterfeit medicines. Vol.88.(4). 
241-320.  “A Pfizer-sponsored study, one of the largest investigations conducted in 14 European countries, 
estimated that western Europeans spend more than US$ 14 billion a year on illicitly-sourced drugs, many of them 
counterfeit. A big share of the market constitutes the so-called “lifestyle” drugs. The study found that almost half 
the counterfeit drugs sold on the Internet were for weight loss, followed by influenza medicines. Another key market 
for counterfeits in Europe, as in Asia, is erectile dysfunction, nourished by the growth in online pharmacies that 
offer access to prescription-only medicines without the embarrassment of consulting a doctor. A Dutch study cited 
by the International Journal of Clinical Practice found that, of 370 seized Viagra samples, only 10 were genuine.” 
417 Operation Singapore is the name given to the case Regina v. Gillespie and others. (2010). Crowns Court at 
Croydon. Confidential case notes. 
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Customs and Law Enforcement Authority that took the lead in solving the case. In 
the UK and in Italy, the Medicines Authorities led the investigations. A similar 
structure involving bogus operators existed in Romania.418 One could raise 
questions as to why the inspections carried out by the NCAs did not ring alarm 
bells while routine inspections were being carried out and vials were clearly being 
manipulated, which was visible to the naked eyes. Also, even when the local 
authorities discovered manipulation of the Herceptin vials, there was no obligation 
to send notifications to the relevant authorities within the country and in the other 
EU Member States.  
 
3.6. Concluding remarks 
It is apparent from the case studies that the problem of counterfeit medicine is not 
restricted to Asia, Africa, America or Europe. In most of the cases pertaining to 
falsification and counterfeiting of medicines, more than one country is involved.419 
This is a problem of gargantuan proportion and involves people having 
sophisticated knowledge about the pharmaceutical sector and well-versed in the art 
of trade and commerce.420 In most cases, they are highly educated people who 
understand the financial sector, the legal frameworks and are adept at by-passing 
and side-stepping the current system of protection, which is erected to safeguard 
the vulnerable sections – people suffering from illnesses that are sometimes, life-
418 AIFA case files, (8 August 2014). Rapid Alert issued by AIFA; Di Giorgio, D. (Director of Publication). 
(2015).White Paper on Operation Volcano, The Herceptin Case: story, lesson learned, proposals, AIFA, AEMPS, 
AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco.  
419 Surveying, Ö. B. I. G. (2006). Assessing and Analyzing the Pharmaceutical Sector in the 25 EU Member 
States. Report Commissioned by the DG Competition—European Commission. Brussels: Office for Official 
Publications of the European Communities; See more in Attaran, A. (2015). Stopping murder by medicine: 
introducing the model law on medicine crime. The American journal of tropical medicine and hygiene,92 
(6_Suppl), 127-132. 
420 R. v Gillespie (Peter Hugh), Court of Appeal (Criminal Division) 29 November [2011] EWCA Crim 3152; 
[2012] 2 Cr. App. R. (S.) 24. See section 3.3 for more details. 
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threatening.  
 
From the case studies, it has become apparent that the crime of counterfeiting and 
falsification of medicines does not occur in isolation.421 It is inevitably 
accompanied by the crimes of money laundering, smuggling, theft, forgery of 
documents, fraud and IP violations.422  As Operation Robin illustrated, money 
laundering to Cayman Islands, Marshall Islands and Switzerland was associated 
with the counterfeiting and falsification of the medicines, steroids and narcotics.423 
In Operation Singapore, IP violations were also recognised, in addition to fraud, 
money laundering and forgery of documents.  
 
The case studies also indicate that several ways are employed to conduct trade in 
counterfeit medicine. Some of the common features of this trade include the 
presence of a complex and specialised machinery of people that are employed to 
infiltrate the legal supply chain. In all the three operations, the tasks to execute 
falsification and counterfeiting were specialised and divided into marketing, 
assembly of the product, sale and manufacture. Another common feature in all the 
operations was that the postal services were used as means of transportation and 
web-based chat rooms and telephones were used for communication between one 
criminal and another. From the three legal case studies, it also emerged that drugs 
can either be manufactured with false ingredients or can be stolen and tampered 
with or sometimes stolen and re-introduced in the black market.  
421 Spink, J., Moyer, D. C., Park, H., & Heinonen, J. A. (2013). Defining the types of counterfeiters, counterfeiting, 
and offender organisations. Crime Science, 2(1), 8. 
422  UNODC. (2014). Counterfeit - don’t buy into organised crime. In The illicit Trafficking of Counterfeit Goods 
and Transnational Organised Crime. United Nations Office on Drugs and Crime. Vienna, Austria. 
423 Riccardi, M. (2014). When criminals invest in businesses: Are we looking in the right direction? An exploratory 
analysis of companies controlled by mafias. In Organised crime, corruption and crime prevention (197-206). 
Springer International Publishing. 
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In a nutshell, the common issues of concern that have emerged are that the legal 
supply chain is infiltrated by the illegal supply chain; sale of counterfeit and 
falsified medicine takes place not only through brick and mortar pharmacies but 
also through online websites; and the types of medicines being falsified and 
counterfeited are not restricted to lifestyle drugs but live-saving drugs are also 
targeted. Furthermore, mostly, the counterfeit and falsified medicinal products are 
transported in small consignments from one place to the other using courier 
services or mail box delivery services. 
 
The legal framework does not appear to be geared to deal with the influx of 
counterfeit medicines as is evident from the increasing number of falsified and 
counterfeit products being introduced in the market.424 The following segment of 
the thesis - Part III, it will be analysed how these issues identified in the case 
studies, are tackled by the legal instruments (the Falsified Medicines Directive, the 
Enforcement Directive and the Customs Regulation). If there are any gaps in the 
laws, they will also be pointed out.  
424 As also recognised in Recital 2, in the preamble to the Falsified Medicines Directive (Directive 2011/62/EU). 
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Part III consists of four chapters, wherein using the legal dogmatic method, the 
legal instruments containing provisions that provide tools to combat falsification 
and counterfeiting of medicinal products are analysed, in the light of the common 
issues identified in Part II. In Chapter 4, the Falsified Medicines Directive 
(Directive 2011/62/EU) is analysed with a focus on the provisions such as 
introduction of safety features to prevent falsification of medicines; measures to 
ensure the sanctity of the legal supply chain and provisions to protect the online 
sale of medicines. This is followed by Chapter 5, wherein the Enforcement 
Directive (Directive 2004/48/EC) is analysed with emphasis on the provisions that 
assist the right holders to enforce their rights and the issues with respect to 
counterfeiting of medicinal products. In Chapter 6, the Customs Regulation 
(Regulation 608/2013) is analysed with reference to issues raised in Part II and 
140 
 
 
 
 
with special reference to the problems of counterfeit medicinal products entering 
in small consignments, traveller’s luggage and the issues like parallel import, 
which have not been addressed by the Regulation. This Part ends with Chapter 7 
on global initiatives wherein the Medicrime Convention, the ACTA and a few 
multi-lateral and bilateral agreements are analysed. The primary aim of the 
analysis of the global initiatives is to ascertain if any of the provisions can be 
beneficial for the EU legal framework. 
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Chapter 4: Analysis of the Falsified Medicines 
Directive (Directive 2011/62/EU) 
 
4.1. Introduction 
The Falsified Medicines Directive (Directive 2011/62/EU), henceforth ‘the 
FMD,’425 represents the health law perspective.426 The IP law and Criminal law 
perspective will be dealt with later in the thesis. The chapter will begin by 
providing a general background to the formation of the FMD, followed by the 
description of some of the main relevant provisions of the FMD. Subsequently, the 
focus narrows down on the provisions that are related to the primary issues raised 
in the previous chapter. The practical challenges that arise in combatting 
falsification and counterfeiting of medicines in the EU were identified as being the 
manipulation of the medicinal product itself;427 the infiltration of the legal supply 
chain by prevalence of fake market authorisation and the use of disguise of 
parallel importers;428 the sale of counterfeit medicinal products online;429 the 
presence of cross-border element;430 and the role played by organised crime. 
 
The ‘FMD’ amended the Directive 2001/83/EC,431 (henceforth, referred to as the 
‘Medicines Directive’) in order to update the Medicines Directive for meeting the 
challenges raised by the infiltration of the legal supply chain by falsified 
425 Directive 2011/62/EU. 
426 See more in Chapter 2, Section 2.3.4.1. 
427 Chapter 3, Section 3.4. Operation Robin, Section 3.2. Operation Volcano, and Section 3.3. Operation Singapore. 
428 Chapter 3, Section 3.2. Operation Volcano. 
429 Chapter 3, Section 3.4. Operation Robin. 
430 Chapter 3, Section 3.3. Operation Singapore, Section 3.2. Operation Volcano. 
431 Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community 
code relating to medicinal products for human use. 
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medicines in the EU. The Medicines Directive, which was developed in 2001, was 
the first comprehensive directive on medicinal products for human use.432 The 
broader aim of the Medicines Directive was to establish exhaustive rules to 
facilitate the functioning of the internal market for medicinal products while 
ensuring a high level of protection of public health in the EU.433  Due to the 
escalation of falsification and counterfeiting of medicines and other related 
pharmaceutical crimes,434 such as the sale of unregulated and counterfeit medicine 
through online pharmacies and websites, along with infiltration of the legal supply 
chain by falsified and counterfeit medicine,435 the need to amend the Directive was 
recognised. The required changes to the Medicines Directive were articulated in 
the FMD. The objectives, scope, and relevance of the FMD have been discussed in 
detail in Chapter 2,436 where it was established that the FMD is in consonance with 
the provisions of the TFEU (Articles 168, 26 and 114); the TEU (Articles 4, 5 and 
9) and Charter of Fundamental Rights of the EU (Articles 2, and 35). The FMD 
promotes the realisation of the goals of the internal market along with the aims of 
public health and protection (Article 168, TFEU). It supports access to high-
quality medicines to all. The provisions of the FMD should, thus, be viewed 
432 Jones, G. (2014). The Falsified Medicines Directive: time to get it right. The Pharmaceutical Journal, 293, 
7832. 
433 The legal basis springs from Article 114 (3) (ex- Article 95 TEC) of the Treaty on the Functioning of the 
European Union, 2012, which states: 
“The Commission, in its proposals envisaged in paragraph 1 concerning health, safety, environmental protection 
and consumer protection, will take as a base a high level of protection, taking account in particular of any new 
development based on scientific facts. Within their respective powers, the European Parliament and the Council 
will also seek to achieve this objective.” 
434 For example, ’Operation Robin’ conducted in Sweden revealed that fake medicines, steroids, narcotics were 
being smuggled through small packets from Asia, Egypt, Denmark, and then ended in Sweden. In Sweden, they 
were being sold through three websites and were delivered by using the postal system. Source:  
Source: Europol & OHIM. (June 2013). Reports and Conclusions, Knowledge Building in IP Enforcement, 
Combating Pharmacrime A knowledge –building Conference on Counterfeit Medicines. Alicante. Spain 
435 Di Giorgio, D. (Director of Publication). (2015).White Paper on Operation Volcano, The Herceptin Case: story, 
lesson learned, proposals, AIFA, AEMPS, AGES, ICZ, MHRA. Rome, Agenzia Italiana del Farmaco. In Operation 
Volcano, in Italy, identified that a cancer treatment drug, Herceptin was stolen from an Italian hospital and 
tampered with and ended up in the legal supply chain; See also Newton, N., Amin, A. A., Bird, C., Passmore, 
Dukes, G., Tomson, G., & White, N. J. (2011). The primacy of public health considerations in defining poor quality 
medicines. PLoS Med, 8(12), e1001139. 
436 See Chapter 3. 
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against this backdrop. 
As falsified and counterfeit medicine had been identified across the EU, a 
consensus emerged that the solutions to the problem of falsified and counterfeit 
medicine would have to be sought at the EU level and not exclusively at the 
national level alone. This consensus of finding solutions at the EU level was 
articulated in various EU policies as part of the strategy for safe, innovative, and 
accessible medicines,437 as well as a general strategy for health in the EU.438 Three 
main goals were envisioned for the European Union — to strive towards a single 
and sustainable market in pharmaceuticals; to confront the opportunities and 
challenges of globalisation; and lastly, to make science deliver for European 
patients. The long term aim of the collective strategy is to restore the role of the 
EU as a leader in pharmaceutical innovation.439  
 
The FMD was specifically developed to combat falsified medicinal products in the 
legal supply chain. In the following sections, the FMD will be evaluated in the 
context of three main areas that are formulated on the basis of problem areas that 
came to light and were discussed in Chapter 3 — the manipulation of the 
medicinal product, the infiltration of the legal supply chain and the sale of 
medicines online. The FMD contains measures that regulate the medicinal product 
itself (addressing the problem of manipulation of the medicinal product), which 
has the aim of safeguarding the product through the introduction of safety 
features.440 The safety features include installation of anti-tampering devices 
(ATDs), as well as Unique Identifiers (UIs), setting up of a verification system, 
437 Safe, Innovative and Accessible Medicines: A renewed Vision for the Pharmaceutical sector, Communication 
from the Commission to the European Parliament, the Council the European Economic and Social Committee and 
the Committee of the Regions- Safe, Innovative and Accessible Medicines: a Renewed Vision for the 
Pharmaceutical Sector, COM (2008) 666 final, 10. 
438 White Paper, Together for Health: A Strategic Approach for the EU 2008-2013, COM (2007) 630 final. 
439 ibid., 4. 
440 Article 47a, 54a inserted in Directive 2001/83/EC and Recital 11 and 12 in Directive 2011/62/EU. 
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and a list of exceptions.  
In order to safeguard the legal supply chain, there are provisions that need to be 
followed while importing and exporting medicinal products for ensuring that 
counterfeit products do not enter the legal supply chain in the EU.441 For this 
purpose, the Good Manufacturing Practices (GMP), which have existed since 
2003,442 have been expanded and will need to be observed and strictly enforced.443 
Also, there are rules regarding Active Pharmaceutical Ingredients (API)444 that 
also concern the distribution system445 in the legal supply chain of the medicinal 
sector, which is regulated to ensure that there is no infiltration of counterfeit 
medicines through a large number of players in the distribution chain.446Another 
key feature of the FMD is the introduction of an online logo447 that must be 
displayed on any website that sells pharmaceutical products in the EU in order to 
safeguard online sale of medicines. Moreover, the FMD has many legal 
instruments as offshoots, which are relevant for the thesis and assist in combatting 
falsification of medicines. These are summarised in the following table (Table 2): 
441 Clift, C. (2010). Combating counterfeit, falsified and substandard medicines: defining the way forward?. 
London UK: Chatham House. 
442 GMP laid down in Directive 2001/83/EC under Article 47provide for a Directive 2003/94/EC of 8 October 2003 
laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for 
human use and investigational medicinal products for human use; See also EudraLex – Volume 4 Good 
Manufacturing Practice (GMP) Guidelines.   
443 The manufacturers are obliged to comply with GMP for active substances, including stricter controls and 
inspections through Commission Delegated Regulation (EU) No 1252/2014 of 28 May 2014 supplementing 
Directive 2001/83/EC of the European Parliament and of the Council with regard to principles and guidelines of 
good manufacturing practice for active substances for medicinal products for human use. 
444 Active Pharmaceutical Ingredient is the core ingredient in the medicinal product that carries the disease fighting 
power.   
445 Good Distribution Practices  originally laid down under Article 84 and Article 85b(3) of Directive 2001/83/EC 
are updated regularly; the latest being in Guidelines of 5 November 2013 on Good Distribution Practice of 
medicinal products for human use, 2013/C 343/01 have also been updated by the FMD, and subsequent 
introduction of Commission Delegated Regulation (EU) No.1252/2014 of 28 May 2014 and Guidelines of 19 
March 2015 on principles of Good Distribution Practice of active substances for medicinal products for human use 
(2015/C 95/01). 
446 Besides the traditional players in a distribution chain such as manufacturers, wholesalers, distributors, retailers 
there are also brokers and parallel importers. Another method of distribution of medicinal products is the online 
channel. 
447 Commission Implementing Regulation (EU) No. 699/2014 of 24 June 2014. 
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Type of Feature 
Reference in 
Directive 
62/2011/EU 
 
Type of legal instrument 
 
Safety features in 
medicinal product 
Article 4 Commission Delegated Regulation (EU) 2016/161 
of 2 October 2015 
Good Manufacturing 
Practices for active 
substances 
Article 1(5) Commission Delegated Regulation (EU) 
No.1252/2014 of 28 May 2014 
 
Principles of Good 
Distribution practices 
for active substances 
Article 1(5) Guidelines of 19 March 2015 on principles of Good 
Distribution Practice of active substances for 
medicinal products for human use (2015/C 95/01) 
 
Design of the common 
logo 
Article 1(20) Commission Implementing Regulation (EU) No. 
699/2014 of 24 June 2014 
 
Good Manufacturing 
Practice for excipients 
Article 1(7) Guidelines of 19 March 2015 on the formalised risk 
assessment for ascertaining the appropriate good 
manufacturing practices for excipients of medicinal 
products for human use (2015/C 95/02) 
 
Provisions for 
brokering in the 
guidelines on Good 
Distribution Practices 
Article 1(19) Guidelines of 5 November 2013 on Good 
Distribution Practices of medicinal products for 
human use (2013/C 343/01) 
 
Table 2 
 
4.2. The Medicinal product – safety features  
The manipulation of the medicinal product is a central issue in counterfeiting and 
falsification. Therefore, the importance of having safety features in place cannot 
be emphasised enough for products in general, and for pharmaceutical products, in 
particular.448 The urgency of installing safety features449 was prompted by the 
escalation in the number of counterfeit medicines entering through both the illegal 
448 Abril, J. L., Holt, D. W., & Wilson, R. R. (2016). Falsified Medicines in the European Union and North 
America: What are we doing to Protect Public Health? Journal of Pharmacovigilance. 
449 Krähenbühl, C. (2016). The EU-FMD Clock Is Ticking!. Industrial Pharmacy, 49(1), 4-6. 
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and legal supply chain,450 as revealed in Chapter 3 through the three case studies – 
Operation Volcano (the cancer treatment drug which was manipulated and injected 
with fake products, repackaged, and re-entered the legal supply chain),451 
Operation Singapore (where three prescription only medicines were imported from 
China, re-packaged, and introduced into the legal supply chain),452 and Operation 
Robin (steroids and medicines manufactured and packaged in Sweden after 
obtaining raw materials from Asia and sold over the internet). The counterfeit 
drugs that were injected with fake substances were reintroduced in the market by 
copying the labels and identifiers that make the counterfeit drugs appear 
authentic.453 It has been advocated that the packaging of pharmaceutical products 
should aim at protection, easy identification, and display.454 Against this backdrop 
of an exponential increase in the number of risk profiles,455 it was considered 
imperative to initiate concrete measures to strengthen the safety of the medicinal 
product itself and impart legal basis to it.456 The safety features that are introduced 
are expected to be fully implemented by 2019 in the EU.  
450 Chapter 3.   
451 See Chapter 3. For instance in Section 3.2 of the thesis, Operation Volcano revealed that Herceptin drug, which 
is a drug used for treatment of cancer was stolen from a truck delivering the medicine to an Italian hospital and then 
was injected with fake pharmaceutical products and re-introduced in the legal supply chain. 
452 See Chapter 3, Section 3.3. 
453 Discussed in detail in Chapter 3, Section 3.4. 
454 Tiwari, B. (2016). “Current Aspects of pharmaceutical packing materials, importance and its future Trends - A 
Review. International Journal of Chemical and Pharmaceutical Analysis, 3(1).  
455 Recital 11, Falsified Medicines Directive 2011/62/EU. 
456 Regulation on Safety Features 2016/161. (2015) Impact Assessment. SWD (2015)189 final. 
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4.2.1. Main safety features 
 
 
 
Figure 5 
 
The main safety features that have been introduced by the Regulation457 which 
stems from the FMD (see Table 2) include introduction of alphanumerical code 
enabling the identification and authentication of individual packs bearing Unique 
Identifiers (UI);458 Anti- tampering devices (ATD)459 that will allow for 
ascertaining if tampering has taken place;460 the introduction of repositories 
457 The delegated act entails the characteristics that the safety features should possess; how the authenticity of the 
medicinal products should be determined and verified; and by which actors. This act came into being in 2016 via 
Commission Delegated Regulation (EU) 2016/161 of 2 October 2015 supplementing Directive 2001/83/EC of the 
European Parliament and of the Council by laying down detailed rules for the safety features appearing on the 
packaging of medicinal products for human use. The Regulation will be applicable with effect from February 9, 
2019 in all but three of the Member States in the EU. These three Member States – Italy, Greece and Belgium 
already have similar systems in place, therefore, they have been given an extended deadline of February 9, 2025 to 
switch over to the common system.  
458 Articles 3 and 4 Regulation on Safety Features (EU) 2016/161. 
459 Article 3 Regulation on Safety Features (EU) 2016/161. 
460 Article 10 Regulation on Safety Features (EU) 2016/161. 
Safety 
Features 
Unique 
Identifiers 
Verification 
System 
List of 
exceptions 
Anti-
tampering 
Devices 
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systems461 for the UI to keep a record across EU, as well as formulation of lists of 
exceptions for bearing462 or not bearing463 the safety features.  
 
The UI and the ATDs are expected to be installed on all medicinal products. The 
UI can be alphanumerical code enabling identification and authentication of 
individual packs. The technical characteristics of a UI include a product code, a 
serial number and national reimbursement or identification number, a batch 
number, and an expiry date.464 The ATDs are meant to verify whether a pack of 
medicine or product has been opened or tampered with. For example, it could be 
film wrappers, shrinkable seals, breakable caps, tape seals, blister packs, etc.465 
The main idea is to have such type of packing that if it is tampered with, it would 
leave audible or visible traces and the consumer or the authorities will be able to 
detect the problem.  
 
In addition to having UI and ATDs, an end-to-end verification system is expected 
to be put in place.466 It is not a full track & trace system.467 Essentially, an end-to-
end verification system entails the manufacturers or the Market Authorisation 
Holders (MAH) on one end, and the pharmacies or hospitals that receive the 
medicinal products, on the receiving end. Firstly, the manufacturers or the MAH 
are responsible for ensuring that the UIs are printed or applied to the packaging of 
461 Article 31-37, Regulation on Safety Features (EU) 2016/161. 
462 List of medicinal products categories not subject to prescription that shall bear the safety features referred to in 
Article 45(2), Regulation on Safety Features (EU) 2016/161. 
463 List of medicinal product categories subject to prescription that shall not bear the safety features, referred to in 
Article 45(1), Annex I, Regulation on Safety Features (EU) 2016/161. 
464 Patrizia, T. (2016). Medicines verification in Europe: What to expect in 2019, DG Sante, European Commission 
Stakeholders’ Workshop. 9. 
465 Gupta, A. K. K. N. V., & Lalasa, P. (2013). A Review on Packaging Materials with Anti-Counterfeit, Tamper-
Evident Features For Pharmaceuticals. International Journal of Drug Development and Research. 4. 
466 Recital 4 of Regulation on Safety Features, 2016 /161. 
467 Patrizia, T. (2016). Medicines verification in Europe: What to expect in 2019, DG SANTE, European 
Commission Stakeholders’ Workshop; See also Kelly, S. (2007). Tracking and Tracing Pharmaceutical Products 
through the Supply Chain. Supply Chain Europe, 16(5), 40-42. 
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the medicines and the information regarding the UIs is uploaded in the secure 
repository system. Secondly, it is also the responsibility of the manufacturer or the 
MAH to apply the ATDs on the packaging. At the receiving end, it is the 
responsibility of pharmacies or hospitals to verify and determine the authenticity 
of the medicinal products. If it is deemed as a counterfeit, or not original, or is 
opened or tampered with, it is also the responsibility of the pharmacy or the 
hospital in question, to decommission the product. Furthermore, it is the 
responsibility of the pharmacy or the hospital at the receiving end to check the 
integrity of the ATD attached to the medicinal product. In addition to the 
aforementioned, a risk-based verification by the wholesalers has to be conducted 
when the product is returned by another wholesale distributor or a pharmacy - and 
when the product is not directly provided by a manufacturer or a MAH. 
 
In addition to having UIs and ATDs on the medicinal products, the verification 
system has also been established to further strengthen the protection of the 
medicinal products. Furthermore, the Regulation provides for the establishment of 
a Repositories system.468 The primary responsibility of the repositories system is 
to store information on the legitimate UIs and facilitate the authentication, 
verification and decommissioning of UIs at any point of the supply chain. In 
addition, it would also be the central database, where the detection of potential 
468 This is meant to be established and managed by stakeholders with supervision of the competent authorities, as 
provided for under Article 32, Regulation on Safety Features 2016/161. The European Medicines Verification 
Organisation (EMVO) is a non-profit organisation based in Luxembourg and represents the interests of the primary 
stakeholders and has the primary goal of securing the legal supply chain from illicit medicines. Its members include 
the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Generic and 
Biosimilar Medicines Association (EGA), the Pharmaceutical Group of the European Union (PGEU), GIRP, the 
European Association of Pharmaceutical Full-line Wholesalers and, the European Association of Euro-
Pharmaceutical Companies (EAEPC). The primary task of the EMVO is to implement the repositories system and 
ensure that the repositories systems are in compliance with the provisions of the Falsified Medicines Directive. The 
EMVO has designed a blueprint model for National Medicines Verification Organisations (NMVO) to follow. It is 
the NMVOs that will be responsible for carrying out the management and the establishment of the systems. Source:  
Andreas W., (22 June 2015). The European Verification Organisation signs framework agreement with service 
providers to establish blueprint systems, Press Release. Luxembourg. EFPIA. 
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falsification of pharmaceutical products will come to light. The Member States 
will be in charge of supervising the repositories system and enforcing the 
requirements of the delegated Regulation. 
 
In addition to the above, the Regulation on Safety Features also provides for two 
lists of exceptions. The general rule governing the principle of application of 
Safety Features is that if it is a prescription medicine, it has to bear the safety 
features and if it is a non-prescription medicine, it will not bear the safety features. 
However, there is a possibility of having an exception to these rules, if an 
assessment shows that there is a considerable risk of falsification. These 
exceptions are included in Annex I and II of the Regulation 2016/161. Annex I 
enumerates the list of medicinal product categories that are subject to prescription 
but do not bear the safety features, referred to in Article 45(1).469 The prescription 
medicines exempted from the Safety features are, for example, homeopathic, 
radiopharmaceuticals, ATMPs, medical gases, certain solutions, contrast media, 
allergy tests and allergen. In addition, Annex II470 enumerates the list of product 
categories that are not subject to prescription and do not bear the safety features, 
referred to in the Article 45(2).471  
 
4.2.2. Deficiencies in the provisions on Safety Features 
The provision of safety features was introduced due to the rise in the number of 
counterfeit and falsified medicines in the EU.472 Against the backdrop of the case 
studies, it is evident that protecting the medicinal product itself is a crucial step in 
469 Annex I, Regulation on Safety Features 2016/161. 
470 Annex II, Regulation on Safety Features 2016/161. 
471 This includes Omeprazole only, at the moment, since there were reported incidents of falsification of this 
medicinal product in Annex II, Regulation on Safety Features 2016/161. 
472 Almuzaini, T., Sammons, H., & Choonara, I. (2013). Substandard and falsified medicines in the UK: a 
retrospective review of drug alerts (2001–2011). BMJ open, 3(7), e002924. 
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combatting falsification of medicines.  The provisions on safety features – UIs; 
ATDs; verification system; repository system and the introduction of lists will 
make a significant difference for securing the integrity of the medicinal products.  
 
However, there are certain challenges that can be anticipated by the introduction 
of the safety features.473 The tracing and tracking system envisaged by the 
Regulation is an end-to-end system and not a full track and trace system. In a full 
track and trace system, it is possible to follow the movement of the medicine from 
the moment it is manufactured, to the end, when it is dispensed or sold to the 
customer. In contrast, the end-to-end system involves the check at two points only 
– the starting point and the end point. At the entry point, when the manufacturer 
introduces the product in the legal supply chain and at the end, by the hospital or 
the pharmacy when the product is sold to the patient.   
 
It is evident that in a full trace and track system, it is possible to authenticate the 
product at any time, and thus, chances of manipulation are greatly reduced. 
However, in an end-to-end system, there is still some scope for manipulation in 
the middle of the supply chain. This may result in late detection, which makes it 
challenging to trace exactly where and when the counterfeit drug was introduced. 
This system, not being a full track and trace system implies that certain gaps can 
still prevail in the system, leaving the system vulnerable. Hence, a full track and 
trace system would have been the preferred system, even though it would be more 
expensive.474 Since it would have provided the capability to track the medicine’s 
473 Bogaert, B. C., & Burton, C. (2015). The mysteries of the Falsified Medicines Directive-where is the logic on 
safety features. London: Script Regulatory Affairs, 1-3; Paxton, M. (2011). Current challenges with supply chain 
integrity and the threat to the quality of marketed drugs. Clinical Pharmacology & Therapeutics, 89(2), 316-319. 
474 Gostin, L. O., Buckley, G. J., & Kelley, W. (2013). Stemming the global trade in falsified and substandard 
medicines. JAMA, 309(16), 1693-1694; Kang, Y. S., & Lee, Y. H. (2013). Development of generic RFID 
traceability services. Computers in industry, 64(5), 609-623. 
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present and past location at any point in the supply chain.475 
 
The system of risk-based verification places an obligation on not only the 
manufacturers, but also on the distributors, and wholesalers. The down side of the 
imposition of these obligations is that the various players in the legal supply chain 
are at the risk of non-compliance with these risks based verifications. As was 
evident in Operation Volcano and Operation Singapore,476 the different MAH 
were lax in carrying out these risks based verifications. In Operation Volcano, it 
was discovered that the illegitimate wholesalers sold the medicine that was 
tampered with to the legitimate wholesalers. That is how the falsified medicine 
entered the legal supply chain, as the legitimate wholesalers did not check the 
authorisation of the previous link in the legal supply chain. Therefore, placing the 
onus on the manufacturers, distributors and wholesalers through excessive 
regulation may increase the danger of non-compliance. 
 
4.3. The supply chain 
Besides manipulation of medicinal products, the case studies also revealed that the 
legal supply chain can be infiltrated by the illegal supply chain at various 
points.477 Therefore, besides securing the integrity of the medicinal product, the 
FMD also contains provisions that aim at strengthening the legal supply chain.478 
Essentially, a supply chain is composed of many market players, both upstream 
475 Rotunno, R., Cesarotti, V., Bellman, A., Introna, V., & Benedetti, M. (2014). Impact of Track and Trace 
Integration on Pharmaceutical Production Systems. International Journal of Engineering Business Management, 6, 
25; Castro, L., & Fosso Wamba, S. (2007). An inside look at RFID technology. Journal of Technology 
Management & Innovation, 2(1). 
476 See Chapter 3, Sections 3.2. and 3.3. 
477 Chapter 3, Section 3.2. Operation Volcano, the medicines were stolen and then re-introduced in the supply 
chain. 
478 Smith, G., Smith, J. A., & Brindley, D. A. (2014). The Falsified Medicines Directive: How to secure your supply 
chain. 
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(i.e. supply) and downstream (i.e. distribution), including the last link in the chain, 
the consumer.479 By using fake authorisation and posing as legitimate wholesalers 
or parallel importers, falsified and counterfeit medicines were introduced in the 
legal supply chain. The problems highlighted in the three case studies are not 
stand alone instances but an illustration of the typical trend in the falsification of 
medicines in the EU.480 In the light of the general trend also recognised in the 
preceding legal instruments in the field of medicine in the EU and combined in 
EudraLex Volume 1,481 the FMD contains provisions specifically related to 
proliferation in the number of market players in the legal supply chain;482 rules 
governing authorisations (market as well as manufacturing authorisation); and 
provisions regulating import and export of APIs.  
 
4.3.1. Proliferation in the number of market players 
A few decades ago, the supply chain included just three main actors: the 
manufacturer supplied the goods to the wholesaler, who, in-turn, supplied it to the 
pharmacy or the hospital. There were no middlemen (Figure 6). However, the 
rapid pace of technological and economic development has led to an increase in 
the number of intermediaries.483 Therefore, every movement – from one market 
player to the other, is an opportunity for counterfeit medicines to infiltrate the 
market (Figure 7).484 The pharmaceutical supply chain is not only threatened by 
479 Mentzer, J. T., DeWitt, W., Keebler, J. S., Min, S., Nix, N. W., Smith, C. D., & Zacharia, Z. G. (2001). Defining 
supply chain management. Journal of Business logistics, 22(2), 1-25; Christopher, Martin L. (1992), Logistics and 
Supply Chain Management, London: Pitman Publishing. 
480 Almuzaini, T., Sammons, H., & Choonara, I. (2013). Substandard and falsified medicines in the UK: a 
retrospective review of drug alerts (2001–2011). BMJ open, 3(7), e002924. 
481 ‘The Rules Governing Medicinal Products in the European Union’, EudraLex Volume 1, available at 
https://ec.europa.eu/health/documents/eudralex/vol-1_en accessed June 29 2017. 
482 See Recital 6, Directive 2011/62/EU. 
483 Tremblay, M. (2013). Medicines counterfeiting is a complex problem: a review of key challenges across the 
supply chain. Current drug safety, 8(1), 43-55. 
484 Buckley, G. J., & Gostin, L. O. (Eds.). (2013). Countering the problem of falsified and substandard drugs. 
National Academies Press, 197. 
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the existence of an illegal supply chain, but also by the infiltration of a number of 
intermediaries that are not accountable or accounted for.485 This problem was also 
evident in the case studies in Chapter 3, wherein the illegal wholesalers based in 
other countries ‘whitewashed’ the falsified medicinal products by using fake 
authorisations right before the products were reintroduced in the legal supply 
chain.486 
 
The supply chain has, thus, become increasingly complex487 and the vast number 
of intermediaries has led to a legal necessity of formulation of stricter rules with 
respect to the distribution system.488 The Falsified Medicines Directive addresses 
the issue of diversity and proliferation in the number of market players in the 
supply chain.489 These market players are mainly categorised as manufacturers, 
distributors, brokers, wholesalers, and retailers. The Community pharmacies 
(independent and multiple pharmacies) as well as hospital dispensaries are part of 
the supply chain and are thus market players.490 In addition, parallel importers 
play an important, though controversial, role in the legal pharmaceutical supply 
chain. If one were to categorise the different players in the market, at the moment, 
and their role in the legal supply chain, it would appear in the following manner 
(Figure 7): 
485 Tremblay, M. (2013). Medicines counterfeiting is a complex problem: a review of key challenges across the 
supply chain. Current drug safety, 8(1), 43-55. 
486 Chapter 3, Section 3.2. Operation Volcano. 
487 Tremblay, M. (2006). Finding Common Ground: policy imperatives for Europe. Coincidence or Crisis: 
Prescription Medicine Counterfeiting. London: Stockholm Network. 
488 Explanatory Memorandum, for  a Proposal for a Directive of the European Parliament and of the Council 
amending Directive 2001/83/EC as regards the prevention of the entry into the legal supply chain of medicinal 
products which are falsified in relation to their identity, history or source, COM (2008) 668 final. 
489 Recital 6, Falsified Medicines Directive 2011/62/EU. 
490 Attaran, A., Barry, D., Basheer, S., Bate, R., Benton, D., Chauvin, J., & Newton, N. (2012). How to achieve 
international action on falsified and substandard medicines. Bmj, 345, e7381. 
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Figure 6 
 
 
Figure 7 
 
Within the EU, all actors (be it manufacturers, wholesalers, distributors, retailers, 
brokers or re-packagers of a medicinal product or importers of a medicinal product 
from a third country) are subject to the provisions of Title IV of Directive 
2001/83/EU – Articles 40-53, which have been amended and updated by the 
FMD. These provisions deal with requirements of obtaining a manufacturing 
authorisation;491 the obligations of a manufacturing authorisation holder;492 
compliance with GMP and GDP;493 requirement of upholding safety features;494 
491 Article 1(5), Directive 2011/62/EU. 
492 ibid. 
493 Articles 1(5) and 1(7) Directive 2011/62/EU. 
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and personal qualifications of a manufacturing authorisation holder.495 The term 
‘manufacturer’ covers distributors, exporters, sellers etc. Each activity requires an 
authorisation – manufacturing or distribution and associated activities also need an 
authorisation. All these authorisations spring from the Articles 40-53 in the 
Directive but validate different activities. Thus, a manufacturer is any person, who 
manufactures or just packages the medicinal product, is part of the supply chain, 
and holds a Manufacturing Authorisation (MA).496  
 
It is incumbent upon the authorisation holder to be responsible for packaging the 
manufactured product497 and for taking into account the safety features498 that are 
applicable to the medicinal product. Also, there can be actors who are categorised 
as manufacturers, but who have not actually manufactured the medicinal product 
but have just purchased it from another wholesaler. Essentially, they hold a MA 
that makes them responsible for ensuring that if they deal in a product and if they 
need to repackage, remove, or replace the packaging of the product, the safety 
features that they attach to the medicinal product, are equally effective and meet 
the quality standards of the original safety features. All manufacturers of 
medicinal products are required to be registered by the NCA of the Member State 
that they are located in.499 
 
The authorisation holders, which include all market players now, such as 
wholesaler, distributors, repackagers, and parallel importers, also have the 
responsibility of informing the NCA and market authorisation holder, in case they 
494 Article 4, Directive 2011/62/EU. 
495 Title IV Manufacture and Importation, Articles 40 -55, Directive 2001/83/EC.  
496 De Weerdt, E., Simoens, S., Hombroeckx, L., Casteels, M., & Huys, I. (2015). Causes of drug shortages in the 
legal pharmaceutical framework. Regulatory toxicology and pharmacology, 71(2), 251-258. 
497 Recital 12, Falsified Medicines Directive 2011/62/EU. 
498 See discussion on safety features discussed in Section 4.2.1. 
499 Article 52a of Medicines Directive 2001/83/EC inserted by Falsified Medicines Directive 2011/62/EU. 
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detect that the products entering the legal or illegal supply chain are counterfeit.500 
The manufacturers of active substances, in addition to the other responsibilities 
meant for all authorisation holders, are also subject to inspection501 on the basis of 
risk-analysis and on the grounds of non-compliance.502 Further, it is also the duty 
of the authorisation holders to abide by the GMP503 and Good Distributing 
Practices504 (GDP), when assessing the viability of excipients to be used in the 
process of manufacturing the medicines.505 An authorisation holder is also 
responsible for conducting audits506 of the manufacturing and distribution sites 
that manufacture and distribute the active substance, in order to confirm that the 
500 Article 1 (5) (g), Directive 2011/62/EU. 
501 Recital 18, Directive 2011/62/EU; Article 111 (1a) of Directive 2001/83/EC. 
502 Recital 7, Directive 2011/62/EU. 
503 Article 8 (3) inserted in the Directive 2001/83/EC by Article 1 of the Directive 2011/62/EU. GMP guidelines are 
not a new phenomenon. GMP are a collection of rules that are systematised, which are in the form of guidelines, 
and lay down certain standards for necessary adherence. The manufacturing and importation of all types of 
medicinal products for human use are subject to authorisation. The holder of market authorisation has to adhere to 
GDP and GMP. The GMP are provided for in the Medicines Directive under Article 47, wherein the Commission is 
obliged to adopt principles and guidelines of GMP for medicinal products for human use in the form of a Directive. 
In 2014, the Directive 2003/94/EC was repealed and replaced by a Delegated Act on principles and guidelines of 
GMP for investigational medicinal products with its legal basis as Article 63(1) of Regulation (EU) No. 536/2014 
and a new Implementing Directive on principles and guidelines of good manufacturing practice for medicinal 
products for human use with the Article 47 of the Medicines Directive as its legal basis. The main purpose of these 
guidelines is to ensure that the medical products being produced or imported, including import of active substances, 
are consistent in quality and are being produced under controlled conditions that adhere to the common standards. 
Safety of medicines is ensured by replicating the initial design of the medicine in exactly the same manner as 
approved by the approving agency, for instance FDA in the US or the National Competent Authority of the 
Member States. Each of the market players are expected to follow and adhere to the GMP and GDP.  
504 (GDP) play a pivotal role in the legal supply chain. The GDP in the EU visualises greater safety of the legal 
supply chain in the pharmaceutical industry, which is also recognised by the WHO Guidelines. Firstly, by defining 
the role of the Distributors, the GDP. The Commission published the guidelines in 2013 – Guidelines on Good 
Distribution Practice of medicinal products for human use. The Guidelines are based on Article 84 and 85 b (3) of 
Directive 2001/83/EC. The GDP make certain that the quality ensured by the GMP is upheld by the distributors. 
The principles of the GDP are enshrined in the Directive 92/25/EEC, wherein it is provided for that the medicinal 
products are distributed in accordance with the EU legislation. The quality as well as the integrity of the legal 
supply chain can be affected if the GDP are not adhered to. This was evident in the Operations discussed in Chapter 
3. For example, Operation Volcano revealed that the integrity of the legal supply chain was compromised, wherein 
the illegal wholesaler sold the medicines to the legal wholesaler, who sold them to another legal wholesaler based 
in Germany, who actually detected the flaw and mismatch in the packaging and batch numbers. Even the names of 
the distributors that were not adhering to the GMP and GDP were listed on the website of the National competent 
authority. This was a clear example of how counterfeit medicine enters the legal supply chain if the integrity of the 
legal supply chain is compromised. Had the rules regarding inspections, and audits been in place, at least the legal 
wholesalers would have been able to detect the mismatch between the batch numbers and bring it to the attention of 
the competent authorities at the national, as well as the EU level. 
505 Recital 8, Falsified Medicines Directive 2011/62/EU. 
506 Article 46 (f) Medicines Directive 2001/83/EC. 
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GMP and GDP have been complied with. 
 
Another step forward in the EU legal framework in securing the pharmaceutical 
supply chain is the identification and definition of ‘brokers’ for the first time in the 
FMD. It recognises ‘brokers’507 as a part of the legal supply chain for medicinal 
products. A definition of ‘brokering’ has been inserted in the Medicines 
Directive,508 which includes all the actors, who do not physically handle the 
medicinal product but are involved in the sale or purchase of the medicinal 
products without directly being involved in the sale or purchase themselves or 
physically owning the products. 
 
The historical reason for the introduction of the market players like ‘brokers’ in 
the FMD, has been because of the problems that have been caused by them in the 
past. The brokers that existed in the past in the legal supply chain were not 
accountable for their actions. Therefore, they were playing a key role in the market 
but did not have any accountability. Now that the ‘brokers’ are officially added as 
market players, they are also subject to rules and obligations. 
 
The brokers are expected to abide by the requirements of the Directive, as the 
other actors in the Directive with respect to upholding the integrity of the legal 
supply chain. In addition, they are also expected to ensure that the products they 
are involved in brokering are covered by market authorisation,509 which is granted 
by the competent authorities of the Member State that they are located in, in 
accordance with the Directive. The Market Authorisation also needs to be in 
507 Recital 6, Falsified Medicines Directive 2011/62/EU.  
508 Article 1 (b) of the Falsified Medicines Directive 2011/62/EU introduces 17a in Article 1 of the Medicines 
Directive 2001/83/EC. 
509 Article 85b of the Medicines Directive 2001/83/EC. 
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consonance with the provisions of the Regulation (EC) No. 726/2004.510   
 
In its bid to tighten the noose around vulnerable parts of the legal supply chain, 
which includes the ‘brokers’, it was a step in the right direction to discuss 
penalties that can come about for non-compliance. Even though the Member 
States have the powers to introduce penalties that need to be dissuasive, 
proportionate and equitable, the Directive clearly states one such provision. At the 
moment, the only penalty that appears in the Directive is that the broker will be 
removed from the register if the provisions of the Directive (Directive 
2011/62/EU) are not upheld.511 However, this is inadequate, because if one 
‘broker’ is removed on the grounds of non-compliance from the list, another one 
can appear swiftly. The system stands to be defeated and can get embroiled in 
handling the new versions of the same broker reappearing time and time again. 
Therefore, it is important to emphasise that the penalties that are imposed should 
have teeth to bite and the system that is erected promotes compliance. 
 
In order to strengthen the integrity of the legal supply chain against infiltration by 
falsified products, regular inspection of the manufacturers and wholesale 
distributors should also be carried out.512 In addition, it is also the responsibility of 
the wholesale distributors to verify the authenticity of the medicinal product and 
the identity of the individual packs, as well as whether the products have been 
510 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, lays down 
Community procedures for the authorisation and supervision of medicinal products for human and veterinary use 
and establishing a European Medicines Agency. A broker is also subject to requirements such as have a permanent 
address, contact details in the Union so as to ensure identification, location communication and supervision of their 
activities by competent authorities.  All brokers are also required to be registered with the Competent Authority of 
the Member State that they are located in. Non-compliance with the requirements can lead to removal from the 
register. 
511 Article 85b (4), Medicines Directive 2001/83/EC. 
512 Recital 18, Falsified Medicines Directive 2011/62/EU. 
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tampered with.513 The possessor of a wholesale distributions authorisation, if 
purchasing the products from another wholesale distributor, is obliged to check the 
wholesale distribution authorisation of the distributor he is purchasing from, in 
addition to verifying whether GDP is being complied with.  
 
The case studies revealed that these requirements were not strictly enforced, as it 
came to light in Operation Singapore,514 and Operation Volcano.515 In Operation 
Singapore, the wholesale distributors did not check the authorisation of the 
manufacturer of the product. Since the compliance is slack, the counterfeiters 
actually took advantage of non-compliance and introduced counterfeit medicines 
by employing fake authorisation certificates.516 In Operation Volcano, it was 
illustrated that there was an organised body of illegitimate manufacturing 
authorisation holders, who dealt with introducing counterfeit medicinal products 
into the legal supply chain by introducing the medicinal products to legitimate 
authorisation holders.517 The FMD has definitely tried to clarify the role of 
wholesale distributors. However, the number of responsibilities that the wholesale 
distributor has been saddled with in the Directive may lead to non-compliance in 
practice, as was evident in Operation Singapore and Operation Volcano. 
Inspections, verification of authenticity of individual packs of medicinal products 
as well as ensuring that all activities are in compliance with GDP and GMP 
require an increased investment of resources and manpower for distributors and 
manufacturers.  
 
Retailers are yet another layer of actors in the legal supply chain of selling 
513 Article 54, Medicines Directive 2001/83/EC. 
514 Discussed in detail in Chapter 3, Section 3.3. 
515 Discussed in detail in Chapter 3, Section 3.2. 
516 See Chapter 3, Sections 3.2. 
517 See Chapter 3, Sections 3.2. and 3.3. 
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medicinal products. Retailers, as generally understood supply the medicine 
directly to the public, such as the pharmacies and hospitals. The companies selling 
medicines online to members of the public also fall under this category and must 
possess the required authorisation from the Member State, wherein they are 
located. All companies having an authorisation to sell prescription and non-
prescription medicines fall under the umbrella of the term retailers. These retailers 
are required to display the logo518 if they are selling the medicinal products online. 
The Member States are allowed discretion in the restrictions that they impose on 
such retailers in the interest of protecting the general public and in the interest of 
public health.519 It is also possible for the Member States to restrict the sale of 
medicines through physical pharmacists only and forbid the online sale of 
medicines if they deem fit.520 In 2009, the Court of Justice reached the same 
conclusion that the Member States may impose conditions provided that the 
conditions can be justified as measures to protect public health and do not restrict 
the functioning of the internal market.521  
 
The retailers are obliged to determine that the safety features on the medicinal 
products are intact and that the medicinal products have not been tampered with. 
Further, it is the retailers that will also bear the responsibility of carrying 
information relating to counterfeit medicines and advising on such information to 
the patients, if they are questioned on counterfeit medicines. As for the hospitals, 
which are also the final point of the dispensation of medicines, it is required that 
they also comply with the requirements of the Directive. However, hospitals are 
518 Discussed in Section 4.4 in detail. 
519 By virtue of Principle of subsidiarity, Article 4 and 5 TFEU, discussed in Chapter 2, Section 2.3.3.2. 
520 Recital 23 of Falsified Medicines Directive 2011/62/EU. 
521 Joined cases C-171/07 and C-172/07, Apothekerkammer des Saarlandes and Others V Saarland ECR [2009] I-
4171, paragraph 34 and 35. 
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also given certain dispensations with regard to compliance with the FMD.522 
 
Whether the retailers are able to live up to the expectations of the FMD concerning 
the obligations of checking the safety features will only be evident once the safety 
features are fully implemented in 2019. So far, non-adherence to GMP523 and 
GDP was a major cause of infiltration of the legal supply chain as revealed in 
Chapter 3, wherein the wholesalers did not follow on checking the authorisations 
of the manufacturers. Therefore, in the absence of stringent penalties in the FMD, 
it is hard to be optimistic about compliance. 
 
In addition to manufacturers, brokers, wholesalers, and retailers, parallel importers 
also play a significant role in the legal supply chain of medicinal products in the 
EU.524 Parallel trade has an impact on innovation, pricing, and availability of 
medicinal products, as voiced from within the CJEU.525 For obvious reasons of 
making a profit, the parallel traders purchase medicines in the EU in countries 
where the medicine prices are low and sell them in the countries where the prices 
of the same products are higher.526 On the other hand, a study concluded in 2005 
indicated that the savings by parallel trade for health insurers are approximately 
100 million Euros in the six prominent importing countries.527 In the EU, the 
TFEU and TEU, and the CFREU lay down the fundamental principles of free 
movement of goods, but at the same time, the Union laws on anti-competition and 
522 Smith, J. A., Naughton, B., Kramm, A., Smith, G., Ohanjanyan, A., De Simone, M. & Brindley, D. A. EU 
Falsified Medicines Directive: Requirements and Implications for Multi-Stakeholder Healthcare Delivery. 
Regulatory Affairs Professionals Society. Chapter  8, 76. 
523 Bate, R. (2012). Phake: the deadly world of falsified and substandard medicines. AEI Press, 36. 
524 Orizio, G., Schulz,, Domenighini, S., Caimi, L., Rosati, C., Rubinelli, S., & Gelatti, U. (2009). Cyberdrugs: a 
cross-sectional study of online pharmacies characteristics. The European Journal of Public Health, 19(4), 375-377. 
525 CF. conclusions of AGD. Ruiz- Jarabo Colomer of 1 April 2008 in case C-468/06 and in C 53/03. 
526 Kanavos, & Costa-Font, J. (2005). Pharmaceutical parallel trade in Europe: stakeholder and competition 
effects. Economic policy, 20(44), 758-798; Ganslandt, M., & Maskus, K. E. (2004). Parallel imports and the pricing 
of pharmaceutical products: evidence from the European Union. Journal of health economics, 23(5), 1035-1057. 
527 Kanavos, & Costa-Font, J. (2005). Pharmaceutical parallel trade in Europe: stakeholder and competition 
effects. Economic policy, 20(44), 758-798. 
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the legal situation concerning parallel pharmaceutical trader (PPT) are 
controversial. The PPT are required to hold a pharmaceutical wholesale 
authorisation, which is issued (in accordance with Article 77 of Directive 
2001/83/EC) by the NCA in the Member States in which they are located. 
Essentially, as a manufacturing operation, all repackaging/re-labelling require a 
pharmaceutical manufacturing authorisation issued by a competent authority of the 
Member State where the parallel importer is located. 
 
However, there are shortcomings in terms of the adequacy of legal interpretation, 
regulatory provisions and their effective implementation with regard to 
management, especially when it comes to parallel importers.528 The supply chain 
complexity in the EU has also been identified in the EC 2003 Communication.529 
An analysis of this report clearly indicates examples highlighting the uncertainty 
stemming from the ambiguities of interpretation of EU rules, which spurs different 
interpretation in Member States. For instance, the potential problem with respect 
to regulation is the use of the term ‘sufficiently similar’, regarding import of 
excipients by parallel traders. When it is articulated in this manner that the 
importer may import a product that is sufficiently similar – it is an invitation for 
counterfeiters to introduce counterfeit products into the legal supply chain.  
 
4.3.2. Import of APIs 
Counterfeit medicines find their way into the EU borders in many forms. As 
discussed in the preceding chapter on case studies, it came to light that at times, 
counterfeit medicines enter the legal supply chain through actions of parallel 
528 Dégardin, K., Roggo, Y., & Margot, (2014). Understanding and fighting the medicine counterfeit 
market. Journal of pharmaceutical and biomedical analysis, 87, 167-175. 
529 Communication from the Commission on Regulation (EC) No. 141/2000 of the European Parliament and of the 
Council on orphan medicinal products. (2003). OJ C 178, 29.7.2003, 2 – 8. 
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importers (Operation Robin)530 and at other times, the API is imported from other 
countries (Operation Singapore531 and Operation Robin).532 Subsequently, the 
counterfeit medicinal product is assembled in the country that sells the product 
and the sale of the counterfeit medicinal product also occurs online (Operation 
Robin).533 
 
The API,534 commonly known as ‘bulk pharmaceuticals’, form the “backbone” of 
a medicine. Each medicinal drug is composed of two parts – the API or the active 
substance,535 which is the healing ingredient of a medicinal product, and an 
excipient,536 which is any constituent of a medicinal product other than the active 
substance and the packaging material. Therefore, it is important to ensure the 
quality and safe manufacturing standards of APIs. This is particularly significant 
for APIs manufactured outside the EU as increasing number of medicines being 
manufactured are composed of active substances that are imported from a third 
country. If the active substance, which is imported in the EU is counterfeit, the 
medicine will obviously be counterfeit.537 
 
In the case study – Operation Robin, the import of active substances transpired, 
530 Chapter 3, Section 3.4. 
531 Chapter 3, Section 3.3. 
532 Chapter 3, Section 3.4.  
533 Chapter 3, Section 3.4.   
534 “An active pharmaceutical ingredient is defined in ICH Q7 as “any substance or mixture of substances intended 
to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active 
ingredient in the drug product. Source: International Council of Harmonisation. (2015). ICH Q7 Guideline: Good 
Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Geneva. ICH Secretariat.  
535 Article 1 (3a) of the Medicines Directive 2001/83/EC inserted by Article 1 of the Falsified Medicines Directive 
2011/62/EU. 
536 Article 1 (3b) of the Medicines Directive 2001/83/EC inserted by Article 1 of the Falsified Medicines Directive 
2011/62/EU. 
537 Bera, A., & Mukherjee, A. (2013). Counterfeit and Spurious drugs: Big Challenges to the Health Care system 
worldwide. Pharma Science Monitor, 3(3); See also De Weerdt, E., Simoens, S., Hombroeckx, L., Casteels, M., & 
Huys, I. (2015). Causes of drug shortages in the legal pharmaceutical framework. Regulatory toxicology and 
pharmacology, 71(2), 251-258. 
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which resulted in manufacturing of fake medicines in a factory in Sweden.538  
 
Furthermore, another complicating factor is that, at times, an API can be used in 
different permutations and combinations for multiple products. For instance, the 
same API can be used for non-medicinal purpose, as well as medicinal purpose, 
just as medicines can be used for medical or non-medicinal purposes.539 Once the 
API has been imported into the EU under the guise of being used for a non-
medical purpose, there is no way to ensure that the API will not be used for a 
medicinal purpose, as there are limited ways to precisely ascertain it. Therefore, 
the EU reformed the rules for importing API.540 It is a requirement that all 
imported APIs must have been manufactured in compliance with standards of 
GMP, at least equivalent to the GMP of the EU,541 which introduced an EU wide 
rule for the importation of active substances. In addition, the European 
Commission issued further guidelines on principles of Good Distribution Practice 
of active substances for medicinal products for human use in 2015, which also 
need to be complied with.542 
 
As evident from the legal case studies, counterfeit APIs are often imported in 
small packages and escape undetected because they arrive at mailboxes in parcels 
538 See Chapter 3, Section 3.4. 
539 Abadinsky, H. (2010). Drug use and abuse: A comprehensive introduction. Cengage Learning. 
540 European Commission. (2013). New Rules on importing active pharmaceutical ingredients into the European 
Union. Press Release. Brussels.  
541 Article 46 b (2) Medicines Directive 2001/83/EC states that active substances can only be imported if, inter alia, 
the active substances are accompanied by a written confirmation from the competent authority of the exporting 
third country, which, as regards the plant manufacturing the exported active substance, confirms that the standards 
of good manufacturing practice and control of the plant are equivalent to those in the Union. 
542 Guidelines on principles of Good Distribution Practice of active substances for medicinal products for human 
use, of 19 March 2015, 2015/95/01); See also The manufacturing standards recognised in the EU for APIs are those 
of the ‘International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 
(ICH). (2015). The ICH Quality Guidelines, Q7 relate to Good Manufacturing Practices. It is part of tripartite 
guidelines, developed by an expert working group, for adoption and sent to the regulatory bodies of the European 
Union, Japan and USA. Geneva. ICH. 
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and couriers.543 Furthermore, at times, the APIs imported for non-medicinal 
purpose penetrate the legal supply chain. This issue is especially convoluted, 
because these APIs are not imported as APIs, and therefore, these substances 
cannot be apprehended at the EU borders. After these substances enter the EU 
borders, under the guise of ‘fertilisers’ or vitamins or such, they are assembled in 
factories, as occurred in Operation Robin,544 and thereafter, are sold as medicinal 
products.  In the regulation of chemical substances, which can be hazardous,545 
there is a provision of reverse burden of proof. In that provision, a substance that 
can be used as a chemical substance is considered a hazardous chemical substance 
unless otherwise proven. Even though APIs, if used in manufacture of falsified 
medicines can be equally hazardous to public health and safety, such a ‘reverse 
burden of proof’ does not exist in the sphere of Medicine law, as yet. 
 
4.3.3 Deficiencies 
4.3.3.1 Illegal supply chain feeds the legal supply chain  
In the EU, the legal supply chain for pharmaceutical products involves a series of 
market players.546 The typical flow of the supply chain is like this: the 
manufacturer sends over the pharmaceutical products to the distributor, who 
delivers to the wholesaler and the wholesaler delivers to the retailers, which can be 
the pharmacy, the hospital, or any other authorised retailer, like Boots in the UK 
or Matas in Denmark. At times, the retailers can also be online pharmacies or 
543 Chapter 3, Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013 discussed in Section 3.4. 
Operation Robin.  
544 Chapter 3, Section 3.4., Operation Robin. 
545 Hansson, S. O. (1997). Can we reverse the burden of proof? Toxicology Letters, 90(2-3), 223-228. 
546 Tremblay, M. (2013). Medicines counterfeiting is a complex problem: a review of key challenges across the 
supply chain. Current drug safety, 8(1), 43-55. 
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other authorised sellers who hold a market authorisation. The retailers finally sell 
the medicinal product to the patients. In the legal supply chain in the EU, the 
complexity of the supply chain is amplified by the presence of parallel importers, 
brokers, and re-packagers as well. In addition, to these additional actors in the 
legal supply chain, there can also be secondary wholesalers or multiple 
wholesalers in the legal supply chain, as illustrated in (Figure 8). It is presumed 
that, in the legal supply chain, the end product is purchased by the patient, who 
believes that he is paying for the original/non-counterfeit medicinal product. 
 
 
Figure 8: Adapted from 2015 Situation Report on Counterfeiting in the European Union 
 – A joint project of Europol and OHIM547 
 
It is important to recognise that parallel to the legal supply chain, there is also an 
illegal supply chain, which has a similar structure (see Figure 8), as was revealed 
547 Adapted from Office of Harmonisation in the Internal Market & Europol. (2015). Situation Report on 
Counterfeiting in the European Union – A joint project between Europol and the Office for Harmonization in the 
Internal Market. 20.  
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in Operation Singapore, Operation Volcano548 and Operation Robin, as discussed 
in Chapter 3.549 In the documentary evidence for Operation Robin, the entire 
management structure carrying out the counterfeit operation network was pieced 
together and revealed.550 It can be deduced, as was also presented in the Situation 
Report 2015551 that parallel to the legal supply chain, there exists an illegal supply 
chain comprises of illegal manufacturer, distributor, wholesaler, and retailers, who 
sell to patients, who are sometimes aware of what they are getting themselves into. 
In other words, sometimes, the patients willingly buy illegal products.552 
 
However, the complexity of the supply chains that compounds the problems for 
the legal framework is the fact that the illegal supply chain feeds the legal supply 
chain. For instance, as illustrated in Figure 8, a parallel importer can unwittingly 
purchase products from the illegal distributor and supply the products to a 
legitimate wholesaler. At times, a legitimate retailer may also purchase medicinal 
products from an illegal wholesaler. There have also been instances, where a 
patient has unknowing purchased medicines from an illegal website, assuming that 
the products being sold are legitimate. 553 
548 The medicines, after being stolen from the truck carrying the authentic medicines, were sent to an illegal 
wholesaler, who manipulated the drugs and re-introduced them in the legal supply chain by delivering them to a 
legitimate wholesaler. See more in Chapter 3, Section 3.2. 
549 Chapter 3, Section 3.4. 
550 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
551 Office of Harmonisation in the Internal Market & Europol. (2015) Situation Report on Counterfeiting in the 
European Union – A joint project between Europol and the Office for Harmonization in the Internal Market. 
552 Pál, S., Laszlo, K., Andras, F., Gabriel, H., Hajnal, F., Adriana, C. I. U. R. B. A., & Lajos, B. (2015). Attitude of 
patients and customers regarding purchasing drugs online. Farmacia, 63(1), 93-98; Fittler, A., Lankó, E., 
Brachmann, B., & Botz, L. (2013). Behaviour analysis of patients who purchase medicines on the internet: can 
hospital pharmacists facilitate online medication safety? European Journal of Hospital Pharmacy: Science and 
Practice, 20(1), 8-12. 
553 Lavorgna, A. (2015). The online trade in counterfeit pharmaceuticals: new criminal opportunities, trends and 
challenges. European Journal of Criminology, 12(2), 226-241; See also Hoofnagle, C. J., Altaweel, I., Cabrera, J., 
Choi, H. S., Ho, K., & Good, N. (2017). Online pharmacies and technology crime. The Routledge Handbook of 
Technology, Crime and Justice, 146. 
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4.3.3.2. Lack of clear regulation 
A closer assessment of the three Operations, as well as the exploration of other 
cases,554 reveal that the reason for late detection of counterfeit medicine is not lack 
of regulation, as much as lack of clear regulation. The overlap in the 
responsibilities of a Market Authorisation Holder, as a distributor, or wholesaler 
has an inbuilt scope for ignoring responsibilities or relying on the previous 
member of the supply chain for having complied with the requirements. Hence, 
there is a clear possibility that no action or checking actually takes place. For 
instance, in Operation Volcano,555 the investigations556 were commenced when a 
wholesaler filed a complaint for incongruence between batch numbers discovered 
in some packages of Herceptin purchased from an Italian wholesaler, 
Farmaceutica Internationale S.r.l., which were on their way to Germany. Up until 
that point, the counterfeit medicine had travelled from Italy to the UK, bound for 
Germany, without suspicion.  
 
In order to encourage compliance, it is imperative to strike the right balance.557 
For instance, loading too much responsibility on the wholesalers as regards to 
compliance with GDP and GMP, and expecting them to cross check 
manufacturing authorisation of all the previous holders of medicinal products, or 
expecting hospitals, pharmacies and retailers to check the safety features without 
554 Jack, A. (15 February 2017). Teva Discovers Sophisticated Fake Drugs. Financial Times. Omeprazole (for 
gastroesophageal reflux disease), fake drugs were supplied to wholesale drug distributors and reached patients 
discovered in Germany in 2013. 
555 See more in Chapter 3, Section 3.2.Herceptin (for breast cancer) was discovered in Finland, Germany, Austria, 
and Sweden in 2014 where vials labelled as Herceptin were thought to have labels and packaging tampered with, 
following theft of Herceptin in Italy. The product was suspected to be in possession of many wholesalers in several 
countries. 
556 AIFA case files. (16 April 2014). Theft and laundering of medicines: early results of the AIFA project: The 
Herceptin Case Press Release n. 355. Rome. Agenzia Italiana del Farmace (AIFA).  
557 Hamilton, W. L., Doyle, C., Halliwell-Ewen, M., & Lambert, G. (2016). Public health interventions to protect 
against falsified medicines: a systematic review of international, national and local policies. Health policy and 
planning, 31(10), 1448-1466. 
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having effective means to check compliance, may actually lead to non-
compliance, as recognised in the previous chapter. And non-compliance with the 
requirements opens up the legal supply chain to infiltration by falsified and 
counterfeit products.   
 
One major hurdle in dealing with an inflow of falsified and counterfeit medicines 
in the EU is controlling entry of counterfeit APIs into the EU. This typically 
occurs when the APIs arrive in small consignments.558 Although it is recognised 
that the solution to this problem may lie in Customs Regulation, it is nevertheless 
vital to recognise this deficiency in the system. Secondly, the APIs are sometimes 
imported under the disguise of non-medical ingredients like vitamins, antioxidants 
and minerals when there are very strict guidelines in place in the EU with regard 
to dealing with import of APIs.559  
 
As was discovered in Operation Volcano, as well as Operation Singapore – a 
common problem has been the use of falsified documents to facilitate infiltration 
of the falsified and counterfeit medicines in the legal supply chain. In Operation 
Volcano, fake authorisations and forged receipts were issued by fake wholesalers 
and distributors based in other countries.560 Unlike the paper currency, which has 
an authenticating watermark which makes it difficult to forge currency, the 
authorisation certificates used in the trade of medicinal products lack such security 
features required by law. Thus, there is a lack of concrete methodology for 
ensuring the authenticity of the official certification documents in the trade of 
medicinal products.  
558 Chapter 3, Section 3.3. 
559  European Commission, New Rules on importing active pharmaceutical ingredients into the European Union, 
Press Release, October 2013.  
560 Chapter 3, Section 3.2. 
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Further, in the light of the fact that a cross- border element is always involved in 
cases of counterfeiting and falsification of medicines, having clarity as to which 
Member State should take the lead and on what basis, in the Directive is 
imperative. In certain matters, clarification of the role and responsibilities of the 
Member States is also provided. For example, under Article 85c 1(c)561 wherein it 
is stated that the Member State (where the natural or legal person offering the 
medicinal products for sale at a distance is based) shall ensure that the medicinal 
products comply with the national legislation of the Member State of destination. 
However, this degree of clarity does not exist in the context of initiation of 
inquiries and investigations. Therefore, it continues to be challenging to assess 
which particular Member State should lead the investigations. It could potentially 
be the Member State that received the falsified substances to be used in the 
manufacturing process of a falsified medicine. But it could also be the Member 
State where the counterfeit medicines were put together. This unresolved dilemma 
that confronts the authorities, in practice, results in loss of crucial time and has an 
impact on the detection of cases of counterfeiting and falsification medicines. 
 
4.4. Online sale of medicinal products 
Besides the traditional means of distributing medicines through brick and mortar 
pharmacies, there is a marked global increase in the number of medicines (both 
prescription as well as non-prescription) being sold online.562 In fact, a lot has 
changed since Soma.com563 came into existence in January 1999, as the first 
561 Article 85c (1) (c) of Medicines Directive (Directive 2001/83/EC) was inserted by Article 1(20) of Falsified 
Medicines Directive (Directive 2011/62/EU). 
564 Clark, F. (2015). Rise in online pharmacies sees counterfeit drugs go global. The Lancet, 386(10001), 1327-
1328; Eban, K. (2006). Dangerous doses: A true story of cops, counterfeiters, and the contamination of America’s 
drug supply. Houghton Mifflin Harcourt. 
563 Gallagher, J. C., & Colaizzi, J. L. (2000). Issues in Internet pharmacy practice. Annals of 
Pharmacotherapy, 34(12), 1483-1485. 
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pharmacy to operate via the internet for selling medicines. Currently, it is 
estimated that there are around 35,000 internet pharmacies operating 
worldwide.564 This trend of selling and buying medicines online has led to an 
increase in the number of cases of sale of counterfeit medicinal products in 
general.565  
 
In the EU, Operation Robin566 revealed the role of online pharmacies in the sale of 
counterfeit medicines as a game changer. As discussed in depth in Chapter 3,567 
three different websites were used to sell counterfeit medicinal products,568  – 
www.steriodakuten.org, www.vikingstore.org  and www.anabolic.cc.569 In this 
case, the crucial point of contact between the customers and the sale of illegal 
products was through the websites. This practice of sale of counterfeit medicine 
through online pharmacies is not exclusively occurring in the EU, and is, in fact, a 
worldwide phenomenon since the sale and purchase of pharmaceutical products is 
possible through the internet, and is accessible in all parts of the world. 
 
In the light of increasing number of such incidents and reports of fake 
pharmaceutical websites in the EU, the 2001 Medicines Directive was amended to 
address the online sale of medicines by the FMD. As acknowledged in the 
Preamble of the FMD, 570 the illegal sale of medicines to the public through the 
internet is perceived as an important threat to public health. Due to the recognition 
of the seriousness of the risk, the Member States have been given the power to 
564 CSIP, LegitScript, (January 2016) The Internet Pharmacy Market in 2016: Trends, Challenges, and 
Opportunities. Center for Safe Internet Pharmacies. USA..  
565 Seeberg-Elverfeldt, N. J. (2009). Mail-Order Trade in Medicines in Europe—A Guide for Legislators to Protect 
Consumers. European journal of health law, 16(4), 351-366. 
566 See Chapter 3, Section 3.4. 
567 Chapter 3. 
568 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
569 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013, 47. 
570 Recitals 21 and 24 Falsified Medicines Directive 2011/62/EU. 
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restrict the sale of pharmaceutical products through online pharmacies.571 
 
Recognising the importance of assisting the general public in sifting the legitimate 
websites selling medicines from the illegitimate websites,572 the FMD introduced a 
provision enlisting the requirements to be fulfilled by all legitimate websites 
selling medicinal products. They are required to bear a common EU logo, which 
must be prominently displayed, as introduced by the Medicines Directive 
2001/83/EC amended by the FMD.573 
 
The exact provisions pertaining to the features of the logo for online pharmacies 
are contained in the Regulation (EU) no. 699/2014.574 The logo is expected to 
identify persons offering medicinal products for sale at a distance to the public and 
the technical, electronic, and cryptographic requirements for verification of its 
authenticity for online retailers and the establishment of registers of legitimate 
online retailers.  
 
The primary goal of the EU logo for online pharmacies in the EU is to serve as a 
mark of authentication575 and aid in identifying legitimate online pharmacy in the 
EU.576 Each online pharmacy is required to be linked to the national competent 
authority’s website, i.e. the National Medicines Agency of a Member State. By 
571 Judgment of the Court of 19 May 2009 in Joined Cases C 171/07 and C 172/07 Apothekerkammer des 
Saarlandes and Others v Saarland ECR [2009] I-4171, paragraph 34 and 35. 
572 Recital 25, Falsified Medicines Directive, 2011/62/EU. 
573 Article 85 (c) inserted in Directive 2001/83/EC by  Directive 2011/62/EU of the European Parliament and of the 
Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for 
human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products 
574 Commission Implementing Regulation (EU) No 699/2014 of 24 June 2014 on the design of the common logo to 
identify persons offering medicinal products for sale at a distance to the public and the technical, electronic and 
cryptographic requirements for verification of its authenticity. 
575 Concept Paper, Implementing Act on a Common Logo for legally operating online pharmacies/retailers offering 
medicinal products for human use for sale at a distance to the public, Sanco.ddgl.d. 6 (2012) 1117232. 
576 Consultation paper October 17, 2012, Implementing Act on a Common Logo for Legally Operating Online 
Pharmacies/Retailers Offering Medicinal Products for Human Use for Sale at a Distance to the Public. 
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clicking on the link, the consumer should be led to the national competent 
authority’s website and this would imply that the online pharmacy is a legitimate 
website and is registered in the Member State. A list of all legitimate online 
pharmacies is maintained by the NCAs for assisting the patients in determining the 
legitimacy of the online pharmacies/websites selling medicines. For instance, in 
Denmark, each legitimate online pharmacy577 would have a logo prominently 
displayed on its website, in fact, on each of its webpages. When a consumer clicks 
on the logo, the consumer is led to the Danish Medicines Authority's webpage, 
where the name, address, and website of the online pharmacy is clearly stated.578 
 
The foremost advantage579 of the EU logo is that it is user-friendly because all that 
is required is to click on a logo, which leads to the verification of the website. 
Thus, in a relatively easy manner, it is easy for an average person to determine the 
legitimacy of the website.  
 
4.4.1. Deficiencies  
Firstly, although there is a mechanism set in place to determine the authenticity of 
the website,580 there are no concrete measures to determine whether the website in 
question is leading to the national website or a fake one. Unlike the preferred 
strategy in the US, where the top level domain (TLD) ‘.Pharmacy’ (dot Pharmacy) 
is encouraged to be used by legitimate pharmacies and retailers selling medicines 
577 As an example http://www.apoteket.dk/Webshop.aspx last accessed on January 23 2017. 
578 Danish Medicines Agency. (September 2015). Pharmacies selling medicines legally online. In Pharmacies and 
sale of medicines. Copenhagen. Danish Medicines Agency. 579 Kohli, V. P. (2015). New EU Logo for Online Pharmacies: Is it geared to serve its Purpose? In Erhvervsretlige 
Emner. Copenhagen. Djøf/Jurist-og Økonomforbundet. 101-114. 
580 Jack, A. (2016). Can anyone stop the illegal sale of medicines online? BMJ: British Medical Journal 
(Online), 352. 
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as it allows the patients to identify authentic and legitimate websites easily,581 in 
the EU the system is more complex. Therefore, it is difficult to assess if the 
website connecting to the online pharmacies is an authentic national website. 
 
Secondly, there is a marked proliferation of the methods in which the medicines 
are finding their way online.582 For instance, the social media such as Facebook583 
and Twitter are also being used, at times, as a legitimate source of advertising,584 
but also for malvertising585 to sell medicines online. For instance, when 
unsolicited bulk email messages or spam are sent to compromised computers. 
Recently, in case studies conducted,586 it was revealed that sometimes the 
perpetrators are hired to spam. Another form of malvertising is when peer-to-peer 
advertising is done on online forums, mainly dealing with dangerous substances, 
for example, hazardous slimming treatment or anabolic steroids that have not 
undergone the required clinical tests and thus, have a potentially harmful effect.587 
 
Currently, there are a number of websites, one for each NCA, which is linked to 
the online pharmacies. Therefore, there are at least 28 Member State websites that 
need to be maintained and protected from fraud and need to have exactly the same 
581 In the US, the National Association of Boards of Pharmacies (NABP) is the mastermind behind the initiative to 
handle the challenges of sale of counterfeit and falsified medicines online. 581NABP owns the ‘Pharmacy’ (top level 
domain) TLD. This TLD is devoted to patient safety and health. The ‘Pharmacy’ TLD can only be obtained for the 
legitimate purpose of selling authentic medicines and they have to adhere to ten core safety standards. It is a 
significant method used to pre-validate online pharmacies. This venture is supported by FIP (the global federation 
of 126 national associations of pharmaceutical scientists and federations). 
582 Hall, A., Koenraadt, R., & Antonopoulos, G. A. (2017). Illicit pharmaceutical networks in Europe: organising 
the illicit medicine market in the United Kingdom and the Netherlands. Trends in Organised Crime. 
583 Zabyelina, Y.G. (2017).United States v. Eric L. Crocker, ‘The United States District Court’ in Can criminals 
create opportunities for crime? Malvertising and illegal online medicine trade., Global Crime Vol. 18, (1) 
584 The legitimate advertising method of sale would be in consonance with the FMD and the Regulation as long as 
the logo is clearly visible. 
585 A term which denotes malicious advertising and is used while referring to legitimate online advertising, which is 
maliciously embedded with malware to latch on to legitimate advertising. The malvertising phenomenon is hard to 
trace and the victims are often unfamiliar with the process. 
586 Zabyelina, Y.G. (2017). Can criminals create opportunities for crime? Malvertising and illegal online medicine 
trade. Global Crime Vol. 18, (1) 
587 ibid. 
176 
 
                                           
 
 
 
authentication function. It would have been simpler to have one common link to 
one EU wide authentication website, as also recommended by the EFPIA in the 
response to the Public Consultations.588 Thereby, a consumer based in the 
Netherlands buying from a legitimate Italian website could still get the required 
authentication data. The requirement for national websites has given a broader 
area for illegal operators to play with. 
 
The problem with the current approach is that not only is the onus shifting from 
the authorities to the general public – especially when it comes to managing the 
problem - it is also going to give rise to the problem of enforcement. In the current 
context of online pharmacies and counterfeit medicines in general, the patients 
have to be aware of the problem of illegitimate websites, as it is the consumers 
that are required to check if the websites are linked to the competent authority’s 
website. The authorities will only intervene if illegitimate websites are brought to 
their attention. A questionable practice that seems to emerge here is that the FMD, 
being part of the public law, is swerving towards placing the onus on private 
citizens to take action just like it was enforcement of a private right such as an 
IPR. 
 
Furthermore, the use of the online logo is a symptom of this trend. There is also no 
effective way, provided by law, of technically withdrawing the logo after it is 
granted to an online pharmacy, if that pharmacy turns rogue. The only action that 
can be taken is the removal of the name of the pharmacy from the Member States 
link to list of valid online pharmacies. If the potential consumer only looks at the 
588 EFPIA. (17 January 2013). Implementing Act on a common logo for legally-operating online 
pharmacies/retailers offering medicinal products for human use for sale at a distance to the public - Concept Paper 
submitted for Public Consultation EFPIA Response.2.  
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logo and buys from the online pharmacy without checking if the name of the 
website appears on the list of valid online pharmacies maintained by the Member 
State, the goal of controlling counterfeit medicines in the EU stands to be 
defeated. 
 
4.5. Concluding remarks 
The FMD only addresses the legal supply chain; the trade in counterfeit and 
falsified medicines is illegal in nature and when this trade occurs with the 
knowledge and consent of the consumer in the illegal supply chain, it is more 
difficult to detect. However, the problem becomes even more convoluted when the 
illegal supply chain permeates the legal supply chain, as illustrated in Figure 8.589 
Therefore, while addressing the general problem of counterfeiting in the 
pharmaceutical sector in the EU, it is pertinent to take into consideration all 
channels that allow entry of counterfeit medicines in the EU. 
 
In efforts to control counterfeiting of medicines in the EU, the legal framework 
has to be cautious about zealously pursuing regulation. Lack of clear regulation 
can lead to non-compliance, as has been evidenced in the case of the supply chain, 
where manufacturing authorisation holders did not check the authorisation of the 
previous holders of the medicinal products and did not verify if GDP and GMP 
were being complied with. The legal supply chain has been made clearer by 
defining the roles of the various players. By explicitly requiring specific 
authorisations for all the market players, including the brokers as introduced by 
the FMD attempts to impart greater clarity to the individual role of each actor in 
the legal supply chain. If the authorisation certificates were secured with 
589 See Figure 8 in Section 4.3.3.1. 
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watermarks, as employed in the currency or with other security mechanisms, 
which would be difficult to imitate and copy, it would assist in eliminating the 
problem of fake authorisations. By doing so, one common avenue of the 
introduction of falsified medicines into the legal supply chain can be blocked. 
 
Furthermore, the importation of APIs is also a critical matter in which products 
that aid in the production of falsified medicines, enter the EU, as was witnessed in 
Operation Robin. Therefore, it is important to have a strong dissuasive measure in 
order to be more effective such as ‘reverse burden of proof’ used in import of 
chemical substances because falsified medicines can be just as hazardous as 
chemical substances. 
 
Another important contribution of the FMD is the rules pertaining to the online 
sale of medicines in the EU.  The introduction of the online logo will go a long 
way in protecting the patients in the long run. However, there are still certain gaps 
that need to be bridged in this area. For instance, determining the authenticity of 
the website itself and a mechanism for dealing with pharmacies that turn rogue. 
 
The other issues that remain to be tackled are, firstly, the question of which 
Member State should take the lead in initiating investigations of the act of 
counterfeiting. It could be beneficial to the case to require the Member State where 
the raw materials (for example, the counterfeit APIs) are found to head the 
investigations but the Member State where the counterfeit product is manufactured 
or assembled is equally relevant and crucial to resolving such cases. However, as a 
result of lack of clarity on this matter, potential cases run the risk of not getting 
addressed. It would be prudent to involve the Member State in which the 
counterfeit material is received, as well as the State where the manufacturing of 
the counterfeit product actually takes place. These are, in fact, two steps of the 
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larger process of counterfeiting and falsification of the medicinal product. Hence, 
there needs to be clarity regarding the role of the Member States involved.  
Moreover, being a cross-border activity where there are at least two different 
Member States involved, sharing of information and coordination of resources is 
crucial. As the case studies revealed, Operation Singapore and Operation Robin 
were two distinct operations involving an investment of the huge amount of 
resources. There have been similar cases across the EU, but common coordinated 
efforts have been few.  
 
In the Medicines Directive, there is a provision for coordinated action requiring 
issuing of Rapid Alerts under 117a (3),590 which as introduced by the FMD, 
Article 1(24), whereby all the relevant authorities across the Member States must 
be informed if falsified medicines having life threatening consequences are 
discovered. Further, if the medicinal product in question has reached the patients, 
then urgent recalls591 must be issued, making public announcements incorporating 
information on the suspected quality defect and the possible risks. However, a 
similar provision pertaining to this problem, where more than two Member States 
are involved is lacking. 
 
In the light of the fact that it is asserted in the thesis that counterfeiting and 
falsification of medicines lies at the intersection of IP Law, Medicine Law, and 
Criminal Law,592 it is of utmost importance to have lines of communication and 
information sharing open between the authorities representing the three spheres of 
law in order to effectively combat the problem of counterfeiting and falsification 
590 Article 117a (3), Directive 2001/83/EC inserted by Article 1(24) of Directive 2011/62/EU. 
591 A drug recall means removal of a prescription or over-the-counter drug from the market by the national 
competent authority, usually a medicines agency. 
592 See Chapter 1, Section 1.2.  
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of medicinal products in the EU. Therefore, a similar provision for building 
synergies between the three streams of law – Medicine law, IP law and Criminal 
law, between the different relevant authorities within and across the Member 
States in connection with general coordination strategy could be extremely 
relevant for resolving matters revolving around counterfeiting and falsification of 
medicinal products. However, in the current laws, such a provision is absent. 
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Chapter 5: Analysis of Enforcement Directive 
(Directive 2004/48/EC) 
 
5.1. Introduction 
Since the issue of counterfeiting and falsification of medicinal products lies at the 
intersection of IP law, Medicine law and Criminal law,593 it is imperative to 
consider all the relevant spheres of laws to obtain a complete understanding. In the 
previous chapter, the perspective of Medicine law was presented by analysing the 
FMD, specifically with reference to areas pertaining to manipulation of the 
product, infiltration of the legal supply chain and online sale of medicines.594 It 
was also explained in the preceding chapter that the FMD does not address the IP 
law violations.595  
 
Therefore, in this chapter, the Directive 2004/48/EC596 (henceforth, referred to as 
‘the Enforcement Directive’) is analysed, representing the IP Law perspective.597 
The general background to the formation of the Enforcement Directive serves as 
the starting point of the discussion, followed by a broad legal analysis with respect 
to the fundamental difference between the nature of Enforcement Directive and 
Customs Regulation, on the one hand, and the FMD, on the other hand. 
Thereafter, the repercussions of this crucial difference on combatting 
counterfeiting and falsification of medicinal products will be analysed. Thereafter, 
593 Chapter 1, Section 1.2. 
594 Chapter 4, Sections 4.2, 4.3, and 4.4. 
595 Recitals 5 and 29, Directive 2011/62/EU. 
596 Directive 2004/48/EC of the European Parliament and of the Council of 29 April 2004 on the enforcement of 
intellectual property rights. 
597 See more in Chapter 1, Section 1.2. and Chapter 2, Section 2.3.4.2. 
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the focus of the chapter narrows down to analysing the challenges that arise while 
combatting counterfeit medicines in the EU, as highlighted in Chapter 3.598 The 
main challenges recognised in Chapter 3 included the manipulation of medicinal 
products; infiltration of the legal supply chain due to prevalence of fake market 
authorisations and use of disguise of parallel imports; sale of counterfeit medicinal 
products online; involvement of more than one Member State and the role played 
by organised crime.599 In other words, an analysis of the challenges that arise due 
to cross-border applicability of the provisions while enforcing IP rights will be 
considered. After that, the role of intermediaries in cases of online sale of 
medicines will be evaluated. Finally, the lack of harmonisation of criminal 
measures with respect to violation of IP rights will be taken into consideration.  
 
While examining with the problem of counterfeiting of medicines in the sphere of 
IP law, primarily the area of trademarks is most relevant for the purposes of this 
thesis. In the EU, the Directive 2015/2536600 (henceforth, referred to as ‘the 
Trademarks Directive’), contains provisions that approximate the laws of the 
Member States relating to trade marks. The Trademarks Regulation601 provide the 
legal basis of protection of EU trade marks (EUTM) and contains other measures 
to streamline the entire system to grant more legal certainty and foster a well-
functioning internal market. The most common issues that arise with respect to 
counterfeit medicines usually pertain to false representation due to products not 
being in original packaging602 as illustrated in C – 102/77 Hoffmann-LaRoche v. 
598 Chapter 3, Section 3.5. 
599 ibid.  
600 Directive (EU) 2015/2436 of the European Parliament and of the Council of 16 December 2015 to approximate 
the laws of the Member States relating to trade marks. 
601 See Articles 9 and 10, of Regulation (EU) 2017/1001 of the European Parliament and of the Council of 14 June 
2017 on the European Union trademark, applicable from October 1, 2017. 
602 Most of the case law available on counterfeit medicine in the EU, revolves around the question of re-packaging 
and conditions which were not upheld, thus infringing the rights in the trademarks. See Case 102/77 Hoffmann-
La Roche v Centrafarm [1978] ECR 1139 paragraph 7, Case 1/81 Pfizer v Eurim-Pharm [1981] ECR 2913, 
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Centrafarm, C 1/81 Pfizer v. Eurum –Pharm. The false products can also appear in 
false packaging,603 which cause loss of reputation and goodwill of the original 
producer and the proprietor of the trademark in violation of Article 10(2) and (3) 
and Article 11 of Directive 2015/2536. This was very well illustrated in Operation 
Singapore, wherein the primary accused P. Gillespie was sentenced for three years 
of imprisonment on the counts of selling counterfeiting medicines.604Therefore, it 
is relevant to consider the Enforcement Directive, which encompasses rules 
pertaining to the enforcement of IPRs, including protection of trademarks in the 
EU.  
 
The Enforcement Directive came about in accordance with the provisions of the 
internal market of the Treaty of Rome.605 The main aim of the Enforcement 
Directive is the protection and enforcement of IPRs and it further contributes to 
the realisation of freedom of movement; elimination of distortions of competition, 
and promotion of innovation and investment in the EU.606 The goals of the 
Enforcement Directive are in consonance with the right to property as well as the 
right to IP as envisaged respectively, in the Charter of Fundamental Rights of the 
European Union607 and the TFEU.608 
paragraph 7; See more examples in C 71/94 Judgment of the Court of 11 July 1996. Eurim-Pharm Arzneimittel 
GmbH v Beiersdorf AG (C-71/94), Boehringer Ingelheim KG (C-72/94) and Farmitalia Carlo Erba GmbH (C-
73/94). Reference for a preliminary ruling: Bundesgerichtshof - Germany. Repackaging of trade-marked products - 
Article 36 of the EC Treaty. Joined cases C-71/94, C-72/94 and C-73/94.European Court Reports 1996 page I-
03603.  See also Chapter3, Section 3.2.  Operation Volcano, where Herceptin, the cancer treatment drug was stolen 
from a delivery truck on its way, to deliver authentic medicines, to a hospital. Thereafter, the drug was manipulated 
and re-introduced in the original packaging of its manufacturer, Roche, and re-introduced in the legal supply chain. 
603 See more in Chapter 5, Section 3.3., R v. Peter Hugh Gillespie and others, Crown Court at Croydon in R v. Peter 
Hugh Gillespie (2012) 2 Cr. App. R. (S) 24 . Peter Gillespie was convicted and sentenced Trade Mark offence for 
selling counterfeit goods (Casodex, Plavix and Zyprexa). 
604 ibid. 
605 Treaty establishing the European Economic Community, 25 March 1957, 294 U.N.T.S. 3 (entry into force 1 
January 1958). 
606 See Article 26, TFEU, and Recital 32, Directive 2004/48/EC. 
607 See Article 17(2), CFREU. 
608 See Article 118, TFEU. 
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The need for a legal framework in the EU as regards enforcement of IP was 
recognised much before,609 but only later in the 1980s with regulation regarding 
counterfeit goods (see Table 3 below), it began to be formalised with respect to 
combatting counterfeit goods. Subsequently, in the 1990s, as an aftermath of the 
TRIPS Agreement610 and especially through the Green Paper on Combatting 
Counterfeiting and Piracy in the Single Market,611 the differences in the 
legislations of the Member States were brought to light. The Green Paper also 
underlined the negative impact of these disparities on realisation of the goals of 
the internal market.  These deliberations culminated in establishment of the 
Enforcement Directive.612 Although it was the first endeavour at the EU level to 
introduce harmony in laws of the Member States in civil law legislations, the 
Enforcement Directive was a target of extreme criticism.613 As is evident from the 
table (Table 3 below), continuous efforts have been made over the year through 
specific strategies designed particularly, in 2008, 2010, and 2014 to address the 
pertinent issues of counterfeiting and piracy.  
 
 
609 See Chapter 2, Section 2.3.4.2. 
610 TRIPS: Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Marrakesh 
Agreement Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197 (1994). 
611 Green Paper of 15 October 1998 ‘Combating Counterfeiting and Piracy in the Single Market’, COM (98) 569 
final. 
612 Vrins, O., & Schneider, M. (2014). Cross-border enforcement of intellectual property: The European Union. 
Torremans,P. (Ed.) (2014). Research handbook on cross-border enforcement of intellectual property. 166-328. 
613 The Directive was passed just days before ten East and Central European countries were going to accede to the 
EU. The Accession Treaty entered into force on 1 May 2004 and the European Union’s biggest expansion. Cyprus, 
the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, the Slovak Republic, and Slovenia joined 
Europe. See more in Gateva, E. (2016). European Union enlargement conditionality. Springer.  Therefore, the 
Directive was labelled as ‘fear-driven’ to protect IPRs and have the new Member States regulate their legislation on 
the same level as in the rest of the EU; See also Torremans, P., (Ed.). (2014). Research Handbook on Cross-border 
Enforcement of Intellectual Property. Edward Elgar Publishing. 
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Year Regulation 
1986 Council Regulation (EEC) No. 3842/86 of 1 December 1986 laying down measures to 
prohibit the release for free circulation of counterfeit goods (1986) OJ L347/1. 
1994 Council Regulation (EC) No. 3295/94 laying down measures to prohibit the release for free 
circulation, export, re-export or entry for a suspensive procedure of counterfeit and pirated 
goods (1994) OJ L341/8. (This was extended in 1999, 2003, and 2013). 
1998 Green Paper of 15 October 1998 ‘Combating Counterfeiting and Piracy in the Single 
Market’, COM (98) 569 final. 
2000 Communication from the Commission to the Council, the European Parliament and the 
European Economic and Social Committee, ‘Follow-Up’ to the Green Paper on Combating 
Counterfeiting and Piracy in the Single Market’, COM(2000) 789 final. 
2004 Directive 2004/48/EC of the European Parliament and the Council of 29 April 2004 on the 
enforcement of intellectual property rights (2004) OJ L157/45. 
2005 Strategy for the Enforcement of Intellectual Property Rights in Third Countries (2005) OJ 
C129/3. 
2008 Communication on a New Industrial Property Rights Strategy for Europe, COM (2008) 465 
final. 
2008 Council Resolution on Comprehensive European Anti-Counterfeiting and Anti-Piracy Plan. 
2009 Council Resolution of 16 March 2009 on the EU Customs Action Plan to combat IPR 
infringements for the years 2009 to 2012 (2009) OJ C71/1. 
2010 Council Resolution of March 1 2010 on the enforcement of intellectual property rights in the 
internal market, (2010) OJ C56/1. 
2012 New Customs Action Plan to combat IPR infringements for the years 2013-17. European 
Commission, 'Enforcement of Intellectual Property Rights MEMO/14/449. 
2014 Communication from the Commission to the European Parliament, the Council and the 
European economic and Social Committee 'Towards a renewed consensus on the 
enforcement of Intellectual Property Rights: An EU Action Plan', COM (2014) 392 final. 
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The scope of application of Enforcement Directive encompasses protection of 
IPRs such as trademark rights, copyrights, patent rights, utility models, design 
rights, plant variety rights, trade names, etc.614 The Enforcement Directive does 
not only deal with the issue of counterfeit medicine, but it also entails the 
enforcement of all types of IP rights irrespective of the sector the IP rights may be 
associated with.615 
 
Even though the Enforcement Directive is a broad directive, it is of relevance in 
combatting counterfeiting of medicinal products in the EU. The term counterfeit 
medicine refers to those medicines, which violate an IP right (be it trademark right 
that is violated, or design right, or patent right).616 This is different from the term 
falsified medicine as defined in the FMD.617 Typically, when a falsified medicinal 
product, defined as any product that has false representation pertaining to its 
origin, history, or source,618 is discovered, it almost always presents a component 
of violation of an IP right. Usually, it is violation of a trademark right with respect 
to false packaging.619 While the FMD deals with the violation of the FMD, the 
Enforcement Directive specifically provides for the provisions of enforcing the 
private rights of the right holder in case of violation of IP rights.620 For example, 
in Operation Volcano, the cancer treatment medicine Herceptin was stolen from 
the delivery truck on its way to deliver the medicines to the hospital.621 This stolen 
medicine was manipulated and re-introduced in the legal supply chain. It not only 
614 Statement by the Commission concerning Article 2 of Directive 2004/48/EC of the European Parliament and of 
the Council on the enforcement of intellectual property rights (2009/295/EC). 
615 Kur, A., Planck, M., & Dreier, T. (2013). European intellectual property law: text, cases and materials. Edward 
Elgar Publishing. 
616 See, Chapter 1, Section 1.6. on Terminology. 
617 Article 1, Directive 2011/62/EU. 
618 ibid. 
619 See Articles 10 and 11, Directive (EU) 2015/2436 of the European Parliament and of the Council of 16 
December 2015 to approximate the laws of the Member States relating to trade marks. 
620 Torremans, P. (2016). Holyoak and Torremans intellectual property law. Oxford University Press. 
621 Chapter 3, Section 3.2.  
187 
 
                                           
 
 
 
was ‘false representation’ with respect to its origin and source, and thus a violation 
of FMD, it also violated the trademark rights of the right owner ‘Roche’, who 
owns the trademark rights, because it affected their goodwill and reputation.   
 
5.2. Private rights vis-à-vis public rights 
The protection of IPRs is protection of private rights of the right holder.622 The IP 
rights bestow upon the owner: the right to sell, transfer, assign, subdivide, or 
invoke the power of the State to assert their rights in case of violation of the 
same.623  
 
The Enforcement Directive and the Customs Regulation fall under the umbrella of 
private law, as opposed to the FMD that lies under the purview of public law. The 
private law governs the relationship between subjects, and public law governs the 
relationship between institutions of the State, or between the State and the 
subjects.624 Traditionally, private law is believed to be the law that revolves 
around serving private interests, and not public interests. In that sense, IP rights 
form a part of private law, since they are concerned with protection of personal 
interests.625 Secondly, the aim of private law is to deal corrective justice in 
contrast with public law, where the main goal is to impart distributive justice,626 as 
622 Merges, R. (2017). What Kind of Rights Are Intellectual Property Rights? (Forthcoming in Rochelle C Dreyfuss 
& Justine Pila (eds), The Oxford Handbook of Intellectual Property Law © RP Merges 2017; Michaels, R., & 
Jansen, N. (2006). Private law beyond the state? Europeanisation, globalisation, privatisation. The American 
Journal of Comparative Law, 54(4), 843-890. 
623 Geiger, C. (2006). Constitutionalising intellectual property law? The influence of fundamental rights on 
intellectual property in the European Union. International Review of Intellectual Property and Competition 
Law, 37(4). 
624 Loughlin, M., & Tschorne, S. (2016). Public law (pp. 324-337). Routledge. 
625 Michaels, R., & Jansen, N. (2006). Private law beyond the state? Europeanization, globalization, privatization. 
The American Journal of Comparative Law, 54(4), 843-890. 
626 Weinrib, E. J., (2012). The idea of private law. Oxford University Press.19. 
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in the case of the FMD, which is a public law. Thirdly, the IP law, as with other 
laws in the realm of private law, governs the relationship between private parties 
(it may include the State as a party in its role as a market participant). In 
comparison, the sphere of public law involves the State, as the sovereign, as one of 
the parties.627 
 
The Enforcement Directive aims to enforce the IP rights in the EU, belongs to the 
realm of private law. On the contrary, the FMD strives to realise the goals of 
safeguarding public health and safety, and thus, falls under the area of public law. 
This distinction between the two streams of law is of crucial importance. The 
significance lies in diversity of the fundamental aims of the two types of law – IP 
law and Medicine law. The IP law aims to protect the rights of the individual or 
select few as it lies in the realm of private law, while the Medicine law aims at 
protecting the rights of the public health and safety, belonging to the fold of public 
law.  
 
The distinction between the two spheres of law does not end here. Procedurally 
and in terms of enforcement mechanisms the two streams of law are different. In 
the case of infringement of trademarks due to counterfeiting of a medicinal 
product, the proprietor of the trademark is responsible for taking the initiative to 
seek redressal because it is a violation of a private right. However, in case of 
detection of a falsified medicine, the State or an agency of the State is responsible 
for taking the initiative to protect the citizens.  
 
The paths of the two types of law intersect, while addressing the problem of 
falsification and counterfeiting of medicines. However, both types of laws govern 
627 Weinrib, E. J., (2012). The idea of private law. Oxford University Press.19. 
189 
 
                                           
 
 
 
separate and distinct aspects of the same problem – counterfeiting and falsification 
of medicinal products. Even though it would be more expedient to concurrently 
address the problem, it is not the current practice. 
 
5.3. Lack of cross-border applicability of the Enforcement 
Directive 
In the EU, the cross-border concept of enforcement has attributes of confusion,628 
because on one hand, the internal market implies free movement of goods, 
services, people, and capital implemented through Directives, Regulations, and 
other legal instruments and supranational institutions. While, on the other hand, 
the Member States enjoy full control over other matters such as criminal matters 
and judicial systems. The Enforcement Directive delimits629 itself from dealing 
with rules pertaining to judicial cooperation, jurisdiction, the recognition and 
enforcement of decisions in civil and commercial matters. 
 
However, counterfeiting and falsification of medicinal products is, typically, a 
cross-border element is present in the counterfeiting and falsification of 
medicines.630 The case studies, as discussed in Chapter 3, highlighted the act of 
falsification and counterfeiting of medicines usually involves two or more 
countries. For instance, Operation Robin revealed that the raw materials were sent 
from China to Belgium and delivered in Sweden via Denmark and other 
628 Vrins, O., & Schneider, M. (2014). Cross-border enforcement of intellectual property: The European Union. 
Torremans,P. (Ed.) (2014). Research handbook on cross-border enforcement of intellectual property. 166-328. 
629 Recital 11, Directive 2004/48/EC. 
630 See European Commission. (2014). The EU explained: Borders and security. Building an open and secure 
Europe. Brussels. European Commission. 
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countries.631 The counterfeit APIs were delivered in Belgium, which arrived in 
small packages in Denmark alongside other Member States, before they finally 
were received in Sweden.632 Thereafter, the manufacturing of the counterfeit and 
falsified medicine was conducted in a factory in Sweden.633 Similarly, within 
Europe, other cases have revealed identical pattern involving more than two 
Member States.634 
 
In the context of counterfeiting of medicinal products in the EU there are certain 
provisions in the Enforcement Directive that present potential for contributing to 
speedier resolution of cases, subject to room for cross-border applicability. These 
include, particularly,  the Right of Information (Article 8);635 application of 
provisional and precautionary measures (Article 9) 636 and injunctions (Article 
11) 637 because these provisions contain the tools needed to hinder the act of 
counterfeiting, with almost an immediate effect.  
 
The Right of Information under Article 8 of the Enforcement Directive aims to 
increase transparency and grant access to information in order to ensure effective 
governance. Thus, Article 8 of the Enforcement Directive extends the right to 
obtain information about the involvement of the third parties. As recognised in 
Recital 21 of the Enforcement Directive, the primary motive of introducing right 
of information is to allow for precise information access with respect to origin of 
the infringing goods or services, the distribution channels, and the identity of any 
631 See Chapter 3, Section 3.4. 
632 ibid. 
633 ibid. 
634 Bate, R. (2012). Phake: the deadly world of falsified and substandard medicines. AEI Press.50. 
635 Article 8, Directive 2004/48/EC. 
636 Article 9, Directive 2004/48/EC. 
637 Article 11, Directive 2004/48/EC. 
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third parties involved in the infringement.638 As a result of this provision, the IPR 
holder can request for information such as: names, addresses of producers, 
manufacturers, distributors, suppliers, intended wholesalers, previous holders of 
goods or services, quantities of goods produced, manufactured, delivered, received 
or ordered, as well as prices obtained for the goods or services in question.  The 
extended right to information had been attempted previously in Directive on the 
Legal Protection of Industrial designs (OJ L 289/28), and existed in Germany639 
and some Benelux countries.640 
 
The practical application of this provision over the past decade has revealed that, 
there are certain challenges associated with pursuing offenders in different 
countries, where national procedures are applied in their unique way.641 Since each 
Member State has its own judicial system and set of procedures, crucial time is 
expended to obtain the required orders to pursue the accused in cases of 
counterfeiting in different Member States, as also acknowledged in Operation 
Robin.642 
 
In cases involving counterfeiting and falsification of medicines, time is an 
important factor. As evident from the case studies, the counterfeit material arrives 
in small consignments and travels from one Member State to another, as 
specifically witnessed in Operation Robin.643 Further, procedural delays can result 
638 Recital 21, Enforcement Directive 2004/48/EC. 
639 Right to third party information was introduced in Germany in 1990 by the Product Piracy Act 
(Produkthaftungsgesetz).1990. 
640 Confined to trade mark infringements, see Article 13bis of the Benelux Trademark Act (Uniform Benelux Law on 
Marks (amended by the Protocol of November 10, 1983, amending the Uniform Benelux Law on Trademarks and 
by the Protocol of December 2, 1992, amending the Uniform Benelux Law on Marks). 
641 Vrins, O., & Schneider, M. (2014). Cross-border enforcement of intellectual property: The European Union. 
Torremans, P. (Ed.) (2014). Research handbook on cross-border enforcement of intellectual property. 166-328. 
642 Chapter 3, Section 3.4. 
643 See Chapter 3, Section 3.4. 
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in potential cases not being detected within reasonable timeframe. Therefore, 
having limited relevant automatic procedures, to assist in controlling 
counterfeiting and falsification of medicines can result in better IPRs enforcement. 
For instance, as recommended in the Public Consultation Report,644 a provision to 
institute a near automatic procedure, whereby courts in Member States could 
enforce the production of documents, which have been ordered by courts in other 
Member States, could be beneficial.  
 
The precautionary and preventive measures arm the legal machinery to prevent 
damage before it is done, rather than relying on the law to compensate afterwards. 
In the Enforcement Directive, Article 9645 provides for provisional and 
precautionary measures. It specifically means that the judicial bodies are 
authorised to issue interlocutory injunctions, which aim to prevent a possible 
infringement of an IPR. In addition, it is provided that the judicial authority may 
also order a seizure of goods suspected of infringing an IPR before the said goods 
enter the channels of commerce.646 In those cases, where infringement of an IPR 
occurs on a commercial scale, after taking into consideration the existing 
circumstances, the judiciary can subsequently provide for precautionary seizures. 
It can only happen in cases where it is demonstrated that recovery would be 
endangered.647 These seizures, as part of the precautionary measures, can include a 
seizure of movable as well as immovable property, blocking of bank accounts, 
communications relating to ban, financial or commercial documents, and other 
relevant information. 
644 European Commission. (14 September 2016). Summary of responses to the public consultation on the evaluation 
and modernisation of the legal framework for the enforcement of intellectual property rights. Ref. Ares (2016) 
5286091-14/9/2016. Brussels. European Commission. 23. 
645 Article 9(1) (a), Enforcement Directive 2004/48/EU. 
646 Article 9 (1) (b), Enforcement Directive 2004/48/EU. 
647 Article 9(2), Enforcement Directive 2004/48/EU. 
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The main goal of the introduction of provisional measures was to provide for 
instant termination of infringements, without waiting for a decision on the 
substance of the case inaudita altera parte.648 This provision is a reflection of the 
Mareva injunctions developed in the UK.649 The Mareva injunctions are also 
known as freezing orders against the movement of assets, pending decision of the 
courts.650 The introduction of provisional measures was considered justifiable 
particularly in those situations, where it is believed that these would not cause 
irreparable harm.651  
 
This provision is especially relevant in cases of violations concerning medicinal 
products. For instance, when the law enforcement agency becomes aware of a 
particular business engaging in an illegal activity i.e. printing labels for a 
counterfeit medicine and that business is packaging counterfeit medicine to be 
introduced in the legal supply chain, as was the case in Operation Singapore,652 
such a provision would have prevented loss of significant evidence. A similar 
problem was also witnessed in Operation Robin carried out by the Swedish Law 
Enforcement Authorities. In their bid to capture evidence, the Swedish Customs 
and Law Enforcement authorities had to keep track of the investigations carried 
out between January 1 2009 and May 8 2012, with the help of surveillance teams, 
hidden cameras, historical deliveries of parcels, etc.653 In the light of these 
circumstances, the importance of the precautionary and preventive measures 
648 Recital 22, Enforcement Directive 2004/48/EU; Article 9 (2) and 9 (4), Directive 2004/48/EC. 
649 Vrins, O., & Schneider, M. (2014). Cross-border enforcement of intellectual property: The European Union. 
Torremans, P. (Ed.) (2014). Research handbook on cross-border enforcement of intellectual property. 166-328. 
650  See more in Mareva Compania Naviera S.A. v. International Bulk-carriers S.A. [1975] 2 Lloyd's Rep. 509; 
[1980] 1 All E.R. 213, C.A. Pending the final result of the law suit, this order of the court prevents a defendant 
from transferring assets.  
651 Devonshire, P. (1999). Mareva Injunctions and Third Parties: Exposing the Subtext. The Modern Law 
Review, 62(4), 539-563. 
652 See Chapter 3, Section 3.3. 
653 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013. 
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cannot be underestimated because the counterfeiting and falsification of 
medicines, by nature, are illegal activities that transpire behind closed doors.  
 
The practical application of this provision in the past decade has shown that right 
holders face some specific problems in the application of this provision, especially 
in cross-border contexts. In addition, the issue of legal uncertainty in cross-border 
situations causes a lot of IPR holders to refrain from availing these measures.654 
And those who do resort to the first step of obtaining provisional or precautionary 
measures, the additional costs, such as for translations in cross border situations, 
add another burden to the already cumbersome process.655 Further, variable time 
span for procedures in different Member States and differences in procedures 
itself, also fail to persuade the right holders to go forward with the legal redress 
channel, as the first priority. Another factor that has emerged and contributed 
towards complaints on part of the right holders towards the current system is the 
domestic geographical limitation, with specific reference to scope of injunctions 
and no recognition of judgments or evidence in different Member States.656 This 
issue is particularly relevant to the counterfeiting in the pharmaceutical sector, 
which is notoriously a cross-border activity within the EU as denoted by 
Operation Volcano, where the wholesalers were located in Italy, and parallel 
importers were located in the UK, and another wholesaler was located in 
Germany.657  
 
654 European Commission. (July 2013). Synthesis of the Responses: Civil Enforcement of Intellectual Property 
Rights: Public Consultation on the Efficiency of Proceedings and Accessibility of Measures. Directorate General 
Internal Market and Services. Intellectual Property, Fight against counterfeiting and piracy. Brussels. European 
Commission. 
655 ibid. 
656 European Commission. (14 September 2016). Summary of responses to the public consultation on the  on the 
evaluation and modernisation of the legal framework for the enforcement of intellectual property rights. Ref. Ares 
(2016)5286091-14/9/2016. Brussels. European Commission. 31. 
657 See Chapter 3, Section 3.2., 3.3, and 3.4.   
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Therefore, it is important to point out that the lack of case law and empirical data 
on the application of the provisions of the Enforcement Directive need to be 
viewed against the exponential increase of statistical data indicating increase in 
counterfeiting and falsification of medicinal products in the EU.658 This 
juxtaposition reveals the lack of effectiveness of these provisions, especially in 
context of counterfeit medicines, which is essentially a cross-border crime. 
 
Injunctions 
Article 11 of the Enforcement Directive provides for injunctions applied by the 
national courts659 and Article 12 lays down the provisions for alternative measures 
that may be employed to resolve IPR conflicts. The central goal of these 
provisions is to allow the Member States to prohibit the continuation of 
infringement. For example, an injunction would usually be sought for blocking 
access to infringing content online or by stopping the manufacturing of the 
infringing products, or to prevent infringing content from appearing. Article 11 
and 12 should ideally work together in the sense that the phrasing of Article 11 
(using the word ‘may’) and the existence of Article 12 in the Directive, indicate 
that there is an alternative to injunctive relief. It further imparts the idea that the 
Courts in Europe would have discretion in determining the final injunctions, 
which should be granted or an alternative should be the appropriate course of 
action,660 as is now the method employed in the US.661 The past decade shows 
that, in the EU, courts usually grant injunctive relief when the merits of the case 
658 Recital 2, Directive 2011/62/EU. 
659 The Information Society Directive (Directive 2001/29/EC od the European Parliament and of the Council of 22 
May 2001 on the harmonisation of certain aspects of copyrights and related rights in the information society, OJ L 
167 22 June 2001, 10-19) Article 8 (3) also stands in relation to Article 11 of the Enforcement Directive 
(2004/48/EC). 
660 Cook, T. (2015). Enforcement Directive & Harmonisation of the Remedies for IP Infringement in the EU, 
Journal of Intellectual Property Rights, Vol 20., 264-269. 
661 eBay v. Merc Exchange 546 US 1029; 126 S Cr. 1837; 78USPQ 2D 1577 (Supreme Court). 
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allow for it. However, there have been no references made to the Court of Justice 
for seeking clarification on this practice up until this date for any type of IP matter 
that can challenge this practice.662 
 
Over the past decade, the practice has revealed the use of this provision by the 
majority of right holders who have taken the course of litigation.663 While in 
domestic scenarios, where the injunction was sought in the Member State of the 
right holder, the procedure went more smoothly compared to cross-border 
situations. Right holders were confronted with a number of problems in cross-
border situations, such as costs (translations), length of procedures, test purchase 
in all jurisdictions, notarisation of evidence, diverging substantive scope of 
injunctions, rules on jurisdictions and the lack of adequate legal basis.664 
 
Further, the discrepancy in the application of the Enforcement Directive between 
Member States665 can also have consequences for the pharmaceutical sector with 
reference to counterfeiting and falsification of medicines, while also affecting 
other sectors. The lack of a uniform action in the Member States can make certain 
countries the target of counterfeiting, and other nations within the EU will be 
662 The decision of the Court of Justice while considering whether permanent injunction should be granted in a case 
where a standard essential patent is found valid and infringed because to sticking to the standard, Case C-170/13 
Huawei Technologies Co., Ltd., v ZTE Corp., ZTE Deutschland GmbH (Court of Justice, 16 July 2015) hinged 
upon Article 102 Treaty on the Functioning of the European Union, which forbids abuse of dominant position in the 
relevant market and not Article 11 of the Enforcement Directive.  
663 European Commission. (July 2013). Synthesis of the Responses: Civil Enforcement of Intellectual Property 
Rights: Public Consultation on the Efficiency of Proceedings and Accessibility of Measures. Directorate General 
Internal Market and Services. Intellectual Property, Fight against counterfeiting and piracy. Brussels. European 
Commission. 
664 Vrins, O., & Schneider, M. (2014). Cross-border enforcement of intellectual property: The European Union. 
Torremans, P. (Ed.) (2014). Research handbook on cross-border enforcement of intellectual property. 166-328. 
665 ibid.; European Commission. (July 2013). Synthesis of the Responses: Civil Enforcement of Intellectual 
Property Rights: Public Consultation on the Efficiency of Proceedings and Accessibility of Measures. Directorate 
General Internal Market and Services. Intellectual Property, Fight against counterfeiting and piracy. Brussels. 
European Commission. 
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vulnerable to the housing the counterfeiters.666 This trend was already apparent in 
Operation Volcano, which revealed that Latvia, Romania, Malta, and Cyprus 
primarily were those countries, which had fake authorisation holders, while 
Germany was one of the target countries receiving the falsified medicines.667 
 
5.4. The role of Intermediaries 
The online sale of counterfeit and falsified medicines is a recognised threat in the 
EU.668 Consequently, a specific provision to regulate the online sale of medicines 
was introduced in the FMD,669 whereby all websites based in the EU selling 
medicinal products are required to display the common EU logo on each page of 
their respective websites.670 In addition to the FMD, which deals only with 
falsification of medicines, the Enforcement Directive is important and relevant as 
regards the enforcement on IPRs.  In addition to the FMD, the Enforcement 
Directive, the E-Commerce Directive,671 and the Info-Society Directive672 also 
contain specific rules regarding the role of intermediaries in the digital 
environment, which have an impact upon the sale of medicinal products online. 
However, for the purposes of this chapter, only the Enforcement Directive is being 
assessed. 
 
There are no special provisions with regard to online sale or digital infringements 
666 Ekwall, D., Brüls, H., & Wyer, D. (2016). Theft of pharmaceuticals during transport in Europe. Journal of 
Transportation Security, 9(1-2), 1. 
667 See Chapter 3, Section 3.2.; See also Theft of medicines, Trends over the years, (2017), AIFA.  
668 Hall, A., & Antonopoulos, G. A. (2016). Introduction. In Fake Meds Online (1-17). Palgrave Macmillan UK. 
669 Article 85c in Directive 2001/83/EC was introduced by Article 1(20) of Directive 2011/62/EU. 
670 Commission Implementing Regulation, 699/2014/EU, of 24 June 2014 on the design of the common logo to 
identify persons offering medicinal products for sale at a distance to the public and the technical, electronic and 
cryptographic requirements for verification of its authenticity. OJ L184, 25.6.2014, 5-7. 
671 Directive 2000/31/EC of the European Parliament and of the Council of 8 June 2000 on certain legal aspects of 
information society services, in particular electronic commerce, in the Internal Market. OJ L178, 17.7.2000, 1-16. 
672 Recital 59, Directive 2001/29/EC.  
198 
 
                                           
 
 
 
of IPRs in the Enforcement Directive, it applies equally to online and offline 
cases.673 Article 9(1) (a) provides for interlocutory injunctions674 and Article 11 
provides for permanent injunctions.675 Both types of injunctions can be used 
against infringers and intermediaries (whose services are used by the infringers). 
The CJEU has ruled that the national courts should rule in favour of ending an 
infringement, and prevent such acts of infringement from occurring in the future. 
Such injunctions must be effective, proportionate and dissuasive, and should not 
create hurdles in legitimate trade.676 The CJEU reached a similar conclusion with 
respect to Internet Service Providers (ISPs) and hosting service providers in cases 
C-7-70/10 Scarlet Extended v. SABAM677 and C-360/10 Netlog v. SABAM.678 
 
The sale of counterfeit and falsified medicines online is difficult to trace.679 The 
requirement for an online logo on all legitimate websites is a progressive step in 
the right direction in equipping the customers with the ability to detect legitimate 
websites in the EU.680 The Enforcement Directive, through the provisions in 
Articles 9 and 11, presents the potential to assist in the fight against counterfeiting 
- also of medicinal products. While considering the online sale of products, it is 
often easier to identify the intermediaries rather than the infringers.681 Moreover, 
the intermediaries can be instrumental in curtailing the infringement. Therefore, 
673 Vrins, O., & Schneider, M. (2014). Cross-border enforcement of intellectual property: The European Union. 
Torremans, P. (Ed.) (2014). Research handbook on cross-border enforcement of intellectual property. 166-328. 
674 Interlocutory injunctions are issued to prevent an imminent infringement of forbid the continuation of an alleged 
infringement. See more in Section 5.3. 
675 A court order prohibiting someone from doing some specific act or commanding someone to undo some wrong 
or injury. This type of injunction is intended to be in force until the end of the specific law suit. See more in Black, 
H.C., Nolan, J.R., & Nolan-Haley, J.M. (1990). Black’s Law Dictionary.  (Sixth Edition). St. Paul, Minn. West 
Publishing Co.784. 
676 Case C-324/09 L’Oreal v. eBay (2011) ECR I-06011. 
677 C-70/10 Scarlet v.SABAM , (2011) ECR I-11959, para.31. 
678 Case C-360/10 Netlog v. SABAM, 16 February 2012, para 29. 
679 Lee, K. S., Yee, S. M., Zaidi, S. T. R., Patel, R., Yang, Q., Al-Worafi, Y. M., & Ming, L. C. (2017). Combating 
Sale of Counterfeit and Falsified Medicines Online: A Losing Battle. Frontiers in pharmacology, 8. 
680 See more in Chapter 4, Section 4.4. 
681 Vrins, O., & Schneider, M. (2014). Cross-border enforcement of intellectual property: The European Union. 
Torremans.. (red.)(2014). Research handbook on cross-border enforcement of intellectual property. 166-328. 
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both offline682 and online intermediaries are targeted by the IP right holders for 
enforcement of their rights.683 The Enforcement Directive extends to the national 
courts in the Member States the right to issue injunctions on intermediaries, even 
though the intermediaries have acted in good faith.684 
 
Currently, some jurisdictions only allow for issuing injunctions on proven active 
involvement of the intermediaries, while in other jurisdictions, for issuance of an 
injunction, the proof of intermediary’s prior knowledge of the act is sufficient. 
Similarly, while in some jurisdictions general monitoring obligations cannot be 
imposed, it is possible in others. These disparities also necessitate uniformity in 
rules.685  
 
The provisions for injunctions in the Enforcement Directive have been effective in 
putting a stop to the act of infringement when pursued, as illustrated by case law 
discussed above with regard to cases, C-7-70/10 Scarlet Extended v. SABAM686 
and C-360/10 Netlog v. SABAM.687 However, it is not adequate, because the 
Enforcement Directive is not suitably equipped to trace the infringer. The sellers 
of counterfeit products operate anonymously, as was observed in Operation 
Robin, 688 and use shell companies as was evident in Operation Singapore.689 The 
682 O'Byrne, P., & Burstall, R. (2011). Liability of landlords for infringing activities. Journal of Intellectual 
Property Law & Practice, 6(10), 738-742. 
683 European Commission. (July 2013). Synthesis of the Responses: Civil Enforcement of Intellectual Property 
Rights: Public Consultation on the Efficiency of Proceedings and Accessibility of Measures. Directorate General 
Internal Market and Services. Intellectual Property, Fight against counterfeiting and piracy. Brussels. European 
Commission. 
684 See Recital 23, Directive 2004/48/EC; Case C-324/09 L’Oreal v. eBay. (2011). para 128. ECR I-06011; See also 
Husovec, M. (2013). Injunctions against innocent third parties: Case of website blocking. Journal of Intellectual 
Property, Information Technology and E-Commerce Law: JIPITEC, 4(2), 116-129. 
685 European Commission. (14 September 2016). Summary of responses to the public consultation on the  on the 
evaluation and modernisation of the legal framework for the enforcement of intellectual property rights. Ref. Ares 
(2016)5286091-14/9/2016. Brussels. European Commission, 35. 
686 C-70/10 Scarlet v.SABAM , (2011) ECR I-11959, para.31. 
687 Case C-360/10 Netlog v. SABAM, 16 February 2012, para 29. 
688 See Chapter 3, Section 3.4. 
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goal, especially in context of counterfeiting and falsification of medicines, is to 
prevent further counterfeiting and falsification of medicinal products. Therefore, it 
is important to trace the perpetrators of the crime, and hence, location of the 
person (or persons) selling the counterfeit medicines online. Currently, the 
Enforcement Directive provides for shutting down the access points - the websites 
- with the help of the intermediary, but that does not weed out the problem, as 
another website can easily replace the website that has been shut down.  
 
While addressing the problem of counterfeit and falsified medicines, it is apparent 
that only one sphere of law is not adequate to resolve the problem of counterfeit 
and falsified medicines. The Medicine law primarily governs from the public 
health and safety perspective and targets online sale of medicine by provision of a 
logo for identification by the consumers. This is one part of the solution. The 
second part of the solution is provided by the provision of injunctions in the 
Enforcement Directive, whereby the online sellers can be blocked with the help of 
ISP. However, the problem that remains to be solved is tracing the online sellers. 
In certain cases, the ISPs may be forced to reveal their identity,690 but in other 
cases, the infringers are not traceable, because they cease to work under one 
identity and create a new identity in relatively short time span. Therefore, this is 
one problem that needs a solution.  
 
689 See more in Chapter 3, Section 3.3., in Operation Singapore Gillepsie worked through a shell company based in 
Luxembourg. 
690 Jakobsen, S. S. (2010). Mobile Commerce and ISP Liability in the EU. International Journal of Law and 
Information Technology, 19(1), 29-52. 
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5.5. Lack of criminal measures 
The need for harmonisation of criminal measures with respect to enforcement of 
IPR has been raised and acknowledged at both, EU level691 and at the International 
level.692 In Articles 82 and 83(2) of the TFEU, the importance of approximation 
criminal measures is explicitly articulated.693 The Enforcement Directive contains 
only civil measures that may be applied in case of infringement of IPRs in its 
current form. The original proposal for the Enforcement Directive contained 
criminal measures for enforcement of IPRs as well, which was not taken forward 
in the final draft.694 However, the preamble695 of the Enforcement Directive, states 
the importance of incorporating criminal measures in the legal framework at the 
Member State level. The European Commission published an amended proposal 
for a Directive containing criminal measures, which would have enforced IPRs 
(2005/0127 COD) popularly known as IPRED II,696 which was later withdrawn697 
due to widespread disagreement.698 
 
The need for having harmonisation of provisions of criminal measures in the 
enforcement of IPRs at EU level has been emphasised due to the increase in trade 
691 The proposal for a directive on criminal measures (2005/0127 COD) aimed at ensuring the enforcement of 
intellectual property rights was a proposal to supplement Directive 2004/48/EC. 
692 The ACTA contained concrete provisions and some bilateral and multilateral trade agreements carry forward 
some of the provisions. 
693 Articles 82 and 83 of TFEU. 
694 Hilty, R. M., Kur, A., & Peukert, A. (2006). Opinion-Statement of the Max Planck Institute for Intellectual 
Property, Competition and Tax Law on the Proposal for a Directive of the European Parliament and of the Council 
on Criminal Measures Aimed at Ensuring the Enforcement of Intellectual Property Rights. IIC. International review 
of industrial property and copyright law, 37(8), 970. 
695 Recital 28, Directive 2004/48/EC. 
696 Proposal for a European Parliament and Council Directive on criminal measures aimed at ensuring the 
enforcement of  intellectual property rights.  OJ C/2006/49/37. The proposal for a directive on criminal measures 
aimed at ensuring the enforcement of intellectual property rights was a proposal to supplement Directive 
2004/48/EC. 
697 The withdrawal was announced in the ‘Withdrawal of obsolete Commission proposals in the Official journal of 
the European Union.  (18 September 2010), 2010/C 252/9. 
698 Geiger, C. (Ed.). (2012). Criminal Enforcement of Intellectual Property: A Handbook of Contemporary 
Research. Edward Elgar Publishing. 
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in counterfeit goods. The recent OECD estimates indicate that the trade in 
counterfeit and pirated products amounted to up to 5 percent of imports in 2013 in 
the European Union.699 In monetary terms, the trade amounted to 85 billion Euros 
(USD 116 million).  
Even though national laws have provisions of criminal measures against 
infringement of IPRs in the Member States, in accordance with Article 61 of the 
TRIPS agreement, the level of enforcement and penalties are variable. The 
harmonisation envisaged by the TRIPs agreement has failed to produce the 
anticipated results.700  The risk of having variations in penalties as well as 
enforcement is that some Member States with comparatively weaker penalties and 
enforcement can become ‘havens’ or focus areas for counterfeiters to camp and 
base their activities out of those Member States. However, more importantly, the 
entire EU would remain vulnerable to counterfeit products, because of the fluid 
borders and free movement of goods in the EU.701 At the moment, countries such 
as Italy, Latvia, and Romania702 have been known to house the counterfeiters of 
medicinal products, because of the weaker enforcement in these countries.703 As 
also indicated in Operation Volcano, the fake authorisation holders were based in 
these countries.704  
 
In the EU, the violation of IPRs ranges from copying music to the sales of 
counterfeit medicines. In the industries such as the medicinal sector, the toy 
manufacturing sector, the automobile industry, and the food & beverages industry 
- the threat of counterfeiting in regard to public health and safety is more 
699 Trade in Counterfeit and Pirated Goods, Mapping the Economic Impact, OECD- EUIPO Report, 2016. 
700 Geiger, C. (2016). Towards a Balanced International Legal Framework for Criminal Enforcement of Intellectual 
Property Rights. In TRIPS plus 20. Springer Berlin Heidelberg. 645-679 
701 See Article 26, TFEU. 
702 See Chapter 3, Section 3.2.  
703 ibid. 
704 ibid. 
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pronounced, which can have serious consequences, including causing loss of 
lives.705 In the context of counterfeiting in the medicinal sector,706 as indicated by 
the case studies in Chapter 3, one of the reasons contributing to trade in counterfeit 
medicines is the high profit margins and the low penalties.707 Penalties act as a 
strong deterrent to the commission of crime.  
 
Therefore, due to the potentially serious impact of counterfeiting and falsification 
of medicinal products on public health and safety, and also in order to uphold the 
goals of public health and consumer protection, as envisaged in the TFEU, it is 
important to seriously consider criminal enforcement. 
 
5.6. Concluding remarks 
The Enforcement Directive complements the Customs Regulation708 in combatting 
counterfeiting of medicinal products in the EU, in the sphere of IP law.709 The 
Enforcement Directive came about in an unprecedented swift manner in the wake 
of ten European nations joining the EU. The Enforcement Directive has achieved a 
degree of success in the harmonisation of civil measures in regard to the 
enforcement of IPRs in the EU with respect to provisions such as provisional and 
precautionary measures enshrined in Article 9, and injunctions stated under Article 
11 that may be issued to ensure enforcement of IPRs. But for the precise purpose 
of combatting counterfeiting of medicinal products, it hasn’t proved to be very 
useful. This is primarily because counterfeiting is usually a cross-border activity 
705 ibid. 
706 Attaran, A. (2015). Stopping murder by medicine: introducing the model law on medicine crime. The American 
journal of tropical medicine and hygiene, 92(6_Suppl), 127-132. 
707 Blackstone, E. A., Fuhr Jr, J., & Pociask, S. (2014). The health and economic effects of counterfeit 
drugs. American health & drug benefits, 7(4), 216. 
708 Discussed in Chapter 6. 
709 Discussed in Chapter 2, Section 2.3.4.3. 
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involving more than one Member State and the Enforcement Directive 
categorically delimits itself from cross-border applicability.710 Consequently, in 
the usual cross- border scenario, the right holders have to pursue cases in each 
jurisdiction where the violations have been known to occur, which is not practical 
for the right holders, as indicated in the public consultation reports.711 Therefore, 
using the enforcement route through courts is seldom adopted by the right holders 
as indicated by the almost negligible case law in the area and also put forward in 
the public consultation reports of the European Commission. Most of the case law 
relates to repackaging of medicinal products and conditions, which need to be 
upheld while doing so in the EU.712 
 
Furthermore, as highlighted in Section 5.2, the Enforcement Directive falls under 
the broad category of private law contrary to the FMD, which is a public law.  The 
basic differences in the types of law that the two major Directives fall under, is 
also significant. It is recognised that goals of the two types of laws, and the 
procedures for enforcement of the two spheres of law are different. While 
enforcing public law such as the FMD, the State takes initiative for enforcement. 
On the contrary, the enforcement of private law, such as the Enforcement 
Directive, it is the private right holder, who has to take the initiative. The 
differences in the aims of the two types of law, also underline the differences in 
710 Recital 11, Directive 2004/48/EC. 
711 European Commission. (July 2013). Synthesis of the Responses: Civil Enforcement of Intellectual Property 
Rights: Public Consultation on the Efficiency of Proceedings and Accessibility of Measures. Directorate General 
Internal Market and Services. Intellectual Property, Fight against counterfeiting and piracy. Brussels. European 
Commission. 
712 See Case 102/77 Hoffmann-La Roche [1978] ECR 1139, Case 1/81 Pfizer [1981] ECR 2913, Joined Cases C-
427/93, C-429/93 and C-436/93 Bristol-Myers Squibb and Others [1996] ECR I3457, and Case C-232/94 MPA 
Pharma [1996] ECR I3671.See also Case C-400/09 - Orifarm A/S ('Orifarm'), Orifarm Supply A/S ('Orifarm 
Supply'), Handelsselskabet af 5. januar 2002 A/S, in liquidation, ('Handelsselskabet') and Ompakningsselskabet af 
1. november 2005 A/S ('Ompakningsselskabet') and - in Case C-207/10 - Paranova Danmark A/S ('Paranova 
Danmark') and Paranova Pack A/S ('Paranova Pack') and Merck Sharp & Dohme Corp., formerly Merck & Co. 
Inc., Merck Sharp & Dohme BV and Merck Sharp & Dohme.  
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the approaches. The Enforcement Directive is entirely focused on protection of the 
rights of the right holder and the FMD concentrates on the social objective of 
protection of public health and safety. The two legal instruments are not opposed 
to each other but there is no synergy between the two either.   
It was noted that the Enforcement Directive provides for injunctions, which have 
been effective in putting a stop to an online infringing activity. But the provisions 
of the Directive have not always been able to facilitate reaching the perpetrators of 
the infringement. In cases of counterfeiting and falsification of medicinal 
products, it is one challenge that still needs to be tackled. 
 
The pharmaceutical industry rarely resorts to the legal redress mechanism. Even 
though there is widespread disagreement regarding the need for criminal means of 
enforcement of IPR in the EU, for the purpose of combatting counterfeiting of 
medicinal products, it is important to have strong criminal measures because it can 
have serious consequences.713 The importance of having criminal enforcement 
measures with respect to counterfeit medicine has been recognised by the Council 
of Europe, which is the creator of the Medicrime Convention that has been ratified 
by four EU Member States. It is believed that the ratification of the Medicrime 
Convention by the EU has the potential to resolve a large part of the issue 
pertaining to criminal enforcement in context of counterfeit medicinal products.    
713 Attaran, A. (2015). Stopping murder by medicine: introducing the model law on medicine crime. The American 
journal of tropical medicine and hygiene, 92 (6 Suppl), 127-132. 
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Chapter 6: Analysis of the Customs Regulation 
(Regulation 608/2013) 
 
6.1. Introduction 
In the thesis, the legal instruments that govern the counterfeiting and falsification 
of medicinal products in the EU are analysed. It was established in Chapter 1 that 
the issue of counterfeit and falsified medicines lies at the intersection of Medicine 
law, IP law and Criminal Law.714 The area of Medicine law has been dealt with in 
Chapter 4, in which the FMD was analysed. The sphere of IP law entails two legal 
instruments– the Enforcement Directive and the Customs Regulation; detailing 
rules that are applied to combat counterfeiting of medicines. The former 
instrument has been dealt with in the previous chapter and this chapter analyses 
the second major legal instrument715 under IP law regime that governs counterfeit 
medicines - the EU Regulation 608/2013. 
 
The legal analyses in Part III of the thesis is being done in the light of the case 
studies discussed in Chapter 3 (Part II). The case studies brought to light the five 
key issues that have emerged in context of counterfeiting and falsification of 
medicines in the EU – manipulation of the medicinal products; infiltration of the 
legal supply chain; sale of counterfeit and falsified medicinal products online; 
involvement of more than one Member State; and the role played by organised 
crime. Some of these issues have been addressed in Chapter 4 and 5, such as the 
manipulation of the medicinal product, the infiltration of the legal supply chain, 
714 See Chapter 1, Section 1.2. 
715 The first legal instrument being the Enforcement Directive 2004/48/EC discussed in Chapter 6. 
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and online sale of medicinal products.716 
Usually, the probable means through which the counterfeit and falsified products 
can enter the EU are by air, express, post, rail, road, sea or through personal 
baggage of the travellers.717 The EU Regulation 608/2013, henceforth referred to 
as the ‘Customs Regulation’,718 is important for the thesis because it empowers the 
customs authorities to stop the entry of the counterfeit and falsified medicine, at 
the point of arrival into the EU borders. The Customs Regulation was adopted in 
context of the EU’s Customs Action Plan to fight infringement of IPRs.719 The 
main aim of the Customs Regulation is articulated in Recital 4 of the preamble to 
the Regulation, which is to enforce the IPRs at the border in order to effectively 
provide legal protection to the right holder, the users as well as the producers.720  
 
In this chapter the focus will be on provisions that specifically concern small 
consignments, parallel imports and the entry of counterfeit medicinal products 
through luggage of travellers – the diverse ways in which the legal supply chain 
has been known to be infiltrated by the illegal supply chain with counterfeit and 
falsified medicines. 
 
Before delving into the analysis of the Customs Regulation and its relevant 
provisions, it is imperative to outline the background and set the context of the 
customs union in the EU. The European Union Customs Union (EUCU) is a 
customs union composed of all the Member States of the EU, Monaco and some 
territories of the UK, which are not part of the EU and some countries are part of 
716 See Chapter 4, Sections 4.2., 4.3, and 4.4., and Chapter 5, Section 5.4. 
717 See European Commission. (2015). Report on EU customs enforcement of intellectual property rights. Results at 
the EU border 2015. Luxembourg. Publications office of the European Union. 
718 Regulation, 608/2013/EU of 12 June 2013 concerning customs enforcement of intellectual property rights and 
repealing Council Regulation (EC) No 1383/2003. OJ L 181, 29.6.2013, 15–34. 
719 Council Resolution on the EU Customs Action Plan to combat IPR infringement for the years 2013-2017. 
(2013). OJ C 80, 19.3.2013, 1-7. Henceforth, ‘EU Customs Action Plan (2013-2017)’. 
720 Recital 4, Regulation 608/2013. 
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the customs union through separate agreements such as Andorra, and San Marino. 
It was in 1958 that the European Economic Community was formed with the 
customs union as its key component. Some of the main features of the customs 
union include: there are no customs duties levied within the customs union; the 
customs union levies a common tariff on all the goods entering the EU; and the 
European Commission is responsible for negotiating all international trade 
agreements on behalf of the customs union.  
 
Recently, as part of the process of modernisation of the Customs Union, the new 
Union Customs Code (UCC) came into force721 and is expected to be fully 
implemented by the end of 2020722 with the main goal of modernising the customs 
procedures by streamlining the customs processes, legislations and procedures; 
increasing legal certainty and clarity for customs officials in the EU; transform the 
customs authorities into a paperless, fully electronic and interoperable 
environment. The main goal is to enhance competiveness in the EU and 
concurrently ensure safety and security with a contribution to the economic 
growth.723  
 
In this broad framework of the Customs Union, the Customs Regulation deals with 
the civil enforcement of IPRs with respect to border measures that can be initiated 
by the customs authorities. The first Customs Regulation came into being in 1986 
(Regulation 3842/86)724 that lay down measures to prohibit the release for free 
721 The Union Customs Code (UCC) was adopted on 9 October 2013 as Regulation (EU) No. 952/2013 of the 
European Parliament and of the Council. It came into force on 30.10.2013 but most of its substantive provisions 
will be applicable from 1 May 2016; See also Aigner, S. (2017). The Union Customs Code. Global Trade and 
Customs Journal, 12(2), 49-53. 
722 European Commission. (August 2017). UCC – Introduction. In Taxation and customs union. European 
Commission. 
723 Aigner, S. (2017). The Union Customs Code. Global Trade and Customs Journal, 12(2), 49-53. 
724 Council Regulation (EEC) No. 3842/86  of 1 December 1986 laying down measures to prohibit the release for 
free circulation of counterfeit goods. OJ L 357, 18.12.1986, 1- 4. 
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circulation of counterfeit goods. The first Customs Regulation addressed only 
counterfeiting of registered trademarks. In 1994, the second Customs Regulation 
(Regulation 3295/94)725 emerged, which lay down measures to prohibit the release 
for free circulation, export, re-export or entry for a suspensive procedure of 
counterfeit and pirated goods. Thus, the scope of the Customs Regulation 
expanded in 1994 to include design and copyrights. In addition, the powers of the 
customs authorities were enlarged – the customs authorities could act ex-officio is 
certain cases. In 1999, the Customs Regulation was amended (Regulation 
241/1999)726 to include patents in its scope of IPRs as well. The powers of the 
customs authorities were further expanded in 2003 (Regulation 1383/2003)727 
wherein the link between organized crime and counterfeit trade was recognised 
and the scope of IPRs to be addressed by the Regulation was further expanded to 
include plant variety, geographical indications as well. In 2013, the current 
Customs Regulation (Regulation 608/2013)728 came into being, repealing the 2003 
Regulation. 
 
The current Customs Regulation is concerned with customs enforcement of IPRs 
and it strengthens and consolidates customs procedures pertaining to the 
enforcement of IP rights in Europe. The Customs Regulation is a result of a review 
of the Council Regulation No. 1383/2003, which was requested by the Council’s 
resolution of 25th September 2008 via a comprehensive European anti-
725 Council Regulation (EC) No. 3295/94 of 22 December 1994 laying down measures to prohibit the release for 
free circulation, export, re-export or entry for a suspensive procedure of counterfeit and pirated goods. OJ L341, 
30.12.1994, 8-13. 
726 Council Regulation (EC) No. 241/1999 of 25 January 1999 amending Regulation (EC) No. 3295/94 laying down 
measures to prohibit the release for free circulation, export, re-export or entry for a suspensive procedure of 
counterfeit and pirated goods. OJ L 27, 02.02.1999, 1-5. 
727 Council Regulation (EC) N. 1383/2003 of 22 July 2003 concerning customs action against goods suspected of 
infringing certain intellectual property rights and the measures to be taken against found to have infringed such 
rights. OJ L 196, 2.8.2003, 7-14. 
728 Regulation (EU) No. 608/2013 of the European Parliament and of the Council of 12 June 2013 concerning 
customs enforcement of intellectual property rights and repealing Council Regulation (EC) No. 1383/2003. OJ L 
181, 29.6.2013, 15–34. 
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counterfeiting and anti-piracy plan (2009-2012).729 
 
This Council Resolution of 2008 was followed by another Council Resolution on 
the EU Customs Action Plan to combat IPR infringement for the years 2013 to 
2017.730 This action plan is in consonance with the Europe 2020 strategy on smart, 
sustainable and inclusive growth;731 the Commission Communication on a 
comprehensive EU strategy concerning intellectual property rights;732 and Council 
Resolution of 16 March 2009 on the EU Customs Action Plan to combat IPR 
infringements for the years 2009 to 2012.733 The current EU action plan 
emphasises that the IPR legal framework must be backed by effective 
enforcement734 and should contain specific objectives for effective implementation 
and monitoring of the new regulation; tackling major trends in trade of IPR 
infringing goods; tackling trade of IPR infringing goods throughout the 
international supply chain; and strengthening cooperation with the European 
Observatory on infringement of IPRs and law enforcement authorities.735 
729 Recital 1, Regulation (EU) No 608/2013; See also The comprehensive European anti-counterfeiting and anti-
piracy plan came into being parallel to the Commissions strategic report and the new cycle of the renewed Lisbon 
strategy for growth and jobs (2008-2010). The need to fight counterfeiting and piracy and show respect towards 
basic freedoms of the internal market that promote competitiveness, unleash creative forces and innovation were 
recognised in the action plan.  It contained communication regarding customs initiatives to combat counterfeiting 
and piracy at the borders and outside the European Union; setting up of a European counterfeiting and piracy 
observatory which came into being and is now known as the EUIPO; called for rapid exchange of information on 
counterfeit products and proposals for encouraging public/private partnerships for combating counterfeiting and to 
address online sale of counterfeit products. 
730 Council Resolution on the EU Customs Action Plan to combat IPR infringement for the years 2013-2017.(2013). 
OJ C 80, 19.3.2013, 1-7. 
731 Communication from the Commission, Europe 2020 – A strategy for smart, sustainable and inclusive growth, 
COM (2010) 2020 final. 
732 European Commission. (2011). Communication from the Commission to the European Parliament, the Council, 
the European Economic and Social Committee and the Committee of the Region- A Single Market for Intellectual 
Property Rights Boosting creativity and innovation to provide economic growth, high quality jobs and first class 
products and services in Europe. Brussels. European Commission. COM (2011) 287 final. 
733 Council Resolution of 16 March 2009 on the EU Customs Action Plan to combat IPR infringements for the 
years 2009 to 2012. (2009). OJ C 71, 25.3.2009, 1-7. 
734 Council Resolution on the EU Customs Action Plan to combat IPR infringement for the years 2013-2017. 
(2013). OJ C 80, 19.3.2013, 1-7. 
735 Council Resolution on the EU Customs Action Plan to combat IPR infringement for the years 2013-2017. 
(2013). OJ C 80, 19.3.2013, 1-7. 
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The current Customs Regulation (608/2013) has further expanded the scope of the 
type of IPRs to include topography and utility models, trade names and 
instruments used to circumvent technology. The Customs Regulation is divided 
into six chapters dealing with the subject matter, scope and definitions of key 
terms (Articles 1 and 2); formalities with regard to application procedures 
(Articles 3 to 16); the actions that can be taken by the Customs authorities with 
regard to goods (Articles 17 to 26); the provisions dealing with liability, costs and 
penalties (Articles 27 to 30); the provisions relating to exchange of information 
between Member States (Articles 31 to 33); and the final provisions regarding 
implementation and follow up (Articles 34 to 40), respectively. In this chapter, the 
focus will be on the issues, which are most relevant for the thesis, particularly the 
specific areas of measures addressing small consignments, goods in transit, goods 
carried in travellers luggage and parallel imports in context of the Customs 
Regulation. 
 
6.2. Small Consignments 
The trade of counterfeit goods involves use of small consignments for 
transportation purposes, as illustrated by the legal case studies and supported by 
recent statistics.  This was observed in Operation Volcano, Operation Robin and 
Operation Singapore, wherein small packages were used to transport, sell as well 
as deliver counterfeit and falsified medicines.736 The Report 2013 revealed that the 
cases related to postal and courier traffic for counterfeit goods amounted to 72 
percent of detentions.737 It was observed that the medicinal products were the 
736 See Chapter 3, Sections 3.2, 3.3, and 3.4. 
737 European Commission. (2014). Report on EU customs enforcement of intellectual property rights: Results at the 
EU border 2013. Luxembourg. Publication Office of the European Union. 
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category of products that were detained the most.738 The report states that even 
though the volume of medicinal products that are detained has decreased over the 
years from 69 % in 2010 to 19% in 2013, the medicinal products still constitute 
the majority of products that are seized in the postal and courier traffic. The reason 
that the counterfeit operations involving medicinal products make use of the postal 
and courier services is to avoid detection by the authorities. In addition, the online 
sale of counterfeit and falsified medicines has further encouraged the use of postal 
and courier services as channels of distribution.739 
 
An important and relevant provision in this context is Article 26740 of the Customs 
Regulation that empowers the customs authorities to destroy small consignments 
of counterfeit and pirated goods, at the request of the right holder.741 This 
provision explicitly states that if the goods are suspects to be counterfeit; the 
goods are not perishable; the goods are covered by a decision granting an 
application; the holder of the decision has requested the use of the procedure as 
enumerated in this Article; and the goods are transported in small consignments, 
then this provision is applicable. This is further stated that the customs authorities 
are obligated to inform the holder of the goods, once they detain the goods, within 
one working day. The holder of the goods has ten working days to express his 
agreement or disagreement (‘right to be heard’) and the absence of a response is 
interpreted as consent to destruction of the goods.742 
 
The value of this provision in blocking the entrance of counterfeit and falsified 
738 ibid. 
739 Acquah, D. (2015). Trends on the implementation of the EU Customs Regulation: for better or for 
worse? Journal of Intellectual Property Law & Practice, 10(10), 775-784. 
740 Article 26, Regulation 608/2013. 
741 See Article 2(19), Regulation 608/2013, which defines a small consignment as ’a postal or express courier 
consignment, which contains three units or less or has a gross weight less than two kilograms’. 
742 Article 26(4), Regulation 608/2013. 
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medicines in the EU cannot be underestimated. However, this measure finds 
application, on the request of the right holder only and the customs authorities do 
not have the authority to take ex-officio action against small consignments of 
goods that infringe IPRs. In practice, the provision is still effective because in the 
majority of cases, the right holders make a prior application, as required by the 
Customs Regulation.743 
 
The latest Report on EU customs enforcement of IPR744 revealed that the postal 
and courier traffic amounts to 77 % of all detentions despite the more than 20% 
decrease in postal traffic detention. It is significant to point out that when 
considering the numbers of articles detained in postal traffic, medicinal products 
figure at second place, constituting 16 % of all the products detained, just after 
electronic equipment, which constitutes 32 % of all products detained. In 22 % of 
all the cases, the small consignments were destroyed, applying the new provisions.  
In the light of Operation Robin,745 wherein the APIs were delivered in small packs 
arriving from overseas through Belgium and then delivered by making use of 
Brevia and UPS services, such interception of small consignments would have 
been invaluable. In Operation Robin, the Swedish Customs Authorities had 
pointed out that the well-organised body of criminals746 was making use of the 
postal services to deliver their products from one point to another, so as to dodge 
the keen eyes of the legal machinery. The packs containing counterfeit products 
743 See Articles 3-16, Regulation 608/2013. 
744 European Commission. (2015). Report on EU customs enforcement of intellectual property rights. Results at the 
EU border 2015. Luxembourg. Publications office of the European Union.7. 
745 Discussed in Chapter 3, Section 3.4., where in Sweden the Customs Authorities traced the transportation of 
counterfeit medicinal products overseas, land and air were able to trace that counterfeit products were being 
delivered by employing postal services of Brevia and UPS. 
746  Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013; See also (5.10.2016) ‘Operation 
Robin’Presentation by Swedish Customs Authority. In Supplementary confidential case notes. Stockholm.  
Swedish Customs and Law Enforcement Authority.3. 
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were shipped from Belgium to Denmark to Sweden.747 And upon arrival in 
Sweden they arrived at the destination where they were assembled and offered for 
sale through three websites.748 The deliveries were made through postal system. It 
is still reported that the registered cases by means of transport clearly indicate that 
70.51 % of such cases make use of the postal system.749  
 
The years following the implementation of the Customs Regulation indicate that 
this procedure has led to the lowering of administrative burden for customs 
authorities and right holders, and more efficient and timely treatment of 
counterfeit goods that were transported by couriers or through post. It was 
reported that 30 % of the applications for action consisted of applicants requesting 
this procedure by the Customs authorities, for destroying small consignments.750 
 
6.3. Goods in transit 
Goods in transit have been a bone of contention for a decade or even longer,751 
especially with regard to medicinal products.752 It has been observed that in 
context of medicinal products, specifically in respect of generic medicines,753 the 
peculiar feature of goods in transit is that there is no infringement in the country of 
origin and destination, however there is an IPR infringement in the country where 
the goods are in transit.  According to the CJEU in Diesel/ Montex case (C-
747 Europol & OHIM. (June 2013). Reports and Conclusions, Knowledge Building in IP Enforcement, Combating 
Pharmacrime A knowledge –building Conference on Counterfeit Medicines. Alicante. Spain.  
748 Case No. B 6262 -12, Judgement of Stockholms Tingsrätt of 25 June 2013: www.steriodakuten.org, 
www.vikingstore.org and www.anabolic.cc. 
749 European Commission. (2015). Report on EU customs enforcement of intellectual property rights. Results of the 
EU border 2015. Luxembourg. Publications office of the European Union.40. 
750 ibid., 14. 
751 Mercurio, B. (2012). ‘Seizing’ pharmaceuticals in Transit: analysing the WTO dispute that wasn’t. International 
and Comparative Law Quarterly, 61(2), 389-462.  
752 ibid. 
753 See Glossary for definition of generic medicines.  
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281/05), Nokia (C-495/09) and Phillips (C-446/09)754 if the goods were not meant 
to be put on the market in the EU, then the European Customs Regulation would 
not detain them. However, in context of medicinal products, Recital 11 of the 
Customs Regulation places an obligation on the customs authorities to assess the 
risk of IPR infringement to take account of any substantial likelihood of diversion 
of such medicines onto the market of the Union, while making their assessment. In 
addition to Recital 11 of the Customs Regulation, there are also other rules 
regulating medicines in transit, which underline the importance of the trade in 
medicinal products and supplement and strengthen the legal framework 
concerning medicinal products in transit in the EU.755 The Trademark 
Regulation,756 the Trademarks Directive,757 and the Commissions notice on the 
customs enforcement of IPRs concerning goods brought into the customs 
territory758 recognise the need to facilitate the smooth transit of legitimate 
medicines across the EU. 
 
These provisions should also be read in conjunction with Article 52b of the 
Medicines Directive inserted by Article 1(10)(8) of the FMD,759 which empowers 
the Member States to initiate necessary measures for prevention of falsified 
products from entering the EU market, if there are sufficient grounds for 
suspecting that those goods may be falsified. This provision is also valid in those 
situations where the goods are not intended to be placed on the market in the EU. 
Therefore, evidently while greater attention has been extended to infringement of 
754 Case C-281/05 Diesel/Montex ECLI:EU:C:2006:709; and Joined Cases C-446/09 Phillips and C-495/09 Nokia 
ECLI:EU:C:2011:796. 
755 Also see Recital 11, Regulation  608/2013. 
756 Recital 19, Regulation (EU) 2015/2424. 
757 Recital 25, Directive (EU) 2015/2436. 
758 Commission notice on the customs enforcement of Intellectual Property Rights concerning goods brought into 
the customs territory of the Union without being released for free circulation including goods in transit. (2016). OJ 
C 244, 5.7.2016, 4-9. 
759 Article 52b of the Medicines Directive (Directive 2001/83/EC) inserted by Article 1(10) (8) of the Falsified 
Medicines Directive (Directive2011/62/EU). 
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medicinal products, with respect to the other products, ‘reasonable indications’760 
of possible infringement are construed as being enough. 
 
It is vital to distinguish between the trade in generic medicines and trade in 
counterfeit medicinal products. The generic medicines are legitimate medicines in 
the manufacturing country of those medicines and the country, which is the final 
destination of the product. The legitimacy of trade in generic medicines has been 
recognised in the Doha Declaration761 under the TRIPS regime and by the EU in 
its representations at the WTO.762 When these generic medicines are the goods in 
transit, they cannot be equated to counterfeit medicinal products.763 This issue was 
contested and discussed in academic circles764 in great detail especially in context 
of what transpired at the Dutch borders in 2008, when in EU several shipments of 
generic medicines in transit were returned or delayed because they were suspected 
of patent infringements.765 These shipments originated in India and the destination 
countries were developing countries such as Brazil, Venezuela, Columbia, Peru 
and Nigeria. The medicines in transit were protected in the EU and thus, the 
Customs Regulation of 2003 was applicable. The Customs Regulation has since 
been amended to accommodate medicinal products in transit as incorporated in 
Recital 11 of the current Customs Regulation.  
 
In order to cover the risk of counterfeit goods camouflaged as goods in transit 
760 Article 2 (7) Regulation 608/2013. 
761 World Trade Organisation. (20 November 2001). Doha WTO Ministerial Declaration.WT/MIN(01)/DEC/1; 41 
ILM 746 (2002). 
762 See WTO. (2009). Minutes of the Meeting. WTO TRIPS Council (June 8-9 2009). IP/C/M/60 2009. 
763 Kumar, S. P. (2010). Border enforcement of IP rights against in transit generic pharmaceuticals: an analysis of 
character and consistency. European Intellectual Property Review. 
764 Heath, C., & Seizures, C. Transit and Trade—In Honour of Dieter Stauder’s 70th Birthday’ (2010). IIC, 8, 881. 
765 Grosse Ruse-Khan, H., & Jaeger, T. (2009). Policing patents worldwide? EC border measures against transiting 
generic drugs under EC and WTO intellectual property regimes. IIC-international review of intellectual property 
and competition law, 40(5), 502-538. 
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entering the EU market, the Customs Regulation empowers the customs 
authorities to initiate action in likelihood of the goods in transit entering the supply 
chain in the EU. This assessment is carried out by the relevant Member States’ 
customs authority on a case by case basis. However, so far, the guise of goods in 
transit is not the chosen medium of infiltration of counterfeiting medicinal 
products in the EU, as indicated by the EU Customs Report 2015.766 The 
counterfeit medicinal products enter through small consignments through parcels 
and couriers.767 However, this does not completely rules out the use of this 
medium in the future for supplying counterfeit medicinal products in the EU. 
However, a balance needs to be maintained as attempted in the new Customs 
Regulation, between enforcement of IPRs in the EU and maintaining the 
international obligations with respect to goods in transit, specifically with 
reference to flow of generic medicines through the EU.768 
 
6.4. Travellers’ Luggage 
Counterfeit and falsified medicines enter the EU borders through various means 
such as by air, express, post, rail, road and by sea.769 The Report on EU customs 
enforcement of IPR 2015 indicates the postal, air and express means of transport 
to be the most often used means of transport in the majority of cases that were 
detained. In contrast to 2014, there is a decrease in the use of postal traffic but that 
is not only in small consignments but also at times, in the personal luggage of the 
766 European Commission. (2015). Report on EU customs enforcement of intellectual property rights. Results at the 
EU border 2015. Luxembourg. Publications office of the European Union. 
767 ibid. 
768 Rosina, M. S. G. and Shaver, L. (2012), Why Are Generic Drugs Being Held Up in Transit? Intellectual 
Property Rights, International Trade, and the Right to Health in Brazil and Beyond. The Journal of Law, Medicine 
& Ethics, 40: 197–205. 
769 European Commission. (2015). Report on EU customs enforcement of intellectual property rights. Results at the 
EU border 2015. Luxembourg. Publications office of the European Union. 
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passengers.770 In the Report on EU Customs enforcement of IPR 2015, the 
statistics of the goods intercepted at the borders indicate that a large number of 
labels and packaging material that has been intercepted was being carried in 
personal luggage of the travellers.771As was revealed by the EU Customs Report 
from the previous years, the quantity of labels and tags was more than 20 percent 
in 2010 and more than 18.4 percent in 2013,772 which were purportedly on the way 
to the EU to be used on infringing goods. Since the Customs authorities do not 
check every passengers’ luggage upon arrival, the statistics do not reflect the exact 
volume of labels and tags that enter the EU borders through personal luggage of 
the passengers.773 
 
Under Article 1(4) of the Customs Regulation774 it is clearly stated that the goods 
being carried by the passengers for non-commercial purposes are outside the scope 
of the Customs Regulation. The preamble of the Customs Regulation also 
elaborates on the exclusion of travellers’ personal luggage if the products are of 
non-commercial nature.775 Since the personal luggage of travellers carrying goods 
for non-commercial purposes are exempt from application of the Customs 
Regulation776 and the luggage of travellers are not checked as a matter of routine, 
it is difficult to intercept the counterfeit goods if those are slipped in the personal 
luggage disguised as goods for non-commercial personal use. This traditional 
770 European Commission. (2015). Report on EU customs enforcement of intellectual property rights. Results at the 
EU border 2015. Luxembourg. Publications office of the European Union. Annex 8, 38. 
771 ibid. 
772 European Commission. (2014). Report on EU customs enforcement of intellectual property rights: Results at the 
EU border 2013. Luxembourg. Publication Office of the European Union. 
773 Schneider, M., & Maillefer, C. (2015). How Europe deals with private imports of counterfeit and pirated 
goods. Journal of Intellectual Property Law & Practice, 10(4), 262-268. 
774 See Article 1(4), Regulation 608/2013. 
775 See Recital 4, Regulation 608/2013. 
776 Recital 4 and Article 1(4), Regulation 608/2013. 
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practice has encouraged ‘ant traffic’777 and it transmits a signal that ‘a little bit of 
counterfeiting is ok.’778 The Customs Regulation also implies that a counterfeit 
good may be purchased for private use without infringing any IPR, since private 
acts fall outside the ambit of the Customs Regulation and the IP law would be 
invoked only in case showing ‘commercial use’.779 
 
A landmark case that illustrated that the acquisition of counterfeit and pirated 
goods falls under the scope of Regulation 608/2013 was Blomqvist v. Rolex.780 
Martin Blomqvist purchased a counterfeit Rolex from a Chinese website and this 
Rolex was seized by the customs authorities in Denmark. When the customs 
authorities contacted Blomqvist for permission to destroy the fake Rolex, he did 
not give his consent. The matter was referred to the High Court, who referred the 
question to CJEU. THE CJEU interpretation explained that the Customs 
Regulation finds application and holder of an IPR enjoys protection by the 
Regulation even if the goods were purchased through a website of a non-Member 
State.781  Although not related to pharmaceuticals industry, this case illustrated the 
applicability of the Regulation to goods infringing IPRs that are imported for 
private use, inclusive of cases when the buyer is aware of the counterfeit nature of 
the goods that he or she is importing.782  
 
This point is significant and can be kept as a reference while considering import of 
medicine by individual travellers for ‘personal use’. A large number of people buy 
777 Schneider, M., & Maillefer, C. (2015). How Europe deals with private imports of counterfeit and pirated 
goods. Journal of Intellectual Property Law & Practice, 10(4), 262-268. 
778 ibid. 
779 Petersen, C. S., Riis, T., & Schovsbo, J. (2012). Intellectual property enforcement at the EU border: the 
challenge of private imports. Journal of Intellectual Property Law & Practice, 7(10), 747-762. 
780 Judgment in Martin Blomqvist v Rolex SA, Manfacture des Montres Rolex SA (C-98/13, EU: C: 2014:55). The 
decision of the case relates to Regulation 1383/2003 but is still relevant and valid under Regulation 608/2013. 
781 Case C-98/13 Judgment in Martin Blomqvist v Rolex SA, Manfacture des Montres Rolex SA. 
ECLI:EU:C:2014:55, para 35. 
782 ibid. 
220 
 
                                           
 
 
 
medicines abroad and carry them along when they return to their country. Some 
people buy medicines and bring them because of cheaper cost of medicines 
abroad, unavailability without prescription in the EU; or because they are not 
easily available, as in the case of homeopathic medicines. It also needs to be 
recognised that transporting medicines for personal use in reasonable quantity and 
for reasonable time frame should be allowed. This would most likely be cases in 
which an individual has gone on vacation and needed prescription medicine and 
that is what he/she is carrying in their luggage. 
 
Therefore, in this context, the avenue of counterfeit goods entering the EU through 
private travellers also needs to be addressed. The provisions do not need to 
become draconian and unreasonable but the scope for carrying counterfeit 
medicines and packaging material that assists in counterfeiting needs to be dealt 
with. In the present context, it is recognised that it would be a disproportionate 
administrative burden to suggest that the luggage of all passengers should be 
screened upon arrival by the customs authorities. Moreover, it would be against 
the principle of protection of public health, enshrined under Article 168 of the 
TFEU to suggest that the travellers should not be allowed to bring medicines for 
personal use. Therefore, in the current circumstances, this provision of the 
Customs Regulation does not necessarily mandate an amendment but the customs 
authorities need to remain vigilant and continue to take the problem seriously. 
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6.5. Parallel Imports 
The concept of parallel importation783 allows the importation of products, which 
are manufactured and marketed by the right holder in a country other than where 
the right holder intended after the right holder or a person/entity approved by him 
has sold the product in the domestic market. In the Single Market in the EU, the 
benefit of parallel importation is that it keeps the market competitive784 and also 
the practice of parallel import of products is widespread in the EU. The parallel 
import of pharmaceutical products is a vital part of the market. The downside of 
parallel importing in the pharmaceutical sector is that the system of parallel import 
is also used to infiltrate counterfeit and falsified medicines785 in the legal supply 
chain as witnessed in the case studies, discussed in Chapter 3.786 For instance, in 
Operation Singapore (R v. P. Gillespie & others), 787 the counterfeit and falsified 
medicines were portrayed as parallel imported products from France.788 Even 
though the practice of parallel import is good for competition in the Single 
Market, it creates certain issues that must be addressed. 
 
The Customs Regulations does not address parallel imports and overruns,789 as 
stated in Recital 6 of the Customs Regulation,790 because the customs authorities 
783 Bartelt, S. (2003). Compulsory licenses pursuant to TRIPS article 31 in the light of the Doha Declaration on the 
TRIPS Agreement and public health. The Journal of World Intellectual Property, 6(2), 283-310. 
784 Bale Jr, H. E. (1998). The conflicts between parallel trade and product access and innovation: the case of 
pharmaceuticals. Journal of International Economic Law, 1(4), 637-653. 
785 ibid. 
786 Chapter 3. 
787 See more in Chapter 3, Section 3.3. 
788 ibid. 
789 Parallel imports are those products which are genuine and have been manufactured with the consent of the right 
holders. Parallel trade, based on the principle of free movement of goods and has led to the development of the 
Internal Market. Parallel imports tend to occur when price of similar products are significantly different, thereby 
leading to purchase of the products in one Member State and sale of the same product in different Member States to 
achieve profit.. Overruns, are those products which were also produced with the consent of the right holder but not 
in the given number, sometimes called ‘nightshift production’. 
790 Recital 6, Regulation 608/2013. 
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are not concerned with genuine products. As a rule, parallel imported products are 
genuine products and the trade in parallel imports is usually legitimate since the 
production of the goods is carried out with the consent of the right holder or with 
the consent of a person authorised by the right holder. On the other hand, there can 
also be situations, when an illegal trader pretends to be trading in parallel traded 
products, which is especially true in the pharmaceutical sector where there is room 
to make huge profits.791 
 
Within the EU, it is attractive to indulge in parallel trade in pharmaceutical 
products simply because of significant differences in the prices of the same 
medicinal products in different EU Member States. The differences in prices 
occurs primarily because, each EU Member State is guided by its own health 
polices, and other individual systems and structure. Therefore, there is space and 
scope for illegal traders to make profit by leveraging the opportunity of making 
profit at an even bigger scale, if counterfeit products are substituted for real 
products though exploitation of this avenue.  Thereby, it is possible to pass off a 
counterfeit medicinal product as a parallel traded product as occurred in Operation 
Singapore,792 wherein the illegal trader attached fake labels and packaging to 
products to pass off counterfeit products as parallel traded products from France, 
to be sold in the UK.  
 
Therefore, although the logic behind the Customs Regulation not addressing the 
parallel trade is valid because parallel traded products are supposed to be 
legitimate products, the problem arises when counterfeit products use the disguise 
of parallel traded products. This precise problem needs to be addressed, since it 
791 Office of Harmonisation in the Internal Market & Europol. (2015). Situation Report on Counterfeiting in the 
European Union – A joint project between Europol and the Office for Harmonization in the Internal Market.11. 
792 See Chapter 3, Section 3.3. 
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constitutes a major stumbling block for authorities while weeding out counterfeit 
medicine from the legal supply channels. This was also highlighted in Operation 
Volcano,793 where the Italian authorities concluded that the vulnerability of the 
parallel import channel was a contributory factor to prevalence and proliferation of 
falsified medicine in the EU. 
 
The importance of parallel import in context of the Single Market is undeniable 
since it upholds the basic values of the Single Market794 of free movement of 
goods and services and maintaining the market and prices of the products at 
competitive levels.795 The benefits of parallel trade far outweigh the negative 
impact of parallel import of medicinal products. Therefore, it is not prudent to 
consider prohibition of parallel import of medicinal product in order to root out 
trade in counterfeit and falsified medicines. It should, however, also be 
emphasised that the disguise of parallel traded products is often used in selling 
counterfeit medicinal products and therefore, it is imperative to address the issue 
of how to resolve the use of disguise of parallel trade in counterfeiting of 
medicines. 
 
The solution may not directly lie under the Customs Regulation but it can be 
found in the area of Medicine law. In the FMD, there is a requirement of 
authorisation for participating in trade (manufacture, market, sell, broker, 
packaging, etc.) in medicinal products. If these authorisations carry security 
features, such as watermarks, as discussed in Chapter 4796 the issues arising due to 
793 See Chapter 3, Section 3.2. 
794 See Article 26, TFEU. 
795 European Commission. (2011). Communication from the Commission to the European Parliament, the Council, 
the European Economic and Social Committee and the Committee of the Region- A Single Market for Intellectual 
Property Rights Boosting creativity and innovation to provide economic growth, high quality jobs and first class 
products and services in Europe. Brussels. European Commission. COM (2011) 287 final. 
796 See Chapter 4, Section 4.3.3.2. 
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parallel trade in medicines could be resolved because the authorisations would be 
able to ensure authentication and the security features such as watermarks, would 
make forgery of authorisations more difficult.   
 
6.6. Concluding remarks 
The new Customs Regulation came into being in the backdrop of the anti-
counterfeiting and anti-piracy plan, where the specific issue of counterfeiting 
being a serious threat to economic growth was recognised in the EU. As a result, a 
strategy to fight against counterfeiting and piracy was devised at the Union level. 
In this chapter, the Customs Regulation has been analysed in the light of the five 
core issues identified in Chapter 3 with regard to counterfeiting and falsification of 
medicines.797 Specifically, the issue of using small consignments for transport of 
counterfeit and falsified medicines; infiltration of the legal supply chain with 
regard to goods carried in personal luggage of the travellers as well as infiltration 
of the supply chain through parallel imports has been discussed in detail in this 
chapter. In addition, the difference between generic medicines and counterfeit 
medicines – with respect to goods in transit has been clarified. It has been 
concluded that the provisions concerning small consignments798 and goods in 
transit799 are effective and function better since the institution of the new Customs 
Regulation in 2013. 
 
Prior to 2013, the situation was different, as was indicated by the legal case 
797 The five core issues that were identified were manipulation of the medicinal product; infiltration of the legal 
supply chain; online sale of medicinal products; cross border involvement; and small consignments used as means 
of transportation. See more in Chapter 3, Section 3.5. 
798 Article 26, Regulation 608/2013. 
799 Article 22(2), Regulation 608/2013. 
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studies800 covering the period between 2007 to 2014, wherein counterfeit APIs and 
counterfeit medicines entered the EU borders in small consignments, using air, 
land, post and express services. With the changes that have been incorporated in 
the Customs Regulation, especially with respect to Article 23 and Article 26, the 
small consignments that are intercepted can be dealt with instantly. As was also 
indicated in the 2016 EU Customs enforcement Report,801 there has been a decline 
in the number of counterfeits entering through small consignments. 
 
As regards, goods being carried in the personal luggage of the travellers, it is 
apparent that a significant number of labels and packaging material to probably be 
affixed on infringing goods have been regularly detected.802 It is recognised that 
amending the Regulation to check the personal luggage of all passengers or 
prohibit all medicines for personal use entering the EU borders seems unviable. As 
a result, this issue of fake packaging material trickling in the EU through personal 
luggage of the travellers is left unresolved. Further, the prohibiting the travellers 
from bringing medicinal products in the EU will be in violation of the principle of 
proportionality, which is one of the basic tenets of the Union.803 One of the basic 
principles of the Union is that the laws that are made must be proportionate, 
pursuing legitimate aims and necessary in the given circumstances. Therefore, the 
problem of dealing with counterfeiting goods entering the EU in the luggage of 
travellers is still outstanding.  
 
Further, it came to light that the system of parallel trade has allowed for 
infiltration of the legal supply chain of pharmaceutical products. But in the 
800 See Chapter 3. 
801 European Commission. (2017). Report on EU customs enforcement of intellectual property rights. Results of the 
EU border 2016. Luxembourg. Publications office of the European Union. 
802 European Commission. (2017). Report on EU customs enforcement of intellectual property rights. Results of the 
EU border 2016. Luxembourg. Publications office of the European Union. 
803 See Article 5, TFEU. 
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Customs Regulation, there are no provisions that exclusively address parallel 
imported products because the Regulation categorically delimits itself from 
addressing the issue of parallel importation since parallel imported products are 
supposed to be genuine and legitimate products.804  Even though for the 
pharmaceutical sector, it is a significant area that requires attention, the benefits of 
parallel imports for the Single Market far outweigh the negative impact the 
disguise of parallel trade has on the pharmaceutical sector. Therefore, use of the 
disguise of parallel trade to infiltrate the legal supply chain by counterfeit and 
falsified products still needs to be resolved. 
  
804 Recital 6, Regulation 608/2013. 
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Chapter 7: Global Initiatives 
 
7.1. Introduction 
The main purpose of this chapter is to analyse steps being taken in international 
instruments at the global level towards combatting counterfeiting and falsification 
of medicines, in order to draw inspiration for strengthening the legal framework in 
the EU that contains provisions to combat counterfeit and falsified medicinal 
products. Specifically, the Medicrime Convention,805 the Anti-Counterfeiting 
Trade Agreement (ACTA) and a few multilateral and bilateral agreements have 
been analysed.  
 
As established in Chapter 1, the issue of counterfeit and falsified medicines lies at 
the intersection of IP law, Medicine law and Criminal law.806 The harmonisation 
at the EU level in the sphere of Medicines law pertaining to falsified medicines 
has been addressed in Chapter 4. Further, IP law is also harmonised at EU level. 
The Enforcement Directive and the Customs Regulation contain provisions to 
combat counterfeit medicines, which have been dealt with in Chapters 5 and 6. 
However, there is no harmonisation in the area of Criminal law at the EU level so 
far, even though attempts have been made to reach some sort of harmonisation in 
the context of IPR.807 
 
The Medicrime Convention, a Council of Europe (COE) initiative, which aims at 
805 Council of Europe. (2011)  Council of Europe convention on counterfeiting of medical products and similar 
crimes involving threats to public health. Strasbourg. Council of Europe. (Also known as the Medicrime  
Convention). Council of Europe Treaty Series. No. 211. Henceforth, referred to as ‘The Medicrime Convention’. 
806 See Chapter 1, Section 1.2. 
807 Amended proposal for a Directive of the European Parliament and of the Council on criminal measures aimed at 
ensuring the enforcement of intellectual property rights (COM/2006/0168 final - COD 2005/0127). 
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the criminalisation of counterfeiting, is specifically reviewed. It is imperative to 
state that even though the Medicrime Convention uses the term ‘counterfeiting’ as 
used, it actually implies ‘falsified’ as understood in the EU because it is similar to 
the definition of falsified medicinal products,808 as stated in the FMD. 
 
In addition, the Anti-Counterfeiting Trade Agreement (ACTA) is also analysed. 809  
Even though ACTA failed in its current form, the reason for its inclusion is to 
isolate lessons that can be learnt especially in context of criminal measures that 
can be instituted for violation of IPRs, including against counterfeit medicines. 
This is important because the Medicrime Convention does not govern IPR 
violations but only handles the issue from the perspective of public health and 
safety. ACTA came about in 2010 having the goal of establishing a framework 
that would be globally applicable and compatible to curb counterfeiting and 
enforce IP rights. It was negotiated in a non-transparent manner by a few powerful 
countries that sparked a public uproar810 regarding the lack of transparency.811 
There were other controversial elements present in the ACTA, which will be 
discussed in detail in Section 7.3, which led to its ultimate failure. 
 
In the last part of this chapter, the multilateral and bilateral agreements are 
assessed and how those agreements handle counterfeiting and falsification of 
medicines is analysed. The bilateral and multilateral agreements – Tran- Pacific 
808 Article 1(1) (c) Directive 2011/62/EU. 
809 Anti-Counterfeiting Trade Agreement, 2011. (ACTA). ACTA final text, May 2011, Retrieved from: 
http://www.mofa.go.jp/policy/economy/i_property/pdfs/acta1105_en.pdfAccessed April 6, 2017. Henceforth, 
referred to as ‘ACTA, 2011’. 
810 Dür, A., & Mateo, G. (2014). Public opinion and interest group influence: how citizen groups derailed the Anti-
Counterfeiting Trade Agreement. Journal of European Public Policy, 21(8), 1199-1217. 
811 McManis, C. R. (2009). The proposed anti-counterfeiting trade agreement (ACTA): two tales of a treaty. Hous. 
L. Rev., 46, 1235. 
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Partnership (TPP),812 Transatlantic Trade and Investment Partnership (TTIP),813 
RCEP (Regional Comprehensive Economic Partnership),814 Comprehensive 
Economic and Trade Agreement (CETA), 815 stand out as the major global level 
instruments that contain measures to aid in the fight against counterfeiting of 
medicines. The challenge that seems to confront the current international and 
regional agreements is to achieve a balance between the focus on protection of 
IPRs, as in ACTA, TPP, TTIP, RCEP, CETA, and public health and safety 
objectives.  
 
Before commencing a detailed analysis of the Medicrime Convention and other 
global instruments, it would be ideal to provide a background of the different 
initiatives at the international level. Briefly, the Trans-Pacific Partnership (TPP) is 
a trade agreement being negotiated between Australia, Brunei, Canada, Chile, 
Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and the United States 
(until 23 January 2017) and Vietnam.816 Being the largest trade agreement 
negotiated in history, the TPP is purported to enhance innovation, productivity and 
competitiveness, if ratified. The TTIP is another trade agreement being negotiated 
between the US and the EU, primarily oriented towards setting new rules for 
reduction of bureaucratic hurdles in export and import of products and investment, 
812 Trans-Pacific Partnership Agreement- a trade agreement between Australia, Brunei, Canada, Chile, Japan, 
Malaysia, Mexico, New Zealand, Peru, Singapore, the United States (until January 23, 2017) and Vietnam. It 
contained both tariff and non-tariff barriers to trade and it set up investor-state dispute settlement (ISDS). 
813 TTIP is an agreement to scale down the tariffs and regulatory barriers between trade between the US and the 
Member States in the EU and would include certain specific industries, such as, pharmaceuticals, cars, energy, 
finance, chemicals, clothing, and food and drink. It has also reached a stalemate. See Section 7.4. for more. 
814 RCEP is a regional free trade agreement being negotiated by the Association of Southeast Asian Nations 
(ASEAN) (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, 
Vietnam) and six other nations, with which ASEAN has pre-existing free trade agreements. The other nations being 
Australia, China, India, Japan, South Korea and New Zealand. See Section 7.4 for more details.  
815 CETA is an agreement being negotiated between Canada and the EU to promote trade. It has been approved by 
the European Parliament but the approval of the EU national parliaments is awaited. European Commission. Press 
Release. (IP/17/270). 
816  Fergusson, I. F., Cooper, W. H., Jurenas, R., & Williams, B. R. (2013). The Trans-Pacific Partnership 
negotiations and issues for congress. Current Politics and Economics of South, Southeastern, and Central 
Asia, 22(2), 209. 
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thereby contributing to economic growth and development.817 The RCEP is a free 
trade agreement (FTA) being negotiated between the ten countries that are part of 
the (Association of Southeast Asian Nations (ASEAN) and the six countries with 
which the ASEAN has FTAs – Australia, China, India, Japan, South Korea and 
New Zealand. The RCEP is perceived as the alternative to TTP in Asia, which 
proposes common principles in the area of trade in goods, services and 
investments.818 Lastly, CETA is a FTA between Canada and the EU,819 which 
aims at strengthening trade and enhancing economic growth, by lowering customs 
tariffs and other barriers to trade between Canada and the EU.820 
 
The challenge that seems to confront the current international and regional 
agreements is striking a balance between the focus on protection of intellectual 
property rights, as in ACTA, TPP, TTIP, RCEP, CETA, and public health and 
safety objectives. 
 
The bilateral, multilateral and plurilateral trade agreements are similar to a large 
extent because they mainly aim at strengthening and enhancing trade, investment 
and innovation by reducing barriers to trade such as by reducing customs duties 
and by levelling the playing field for creative industries, and innovators by 
providing protection to IPRs, amongst other measures. Besides the differences in 
geographical configurations, the other differences lie in the comprehensive nature 
of the agreements. For instance, the CETA and the TTP, both are composed of 
817 Pitschas, C. (2016). Transatlantic Trade and Investment Partnership (TTIP): The Devil in Disguise or a Golden 
Opportunity to Build a Transatlantic Marketplace? British Journal of American Legal Studies, 5(2), 315-340. 
818 Lewis, M. K. (2013). The TPP and the RCEP (ASEAN6) as Potential Paths toward Deeper Asian Economic 
Integration. Asian J. WTO & Int'l Health L & Pol'y, 8, 359. 
819 The European Parliament votes in favour of CETA on 15 February 2017. European Commission. Press Release 
(IP/17/270)  
820 Grootendorst, P., & Hollis, A. (2011). The 2011 Canada-European Union Comprehensive Economic and Trade 
Agreement: an economic impact assessment of the EU’s proposed pharmaceutical intellectual property 
provisions. Journal of Generic Medicines, 8(2), 81-103. 
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thirty chapters each. The common feature of these bilateral and multilateral 
agreements is their analogous focus on the protection of IPRs under the broad 
circle of IP law. Even though the goal of public health and safety is recognised, 
the rules do not focus on provisions to be incorporated in Medicine law. The 
measures focus on how to make the sectors more competitive, and reduce barriers 
to trade.  
 
In the following sections, the Medicrime Convention, the ACTA and the 
multilateral and bilateral agreements will be analysed, in order to identify the 
unique features and assess if the international instruments can strengthen the legal 
framework governing the counterfeiting and falsification of medicinal products in 
the EU. 
 
7.2. Medicrime Convention 
The Medicrime Conventions is the first of its kind construct that criminalises 
counterfeiting821 of medicinal products. The purpose of including the Council of 
Europe’s ‘Convention on counterfeiting of medical products and similar crimes 
involving threats to public health’ (henceforth ‘Medicrime Convention)822 is with 
a view to analyse if the Medicrime Convention would contribute in combatting 
counterfeiting and falsification of medicines in the EU. The Medicrime 
Convention came into force in January 2016 after it was ratified by six 
countries.823 
821 As explained earlier in Section 7.1, the term ‘counterfeit’ as used in the Medicrime Convention implies 
‘falsified’ as understood in the EU because it is similar to the definition of a falsified medicinal product, as stated in 
the Article 1(1) (c) of Directive 2011/62/EU. 
822 The Medicrime Convention, 2011. 
823 The Medicrime Convention has been ratified by Albania, Armenia, Belgium, France, Hungary, Spain, Moldova, 
and Ukraine from amongst the Members of the Council of Europe. (Status as of 14.7.2017). For updated status, see 
http://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/211/signatures. 
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In the EU, the FMD824 provides for concrete measures from the public health 
perspective such as safety measures to prevent manipulation of the medicines, 
rules for authorisations to prevent infiltration of the legal supply chain, a unique 
online logo for all websites selling medicinal products in the EU, and rules for 
import and export of active substances. The IP law perspective of providing for 
protection and enforcement of IP rights of the right holders is governed by the 
Enforcement Directive and the Customs Regulation dealt with in detail in chapters 
5 and 6. The Enforcement Directive provides for the civil measures that may be 
employed to enforce the IP rights that may be affected by counterfeiting and 
falsification of medicines. So far, criminal measures for enforcement of IPR 
violations or violations of the FMD have not been harmonised at the EU level and 
the Medicrime Convention could potentially provide for harmonisation of the 
missing provisions with regard to criminal measures against falsification and 
counterfeiting of medicinal products in the EU, if ratified by the EU. 
 
7.2.1. Background 
The genesis of having a common treaty on pharmaceutical crime can be traced 
back to 2005 when the (Council of Europe) COE Ad hoc Group on counterfeit 
medicines conducted a seminar “Counteract the counterfeiters: Limiting the risks 
of counterfeit medicines to public health in Europe by adequate means and 
measures”.825 Thereafter, an international conference organised at Moscow 
addressed “Europe against Counterfeit Medicines” in 2006 consolidated the 
824 See Chapter 4 wherein Directive 2011/62/EU discussed in detail. 
825 Hamilton, W. L., Doyle, C., Halliwell-Ewen, M., & Lambert, G. (2016). Public health interventions to protect 
against falsified medicines: a systematic review of international, national and local policies. Health policy and 
planning, 31(10), 1448-1466. 
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political will to formulate a Convention in the field of pharmaceutical crime.826 
Between the period of 2007-2009, the draft of the Medicrime Convention was 
written under the auspices of the Council of Europe Committee of Ministers and 
support of other relevant organs of the COE.827 It is built upon the foundation of 
the fundamental right of right to life,828 since the most serious consequences of 
counterfeit medicine can result in death which is a violation of that inalienable 
right to life. The Medicrime Convention was formally adopted on 8 December 
2010 by the Committee of Ministers of COE and opened for signature in 2011. On 
1 January 2016, after obtaining the required ratifications the Medicrime 
Convention came into force. 
 
The Medicrime Convention is the first international convention against the 
counterfeiting of medical products and other similar offences that threaten public 
health.829 Its main contribution is to criminalise the counterfeiting of medical 
products and use of criminal law in combatting all forms of counterfeiting of 
medical products by integrating rules pertaining to cooperation, prevention, and 
protection of victims.830 It establishes the manufacturing; supplying; offering to 
supply; trafficking; the falsification of documents and marketing of medical 
products and devices as offences.831 The Convention empowers the signatory 
States with tools to introduce common minimum standards on substantive and 
826 Council of Europe. (20 April 2007).The quality of medicines in Europe. Recommendation 1794, Parliamentary 
Assembly, Council of Europe. ( Doc. 11193, report of the Social, Health and Family Affairs Committee, rapporteur: 
Mr Marquet). Text adopted by the Assembly on 20 April 2007 (18th Sitting). 
827 Schmahl, S., & Breuer, M. (Eds.). (2017). The Council of Europe: Its Laws and Policies. Oxford University 
Press. 
828 Article 2, Council of Europe. (1950). European Convention for the Protection of Human Rights and 
Fundamental Freedoms, as amended by Protocols Nos. 11 and 14, 4 November 1950, ETS 5. 
829 Council of Europe. (20 April 2007). The quality of medicines in Europe. Recommendation 1794, Parliamentary 
Assembly, Council of Europe. (Doc. 11193, report of the Social, Health and Family Affairs Committee, rapporteur: 
Mr Marquet). Text adopted by the Assembly on 20 April 2007 (18th Sitting). 
830 Keitel, S. (2012). The MEDICRIME convention: criminalising the falsification of medicines and similar 
crimes. GBI J, 1, 138-41. 
831 Article 8, The Medicrime Convention, 2011. 
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procedural criminal law, as well as provisions aiming at improving cooperation 
and information exchange between national and international competent 
authorities.  
 
7.2.2. Purpose  
The main purpose of the Medicrime Convention is to deal with counterfeiting and 
falsification of medicinal products – an issue of global concern by classifying 
counterfeiting, manufacture, and supply of medicinal products marketed without 
authorisation or without complying with safety requirements - as a crime.832 
Likewise, the criminalisation of the trade in counterfeit medicines is important 
because national or regional responses to this international problem have proved to 
be inadequate and insufficient.833The WHO has articulated a number of reasons, 
which have led to the proliferation of counterfeit and falsified medicines.834 These 
reasons encompass insufficient national regulation of drug manufacturing and 
distribution; weak enforcement of existing legislation; poor penal sanctions for 
violations of drug legislation; insufficient regulation by exporting countries and 
within free trade zones; complex transactions due to proliferation in the number of 
intermediaries; ever increasing demand and escalating prices of curative and 
preventive drugs and vaccines and feeble cooperation among stakeholders.835  
 
The need to categorise counterfeiting of medicines as a ‘crime’ was realised ten 
years ago when the WHO International Conference on Combatting Counterfeit 
832 Article 1, Chapter 1, The Medicrime Convention, 2011. 
833 Attaran, A., Bate, R., & Kendall, M. (2011). Why and how to make an international crime of medicine 
counterfeiting. Journal of International Criminal Justice, 9(2), 325-354. 
834 Counterfeit Drugs: Guidelines for the development of measures to combat drugs, UN Doc, 
WHO/EDM/QSM/99.1.1999. 
835 Counterfeit Drugs: Guidelines for the development of measures to combat drugs, UN Doc, 
WHO/EDM/QSM/99.1.1999. 
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Medicine reached the conclusion that counterfeiting of medicine should be 
categorised as an international crime, which was articulated in the Declaration of 
Rome in 2006836 There are other scholars who have propagated in support of the 
idea to make an international crime of medicine counterfeiting.837 According to 
Bassiouni, crimes are deserving of being elevated to ‘international crimes’ if they 
either amount to an offence against the entire international community, or if 
international cooperation is necessary for effective control over the transgression, 
or both.”838 And likewise, counterfeiting and falsification of medicines do fit the 
bill. 
 
However, the Medicrime Convention has taken a step in that direction by 
criminalising counterfeiting839 and falsification of medicines. Broadly, the 
Medicrime Convention is divided into eleven chapters wherein the first chapter 
(Article 1 to 4) states the object and purpose, scope and provides definitions of key 
terms. The second chapter (Articles 5 to 14) contains the substantive criminal law 
provisions and the third chapter (Articles 15 and 16) states the provisions of 
investigations, prosecution, and procedural law. The following chapters four, five 
and six consist of provisions regarding cooperation of authorities and information 
exchange, measures for prevention and measures for protection respectively. The 
last few chapters contain measures regarding international cooperation and follow 
up mechanisms.840  
836 WHO. (2006). Declaration of Rome, Conclusions and Recommendations of the WHO International Conference 
on Combating Counterfeit Medicines, 18 February 2006. Section 4. 
837 Attaran, A., Bate, R., & Kendall, M. (2011). Why and how to make an international crime of medicine 
counterfeiting. Journal of International Criminal Justice, 9(2), 325-354. 
838Bassiouni, M. Cherif. (1983). Penal Characteristics of Conventional International Criminal Law. Case w. Res. J. 
int'l L. 15 27. 28-29. 
839 As per definition, the term ‘counterfeit’ as used in the Medicrime Convention implies ‘falsified’ as understood in 
the EU because it is similar to the definition of a falsified medicinal product, as stated in the Directive 2011/62/EU 
(the FMD). 
840 Chapters 7 to 11, The Medicrime Convention. 2011. 
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This chapter will focus on some specific provisions most relevant to the thesis. 
Specifically, the definition of the term counterfeiting (Article 4) will be analysed 
followed by the meaning of the term ‘similar crimes’ (Article 8). Thereafter, the 
particular provisions that address the issue of jurisdiction (Article 10); protection 
of victims, particularly regarding investigations (Article 15) and prosecution 
(Article 16) will be discussed. 
 
7.2.3. Main provisions 
The term ‘counterfeit’ is defined in the Medicrime Convention as: ‘a false 
representation as regards identity and/or source’ (Article 4), and ‘similar crimes’ 
as the unauthorised manufacture or supply of medicinal products or the marketing 
of medical devices that do not comply with conformity requirements (Article 8). 
The term ‘similar crimes’ denotes production, stock-piling, trafficking, offering 
for sale of medical products, by passing intentionally the obligatory 
supervision/control of medicines authorities.841  
 
The term used in the Medicrime convention is ‘counterfeiting’ which is different 
from the term used in the FMD, which uses the term ‘falsified medicinal 
products’.842Although the terms used are different,843 a closer examination of the 
terms reveals that the meaning of the term ‘counterfeiting’ as used in the 
Medicrime Convention is actually in consonance with the term ‘falsified 
medicinal product’ as understood in the FMD. The FMD incorporates a more 
detailed definition, which includes false representation with regard to origin, 
841 Article 8, The Medicrime Convention, 2011. 
842 Article 1 (1) (c), Falsified Medicines Directive 2011/62/EU. 
843 See Chapter 1, Section 1.6.for discussion on terminology. 
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source, and history.844 Both the Medicrime Convention and the FMD845 
specifically state that all issues related to IPRs violation are not addressed by the 
Convention and the Directive respectively. Therefore, although the terminology 
used is different in the two legal instruments, the practical implications are not 
totally divergent with respect to the definition of the term ‘counterfeiting’ and 
‘falsified medicinal product’. The definitions are in consonance with each other is 
so far as both the Medicrime Convention and the FMD exclude IPRs issues but the 
FMD provides a broader definition. It also includes false description of history of 
the medicinal product.  
 
The Medicrime Convention takes a significant step forward in terms of 
introducing serious measures against counterfeiting and falsification of medicines 
as it is the first international regulation that aims to prosecute the manufacture and 
sale of counterfeit drugs846 and a convention that obliges the signatory States to 
prosecute criminally the manufacture and trafficking of counterfeit drugs.847 The 
convention also addresses those products that have not procured proper 
authorisation848 before they were put on the market, under Article 8849 It would 
encompass the manufacture, stockpiling for supply, importing, exporting, 
supplying and offering to supply of medicinal products without authorisation. As 
for the medical devices – it would entail those not complying with the standards. 
In this manner, the convention puts an obligation on the signatory States to treat 
placement of products without authorisation, as crimes, since they pose a threat to 
public health. These provisions are aimed at the black market in unauthorised 
844 Article 1 (1), Directive 2011/62/EU. 
845 See Directive 2011/62/EU. 
846 Articles 5 and 6, Chapter 2, The Medicrime Convention, 2011. 
847 Article 16, Chapter 3, The Medicrime Convention, 2011. 
848 Article 7, Chapter 2, The Medicrime Convention, 2011. 
849 Article 8, Chapter 2,The Medicrime Convention, 2011. 
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steroids.  
 
The Medicrime Convention is the first international convention that sets up 
offences with criminal intent: the manufacturing of falsified/counterfeit medical 
products (Article 5); supplying, offering to supply and trafficking in 
falsified/counterfeit medical products (Article 6); the falsification of documents 
(Article 7); ‘similar crimes’ (Article 8); and under Article 9, the Convention 
addresses aiding or abetting to commit the offences also as criminal offences. The 
interpretation of the concept of “attempt” is left up to the individual States. The 
only guideline stated in the preamble of the Convention indicates, that principle of 
proportionality850 must be considered. In essence, the principle of proportionality 
seeks to enforce the fact the law must only be applied to the extent that is 
necessary to achieve the objectives of the Convention. 
 
Within the EU, the Medicines Directive (Directive 2001/83/EC)851 forbids putting 
a product on the market without market authorisation. However, as the case 
studies852 have also revealed, having rules, such as in the Medicines Directive, the 
FMD (Directive 2011/62/EU), and civil measures, as provided for in the 
Enforcement Directive,853 alone have not helped in curbing the proliferation of 
counterfeit and falsified medicinal products in the EU. Therefore, these provisions 
of criminal measures in the Medicrime Convention, as adopted by four Member 
States854 and if adopted by the EU, would strengthen the legal framework against 
the proliferation of counterfeiting and falsified medicinal products. 
850 Principle of proportionality is stated in Article 5 of the TEU. The criteria for its application is stated in Protocol 
(No.2) on the application of the principles of subsidiarity and proportionality annexed to the Treaties.  
851 Article 6, Directive 2001/83/EC. 
852 See Chapter 3. 
853 See Directive 2004/48/EC. 
854 The Medicrime Convention has been ratified by Spain, France, Belgium and Hungary from amongst the EU 
Member. (Status as of 14.7.2017). For updated status, see http://www.coe.int/en/web/conventions/full-list/-
/conventions/treaty/211/signatures. 
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Article 10 of the Convention deals with matters of jurisdiction and it is clear855 
that the main aim of inclusion of this provision is to ensure no criminal acts get a 
chance to seep through the gaps in the legal framework. The principle of 
territoriality is applicable in the strictest sense since the Medicrime Convention 
lays the foundations for States to take legislative action and other initiatives to 
apply sanctions against offences taking place in its territory.  
 
However, as seen in the case studies, the problem that arises, is the purposeful 
spread of their actions in different States by the counterfeiters. For instance, 
Operation Volcano,856 headed by the Italian authorities, revealed that the 
legitimate market authorisation holder transferred the products to the illegitimate 
authorisation holder and the goods switched from being in the legal supply chain 
to being in the illegal supply chain and then finally ended in the legal supply chain 
after having been falsified.857 The fake authorisations showed that the goods were 
moved from Italy to different Member States like Latvia, Malta, Cyprus, and 
Romania, and then back to Italy.858 Therefore, the matter of jurisdiction has been 
accurately identified by the Medicrime Convention as being crucial to enhance 
greater coordination and cooperation between signatory States, as generally 
envisaged in chapter VII of the Medicrime Convention.859   
 
The Convention provides for the promotion of national and international 
cooperation.860 Under these provisions, the convention establishes methods of 
855Cabezas, M. D., & Piqueras, A. J. (2011). Medicrime: The international convention of the Council of Europe as a 
tool to combat counterfeit medicines. Pharmaceuticals Policy and Law, 13(1, 2), 41-55. 
856 See more in Chapter 3, Section 3.2. 
857 See more in Chapter 3, Section 3.2. 
858 ibid. 
859 See Chapter 7, Articles 21 and 22, The Medicrime Convention. 2011. 
860 ibid. 
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cooperation and delineates how to establish an interface between the various 
authorities in different sectors such as the commercial and industrial sectors. 
Further, the preventive measures as proposed by the Convention that the States 
need to implement pertain to an obligation to train personnel in control and 
monitoring activities. It would involve training the police, customs authorities and 
regulatory authorities, awareness-raising campaigns about counterfeit medical 
products, and authorisation of interventions on websites. This provision would 
enhance enforcement of the legal instruments and thereby aid in the 
implementation of the existing rules. 
 
The Medicrime Convention addresses issues such as protection of victims,861 by 
providing for - that victims must have access to information. This entails all 
information relevant to their case, necessary for the protection of their health; 
thereby assisting the victims in their physical, psychological and social recovery. 
The provisions regarding investigation and prosecution (Articles 15 and 16) aim at 
eradicating pressure on the victim by the criminal to withdraw their complaint and 
this is achieved by the provision that the proceedings can be initiated ex-officio 
and not only by the victim himself/herself. Further, the signatories to the 
Convention will be obliged to take necessary legislative and other measures to 
protect the rights and interests of victims, including the provision of legal aid, 
access to information and protection from intimidation.862 
 
7.2.4. Critical analysis of Medicrime Convention 
The main contribution of the Medicrime convention is the criminalisation of acts 
pertaining to counterfeit medicine. It is the first international convention of its 
861 Chapter 6, Articles 19 and 20, The Medicrime Convention. 2011. 
862 Chapter 6, Article 20, The Medicrime Convention. 2011. 
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kind to do so and for that reason alone, is important. It provides tools to the 
signatory States to criminalise the act of counterfeiting and associated acts of 
falsifying accompany documents, which have proven to be a menace in the EU, as 
indicated by the case studies.863  
 
The Medicrime Convention introduces many crucial provisions required to fight 
counterfeiting in the pharmaceutical sector in its bid to achieve its aim of 
‘criminalisation of counterfeiting’. If adopted by all the Member States in the EU, 
it would significantly enhance the legal framework that governs the counterfeiting 
and falsification of medicinal products in the EU and bridge the gap provide for 
the missing harmonised rules in the sphere of Criminal law. However, there are 
certain areas that can still be improved in the Medicrime Convention.   
 
The Convention addresses the term counterfeit in a very broad manner and leaves 
out definition of certain key relevant terms. For example, Article 5 of the 
Convention states that manufacturing a counterfeit medicine is a criminal offence. 
It includes adulteration as a crime but does not define the term explicitly.864 It is 
equally important to define this term, in addition to defining the concept of victim 
and counterfeit medical product. As discussed in Chapter 1, clarity with regard to 
the terminology used and in legal instruments is extremely important.865 This is 
because, the terms that are left undefined or omitted in legal instruments become 
the shield of protection of criminal acts carried out in context of falsification and 
counterfeiting of medicines.866 
 
863 See Chapter 3. 
864 Council of Europe. (2009). Council of Europe Convention on the counterfeiting of medical products involving 
threats to public health, Explanatory Report. 16 fin., paragraph 44. 7. 
865 See Chapter 1, Section 1.6. 
866 Cabezas, M. D., & Piqueras, A. J. (2011). Medicrime: The international convention of the Council of Europe as 
a tool to combat counterfeit medicines. Pharmaceuticals Policy and Law, 13(1, 2), 41-55. 
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Thus, it is extremely rare that an action is initiated against adulteration and other 
related crimes because of the omission of these acts in the legal instruments. One 
of the recorded cases where action was taken is from the US in 2011, when the 
Food & Drug Authority (FDA) imposed a sanction on the pharmaceutical 
company Glaxosmithkline for distributing adulterated medicinal products after the 
accusation of an employee responsible for product quality supervision for the 
company’s products made in a factory in Puerto Rico. In the case, a criminal fine 
and forfeiture of 150 million USD and a civil settlement under the False Claims 
Act and related state claim for 600 million USD was levied.867 The result of lack 
of clarity of the definition of the terms counterfeiting, adulteration, etc. can 
heighten legal uncertainty, when the different States will apply the Convention. 
For instance, the Spanish criminal code distinguishes between adulteration and 
counterfeiting by classifying both actions as crimes against public health.868 
However, it is not the case in the majority of States. 
 
The Medicrime Convention requires under Article 8(a) (i), to enact criminal 
offences against unauthorised activities such as generic drug companies making 
stockpiles or marketing drugs without proper authorisations. Up until now, such 
deviations were considered a civil wrong, however after the implementation of the 
Convention, such offences will become criminal in nature and thus may even 
entail imprisonment as a punishment. The alarming fact that 30 % of drug 
launches infringe, might probably have a chilling effect on the generic drug 
867 The United States Department of Justice. (26 October 2010) GlaxoSmithKline to Plead Guilty & Pay 750 USD 
to Resolve Criminal and Civil Liability Regarding Manufacturing Deficiences at Puerto Rico Plant. Press Release 
number: 10-1205. Washington DC. 
868 Compare Art. 362 Organic Law 10/1995, 23 November of the criminal code), Bernaus  José F, Bernaus Carlos 
G. Adulteración y falsificación de medicamentos. Ed. Quorum 2006:256 in M.D. Cabezas and A.J. Piqueras 
(Pharmaceuticals Policy and Law (2011). 
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industry.869 Another common concern is the Convention may penalise honest 
mistakes of medicine manufacturers.870 For instance, an unintentional mistake on 
part of an authorised seller of false representation could also lead to prosecution 
similar to the case of Heparin products manufactured by Baxter.871 Those products 
had to be taken off the market since they contained an unknown contaminating 
substance. Criminal punishment for such acts can appear too severe. 
 
The Medicrime Convention is also significant because it governs the rights of 
‘victims’, which has not been addressed in this context previously. Further, it 
provides for concrete measures for setting up international cooperation and 
encompasses follow-up mechanisms. Despite the revolutionary measures and 
innovative nature of the Medicrime Convention, it lacks the support and 
involvement of some of the key nations such as the US, the UK and China.872 
Another drawback is that in respect to some provisions, the Medicrime 
Convention appears like a buffet of legal provisions, which allows for picking and 
choosing selective provisions that may be adopted or disregarded. This room for 
making adjustments before adoption can result in inconsistencies between the 
signatory States.873  
 
Despite the room for manoeuvrability, the Medicrime Convention is the first step 
towards achieving harmonisation with respect to criminalisation of acts of 
869Ludwig, S. P., Kosinski, K. B., & Harris, J. (2005). Hatch-Waxman in the Federal Courts: From 1994–
2004. Drug development and industrial pharmacy, 31(2), 215 -222. 
870 Attaran, Amir, & Roger Bate. (2010). A counterfeit drug treaty: great idea, wrong implementation. The 
Lancet 376: 1446-1448. 
871 Briones, S. (2008). Heparin recall: another crisis for China & the FDA. Health Law Perspectives, 24. 
872 It is believed by some scholars that lack of involvement of key countries is more due to political reasons such as 
the locus of power shifting from International organisations such as the WHO, WTO to COE. (Amir Attaran et al. 
2011). 
873 For instance, in case of jurisdiction, the fact that a Party can reserve jurisdiction based on nationality of the 
victim or the perpetrator will corrode the full benefit of the provision, as also indicated by M.D. Cabezas and A.J 
Piqueras (2011). 
244 
 
                                           
 
 
 
counterfeiting and falsification of medicinal products. If the EU ratifies the 
Medicrime Convention, then all the Member States would in effect be obliged to 
provide for the provisions of the Medicrime Convention. This would strengthen 
the enforcement mechanisms as regards falsified medicines because even though 
the Medicrime Convention uses the term ‘counterfeit medicine’, it is concerned 
with, what is understood in the EU as ‘falsified’ medicines. In other words, the 
Medicrime Convention does not address the IP violation. For the purposes of 
combatting falsified medicines in the EU, if the Medicrime Convention is ratified, 
it would harmonise the criminal enforcement against falsified medicinal products, 
at least from the perspective of public health and safety. It would inevitably have a 
positive impact on the IP violations because if there are less falsified medicines, 
there will obviously be less counterfeit medicinal products. This is because the 
product that is falsified inevitably violates the IP rights of the right holder. 
Therefore, even though the Medicrime Convention does not concern itself with IP 
violations, it will result in a proportionate decrease in incidents of counterfeiting 
of medicinal products by virtue of decrease in falsification of medicinal products.   
 
 7.3. ACTA 
The Anti- Counterfeiting Trade Agreement (ACTA)874 was a multi-national 
plurilateral trade agreement conceived in 2010 with the main aim of articulating an 
agreement with global application in combatting counterfeiting and be 
instrumental for enforcement of IP rights by establishing global standard. It was 
negotiated outside the purview of traditional international organisations such as 
874 ACTA, 2011. 
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the WTO or WHO and as a result was a target of much criticism875 for lack of 
transparency.876 The purpose of including ACTA877 (despite the fact that it was not 
passed by the EU,878 and has effectively failed), is to seek inspiration in order to 
improve the legal framework that governs counterfeiting and falsification of 
medicines in the EU. 
 
It needs to be reiterated that counterfeiting and falsification of medicines lies at the 
intersection of Medicine law, IP law and Criminal law, as discussed in Chapter 
1.879 In the EU the FMD governs the Medicine law aspects;880 the Enforcement 
Directive881 and the Customs Regulation882 deal with the IP law aspects and there 
is no harmonisation at the EU level with regard to the Criminal law area. The only 
instrument that deals with criminal measures is the COE initiative – the 
Medicrime Convention,883 which has been ratified by four Member States so 
far.884 It contains criminal measures against counterfeiting and falsification of 
medicines specifically. Another feature of these legal instruments is that the FMD 
deals specifically with the falsified medicines, and thus the other two legal 
instruments that address the IP law sphere, govern the IPRs in general are not 
tailored to address counterfeiting and falsification of medicines, in particular.  
 
875 Dür, A., & Mateo, G. (2014). Public opinion and interest group influence: how citizen groups derailed the Anti-
Counterfeiting Trade Agreement. Journal of European Public Policy, 21(8), 1199-1217. 
876 McManis, C. R. (2009). The proposed anti-counterfeiting trade agreement (ACTA): two tales of a treaty. Hous. 
L. Rev., 46, 1235. 
877 ACTA, 2011. 
878 See The European Parliament. (2012). European Parliament rejects ACTA. Press Release July 4 2012. 
Reference no.:20120703IPR48247.  
879 Chapter 1, Section 1.2. 
880 See Directive 2011/62/EU. 
881 See Directive 2004/48/EC. 
882 See Regulation 608/2013. 
883 The Medicrime Convention. 2011. 
884 The Medicrime Convention has been ratified by Spain, France, Belgium and Hungary from amongst the EU 
Member. (Status as of 14.7.2017). For updated status, see http://www.coe.int/en/web/conventions/full-list/-
/conventions/treaty/211/signatures. 
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The ACTA had the goal to combat counterfeiting in the context of IPRs in general 
and was not specifically tailored to the needs to combat counterfeiting and 
falsification of medicines in the EU. In that respect ACTA resembled the other 
legal instruments in the EU such as the Enforcement Directive and the Customs 
Regulation, which address counterfeit medicinal products in the EU as part of 
other IPRs, and from the IP law perspective. On the other hand, the FMD 
addresses the falsified medicinal products from the Medicines law perspective and 
omits the IP law perspective in the EU. Likewise the Medicrime Convention only 
addresses medicinal products from the public health and safety perspective and not 
the IP law perspective.  
 
7.3.1. Background 
ACTA came about in 2010, with the aim to deliver a framework that would be 
internationally applicable and compatible to curb counterfeiting and enforce IP 
rights. Prior to ACTA, Trade Related Aspects of Intellectual Property Rights 
(TRIPS), existing since 1994, was the only, and till date continues to be the 
hallmark agreement of enforcement of IP rights at the global level. There were 
questions raised regarding the reason underpinning the inception of ACTA, 
associated inadequacy or insufficiency of TRIPS and the absence of ACTA 
negotiation under the WTO regime or any other internationally recognised forum. 
Some of the answers to the questions raised lie in the area of international politics 
and diplomacy rather than in purely legal regulatory arena, for instance, lack of 
transparency885 in the process of negotiations; forum-shifting886 where developed 
countries dominated the process and developing countries and their interests were 
885 Levine, D.S. (2011).Transparency Soup: The ACTA Negotiating Process and “Black Box” Lawmaking. 
American University Journal of International Law and Policy, 26 (3). 811. 
886 Mercurio, B. (2012). Beyond the text: the significance of the anti-counterfeiting trade agreement. Journal of 
International Economic Law, 15(2), 361-390. 
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not represented satisfactorily.  
 
ACTA was conceptualised in the wake of rise in counterfeiting and the impending 
need for an international agreement for enforcement of IP rights. There was and 
continues to be no dearth of statistics that indicate the critical loss of the right 
holders due to counterfeiting world over.887 Counterfeiting is not limited to a 
specific sector or to a specific industry. Therefore, there was and still is an urgent 
need to update and build upon the TRIPS as an international agreement on the 
enforcement of IP rights. Numerous bilateral and multilateral agreements, as 
discussed in Section 7.4888 have been put forward at regional level, such as, TPP, 
RCEP, TTIP and of course ACTA was one such effort at the international level to 
combat counterfeiting.  
 
However, due to the new challenges presented by technological development, it 
was agreed that one such international agreement was necessary or a revision was 
important for the sake of a universal international agreement on enforcement of 
IPRs. ACTA involved the United States, the European Community, Switzerland, 
Japan, Australia, Republic of Korea, New Zealand, Mexico, Jordan, Morocco, 
Singapore, the United Arab Emirates, and Canada.889 
 
The ACTA consisted of civil measures (Article 7 to 12), criminal measures 
(Article 23 -26), as well as measures for border enforcement (Article 14-22). In 
addition, there were also measures that dealt with enforcement of IP rights and 
enhancement of IP enforcement practices. Another important angel in the ACTA 
887 Recent estimates claim that the trade has grown by 90 per cent since 2005, with an approximate turnover of 
$200 billion, suggesting it has now overtaken marijuana and prostitution as the largest illicit market for 
traffickers (IRACM 2013; see also Finlay 2011) in Hall, A., & Antonopoulos, G. A. (2016). Introduction. In Fake 
Meds Online. 1-17. Palgrave Macmillan UK.  
888 See more Section 7.4. 
889 ACTA, 2011. 
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was the enforcement of IP in the digital environment. Due to a number of reasons 
that will be discussed in Section 7.3.4, the ACTA was rejected by the European 
Parliament when the European Parliament did not ratify ACTA in 2012.890  
 
Several of the civil, criminal, border, digital and international measures that were 
incorporated in the ACTA, constitute a part of the legal instruments in the EU in 
one form or another. The civil measures that formed a part of ACTA are available 
under the Enforcement Directive.891 The Customs Regulation entails the 
provisions that mirror border measures as perceived in the ACTA.892 The criminal 
measures in the ACTA have no equivalent at the EU level that can be attributed to 
the lack of harmonisation at the EU level in that sphere of Criminal law. But the 
Medicrime Convention would harmonise the criminal enforcement in context of 
falsified medicines, if ratified by the EU. 
 
7.3.2. Main relevant provisions 
In the ACTA, Section 2 dealt with the civil enforcement measures under Articles 7 
to 12. It contained measures such as availability of civil procedures to right 
holders on the basis of merits of a case. Injunctions were provided for under 
Article 8, which accorded the judicial authorities with the power to issue orders to 
parties to desist from an infringement of an IPR which would in effect, prevent 
goods from entering the channels of commerce. The section on civil remedies 
dealt with provision of damages, and other remedies for possible incorporation 
into the laws of the signatory States, in addition, to information related to 
infringement, which may be passed. Provisional measures that could be 
890 The European Parliament. (2012). European Parliament rejects ACTA. Press Release July 4 2012. Reference 
no.:20120703IPR48247.   
891 Directive 2004/48/EC. 
892 Regulation 608/2013. 
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undertaken, such as seizures, or taking other information or products into custody 
the goods that were suspected of infringing IPRs were also spelt out in this 
section. The provisions on civil measures follow a construct based on the TRIPS 
agreement and much of what has been part of the TRIPS agreement has seen the 
distillation into the national laws of the signatory States. For instance, the civil 
measures that are enumerated in the ACTA, are reminiscent of TRIPs Agreement 
and have similar if not identical provisions in the Enforcement Directive,893 
discussed in Chapter 5 in greater detail. 
 
Section 4 of ACTA, was perhaps the most controversial of all the provisions of 
ACTA.894 Article 23 provided for measures that were supposed to be undertaken 
in case of wilful trademark counterfeiting on a commercial scale. The second part 
of Article 23, constituted a measure with foresight, wherein criminal procedures 
and penalties were to be imposed in cases of wilful importation, domestic use in 
course of trade and on commercial scale of labels or packaging.895 In one of the 
legal case studies - Operation Singapore (R v. P. Gillespie), 896 as discussed in 
detail in Chapter 3, false packaging was used and the accused was sentenced to 
three years of imprisonment on charge of counterfeiting. In the EU, false 
packaging has been an issue since 2010, as also reported in the EU Customs report 
on enforcement897 especially in the luggage of passengers and continues to be an 
issue. 
 
The measure incorporated under Section 3 of the ACTA, dealt with the provision 
893 See Chapter 5. 
894 McManis, C. R. (2009). The proposed anti-counterfeiting trade agreement (ACTA): two tales of a treaty. Hous. 
L. Rev., 46, 1235. 
895 Article 23 (2) ACTA, 2011. 
896 See Chapter 3, Section 3.3. 
897 European Commission. (2015). Report on EU customs enforcement of intellectual property rights. Results at the 
EU border 2015. Luxembourg. Publications office of the European Union. 
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of border measures, set in Articles 14 to 22. Article 14 enumerates the provisions 
with respect to small consignments and personal luggage, wherein ACTA would 
have been applicable to goods sent in small consignments for commercial 
purposes but not to small quantities of goods of a non-commercial nature 
contained in travellers’ personal luggage. This provision is also reminiscent of the 
provisions of the Customs Regulations 608/2013.898  
 
In addition, there were provisions for penalties, seizure, forfeiture and destruction 
of goods.899 Article 26 of ACTA provided for ex-officio criminal enforcement, 
wherein each signatory State would be obliged to provide in relevant cases, the 
power to its authorities to act upon their own initiative investigation or legal action 
with respect to the criminal offences mentioned in ACTA. For these offences, the 
States were also obliged to provide for criminal procedures and penalties. This 
provision was perceived to be of draconian nature with a potential for misuse due 
to lack of typical checks and balances on the use of this provision.900 In the EU, 
there is resistance to harmonisation of criminal law in general, and also resistance 
towards criminal enforcement of IPRs.901 
 
The civil and criminal enforcement measures available in case IPR violations 
would have been extended to issues arising in the digital environment as well. The 
measures would include expeditious remedies to prevent infringement and also 
remedies, which would constitute a deterrent to further infringements. In addition, 
there were measures to avoid creation of barriers to legitimate activity including 
898 Customs Regulation 608/2013. 
899 Article 25, ACTA, final text, 2011. 
900 Shepard, A. (2013). ACTA on Life Support: Why the Anti-Counterfeiting Trade Agreement Is Failing and How 
Future Intellectual Property Treaties Might Avoid a Similar Fate. Wash. U. Global Stud. L. Rev., 12, 673. 
901 The failed attempt to introduce criminal enforcement of Intellectual Property Rights at the EU level in 2007. See 
also the withdrawal was announced in the ‘Withdrawal of obsolete Commission proposals in the Official journal of 
the European Union.  (18 September 2010), 2010/C 252/9. 
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electronic commerce, and consistent with national laws, preservation of 
fundamental principles such as freedom of expression, fair process and privacy. 
 
Chapter 4 of the ACTA dealt with provisions for encouraging international 
cooperation, which was built upon the basic premise that protection of IPR was 
important irrespective of the nationality of the right holder or the location of the 
right holder. In an international environment, where IPRs exist in a global format, 
it is necessary that the protection is also extended in the same format.902  
 
7.3.3. Critical analysis of ACTA 
The main reason for negotiating ACTA was to combat the large scale of 
intellectual property rights violations and for the protection of rights holders in the 
international arena. However, it was marred by lack of faith due to lack of 
transparency903 in the manner in which it was negotiated. It was also blamed for 
‘forum – shifting’,904 away from the WTO and pre-existing forums for negotiating 
of international Intellectual Property rules. ACTA provoked a public outcry of 
unexpected proportion, with associated views ranging from labelling ACTA as an 
“end of democracy”,905 to “censorship of the internet”, to “restriction of access to 
live-saving AIDS medicines in developing countries”.  Concerns were also raised 
902 Moreover, cooperation between States on the subject of enforcement of IPRs was encouraged as well as capacity 
building and technical assistance to be extended to other countries that were signatories to the Agreement. This 
cooperation would have included law enforcement cooperation with respect to criminal enforcement and border 
measures, as covered by ACTA. In addition, the ACTA also included the provision for sharing of information 
between States, which would have contributed greatly to the creation of a database of potential counterfeiters, and 
would have aided in catching criminals in a speedier manner. This would have resulted in greater protection of IPRs 
as well as would have strengthened the enforcement of IPRs. 
903 Levine, D.S. (2011).Transparency Soup: The ACTA Negotiating Process and “Black Box” Lawmaking. 
American University Journal of International Law and Policy, 26 (3). 811. 
904 Mercurio, B. (2012). Beyond the Text: The Significance of the Anti-Counterfeiting Trade Agreement. Journal of 
International Economic Law 15(2), 361-390. 
905 The lack of transparency during the negotiating process (despite Parliaments’ request to make the ACTA 
negotiating documents public, the documents were not made public), also contributed to affirm the anti-democratic 
sentiment against ACTA in the EU.       
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as to whether the ACTA was in consonance with the acquis communautaire of the 
EU and with the World Trade Organisation (WTO) Agreement on the Trade 
Related Aspects of Intellectual Property Rights (the TRIPS). Even though there 
were voices that defended ACTA, such as defence offered by the then European 
Commissioner for Trade, stating his opinion that “ACTA is not an attack on your 
liberties; it is a defence of your livelihoods,”906 these voices were drowned by 
those who opposed the Agreement. Adding to the mix of confusion was the timing 
of the EU Parliament’s vote, which happened before the Court of Justice (CJEU) 
response to European Commissions’ request on clarification on whether ACTA 
was incompatible with EU’s fundamental rights and freedoms, including freedom 
of expression and information and data protection, and the right to property in case 
of intellectual property.907 In July 2012, the European Parliament rejected the 
Proposal for a Council Decision on the conclusion of ACTA.908 
 
Contrary to the criticism levied upon ACTA, it did go a step further than TRIPS  
(still recognised and respected Agreement pertaining to Intellectual Property 
Rights). ACTA offered more solid provisions, which probably erred on the side of 
being too strict. Secondly, ACTA also addressed the element of cross-border 
infringements in more concrete terms, when compared to TRIPs. However, as the 
final draft of ACTA indicated, it needed to be tempered down from its original 
form. It also became evident from the manner of negotiation of ACTA, that equal 
906 De Gucht, K. (29 February 2012). European Commissioner for Trade, ACTA – State of Play, 1st Exchange of 
Views with the Committee for International Trade of the European Parliament. Brussels. 
907 The question put forward by the Commission to the CJEU was, “Is the Anti-Counterfeiting Trade Agreement 
(ACTA) compatible with the European Treaties, in particular with the Charter of Fundamental Rights of the 
European Union?” See European Commission. Press Release IP/12/354. See also Statement by Commissioner De 
Gucht, K. (22 February 2012). On ACTA (Anti-Counterfeiting Trade Agreement). Brussels. Europa Press Release 
MEMO/12/128. 
908 Proposal for a Council Decision on the conclusion of the Anti-Counterfeiting Trade Agreement between the 
European Union and its Member States, Australia, Canada, Japan, the Republic of Korea, the United Mexican 
States, the Kingdom of Morocco, New Zealand, the Republic of Singapore, the Swiss Confederation and the United 
States of America, 24 June 2011, COM (2011) 0380. 
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emphasis needs to be placed in the manner of negotiations, which should be fair 
and transparent as well as the technical content of the Agreement, if it is to be 
unanimously agreed upon at the international level. 
 
An analysis of the main provisions of the ACTA and the comparison of ACTA 
with the EU legal instruments governing counterfeit and falsified medicines in the 
EU reveals that the civil measures are pre-existing in the Enforcement Directive909 
and the border measures are adequately covered by the Customs Regulation.910 
Moreover, the criminal measures that the ACTA provided for are not addressed by 
any one harmonised legal instrument at the EU level. Although the Medicrime 
Convention provides for the criminalisation of counterfeiting of medicinal 
products, it has not been ratified by all the Member States yet. Further, it addresses 
the violations from the public health and safety perspective and not IPR 
infringements, from the IP law perspective. In addition, the ACTA addressed the 
criminal enforcement of IPRs in general from an IP law perspective, which is still 
not harmonised at the EU level.  
 
Therefore, ACTA can serve as a blueprint when harmonisation of IP law with 
regard to criminal enforcement of IPRs is re-considered in the EU since it has 
articulated the criminal offences associated with violations of IPRs under Article 
23. However, for the purposes of regulating criminal enforcement of 
counterfeiting and falsification of medicinal products in the EU, the Medicrime 
Convention is a good starting point. But, there is an evident gap with respect to 
criminal enforcement of counterfeiting of medicines where there is a categorical 
violation of IPRs. Therefore, even though the ACTA as a whole need not be 
909 Articles 8 to 11, Directive 2004/48/EC.  
910 Articles 17 to 26, Regulation 608/2013. 
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transposed into EU legal instruments, the specific measures on criminal 
enforcement of IPRs are extremely relevant. 
 
7.4. Multilateral and bilateral agreements 
7.4.1. Background 
The proliferation in the number of bilateral and multilateral agreements clearly 
indicates a developing dissatisfaction and inadequacy of the international 
agreements in the IPRs domain. The agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS)911 as negotiated in 1994 is the only 
international agreement in the realm of IPRs that is widely recognised and 
implemented. Since TRIPs, no new international agreements have seen success. 
Specifically, the failure of ACTA in 2012 after years of negotiations; the most 
recent set back which might lead to ultimate rejection of Trans Pacific Partnership 
(TTP)912 due to withdrawal by the United States;913 as also the inadequacy of 
Medicrime Convention - indicated by the few countries that have ratified the 
Convention illustrate the lack of success of any international agreement on the 
issue. 
 
While, on one hand, most attempts at international agreements are not seeing 
911 The agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) came into being in 1994. As is 
evident by the large number of bilateral and multilateral agreements regarding enforcement of IPRs, there is 
widespread belief that TRIPs either needs to be amended or abandoned in favour of a more contemporary 
agreement that addresses the needs of the technological developments that has taken place in the past two decades 
also in context of IPRs. 
912 TPP negotiations reached a successful conclusion in October 2015. The 12 TPP parties were Australia, Brunei, 
Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, United States, and Vietnam; See also 
Thow, A. M., & Gleeson, D. (2017). Advancing public health on the changing global trade and investment agenda: 
comment on" the trans-pacific partnership: Is it everything we feared for health?". International Journal of Health 
Policy and Management, 6(5), 295. 
913 Schott, J. J., & Lu, Z. L. (2017). Asia-Pacific Regionalism after the TPP. 17-1 US-China Cooperation in a 
Changing Global Economy, 134. 
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fruition, on the other hand, there is a distinct proliferation in the number of 
multilateral, plurilateral and bilateral agreements. For instance, EU and Canada are 
working on a Comprehensive Economic and Trade Agreement (CETA)914 
covering classic free trade issues, wherein substantive and the enforcement 
provisions are modelled after the beginning of ACTA in 2009 and CETA is still 
under negotiations.915 Another example is the Trans-Atlantic Trade and 
Investment Partnership (TTIP)916 between EU and the US, which also contains 
provisions on IP protection. In addition, Trans Pacific Partnership (TPP)917 has 
also been underway since 2005, however, after the US withdrawal from the 
negotiations of TPP, the future of TPP in its current form is uncertain. In 2012, 
Regional Comprehensive Economic Partnership (RCEP), 918 which is a large scale 
free-trade agreement began to take form between ASEAN member states and 
Australia, China, India, Japan, Korea and New Zealand. Likewise, RCEP has also 
dedicated a chapter on IP enforcement. In the Pacific region, the Trans-Pacific 
Partnership is being negotiated between the Members of the P4 free trade 
Agreement of 2005, (Brunei, Chile, New Zealand, and Singapore) and Australia, 
Canada, Japan Malaysia, Mexico, Peru, the United States and Vietnam. TPP also 
contains provisions on IP enforcement.  
 
As the titles of the various agreements suggests, these are trade agreements, which 
914 Griller, S., Obwexer, W., & Vranes, E. (Eds.). (2017). Mega-Regional Trade Agreements: CETA, TTIP, and 
TiSA: New Orientations for EU External Economic Relations. Oxford University Press. 
915 THE EU Parliament voted in favour of CETA on February 15, 2017. It still needs to be ratified by the national 
parliaments before it can become fully effective. 
916 Griller, S., Obwexer, W., & Vranes, E. (Eds.). (2017). Mega-Regional Trade Agreements: CETA, TTIP, and 
TiSA: New Orientations for EU External Economic Relations. Oxford University Press. 
917 Schott, J. J., & Lu, Z. L. (2017). Asia-Pacific Regionalism after the TPP. 17-1 US-China Cooperation in a 
Changing Global Economy, 134. 
918 Lee, Y. S. (2016). The Eagle Meets the Dragon—Two Superpowers, Two Mega RTAs, and So Many in 
Between: Reflections on TPP and RCEP. Journal of World Trade, 50(3), 475- 496. 
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focus on the economic partnerships. In general, the Trade and Investment 
Agreements (TIAs) have been criticised for the potential negative impact on 
health.919  If the TPP and TTIP become a reality, the impact would be on more 
than half of world trade.920 The impact of these trade agreements will also be felt 
on those countries that are not signatories to the agreements since by default these 
trade agreements would be setting the standard and rules for rest of the world. 
Adherence to these rules would be inevitable if a country would like to remain 
competitive in global trade.921 In addition, the formation of the mega-regional 
trade agreements coincides with the timing of increase in the number of trade 
disputes that concern public health protection.922 Thus, the main focus of 
discussion of multilateral and bilateral agreements will be with reference to 
counterfeiting in the pharmaceutical sector. The main parameters that can serve as 
tools to determine the relevance of the TIAs in terms of counterfeiting in the 
pharmaceutical sector can be shortlisted to enforcement measures as well as sector 
specific measures with reference to the pharmaceutical sector. 
 
7.4.2. IP perspective 
The issue of enforcement of IPRs at the International level was first considered 
seriously in the TRIPs Agreement. However, the provisions regarding the 
919 Kapczynski, A. (2015). The Trans-Pacific Partnership—Is It Bad for Your Health?. New England Journal of 
Medicine, 373(3), 201-203; See also Luo, J., & Kesselheim, A. S. (2015). The Trans-Pacific Partnership agreement 
and implications for access to essential medicines. Jama, 314(15), 1563-1564; Also see Weiss, M., Middleton, J., & 
Schrecker, T. (2015). Warning: TTIP could be hazardous to your health. Journal of Public Health, 37(3), 367-369. 
920 TPP: 26 %; TTIP: 43.6 % (Source: WTO 2014). ‘WT/TPR/OV/ 16’, obtained from the World Bank’s World 
Development Indicators, WTO Statistics and UNSD Comtrade database. 
921 Jones, E., Deere-Birkbeck, C., & Woods, N. (2010). Manoeuvring at the Margins: Constraints Faced by Small 
States in International Trade Negotiations. Commonwealth secretariat; See Yu, K. (2014). TPP and Trans-Pacific 
Perplexities, 37 Fordham Intl. L. J. 1129-1182 (2014); Also see McNeill, D., Barlow,, Birkbeck, C. D., Fukuda-
Parr, S., Grover, A., Schrecker, T., & Stuckler, D. (2017). Trade and investment agreements: Implications for health 
protection. Journal of World Trade, 51(1), 159-182. 
922 WTO, Overview of Development in the International Trading Environment – Annual Report by the Director 
General (2014). WT/TPR/OV/14, 21 Nov. 2011; In 2015, the WTO Technical Barriers to Trade (TBT) Committee 
received fifty-four specific trade concerns. About 33 % of the concerns related to public health issues. 
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enforcement of IP rights in the TRIPs Agreement were not free from criticism. 
The TRIPS Agreement was criticised and debated upon even at the incipient 
stage.923 It was observed that the difficulties predicted in the discussions, such as 
the problematic and cumbersome process of bringing a dispute before the WTO, 
also subsequently came true.924 In fact, the US and the EU would have liked to 
have certain provisions regarding enforcement such as border measures extending 
to all IP rights specified in the TRIPS Agreement, which did not take place. As a 
consequence, most of the TIAs entered into by US and the EU with other countries 
contains specific measures pertaining to enforcement.  
 
Looked through the lens of cleaning the pharmaceutical sector of counterfeiting 
products, it is apparent from the study of the TIAs that most of the TIAs deal 
specifically with the enforcement of IP rights. Therefore, the focus is on the 
measures, such as what can be done if a trade mark is violated and the civil, 
criminal and border measures available in order to enforce the rights as well as 
ensure safety of products. Specifically as regards the pharmaceutical sector, the 
measures pertain more with specific reference to protection of patents, violations 
of trademarks, copyrights and the traditional form of IP rights. For instance, 
Article 9bis 2 of RCEP,925 which is closely reflected in Article 18.74 of the TPP,926 
provides for the courts to use techniques such as taking into consideration lost 
profits and the market price or suggested retail price of goods in calculating 
damages for trademark or copyright infringement. Likewise Article 18.74 and 
18.77 of the TPP are mirrored in Articles 9bis 6 and 9quarter 6 of RCEP, concerning 
923 Reichman, J. H., & Lange, D. (1998). Bargaining around the TRIPS agreement: the case for ongoing public-
private initiatives to facilitate worldwide intellectual property transactions. Duke J. Comp. & Int'l L., 9, 11. 34-39. 
924 Watal, J. (2014). Is TRIPS a Balanced Agreement from the Perspective of Recent Free Trade Agreements? 
In EU Bilateral Trade Agreements and Intellectual Property: For Better or Worse? (41-57). Springer Berlin 
Heidelberg. 
925 Article 9, RCEP. 
926 Articles 18.74 and 18.77, TPP. 
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destruction of infringed goods. These Articles also allow for destruction of 
materials and implements employed for creation of those goods. The criminal 
measures for the enforcement of IP violations proposed in ACTA, have also been 
proposed in the TPP, under Articles 18.77, and under Article 9quarter 1 of RCEP. 
 
These measures propose to criminalise any copyright and trademark infringements 
that occur on a ‘commercial scale’. The TIAs do not specifically address the steps 
necessary to fight counterfeiting although the goals of most TIAs reflect that 
counterfeiting and piracy need to be controlled and weeded out.927 In fact, it is 
highlighted in preparatory documents928 that the IP law umbrella does not deal 
adequately with the issue of counterfeit medicine929 since it is considered an area 
of Medicine law and Medicine law focuses its attention of the Regulation of 
medicine.  
 
Therefore, the problem of counterfeit medicine falls between the cracks of 
otherwise strong and sound foundations of IP law and Medicine law. For instance, 
when addressing the issues of pharmaceutical sector IP law focuses on and deals 
with issues such as length of patents protection; and trademarks protection of 
pharmaceutical companies. However, the real problem lies in the fact that strong 
measures need to be instituted to specifically address counterfeiting in the 
pharmaceutical sector, besides the Medicrime Convention, whose primary focus is 
on criminalising counterfeiting of medicines; also there are no agreements that 
directly address this issue at the International or EU level. Apparently, it requires a 
927 For example, Article 1 (6) of the proposed TTIP states that the parties shall promote increased access to high – 
quality medicinal products, address the threat of antimicrobial resistance and fight against falsified medicinal 
products. 
928 Morin, J-F. (April 2011).  Sustainability Impact Assessment Relating to the Negotiation of the Intellectual 
Property Chapter of the Comprehensive Economic and Trade Agreement (CETA) Between the EU and Canada. 
Université libre de Bruxelles.  
929 Oxfam Canada and Oxfam Québec. (July 15, 2009). Submission regarding the Anti-Counterfeiting Trade 
Agreement.1; Essential Action, Letter to the foreign Affairs and International Trade Canada, (July 2, 2009). 5. 
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fishing expedition to find the most relevant rules to be applied in the sudden 
situations that emerge, which are hard-pressed for time. 
A common element in the multilateral and bilateral agreements is that most of the 
agreements recognise in their broad general goals that the agreement seeks to 
achieve the protection of health and safety as an important goal.930 However, the 
focus of the IPR regulatory framework is not on counterfeiting. Most of the focus 
of IPR regulatory framework is structured around regulatory issues, such as patent 
life span, trademarks violations and is not on necessary steps to be followed if a 
counterfeit drug is discovered. 
 
Regulatory cooperation appears to be a common thread in the multilateral and 
bilateral agreements.931 There are two main problems that arise in this regard. 
Firstly, the focus of most bilateral and multilateral agreements is not on 
counterfeiting in pharmaceutical sector, as the main theme. Secondly, the 
regulatory cooperation would largely result through the mechanism of specialised 
Committees.932 The potential consequence of these committees would be that a 
number of additional steps would be added and consequently the entire regulatory 
process would become long-winded.933 In general, transparency, public access to 
information and public participation in the regulatory cooperation are 
acknowledged as important core values, especially as an aftermath of ACTA, 
where such important values were not accorded paramount importance. 
930 Council of the European Union. (14 September 2016). Comprehensive Economic and Trade Agreement between 
Canada, of the one part, and the European Union and its Member States, of the other part. In Legislative Acts and 
other instruments. Interinstitutional File: 2016/0206 (NLE). Henceforth, referred to as ‘CETA’Council of the 
European Union. (5 August 2016). Draft CETA, Article 19 (Cooperation against illicit drugs); Article 20 (Law 
enforcement cooperation and the fight against organised crime and corruption); and Article 21 (Money laundering 
and the financing of terrorism); and Article 22 (Cybercrime).  Brussels. Document number 5368/16. 
931 CETA, Article 21. 
932 In CETA, 8 specialised committees would be formed that would be responsible for carrying out the regulatory 
processes.  
933 Ronan, O. B. (2016). Moving Regulation out of Democratic Reach: Regulatory Cooperation in CETA and its 
Implications (No. 158). Kammer für Arbeiter und Angestellte für Wien, Abteilung Wirtschaftswissenschaft und 
Statistik. 
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However, a careful analysis of some of the multilateral and bilateral agreements 
reveals that emphasis on these values can be misplaced. For example, in the case 
of CETA, penalties and enforcement measures do not exist as regards Labour and 
Environment issues as well as Sustainable Development. In the context of Labour, 
Environment and Sustainable Development, clear emphasis is placed on 
transparency, public access to information and public participation. However, in 
other areas, where enforcement measures and penalties exist, there is an absence 
of these democratic features. As a result, a regulatory chill may be experienced 
and the absence of these democratic features can be a nail in the coffin, if such 
mishaps are not rectified in the subsequent drafts of the multilateral and bilateral 
agreements.  
 
Another broad problem with the multilateral and bilateral agreements (CETA, 
TTIP, and TPP) is the strong influence of domestic set up of the stronger party to 
the agreement, in the final agreement. For instance, Canada and the United States 
have a lower level of regulation but a higher level of punitive damages (in case of 
harm caused by the negligence of the manufacturer), compared to the EU where 
the emphasis is on a higher level of regulation towards prevention of harm.  The 
most troubling scenario in multilateral agreements is when the process of 
alignment of regulation leads to lowering of the level of regulation.934 
 
In draft CETA, regulatory cooperation encompasses a vast area including goods, 
services, investment, and trade. This is not atypical as other agreements such as 
TPP, TTIP, and RCEP are also expansive in terms of the goods, services, 
934 Ronan, O. B. (2016). Moving Regulation out of Democratic Reach: Regulatory Cooperation in CETA and its 
Implications (No. 158). Kammer für Arbeiter und Angestellte für Wien, Abteilung Wirtschaftswissenschaft und 
Statistik. 
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investments and trade opportunities that they cover. There are thirty chapters in 
the proposed TPP draft, concerning improved market access through a reduction 
in tariffs, and non-tariff barriers, but also disciplines for state-owned enterprises 
(SOEs); anti-competition rules; transparency and anti-corruption; IP protection; E-
commerce, etc.935 
 
These broad multilateral and bilateral agreements have sometimes been accused of 
projecting the agenda of ‘expansion of power and influence’. The TPP, for 
instance, has been hailed as the US agenda for expansion in Asia936while on the 
other hand, RCEP has been exalted as China trying to flex its muscles in the Asian 
region.937 These attempts by the rich countries and their companies to steer 
domestic regulation through international trade agreements that supersede 
domestic laws may938 result in sacrificing the wider public interest. Bargaining 
autonomy in policy design in trade off for access to markets may be ill-advised in 
many cases, especially when it is a question of public health and safety. 
 
7.4.3. Medicines law perspective 
Specifically, with reference to the pharmaceutical sector in the multilateral and 
bilateral agreements, the main aim of the agreements is to enable regulators to 
improve coordination for an increase in the safety and efficacy of the 
pharmaceutical sector. The focus, as mentioned in the draft TTIP, is on primarily 
three key areas of inspections, approvals, and innovation. Inspections have the 
935 European Commission. (2015). The Transatlantic Trade and Investment Partnership, Towards and EU-US trade 
deal, Inside TTIP, an overview and chapter by chapter guide. Belgium, Section 2.10 Pharmaceuticals. 31. 
936 Gantz, D. A. (2016). The TPP and RCEP: Mega-Trade Agreements for the Pacific Rim. Ariz. J. Int'l & Comp. 
L., 33, 57. 
937 ibid. 
938 Ronan, O. B. (2016). Moving Regulation out of Democratic Reach: Regulatory Cooperation in CETA and its 
Implications (No. 158). Kammer für Arbeiter und Angestellte für Wien, Abteilung Wirtschaftswissenschaft und 
Statistik. 
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main goal of ensuring that the standards set in the EU with respect to inspections 
of companies are met and the global supply chain is secure. The TTIP recognises 
that in the current global supply chains, different ingredients are sourced from 
different suppliers from all over the globe.939 Therefore, the necessity of securing 
the global supply chain is imperative.  
 
Secondly, the time spent on obtaining approval of medicine in different regions is 
of crucial importance for the patients as well as the manufacturers. For the 
patients, it pertains to access of medicines and for the manufacturers, it is not only 
about putting their product on the market but also about resources spent on 
obtaining approval. If the method of procuring approval can be streamlined and 
become reciprocal in different parts of the globe, the manufacturers would be able 
to save resources in terms of time as well as money, on obtaining approvals in 
different continents, i.e. if essentially the process of obtaining approvals is the 
same. Therefore, TTIP stresses the importance of aligning the approval of 
medicines in addition to coordination on inspections of companies producing 
medicines.  
 
The third common focus in the multilateral and bilateral agreements is on 
innovation, in context of the pharmaceutical sector. For instance, the TTIP in 
Section 2.10 on pharmaceuticals stresses on the importance of sharing expertise 
and findings and sharing views as regards latest science. In CETA, the provisions 
directly focussed on counterfeiting in the pharmaceutical sector, include Articles 
19-22 that cover cooperation against illicit drugs; law enforcement cooperation 
and the fight against organised crime and corruption; money laundering and the 
939 European Commission. (2015). The Transatlantic Trade and Investment Partnership, Towards and EU-US trade 
deal, Inside TTIP, an overview and chapter by chapter guide. Belgium, Section 2.10 Pharmaceuticals. 31. 
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financing of terrorism and cybercrime.940 
Some of the controversial issues that need greater clarity pertain to the pricing of 
medicines, reimbursing bills, transparency of clinical trial data; and protecting IP 
in the pharmaceutical sector. Although the EU explicitly maintains its position that 
no deal will be struck that would override the current legal regime, however, 
uncertainty still exists regarding these issues and how they will finally be worked 
out.941 
 
7.4.4. Critical analysis of the multilateral and bilateral agreements 
The various multilateral and bilateral agreements such as CETA, TTP, RCEP and 
TTIP are still being negotiated. The reason for conducting an analysis of these 
bilateral and multilateral agreements was mainly to assess if there were some 
unique features that could inspire change or serve as inspiration to strengthen the 
legal framework in the EU. As revealed in the foregoing analysis, these TIAs 
contribute significantly because irrespective of the fact whether a country is party 
to the agreement or not, the bilateral and multilateral agreements contribute to 
setting the general standards. For instance, even though ACTA failed, the 
provisions of ACTA were carried forward in some of the bilateral and multilateral 
agreements discussed in the previous sections. 
 
A noticeable feature in the TIAs with regard to IP law is that most of the TIAs 
concentrate on reaching agreements with respect to the enforcement of IP rights 
940  Council of the European Union. (14 September 2016). Comprehensive Economic and Trade Agreement between 
Canada, of the one part, and the European Union and its Member States, of the other part. In Legislative Acts and 
other instruments. Inter-institutional File: 2016/0206 (NLE); See also European Council, Council of the EU. 
(28.10.2016). EU-Canada trade agreement: Council adopts decision to sign CETA. Press Release 623/16. 
941 European Commission. (2015).The Transatlantic Trade and Investment Partnership, Towards and EU-US trade 
deal, Inside TTIP, an overview and chapter by chapter guide. Belgium, Section 2.10 Pharmaceuticals.32. 
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with specific reference to civil, criminal and border measures. The regulatory 
issues amongst these broad categories centre around life span of patents, etc. The 
analysis of these agreements also revealed that there is a lack of attention to the 
problem of counterfeiting and falsification of medicinal products. 
 
The pharmaceutical sector is addressed in the multilateral and bilateral agreements 
but the main concentration of the provisions is on improving coordination between 
countries that are signatories to the agreement. Basically, three key areas in the 
pharmaceutical sector are recognised to be of core interest in the negotiations – 
inspections, approvals and innovation. It is obvious that besides a general overall 
concern for counterfeit and falsified medicinal products, there is a clear lack of 
focused approach in dealing with counterfeiting or falsification of medicinal 
products in the multilateral and bilateral agreements. 
 
7.5. Concluding remarks 
In this chapter, the initiatives taken at the global plane have been analysed. It 
became obvious that in the previous decade, the rise in global trade and 
investment was hailed as the panacea of solving problems of poverty, public 
health and safety at the international level because it was expected that greater 
investment would lead to economic growth, which in turn, would lead to reduction 
in poverty with greater investment in public health.942However, in more recent 
times, the practical experience has shown that such estimates and claims have not 
reaped the desired results.943 In fact, TIAs have been cited to be a cause of global 
942 Feachem, R. G. (2001). Globalisation is good for your health, mostly. BMJ: British Medical Journal, 323(7311), 
504. 
943 Chanda, R. (2002). Trade in health services. Bulletin of the World Health Organisation, 80(2), 158-163; Also see 
Rayner, G., Hawkes, C., Lang, T., & Bello, W. (2006). Trade liberalisation and the diet transition: a public health 
response. Health Promotion International, 21(suppl 1), 67-74. 
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health inequalities.944 Therefore, there is an urgent need to highlight the provisions 
of TIAs that can impact the pharmaceutical industry, the IP sector with reference 
to civil, criminal and border enforcements as also help achieve general goals for 
protection of public health and broad goals and rules for the pharmaceutical sector.  
 
The Medicrime Convention, which has been ratified by only four EU Member 
States, entails criminal measures that can be instituted for cases involving 
counterfeit and falsified medicinal products. If ratified by the EU as a whole, it 
would bring about harmonisation with regard to criminal measures to a certain 
extent because the Convention leaves some room to pick and choose measures that 
can be instituted.945 The Medicrime is also open to other countries to join. 
However, even if the Medicrime Convention is joined by most countries, the 
scope of the Convention is only specific to public health and safety and does not 
deal with violation of IPRs in connection with counterfeit and falsified medicines. 
 
The ACTA had attempted to deal with the counterfeiting of IPRs in general (not 
specifically counterfeiting of medicines), but ACTA failed. The ACTA can, 
however, serve as a blueprint for institution of criminal measures, when the EU 
reconsiders that option. As far as the TIAs are concerned, the provisions of ACTA 
have been carried forward in various bilateral and multilateral agreements to an 
extent.946 However, the need of entering into bilateral and multilateral agreements 
indicates that at the International level, there is an evident need for global 
consensus on how counterfeit and falsified medicines should be addressed in 
concrete terms because counterfeiting and falsification of medicines is a global 
944 Ottersen, O., Dasgupta, J., Blouin, C., Buss, Chongsuvivatwong, V., Frenk, J.,  & Leaning, J. (2014). The 
political origins of health inequity: prospects for change. The Lancet, 383(9917), 630-667. 
945 See Articles 5(3), 6(2), 7(2), and 8(3), The Medicrime Convention 2011.  
946 See discussion on TPP, TTIP, RCEP and CETA in Section 7.4. 
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problem and is not restricted to any one continent. The strategy of employing local 
patchwork solutions to global problems has the drawback that the overall picture 
is not taken into consideration and the solutions are inclined towards plugging the 
leaks in the pipe carrying the water and not on replacing the corroded pipe. Sooner 
or later, the pipe will burst.   
 
While looking for solutions, it can be reiterated that as identified in Chapter 1, the 
problem of counterfeit and falsified medicines lies at the intersection of Medicine 
law, IP law and Criminal Law, representing three different perspectives of the 
same problem. It is necessary to address the problem of counterfeiting and 
falsification medicines in a cohesive manner, taking into account all three 
perspectives. A violation of Medicine law, concurrently presents associated 
infringement of IPR and the consequent illegal activity requires action by the 
police, activating the Criminal law sphere simultaneously. Therefore, a solution to 
the problem requires a commensurate response from all three spheres of law and 
since it is a global problem, a global response is also required.947 
 
However, the specific area where the EU legal framework can seek inspiration 
from global initiatives lies in the area of criminal enforcement. As a first step it 
would be beneficial for the EU to ratify the Medicrime Convention because that 
would impact a harmonisation of criminal measures with respect to falsification of 
medicines.948 Even though the Medicrime Convention addresses the problem of 
947 Therefore, the role of the international organisations such as the WHO (representing the public health and safety 
perspective), the WIPO (representing the IP interests), the WCO (representing the Customs perspective), and the 
INTERPOL (representing how to deal with crime) should negotiate a common international Convention. Bilateral 
and multilateral agreements may find it challenging to resolve a global problem of very specific nature, which is 
life threatening and a risk to public health and safety. The role of multilateral and bilateral agreements should 
ideally be of supportive nature, whereby the bilateral and multilateral agreements reinforce the provisions laid down 
or agreed upon in an international agreement. 
948 As explained earlier, the Medicrime Convention uses the term ’counterfeit medicine’ but implies ’falsification’ 
of medicine.  
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counterfeiting and falsification of medicines from the public health and safety 
perspective, the fact that it has potential to decrease the cases of falsification of 
medicines also implies that there will be a proportionate decline in the number of 
related cases of counterfeiting since the two problems are interconnected. 
Moreover, the benefits will positively impact both spheres of law. 
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Part IV, the last part of the thesis, contains two chapters. In Chapter 8, it is 
analysed whether the law that provides tools to combat counterfeiting and 
falsification of medicinal products in the EU meets the social objectives of public 
health and consumer protection as envisaged in the Treaty on the Functioning of 
the European Union. The final Chapter 9 summarises the thesis and presents the 
overall conclusion of the thesis, thereby assessing if the objectives of the thesis 
have been achieved. 
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Chapter 8: Are the social objectives of public health 
and consumer protection met? 
 
8.1. Introduction 
In this chapter, it is analysed whether the law that provides tools to combat the 
counterfeiting and falsification of medicinal products in the EU - the FMD,949 the 
Enforcement Directive, 950 and the Customs Regulation951 meets the social 
objectives of public health (Article 9 and 168, TFEU) and consumer protection 
(Article 12 and 169 TFEU), as envisaged by the TFEU. The chapter begins with 
the recapitulation of the relevant law. Thereafter, the social objectives of public 
health and consumer protection as envisaged in the TFEU are identified and 
clarified. Thereafter, the question of whether the aims of public health and 
consumer protection are met is analysed.  
 
8.2. Recapitulation of laws that combats counterfeiting and 
falsification of medicines in the EU 
Law governing counterfeiting and falsified medicines encompasses the FMD 
(Directive 2011/62/EU), the Enforcement Directive (Directive 2004/48/EC) and 
the Customs Regulation (Regulation 608/2013).952 The FMD represents the public 
health and safety perspective and is the key directive in the sphere of Medicine 
949 Directive 2011/62/EU. 
950 Directive 2004/48/EC. 
951 Regulation 608/2013. 
952 See Chapters 4, 5 and 6 for more discussion. 
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law concerning falsified medicines. The FMD came into being as an amendment 
to the Medicines Directive (Directive 2001/83/EC) due to the exponential increase 
in the number of falsified medicines entering the EU.953As the name of the 
Directive suggests, it primarily contains provisions oriented towards protecting the 
legal supply chain against infiltration of falsified medicines in the EU and ensure 
the smooth functioning of the Single Market with regard to medicinal products.954 
The measures that it contains such as introduction of safety features,955 defining 
the role and obligations of the actors involved in the legal supply chain; 
introduction of a logo to be applied by all legitimate websites based in the EU and 
selling medicinal products in the EU, are designed to deal with controlling the 
prevalence of falsified medicinal products in the EU.956  
 
The FMD categorically omits dealing with the violation of IP law and hence, 
counterfeiting of medicines, which is also excluded from the purview of the 
provisions of FMD.957 This is also reflected in the use of the term ‘falsified 
medicinal product’ and not ‘counterfeit medicinal product’.958 However, as 
discussed in Chapter 1, falsification of medicines inevitably leads to violation of 
an IP right, such as a trademark right.959 For this reason, the violation of IP law 
and the Medicine law (the FMD) occur simultaneously. Therefore, the IP law 
instruments, namely the Enforcement Directive and the Customs Regulation also 
form a part of the applicable law while dealing with the counterfeiting and 
falsification of medicines. 
 
953 See Recital 2, Directive 2011/62/EU. 
954 Recital 33, Directive 2011/62/EU. 
955 Bogaert, B. C., & Burton, C. (2015). The mysteries of the Falsified Medicines Directive-where is the logic on 
safety features. London: Script Regulatory Affairs, 1-3. 
956 See more in Chapter 4. 
957 Recital 29, Directive 2011/62/EU. 
958 See Chapter 1, Section 1.6. 
959 See Chapter 1, Section 1.2. 
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The Enforcement Directive (Directive 2004/48/EC),960 in tune with the 
fundamental right to property as enshrined in the Charter of Fundamental Rights 
of the EU,961 has the primary objective of enforcement of IP in the EU.962 The 
Enforcement Directive is applicable to protection of the entire gamut of IPRs, 
including trademarks, copyrights, designs, utility models, geographical indicators, 
patents, etc. This legislation is instrumental in realising the aims of the Single 
Market, wherein the IP is protected because it is believed that IP protection creates 
a conducive environment, which is a fertile ground for innovation, improving 
competition and investment.963 Thereby, protection of IP in the EU  contributes to 
economic growth.964 In context of the counterfeiting and falsification of medicinal 
products in the EU, the Enforcement Directive provides for protection of rights of 
the right holder. For instance, in case of counterfeit medicines, the rights of the 
trademark holder are enforced by applying the provisions of the Enforcement 
Directive, when the counterfeit medicine is discovered and it is detected that the 
counterfeit medicine was packaged to wrongfully represent its production by a 
legitimate manufacturer, such as ‘Roche’.965 
 
The Customs Regulation (Regulation 608/2013) is the third legal instrument that 
contributes to combatting counterfeiting and falsification of medicines in the EU. 
The counterfeit and falsified medicinal products can enter the EU through diverse 
routes – over land, by sea, by air, by post or courier services, and in the luggage of 
960 See Chapter 5 for more details. 
961 European Union. (2012). Charter of Fundamental Rights of the European Union. OJ C 326, 26.10.2012, 391-
407.  
962 See Article 17(2), European Union. (2012). Charter of Fundamental Rights of the European Union. OJ C 326, 
26.10.2012, 391-407.  
963 ibid. 
964 Pila, J., & Torremans, P. (2016). European Intellectual Property Law. Oxford University Press. 
965 See Chapter 3, Section 3.2. 
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passengers.966 The Customs Regulation focuses on the enforcement of IPRs at the 
borders. It empowers the customs authorities to intercept goods suspected of 
infringing IPRs at the borders,967 and under certain circumstances, it empowers the 
customs authorities to destroy small consignments subject to the consent of the 
right holders.968  
 
Two important considerations that must be underlined are that the FMD falls in 
the area of public law, whereas the Enforcement Directive and the Customs 
Regulation lie in the purview of the private law, wherein the private rights of the 
right holders are asserted and protected. The broad nature of the public law and 
private law are essentially different.969 In addition to the divergent basic nature of 
the laws, the goals of the legal instruments are also different. The FMD springs 
from the perspective of public health and safety970 and the Enforcement Directive 
and the Customs Regulation rises from the core idea of protection of IP. These are 
essentially different streams of law that happen to intersect when dealing with 
counterfeiting and falsification of medicinal products. As a result, addressing 
counterfeiting and falsification of medicinal products in the EU is not a result of a 
cohesive policy and resembles a patchwork approach. 
 
8.3. Social objectives of public health in the TFEU 
In order to analyse if the public health goals are met by the legal instruments, it is 
imperative to cast light on the public heath objectives, as envisaged by the TFEU. 
966 European Commission. (2015). Report on EU customs enforcement of intellectual property rights. Results at the 
EU border 2015. Luxembourg. Publications office of the European Union. 
967 See Chapter 6 for more detailed discussion. 
968 Under certain specific conditions enumerated in Article 26, Regulation 608/2013. 
969 Loughlin, M., & Tschorne, S. (2016). Public law. Routledge. 324-337. 
970 See Article 168, TFEU. 
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The ‘Social Europe’,971 a term utilised by the working group XI of the European 
Convention972 mirrors the social values. In other words, the Union is required to 
take into consideration certain common values while formulation and execution of 
its policies.973 These common values are the promotion of employment, social 
protection and welfare, education, and health.  The larger social objectives are a 
reflection of the idea of liberal man and humanity974 where the citizens have the 
opportunities to participate in a self-determined way and the State acts as the 
facilitator and sets parameters and policies. In addition to the maintenance of law 
and order, the State is also responsible for the promotion of policies that allow the 
citizens to exercise their rights and freedoms.975 
 
The issue of public health and safety has been a concern of the Union Law since 
the EEC Treaty. Since then the exercise of market freedoms, i.e. free movement of 
goods, services, people, and capital could be restricted because of reasons 
concerning public health.976 Subsequently, an exclusive title of competence 
regarding public health was introduced by the Treaty of Maastricht,977 which was 
amended by the Treaty of Amsterdam.978 The Treaty of Lisbon979 brought about 
significant changes, which are evident especially with reference to the substantive 
971 Gronden, J., Szyszczak, E., Neergaard, U., & Krajewski, M. (2011). Introduction. Health Care and EU Law, 1-
16. 
972 See Final Report of Working Group XI on Social Europe of 4 February 2003. (2003). Brussels. CONV 516/1/03 
REV 1 
973 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart, 217. 
974 ibid. 
975 ibid. 
976 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart. 678. 
977 European Union. (1992) Treaty on European Union (Consolidated Version), Treaty of Maastricht, 7 February 
1992, OJ C 325, 24.12.2002, 5-32. 
978 Council of the European Union. (1997). Treaty of Amsterdam Amending the Treaty on European Union, The 
Treaties Establishing the European Communities and Related Acts – Consolidated version of the Treaty on 
European Union. OJ C 340, 10.11.1997, 145. 
979 European Union. (2007). Treaty of Lisbon amending the Treaty on European Union and the Treaty establishing 
the European Community, signed at Lisbon. OJ C 306, 17.12.2007, 1- 271.  
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amendments that were brought about in Article 168. In general terms, the 
responsibilities or the competencies regarding governing public health are shared 
between the Union and the Member States as provided for in the Article 4 para 2 
lit k. TFEU (shared competencies) and Article 6 para 2, TFEU ( competence to 
support, coordinate or supplement). In other words, the Union does not have the 
authority to pursue its own health policies as it has a supplementary role to the 
Member States.980 The Union can, however, encourage and support cooperation 
between the Member States in the area of public health.  
 
A close examination of two provisions, Article 9 and 168 in the TFEU, is 
warranted because they are especially relevant for understanding the public health 
goals, as envisaged in the TFEU. 
 
8.3.1. Article 9, TFEU 
The Article 9 of the TFEU is a horizontal clause981 that concerns social protection 
in the EU. It states that while defining and implementing the policies and related 
pursuits, the Union should take into consideration certain key elements such as 
protection of health and the guarantee of adequate social protection.982 Although, 
being a horizontal clause, the provision does not extend any subjective individual 
rights, but it springs into action when specific policies are implemented. Through 
Article 9 of the TFEU, human health has been included in the general horizontal 
980 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart. 679. 
981 In the EU law, in many policy fields, horizontal clauses are used as regulatory instruments. These clauses 
function as constitutional objectives would function in a national constitution. The horizontal clauses reflect the 
goals across policies like public health, consumer protection etc. See more in Geiger, R., Khan, D. E., & Kotzur, M. 
(Eds.). (2015). European Union Treaties; a Commentary: Treaty on European Union: Treaty on the Functioning of 
the European Union. Hart. 216. 
982 See CFREU, Article 3(3). In addition to Article 9, TFEU, Article 3 (3) of the CFREU also have a similar 
provision for social protection and social justice. 
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health policy, in addition to other basic qualities.983 Besides having under its 
purview an area of general health, there are also specific provisions dealing with 
protection of health and safety of workers.984 The specific legislative basis of the 
policy on human health is enshrined in Article 168 of the TFEU (discussed below 
in Section 8.2) and is also mirrored in Article 35 of the CFREU.  Although the 
horizontal clause - Article 9, has been at the centre of criticism for its lack of 
enforceable subjective rights,985 it is significant for the interpretation of secondary 
legislation in the EU, since the secondary legislation (Directives, Regulations, 
Recommendations etc.) has to be in consonance with the objectives of the primary 
legislation (TEU, TFEU, and CFREU). 
 
8.3.2. Article 168 
The legislative basis of the policy on human health is entailed in Article 168, 
which clarifies, specifies, and enlarges the competence of the Union in the public 
health sphere. The specific significance of public health is underlined by Article 
168(1), wherein it is required that all Union policies and activities ensure a high 
level of protection of public health in determining and implementing the Union 
policies. This horizontal level requirement implies that public health concerns are 
to be ensured in all policies and activities and not restricted to health 
regulations.986  Article 168 defines the concept of general health,987 preventing 
physical and mental illness. Secondly, the scope of the Article includes 
983 See Article 9, TFEU which introduces a horizontal clause on social protection, whereby the Union is required to 
promote high level of employment, guarantee adequate social protection, fight against social exclusion, high level 
of education, training and protection of human health.  
984 Articles 153 para 1, 115, 36, 53 para 2, 62 TFEU. 
985 See VHVH/Gassner, Article 9 AEUV mns 13 et seq, in Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). 
(2015). European Union Treaties; a Commentary: Treaty on European Union: Treaty on the Functioning of the 
European Union. Hart. 218. 
986 Cabezas, M. D. (2012). Current trend in pharmaceutical law in EU. Pharmaceuticals Policy and Law, 14(2-4), 
195-207. 
987 Article 168 para 1, TFEU. 
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‘monitoring, early warning of and combatting the serious cross-border threat to 
health’. Likewise, the problem of counterfeiting and falsification is also a cross-
border issue that is a health scourge mandating attention at the EU level. Further, 
Article 168 also includes provisions that encourage cooperation and 
complementarity of health services in cross-border situations.988 
 
Article 168 also provides for setting of high standards of quality, safety for 
medicinal products and devices used for medical use.989 In accordance with this 
provision, under the Directive 2001/83/EC, there is an obligation on the Member 
States to provide for a market authorisation procedure in order to authorise the use 
of medicinal products.990 However, Article 168 is limited from empowering the 
Union to enact legally binding acts in the area of health. The organisation and 
delivery of health services and medical care are competencies that belong to the 
Member States. Therefore, primarily it is the Member States that are responsible 
for defining their health policy. 
 
The specific ambitions of Article 168 can be summarised to mean betterment of 
public health, prevention of physical and mental illnesses and diseases; promotion 
of research to identify causes, transmission and prevention of diseases; reduction 
of drug-related health damage; initiating measures to set high standards of quality 
and safety for medicinal products and devices for medical use;991 and monitoring 
serious cross-border threats to health. In relevant cases, sharing information with a 
988 Article 168, para 1, TFEU. 
989 Article 168 (4) (c), TFEU. 
990 Case C-319/05 Commission  v. Germany (2007) ECLI:EU:C:2007:678 
991 See Article 168, para 4 (c). 
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view to prevent the spread of diseases is also encompassed in these provisions.992 
 
8.4. Social objectives of consumer protection in the TFEU 
In addition to provisions of explicitly stating the importance of public health in the 
TFEU, there are provisions related to protection of consumers,993 which are 
extremely relevant to the thesis because the protection of the consumers against 
counterfeit and falsified medicines also falls under the goals of consumer 
protection. The origin of consumer protection laws in the EU can be traced back to 
the case law beginning with the Cassis decision.994 In this case, the CJEU 
explicitly stated that if a product is legally marketed in one Member State, it may 
be marketed in another Member State as long as it does not come in conflict with 
consumer’s interest.  
 
An independent policy on consumer protection was first introduced in the EU in 
the Treaty of Maastricht in 1992.995 The Treaty of Amsterdam brought about 
deeper changes and under Article 153 TEC and provided a competence for 
measures to be formulates in the sphere of consumer protection. It was under 153 
TEC that a horizontal policy was first introduced with respect to protection of 
consumers that meant that the requirements of consumer protection always had to 
be taken into consideration while formulation and implementation of all Union 
policies. Subsequently, in the Treaty of Lisbon, the horizontal clause in Article 
153 TEC was moved to Article 12 of the TFEU and the rest of the provisions were 
992 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart.  677. 
993 Micklitz, H. W., Reich, N., & Weatherill, S. (2004). EU Treaty revision and consumer protection. Journal of 
Consumer Policy, 27(4), 367-399. 
994 Case C-120/78 Rewe Zentral AG (1979) ECLI:EU:C:1979:42also known as Cassis de Dijon. 
995 European Union. (1992) Treaty on European Union (Consolidated Version), Treaty of Maastricht, 7 February 
1992, OJ C 325, 24.12.2002, 5-32. 
279 
 
                                           
 
 
 
articulated under Article 169 of the TFEU.996 
 
The term consumer protection implies protection of the core interests of the 
consumer, i.e. usually protection against unfair trade, credit practices, involving 
consumer goods, as also protection against faulty and dangerous goods.997 The 
TFEU does not define the term consumer, however, it implies that a consumer is a 
natural person who functions in personal, private and not commercial capacity.998 
The CJEU has articulated that usually, a consumer is assumed to be a reasonably 
well-informed, observant and circumspect average person.999 
 
The protection of consumers is also a shared competence between the Union and 
the Member States.1000 In the EU, the Member States have the primary 
responsibility of consumer welfare and protection, while the Union plays a 
complementary role of supporting, supplementing and monitoring the protection 
of consumers through its policies.1001 The Member States can make stricter 
policies than the Union to safeguard interests of the consumers as long as the 
policies made by the Member States are aligned with the other provisions of the 
Union in the TEU, TFEU, and CFREU. 
 
8.4.1. Article 12, TFEU 
Consumer protection as a horizontal clause is explicitly provided for in Article 12 
of the TFEU. By horizontal clause, it is implied that all union policies and 
996 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart, 683. 
997 Black, H.C., Nolan, J.R., & Nolan-Haley, J.M. (1990). Black’s Law Dictionary.  (Sixth Edition). St. Paul, Minn. 
West Publishing Co. 
998 CJEU Case C 269/95 Benincasa (1997) ECR I-3767. 
999 Weatherill, S. (2013). EU consumer law and policy. Edward Elgar Publishing. 57. 
1000 As articulated in Article 4, para 2. lit f of the TFEU. 
1001 ibid., 684. 
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activities need to take into account the principles of consumer protection.1002 
However, there is no obligation to optimise or prioritise any particular aspects of 
consumer protection and is presented as one of the several criteria that needs to be 
balanced while the formulation of Union policies. The term consumer protection 
entails protection of interests of the consumers with respect to the protection of 
health, safety and the economic interests of consumers; and promotion of the right 
to consumer information, education and the formation of consumer interest 
groups. 
 
8.4.2. Article 169, TFEU 
In addition to Article 12 of the TFEU, the issue of consumer protection is also 
governed exclusively in Title XV, Article 169 of the TFEU. It provides for the 
promotion of consumers interests and states that the Union shall contribute to the 
protection of the health, safety and economic interests of the consumers as well as 
promote the right to information, education and to organise themselves in order to 
safeguard their interests.1003 In this context, various directives have been adopted 
that focus on protecting the interests of the consumers, e.g. Directive 2001/95/EC 
on general product safety, Directive 97/55/EC concerning misleading advertising, 
and Directive 2011/83/EU on consumer rights. 
 
Further, Article 169 para 2 lit a, TFEU mentions that the Union has the 
responsibility for legal harmonisation in the internal market as articulated in 
Article 114 TFEU. In practice, it is one of the important provisions to actualise a 
common consumer protection policy because it provides more detailed guidelines 
1002 Twigg-Flesner, C. (2010). Time to do the job properly—the case for a new approach to EU consumer 
legislation. Journal of consumer policy, 33(4), 355-375. 
1003 Geiger, R., Khan, D. E., & Kotzur, M. (Eds.). (2015). European Union Treaties; a Commentary: Treaty on 
European Union: Treaty on the Functioning of the European Union. Hart. 682. 
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to ensure the protection of consumers. 
 
8.5. Does the law that provides tools to combat 
counterfeiting and falsification of medicinal products, meet 
the social objectives of public health and consumer 
protection? 
In Section 8.3, the public health goals as envisaged in the TFEU have been 
elaborated, and in Section 8.2, the law providing tools to combat counterfeiting 
and falsification of medicinal products has been recapitulated. The public health 
goals can be summarised as improvement of public health of the citizens in the 
EU, prevention of disease and illnesses, reduction in drug related damage, 
ensuring high standard and quality of medicines, monitoring of serious cross-
border threats and information sharing to prevent the spread of diseases between 
Member States.1004 
 
As asserted in Chapter 1, the problem of counterfeiting and falsification of 
medicines lies at the intersection of Medicine law, IP law, and Criminal law.1005 In 
the sphere of Medicine law, the FMD regulates the provisions in the EU and 
addresses falsification of medicines. In the sphere of IP law, counterfeit medicines 
are dealt with in the Enforcement Directive and the Customs Regulation. As 
evident, so far, in the field of Criminal law, there is no harmonisation at EU level. 
1004 See Article 168, TFEU.  
1005 See Chapter 1, Section 1.2. 
282 
 
                                           
 
 
 
However, if EU ratifies the Medicrime Convention1006 then there would be a level 
of harmonisation of criminal measures that may be instituted pertaining to 
counterfeiting and falsification of medicines. Since there is intersection of three 
spheres of law while dealing with counterfeit and falsified medicinal products, an 
assessment of each of these legal instruments against the goals of public health as 
envisaged in Articles 9 and 168 of the TFEU is required. 
At the outset, it must be emphasised again that public health is a shared 
competence between the Union and the Member States.1007 The Member States 
hold the primary responsibility with regard to defining their health policies and 
organising the delivery of healthcare services. Although the Union can make 
broad overarching policies, which affect the EU in general and the Union 
exclusively makes those policies that may not expedient to be formulated at the 
national level because the matter in question is related to most Member States. But 
the primary power with regard to healthcare rests with the Member States and as a 
result of this provision, there are no common Union health policies in the EU. The 
achievement of a Single Market with respect to the pharmaceutical sector has not 
seen much movement since its formulation because of the reason of shared 
competences and the Member States holding most of the authority and power. 
 
Another significant aspect with respect to the legal instruments that contain tools 
to be employed to combat counterfeiting and falsification of medicines is that the 
legal instruments also need to uphold the objectives of the Single Market,1008 in 
addition to achieving the social goals of public health and consumer protection. 
Although the objectives of the Single Market of the Union are not in conflict with 
1006 Council of Europe. (2011)  Council of Europe convention on counterfeiting of medical products and similar 
crimes involving threats to public health. Strasbourg. Council of Europe. (Also known as the Medicrime  
Convention). Council of Europe Treaty Series. No.211. 
1007 Under Article 4(2) (k) and Article 6(2) of the TFEU. 
1008 Article 26, TFEU. 
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the social objectives of public health and consumer protection, yet there is an 
evident need for a careful balance. The Single Market objectives, enshrined in 
Article 26,1009 call for an area without frontiers allowing free movement of goods, 
services, capital, and persons, with an overarching goal to achieve an overall 
integration with no barriers. Thus, the legal instruments not only have to consider 
the social goals but have to be mindful of the overall objective of the Single 
Market. 
8.5.1. Have the public health objectives been achieved? 
Since Article 9 is a horizontal provision, the secondary legislation is expected to 
respect the objectives of the primary legislation. Therefore, the FMD, the 
Enforcement Directive, and the Customs Regulation are required to be in 
consonance with the provisions of Article 9, TFEU, which in addition to other 
social protections1010 states that protection of human health has to be ensured. 
However, in practice, the rising numbers and circulation of counterfeit and 
falsified medicinal products in the EU indicate that the aim of protection of human 
health has not been totally achieved. The FMD has taken steps such as the 
introduction of safety features,1011 introduction of the logo1012 on online websites 
dealing in sale of medicinal products, which are measures directed towards 
protection of human health. However, the FMD addresses only the legal supply 
chain, whereas the illegal supply chain also contributes heavily to circulation of 
1009 Article 26, TFEU. 
1010 The other social protections being promotion of high level of employment, provisions of adequate social 
protection, provision of measures to combat social exclusion, and ensuring high level of education and training. 
1011 Article 54(o) inserted in Directive 2001/83/EC through Article 1(11) of Directive 2011/62/EU. This is further 
expanded in Commission Delegated Regulation (EU) 2016/16 of 2 October 2015 supplementing Directive. 
2001/83/EC of the European Parliament and of the Council by laying down detailed rules for the safety features 
appearing on the packaging of medicinal products for human use. 
1012 Article 85c was inserted in Directive 2001/83/EC by Article 1(20) of Directive 2011/62/EU. This is further 
articulated in Commission Implementing Regulation (EU) No 699/2014 of 24 June 2014 on the design of the 
common logo to identify persons offering medicinal products for sale at a distance to the public and the technical, 
electronic and cryptographic requirements for verification of its authenticity. 
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counterfeit and falsified medicinal products in the EU. The Enforcement Directive 
and the Customs Regulation aim at enforcement of IPR in the EU and are 
activated when counterfeit medicines come into play, because the FMD does not 
address counterfeit medicines. The Customs Regulation has an explicit goal to 
contribute to eradicating the counterfeit goods harmful to public health and 
safety.1013 
 
Regarding the public health goals as envisaged under Article 168, the primary aim 
of improvement of the public health of the citizens in the EU is sought to be 
achieved through the FMD as well as the Medicines Directive framed in 2001.1014 
The FMD has specific provisions that supplement the provisions of the Medicines 
Directive, which in turn strengthen the legal framework that not only contributes 
towards improving public health but also towards the other goals of prevention of 
disease and illnesses and reduction in drug related damage. Specifically, the 
introduction of safety features in the FMD is geared towards ensuring high 
standard and quality of medicines. The Enforcement Directive and the Customs 
Regulation also contribute in specific ways such as the Enforcement Directive 
contains the civil measures like injunctions,1015 preliminary and precautionary 
measures1016 (seizures, etc.) that may be employed in the case of IPR 
infringement. The Customs Regulation is significant because it empowers the 
customs authorities to initiate corrective action when counterfeit or falsified 
medicines are discovered at the borders. The measures relating to destruction of 
small consignments under certain circumstances1017 can be crucial in dealing with 
1013 Recital 11, Regulation 608/2013. 
1014 Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the 
prevention of the entry into the legal supply chain of falsified medicinal products. 
1015 Article 11, Directive 2004/48/EC. 
1016 Article 9, Directive 2004/48/EC. 
1017 Article 26, Regulation 608/2013. 
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entry of counterfeit and falsified medicines in the EU. The Enforcement Directive 
and the Customs Regulations, thus, with the employment of these measures 
contribute towards public health protection. 
 
However, with respect to monitoring of serious cross-border threats and 
information sharing to prevent the spread of diseases between the Member States, 
there is a definite scope for improvement. The escalating number of counterfeit 
and falsified medicinal products in the EU1018 is indicative of the fact that the legal 
instruments are not able to optimally meet all the goals regarding public health in 
the EU. Firstly, the Enforcement Directive categorically limits itself from cross-
border applicability. 1019 The problem is that counterfeiting and falsification of 
medicinal products is typically a cross-border issue, as illustrated in the legal case 
studies.1020 Therefore, it is a significant stumbling block as regards counterfeit 
medicines and in the case of infringement of their rights, the right holders have to 
pursue the cases individually in each Member State since the orders of one 
Member State are not valid in another Member State. The Customs Regulation 
empowers the customs authorities to take action on goods intercepted at the 
borders. However, despite the Customs Regulation encouragement of information 
sharing, there is an evident lack of formal coordination and cooperation between 
the Member States to realise this objective.  
 
Further, with regard to information sharing for prevention of spread of disease, as 
envisaged under Article 168, as part of its goals for ensuring public health in the 
EU, the provision of Rapid Alert System in the Medicines Directive serves this 
1018 Recital 2, Directive 2011/62/EU 
1019 Recital 11, Directive 2004/48/EC. 
1020 Chapter 3. 
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purpose,1021 it requires that the Member States inform the relevant agencies in case 
of detection of falsified medicines in any one Member State.  
 
Therefore, the law governing counterfeiting and falsification of medicines in the 
EU strives towards meeting the public health goals envisaged in Article 9 and 168 
in the TFEU. The legal instrument in the sphere of Medicine law that specifically 
focuses on the falsification of medicines- the FMD, has introduced, for example, 
safety features to be employed in designated medicinal products, i.e. the logo has 
to be displayed on websites selling legitimate medicinal products. These measures 
are geared towards realising the goals of public health as outlined in the TFEU. 
Additionally, the Enforcement Directive and the Customs Regulation have also 
significantly contributed towards realising the goals enshrined in Articles 9 and 
168. The Customs Regulation has specific provisions to monitor serious cross-
border threats to health by empowering the customs authorities to check the 
packages and materials entering the EU borders. 
 
However, the legal instruments have not been entirely successful in achieving the 
public health goals yet. There is scope for improvement especially with respect to 
monitoring cross-border threat to health, sharing of information to prevent spread 
of disease, reduction in drug-related damage caused to health especially due to 
proliferation of counterfeit and falsified medicines in the EU.  
 
8.5.2. Are the consumer protection goals are met? 
The goals of consumer protection have been discussed in Section 8.4, which 
explained that the TFEU: Articles 12 and 169 provide for consumer protection in 
1021 Article 117a, Directive 2001/83/EC. 
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the EU. The Article 12, being a horizontal clause, states that all Union policies 
have to accord due regard to the protection of consumers. And in Article 169, 
detailed provisions pertaining to protection of consumers are listed with reference 
to health, safety, economic interests, the rights to consumer information, education 
and formation of consumer’s interest groups. The legal instruments that provide 
tools to combat counterfeiting and falsification of medicines in the EU (the FMD, 
the Enforcement Directive and the Customs Regulation) have been discussed in 
Chapters 4, 5, and 61022 and summarised above.1023 Since the secondary legislation 
is required to be in consonance with the primary legislation (TEU, TFEU, and the 
CFREU), the aims of consumer protection are integrated in the secondary 
legislation in general, by virtue of Article 12. As a result, the FMD, the 
Enforcement Directive, and the Customs Regulation being secondary legislation 
present due regard for Article 12. 
 
The counterfeiting and falsification of medicinal products work against public 
health and safety goals of the TFEU, as illustrated by the case studies in Chapter 
3.1024 The Union policies need to ensure that the consumers are protected against 
counterfeit and falsified medicines in accordance with the provisions listed in 
Articles 12 and 169. The FMD, through its provisions with regard to safety 
features to prevent manipulation of medicinal products;1025 the logo for online 
websites selling medicinal products;1026 running frequent awareness campaigns1027 
1022 See Chapters 5, 6, and 7 for more details. 
1023 See Section 8.2. 
1024 See Chapter 3 for more details. 
1025 Article 1(11) of Directive inserted Article 54(o) in Directive 2001/83/EC. It was translated into Commission 
Delegated Regulation (EU) 2016/16 of 2 October 2015 supplementing Directive 2001/83/EC of the European 
Parliament and of the Council by laying down detailed rules for the safety features appearing on the packaging of 
medicinal products for human use. 
1026 Article 1 (20) of Directive 2011/62/EU inserted Article 85c in Directive 2001/83/EC. It was translated into 
Commission Implementing Regulation (EU) No 699/2014 of 24 June 2014 on the design of the common logo to 
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– pays attention to consumer protection in the context of falsified medicines in the 
legal supply chain. The Enforcement Directive has the goals of protection of IPRs 
in the EU. Through its provisions of enforcement such as injunctions,1028 
preliminary and precautionary measures,1029 the Enforcement Directive facilitates 
the enforcement of rights of the IPR holders. Thereby, the Enforcement Directive 
protects the consumers from counterfeit goods.  
 
The Customs Regulation empowers the customs authorities’ to intercept goods at 
the borders1030 and this provision is especially useful while dealing with 
counterfeit and falsified medicines. By virtue of Customs Regulations, under 
certain conditions, the customs authorities also have the power to destroy small 
consignments.1031 This is a significant provision that has a far reaching impact 
because the counterfeit and falsified medicines have mostly been known to arrive 
in small consignments.1032 
 
The legal instruments that provide the tools to combat counterfeit and falsified 
medicines in the EU contain measures that pay attention to consumer protection, 
as discussed in the preceding paragraph. However, the fact that despite these 
measures the number of counterfeit and falsified medicines is still on the rise in 
the EU,1033 implies that the consumers are not adequately protected against 
counterfeiting and falsification of medicines.  
identify persons offering medicinal products for sale at a distance to the public and the technical, electronic and 
cryptographic requirements for verification of its authenticity. 
1027 Article 1(26) of Directive 2011/62/EU. See also European Commission. (2015). ‘Buying Medicines Online, 
Think you know what you are getting? ’Brussels. European Commission 
1028 Article 11, Directive 2004/48/EC. 
1029 Article 9, Directive 2004/48/EC. 
1030 Articles 17 and 18, Regulation 608/2013. 
1031 Article 26, Regulation 608/2013. 
1032 See Chapter 3 for more details. 
1033 Recital 11, Directive 2011/62/EU. 
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However, there are certain issues in the legal framework, which result in a 
continued increase in the prevalence of counterfeit and falsified medicines in the 
EU and are thus harmful to the consumers. Firstly, as identified in Chapter 1, the 
problem of counterfeiting and falsification of medicines lies at the intersection of 
three streams of law – Medicine law, IP law and Criminal law.1034 The problems 
related to falsified medicines are addressed by the FMD, however, each falsified 
medicine inevitably has an element of counterfeiting and thus, results in violation 
of IPRs.1035 However, this element of IP violation is not addressed by the FMD 
because it delimits itself from dealing with counterfeiting.1036 In fact, the IP law 
deals with counterfeiting of medicines and therefore to enforce these rights across 
the EU in the context of enforcement of the IP rights, the Enforcement Directive 
and Customs Regulation are activated. Therefore, the consumers, right holders, as 
well as the authorities lack clarity regarding application of law. Either the case is 
dealt with only from one perspective, or the complaint falls through the gaps or 
due to the crucial loss of time in identifying the right authority to deal with the 
case, the evidence is lost. This state of affairs in deduced from the lack of case law 
on the subject, and the overwhelming increase in statistical information indicating 
increase in counterfeiting and falsification of medicinal products.1037 
 
The Criminal law is not harmonised at the EU level, therefore the role of 
organised crime, as illustrated in the legal case studies1038 in the counterfeiting of 
medicines largely goes unattended at the EU level. It is dealt with sporadically at 
the national level by the Member States. As evident, the problem of counterfeit 
1034 Chapter 1, Section 1.2. 
1035 Discussed in Chapter 1, Section 1.2. 
1036 Recital 5, Directive 2011/62/EU. 
1037 OECD/EUIPO (2016), Trade in Counterfeit and Pirated Goods: Mapping the Economic Impact, OECD 
Publishing, Paris. It was estimated that the value of imported fake goods worldwide was estimated to be USD 461 
million in 2013, compared to the total imports in world trade at USD 17.9 trillion. It was also reported that up to 5% 
of goods imported into the European Union are fakes. 
1038 See Chapter 3, Section 3.5.2. 
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and falsified medicinal products inevitably touches three spheres of law 
simultaneously. In such a situation, only one sphere of law cannot solve the 
problem in isolation. At the most, the falsification of medicine can be 
interrupted1039 or the small consignment carrying counterfeit medicine be 
destroyed1040 or the individual manufacturing the counterfeit medicine can be put 
behind bars for a few years.1041 These offer temporary solutions to deep-rooted 
and convoluted problems. However, such complex problems require a thorough 
and well-coordinated effort, requiring participation of the three streams of laws 
affected by the problem in order to comprehensively protect the consumers from 
the harmful effect on their health and safety.  
 
Moreover, there are certain gaps that still exist in the legal instruments, which 
have been highlighted in the legal analysis of the individual chapters.1042 In 
context of counterfeiting and falsification of medicines it was highlighted in 
Chapter 3, in the legal case studies that it is essentially a cross-border activity. The 
lack of cross border synergies between enforcement authorities, especially 
concerning cross-border threats and information sharing1043 needs to be addressed 
in order to better protect the consumers. Further, the lack of harmonisation of 
criminal enforcement1044 and low level of penalties for counterfeiting and 
falsification of medicines also attracts the criminals. Further, the infiltration of the 
legal supply chain by illegal supply chain1045 also places the consumers in a 
1039 See Chapter 3, Section 3.2. 
1040 European Commission. (2017). Report on EU customs enforcement of intellectual property rights: Results at 
the EU border 2016. Luxembourg. Publication Office of the European Union. 
1041Regina v Peter Hugh Gillespie No. 2011/02816/B4 Court of Appeal Criminal Division 29 November 2011 
[2011] EWCA Crim 3152. 
1042 See Chapter 4, Sections 4.2, 4.3, and 4.4.; Chapter 5, Sections 5.3, 5.4, and 5.5; and Chapter 6, Sections 6.2, 
6.3, 6.4, and 6.5. 
1043 Chapter 6. 
1044 Chapter 5, Section 5.5. 
1045 Chapter 4, Section 4.3.3.1. 
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vulnerable position. As a result, the legal mechanism to safeguard the consumers 
against counterfeiting and falsification of medicines is not of optimal level, as yet. 
 
8.6. Concluding remarks 
The EU treaties have both social objectives and economic aims that are 
simultaneously pursued through various policies and legal instruments. Immense 
importance is accorded to social goals like protection of human health, welfare, 
and consumer protection, and equal emphasis is laid on realising the economic 
ambitions like policies that promote competition, innovation and investment 
resulting in economic growth and development. A fine balance is maintained, 
which is not always easy to achieve as in the case of the pharmaceutical sector. On 
the one hand, there are social objectives and values of public health and safety and 
consumer protection that must be ensured, and on the other hand, the 
pharmaceutical sector has to remain competitive and the prices have to be kept at 
reasonable levels in order to encourage innovation.  
 
Moreover, the laws should not be too restrictive, but strict enough to discourage 
counterfeiting and falsification of medicines. To achieve both the social and 
economic targets, the EU law needs to engage in a balancing act – to have strong 
laws to combat counterfeiting and falsification and simultaneously curb the 
introduction of prohibitively expensive restrictions. Although in theory, the social 
and economic objectives do not clash with one another, in practice, there is a price 
– even for the maintenance of public health and safety and economic growth.  
 
The legal instruments that provide tools to combat counterfeiting and falsification 
of medicinal products in the EU strive to meet the social objectives of public 
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health and consumer protection through their provisions. However, the legal 
instruments need to balance the goals of the Single Market1046 against the social 
objectives of public health and consumer protection.1047  
 
In addition, both public health and consumer protection lie in the area of shared 
competences,1048 whereby the Union plays a supplementary and supporting role 
and the Member States shoulder the primary responsibility in designing policies 
and activities concerning public health and consumer protection. Therefore, the 
Union can intervene only in limited issues of common interest in the broad public 
health and consumer protection areas. 
 
Therefore, the given reality is that the goals of public health and safety and 
consumer protection have to be prioritised simultaneously with achieving goals of 
the Single Market in the EU. Taking the above into consideration, it can be 
concluded that the legal instruments are successful in meeting the social objectives 
of public health and consumer protection to a large extent, with definite scope for 
improvement especially in areas of serious cross-border threats, criminal 
enforcement and information sharing to prevent the spread of diseases. 
1046 Articles 26 and114 of the TFEU. 
1047 Articles 9, 12, 168, and 169 of the TFEU. 
1048  Articles 4 and 6 of TFEU. 
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Chapter 9: Conclusion 
The main objectives of the thesis were, firstly, to analyse how the counterfeiting 
and falsification of medicinal products are addressed by the law (Directive 
2011/62/EU, Directive 2004/48/EC, and Regulation 608/2013) in the EU (de lege 
lata), and secondly, to analyse whether the law providing tools to combat the 
counterfeiting and falsification of medicinal products meet the social objectives of 
public health (Articles 9 and 168) and consumer protection (Articles 12 and 169) 
as envisaged by the Treaty on the Functioning of the European Union.  
 
On the basis of the case studies - Operation Volcano (Italy), Operation Singapore 
(the U.K), and Operation Robin (Sweden) 1049 certain common issues are identified 
regarding how counterfeit medicines infiltrate the legal supply chain. The common 
tendencies are primarily by manipulation of the medicinal products as well as 
through highly organised structures managing counterfeiting and falsification of 
medicinal products. Further, it is evident that there tends to be an element of cross-
border activity, usually involving more than two Member States. In addition, it is 
noted that the most common method of transportation of medicines is through 
small consignments, in order to circumvent customs control. One of the frequently 
used methods of offloading the manipulated products is through online sale of 
medicines. Finally, the types of medicines being counterfeited and falsified are 
predominantly life-saving medicines, while life-style drugs are a smaller part of 
the picture.  
 
The legal case studies reveal that counterfeiting and falsification of medicines is a 
complex, lucrative business, often involving highly educated players with 
1049 Chapter 3. 
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sophisticated knowledge of the sector. The three case studies also showcase that 
the counterfeiting and falsification of medicines are on the rise because there are 
certain gaps in the legal framework which are taken advantage of, by the people 
involved in counterfeiting and falsification of medicines.  
 
Thereafter, an analysis of the law dealing with counterfeiting and falsification of 
medicines was conducted in order to identify loopholes, if any, in the existing 
legal framework. The thesis establishes that the problem of counterfeiting and 
falsification of medicinal products lies at the intersection of three spheres of law - 
Medicine law, IP law and Criminal law. This insight provides the foundation for 
the understanding of the weaknesses in the legal regime that contains tools for 
combatting counterfeiting and falsification of medicines in the EU. 
 
The study of the FMD, representing the Medicine law perspective, concludes that 
although initiatives such as the introduction of safety features to prevent 
manipulation of the medicines are a step in the right direction, especially with 
respect to the introduction of the anti-tampering devices, there are areas that leave 
much to be desired. Contrary to a full trace and track system, the choice of using 
the end – to - end verification system may not be able to detect all cases of 
falsification of medicines. 
 
 Further, it is concluded that even though there is a requirement by law, for 
authorisation for all the market players, the high instance of forgery of 
authorisations (both market authorisations and manufacturing authorisations), as 
well as other related documents, significantly contribute to a marked increase in 
the falsification of medicines. The absence of a security feature, such as a 
watermark used in the currency, on the authorisation documents is noted and the 
urgency of a provision of securing the authorisations is underlined.  In addition, 
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even though the logo to be affixed on all legitimate websites based in the EU has 
many advantages, a clear provision for withdrawal of the logo in the case of 
breach of law is a concern that is highlighted. Likewise, a provision of ‘reverse 
burden of proof’ while importing APIs is noticeably absent in the Medicine law1050 
even though the APIs that are imported can be as hazardous to human health as the 
imported chemicals. Finally, in context of involvement of two or more Member 
States in a typical case of counterfeiting and falsification of medicines, a gap 
exists in the legal framework with respect to the sharing of responsibilities 
between the Member States. A provision on the lines of Article 85c (1) (c) of 
Directive 2001/83/EC, which clarifies roles of Member States in a specific 
situation, is absent, but could be potentially beneficial.  
 
Regarding the Enforcement Directive, which addresses the problem of 
counterfeiting of medicines from IP law perspective, it is deduced that it is 
primarily the question of violation of trademark rights that is pertinent in the 
context of counterfeiting of medicinal products, with special reference to the 
product packaging. Usually, it negatively impacts the goodwill and reputation of 
the owner of the trademarks. It is concluded that the civil enforcement of IP rights 
through provisions such as preliminary and precautionary measures encompassing 
the possibility of seizures, as well as measures such as interlocutory and 
permanent injunctions have the potential to be more effective with regard to 
counterfeiting of medicinal products subject to room for cross-border applicability 
of the provisions.  
 
Since there is no cross-border applicability of the provisions and the Enforcement 
Directive clearly delimits itself from the cross-border application, dealing with a 
1050 See Chapter 4, Section 4.3.2. 
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case involving counterfeiting of medicines, which is typically a cross-border 
activity, the legal route is not resorted to, as often. Therefore, the cumbersome 
process involving an application for same reliefs in multiple Member States for 
the right holders is not a viable option, in practice. Likewise, the lack of 
harmonisation of criminal measures in the EU highlights a gap in the enforcement 
of the IP rights. Therefore, it is concluded that the Enforcement Directive in its 
present form is not the most effective legal instrument for combatting 
counterfeiting of medicines in the EU. 
 
The analysis of the Customs Regulation shows that although there are certain key 
features such as measures that can be taken against small consignments, the 
pertinent issues such as the counterfeit goods that come through the personal 
luggage of the travellers, which is usually not subject to regular checks, remain to 
be addressed effectively. The travellers’ luggage has been known to contain 
packaging material for the counterfeit products manufactured in the EU.1051  
 
It is recognised that the Customs Regulation does not address the parallel imports 
because parallel imports are genuine products. However, in the context of 
counterfeiting and falsification of medicinal products, it is important to critically 
consider parallel imports especially because these have been the preferred disguise 
of many counterfeiters of medicinal products. However, establishing stricter laws 
would not be in consonance with the basic principle of proportionality recognised 
in the EU because of the significant advantages of parallel trade in the Single 
Market.   
 
1051 Report on EU Customs Enforcement of Intellectual Property Rights, Results of the EU borders 2016. 
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It is concluded that the Customs Regulation plays a significant role in controlling 
entry of counterfeit medicinal products at the EU borders and there is potential to 
increase critical effectiveness by conducting more frequent checks on small 
consignments and traveller’s luggage. However, it is also recognised that a 
balance needs to be struck as checking each piece of luggage would be impractical 
and forbidding travellers from bringing medicines in the EU for personal use 
would be draconian, and would violate the basic principles of the EU law.  
 
Next, the lack of harmonisation of Criminal law - the third sphere of law that is 
relevant to combatting counterfeiting and falsification of medicinal products - is 
emphasised. It is concluded that the Medicrime convention could be particularly 
useful with reference to criminal enforcement since it could be instrumental in the 
harmonisation of criminal measures with respect to counterfeiting and falsification 
of medicines. If the EU ratifies the Medicrime Convention, following the footsteps 
of the four Member States that have ratified the convention, this important gap in 
the EU legal framework can be bridged. 
 
In order to seek inspiration to strengthen the legal framework in the EU, the 
initiatives taken at the global level in this field are analysed. It is concluded that in 
the ACTA and other multilateral and bilateral agreements - TPP, TTIP, RCEP, and 
CETA, the protection and enforcement of IPRs is the predominant focus. While 
considering the pharmaceutical sector the concentration tends to be on promotion 
of harmonisation of rules pertaining to inspections, approval and innovation of 
medicinal products.  It became apparent that most of the provisions in ACTA that 
related to civil measures, digital environment, and border enforcement are already 
imbibed in different EU legal instruments such as the Enforcement Directive, the 
E-commerce Directive, and the Customs Regulations. However, the provision on 
criminal measures for enforcement of IPRs has no parallel in the EU legal 
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framework.   
In the EU, the sphere of public health and consumer protection are shared 
competencies between the Union and the Member States. In that light, it is 
concluded that the Union, through the secondary legislation, has to a large extent, 
been successful in meeting the goals with respect to the formulation of laws for 
ensuring the safety of the medicinal products, protection of the legal supply chain, 
civil measures for enforcement of IPRs and customs control at the borders. The 
area of law grappling with counterfeiting and falsification of medicines is a 
dynamic area and the full impact of some of the legal provisions is expected to 
unfold in the next five years. 
 
Considering that these developments have taken place in the past decade there is, 
undoubtedly, scope for improvement, especially in the areas of cross-border 
cooperation, criminal enforcement and creation of synergies at the institutional 
level to combat the counterfeiting and falsification of medicines. Since the 
problem of counterfeiting lies at the intersection of Medicine law, IP law and 
Criminal law, it would enhance the effectiveness by building synergies between 
the authorities dealing with these areas of law at national as well as EU level on 
the same lines as synergies exist with regard to the Rapid Alert system under 
Article 117a of the Directive 2001/83/EC.  
 
Overall, it is concluded that the legal instruments in the EU provide important and 
useful tools to combat counterfeiting and falsification of medicines. However, 
there is a definite scope for improvement. The gaps in the legal framework that 
have been identified must be taken seriously in order to minimise the risk of 
serious consequences. Counterfeiting and falsification pose problems in many 
areas, but in the medicinal sector, the ramifications are especially harmful because 
counterfeit and falsified medicines have an impact on the health of the people and 
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can, potentially, be fatal. Therefore, a focussed effort in bridging the gaps in the 
legal framework in this area is needed, which would enhance the health and safety 
of the EU citizens. 
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